A Complete Coil Portfolio

Hydrogel Embolic Coils & Platinum Coils

MicroVention’s comprehensive portfolio features clinically proven Hydrogel coils, which can be used exclusively or in combination with our trusted Platinum coils to treat a wide range of aneurysms and neurovascular lesions.

Breakthrough Hydrogel Technology

• Less Recurrence
• Less Retreatment
• More Progressive Occlusion

Compared to platinum coils with comparable safety¹

REFERENCES:

1. Tascini et al. Second-Generation Hydrogel Coils for the Endovascular Treatment of Intracranial Aneurysm: A Randomized Controlled Trial. 2018;43:00-00. DOI: 10.1161/STRUKEAHA.117.018707

For more information or a product demonstration, contact your local MicroVention representative:
FLOWS-DEPENDENT MICROCATHETER

NOW AVAILABLE THROUGH BLOCKADE™ MEDICAL

ORDERMAGICS@BLOCKADEMEDICAL.COM

MAGIC catheters are designed for general intravascular use. They may be used for the controlled, selective regional infusion of therapeutic agents or embolic materials into vessels.1

1. Magic Catheters IFU – Ind 19
MKTG-068 Rev. A
18 Technology Drive #169, Irvine Ca 92618
P 949.788.1443  |  F 949.788.1444
Now you have 24 hours to make a lifetime of difference in stroke patients like Nora.

The Trevo Retriever is the only device cleared to reduce disability in stroke patients up to 24 hours from time last seen well.

For more information, visit strykerneurovascular.com/trevo24hours
Redefine aspiration.

**AXS Vecta 71 Aspiration Catheter**

- Big 0.071in ID aspiration lumen to ingest more clot
- Deliver through a 0.088in ID long sheath or the new 0.091in AXS Infinity LS™ Plus Long Sheath

Packaged with the Scout Introducer, a 0.044in lumen nitinol cross coil catheter that replaces the need for a 3MAX or other delivery catheter

**AXS Vecta™ 71**

ASPIRATION CATHETER
CALL FOR AJNR EDITORIAL FELLOWSHIP CANDIDATES

2019 Candidate Information and Requirements

GOALS
- Increase interest in editorial and publication-related activities in younger individuals.
- Increase understanding and participation in the AJNR review process.
- Incorporate into AJNR’s Editorial Board younger individuals who have previous experience in the review and publication process.
- Fill a specific need in neuroradiology not offered by other similar fellowships.
- Increase the relationship between “new” generation of neuroradiologists and more established individuals.
- Increase visibility of AJNR among younger neuroradiologists.

ACTIVITIES OF THE FELLOWSHIP
- Serve as Editorial Fellow for one year. This individual will be listed on the masthead as such.
- Review at least one manuscript per month for 12 months. Evaluate all review articles submitted to AJNR.
- Learn how electronic manuscript review systems work.
- Be involved in the final decision of selected manuscripts together with the Editor-in-Chief.
- Participate in all monthly Senior Editor telephone conference calls.
- Participate in all meetings of the Editors during the annual meetings of ASNR and RSNA and the Radiology Editors Forum as per candidate’s availability. The Foundation of the ASNR will provide $2000 funding for this activity.
- Evaluate progress and adjust program to specific needs in annual meeting or telephone conference with the Editor-in-Chief.
- Embark on an editorial scientific or bibliometric project that will lead to the submission of an article to AJNR or another appropriate journal as determined by the Editor-in-Chief. This project will be presented by the Editorial Fellow at the ASNR annual meeting.
- Serve as liaison between AJNR and ASNR’s Young Professionals Network. Participate in meetings and telephone calls with this group. Design one electronic survey/year, polling the group regarding readership attitudes and wishes.
- Recruit trainees as reviewers as determined by the Editor-in-Chief.
- Organize and host a Fellows’ Journal Club podcast.
- Serve as Guest Editor for an issue of AJNR’s News Digest with a timely topic.

QUALIFICATIONS
- Be a fellow in neuroradiology from North America, including Canada (this may be extended to include other countries).
- Be a junior faculty neuroradiology member (< 3 years) in either an academic or private environment.
- Be an “in-training” or member of ASNR in any other category.

APPLICATION
- Include a short letter of intent with statement of goals and desired research project. CV must be included.
- Include a letter of recommendation from the Division Chief or fellowship program director. A statement of protected time to perform the functions outlined is desirable.
- Applications will be evaluated by AJNR’s Senior Editors prior to the ASNR meeting. The name of the selected individual will be announced at the meeting.
- Applications should be received by March 1, 2019 and sent to Ms. Karen Halm, AJNR Managing Editor, electronically at khalmsn.org.
AXS Infinity LS™ Plus Long Sheath
See package insert for complete indications, contraindications, warnings and instructions for use.

INDICATIONS FOR USE
The AXS Infinity LS™ Plus Long Sheath is indicated for the introduction of interventional devices into the peripheral, coronary, and neurovasculature.

RX ONLY

CONTRAINDICATIONS
There are no known contraindications.

POTENTIAL ADVERSE EVENTS

• Ischemia
• Infection
• Inability to completely remove thrombus
• Emboli
• Distal embolization

POTENTIAL ADVERSE EVENTS may result in cross contamination and/or reduced performance.

WARNINGs

• Do not attach a torque device to the shaped proximal end of DOC® Compatible Retriever.

• Prescription only – device restricted to use by or on order of a physician.

• If Retriever is difficult to withdraw from the vessel, do not torque Retriever. Advance Microcatheter distally, gently pull Retriever back into Microcatheter, and remove Retriever and Microcatheter as a unit. Further repositioning may be attempted when withdrawing the Retriever into the Microcatheter. Consider ending the Retriever using the Boston Scientific Vascular, guidewire extension REEPT 425092 so that the Microcatheter can be exchanged for a larger diameter catheter. Jointly withdraw the Retriever into the larger diameter catheter.

• Administer anticoagulation and antiplatelet medications per standard institutional guidelines. Users should take all necessary precautions to limit fluid downflow to patients and themselves by using sufficient shielding, reducing fluoroscopy times, and modifying x-ray technical factors where possible.

• Prescription only – device restricted to use by or on order of a physician.

• If using the device prior to the “Use By” date specified on the package.

• Exposure to a temperature greater than 60 °C (140 °F) may damage devices.

• Torgo or moving the devices against resistance may result in damage to the vessel or device.

• Maintain a constant infusion of appropriate flush solution.

• Acute vessel occlusion

• Infection

• Inability to completely remove thrombus

• Hematoma or hemorrhage at the puncture site

• To reduce risk of vessel damage, adhere to the following recommendations:

• The safety and effectiveness of the Trevo Retriever in reducing disability has not been established in patients with large core infarcts (i.e., ASPECTS ≤ 7). There may be increased risk for intracerebral hemorrhage, in these patients.

• The Trevo Retriever is intended for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke to reduce disability in patients with acute ischemic stroke secondary to intracranial large vessel occlusion (within the internal carotid, middle cerebral – M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset. Patients who are ineligible for interventional tissue plasminogen activator (tPA) or who fail tPA therapy are recommended for Trevo Retrieval System therapy.

• To reduce risk of vessel damage, adhere to the following recommendations:

• Maintain Retriever position in vessel when removing or exchanging Microcatheter.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.

• Prescription only – device restricted to use by or on order of a physician.

• Inability to completely remove thrombus

• Emboli

• Distal embolization

• Use caution when passing Retriever through stented arteries.

• Use caution when passing Retriever through stented arteries.
Statement of Ownership, Management, and Circulation

American Journal of Neuroradiology

800 Enterprise Drive, Suite 205, Oakbrook, IL 60523

1. Title of Periodical: American Journal of Neuroradiology
2. Date of Filing: 9/19/2018
3. Frequency of Issues: Monthly
4. Annual Subscription Price: $400—Individual (U.S)
5. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities: If none, check box
6. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities

7. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor

Karen Halm, AJNR, 800 Enterprise Drive, Suite 205, Oakbrook, IL 60523

8. Complete Mailing Address of Headquarters or General Business Office of Publisher

9. Issue Frequency

Monthly

10. Number of Issues Published Annually

12

11. Annual Subscription Price

$400—Individual (U.S)

12. Tax Status

Has Not Changed During Preceding 12 Months

13. Publication Title

American Journal of Neuroradiology

14. Statement of Ownership, Management, and Circulation

a. Publication Title: American Journal of Neuroradiology

b. Volume: 35

c. Number Published: 2

d. Average No. Copies of Single Copy Published Each Issue: 3287

e. Average No. Copies of Single Copy Published in Nearest 12 Months: 3287

f. Total Number of Copies (Not printer): 3189

(1) Paid Print Distribution

2693

(2) Paid Electronic Distribution

258

(3) Free or Nominal Rate Distribution

2953

(4) Paid Distribution by Other Classes of Mail Through the USPS

0

(5) Total Paid Distribution (Sum of 1, 2, 3, and 4)

2953

(6) Total Distribution (Sum of 5 and 6)

53

(7) Copies not Distributed

0

(8) Copies Disposed of Other Than by Distribution or Return

0

(9) Percentage Paid of Total Distribution

98.2

15. Total Free or Nominal Rate Distribution (Line 13b) (15c divided by 15f times 100)

98.2

16. 50% of all my distributed copies (electronic and print) are paid above a nominal price

17. Total Paid Print Copies (Line 5a) + Paid Electronic Copies (Line 5b)

2693

18. Total Paid Print Distribution (Line 6a) + Paid Electronic Distribution (Line 6b)

2693

19. Total Paid Electronic Copies

258

20. Total Paid Electronic Distribution

258

21. Free or Nominal Rate Distribution Outside the Mail

3287

22. Total Free or Nominal Rate Distribution Outside the Mail

3287

23. Percent Paid

98.2

24. Total Distribution (Sum of 15a and 15b)

3287

25. Statement of Ownership

I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form is subject to the penalties

I certify that 50% of all my distributed copies (electronic and print) are paid above a nominal price.

26. Publication not required.

27. The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:

American Society of Neuroradiology, 800 Enterprise Drive, Suite 205, Oakbrook, IL 60523

28. Available to Members of Participating Societies

American Board of Radiology (ABR) participation!

American Board of Radiology (ABR)

American College of Radiology (ACR)

American Roentgen Ray Society (ARRS)

American Society of Neuroradiology (ASNR)

Commission on Accreditation of Medical Physics Educational Programs, Inc. (CAMPEP)

Radiological Society of North America (RSNA)

Society of Interventional Radiology (SIR)

SNM

The Society for Pediatric Radiology (SPR)

Available to Members of Participating Societies

CMEgateway.org

It’s Easy and Free!

Log on to CME Gateway to:

• View or print reports of your CME credits from multiple societies from a single access point.

• Print an aggregated report or certificate from each participating organization.

• Link to SAMs and other tools to help with maintenance of certification.

American Board of Radiology (ABR) participation!

By activating ABR in your organizational profile, your MOC-fulfilling CME and SAM credits can be transferred to your own personalized database on the ABR Web site.

Sign Up Today!

go to CMEgateway.org
**INDICATIONS AND USAGE**

DOTAREM® (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

**CONTRAINDICATIONS**

History of clinically important hypersensitivity reactions to DOTAREM.

**WARNINGS AND PRECAUTIONS**

- **Hypersensitivity Reactions:** Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of DOTAREM administration and resolved with prompt emergency treatment.
- **Before DOTAREM administration,** assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to DOTAREM.
- **Administer DOTAREM only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.**
- **Gadolinium Retention:** Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver and spleen. The duration of retention also varies by tissue, and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs.
- **Consequences of gadolinium retention in the brain have not been established.** Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention.
- **Acute Kidney Injury:** In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.
- **Extravasation and Injection Site Reactions:** Ensure catheter and venous patency before the injection of DOTAREM. Extravasation into tissues during DOTAREM administration may result in tissue irritation.

**ADVERSE REACTIONS**

- **The most common adverse reactions associated with DOTAREM in clinical trials were nausea, headache, injection site pain, injection site coldness and rash.**
- **Serious adverse reactions in the Postmarketing experience have been reported with DOTAREM.** These serious adverse reactions include but are not limited to: arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

**USAGE IN SPECIFIC POPULATIONS**

- **Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.
- **Lactation:** There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
- **Pediatric Use:** The safety and efficacy of DOTAREM at a single dose of 0.1 mmol/kg has been established in pediatric patients from birth (term neonates ≤ 37 weeks gestational age) to 17 years of age based on clinical data. The safety of DOTAREM has not been established in preterm neonates. No cases of NSF associated with DOTAREM or any other GBCA have been identified in pediatric patients age 6 years and younger.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

**Please see the full Prescribing Information, including the patient Medication Guide, for additional important safety information.**

**References:**


DOTAREM® is a registered trademark of Guerbet LLC, and is available by prescription only.

Gadavist® is a registered trademark of the Bayer group of companies, and is available by prescription only.
INDICATIONS FOR USE:

The LVIS® and LVIS® Jr. devices are indicated for use with neurovascular embolization coils in patients ≥ 18 years of age for the treatment of wide-neck (neck width ≥ 4 mm or dome to neck ratio < 2) saccular intracranial aneurysms arising from a parent vessel with a diameter ≥ 2.0 mm and ≤ 4.5 mm.

Rx Only: Federal (USA) law restricts this device to sale by or on the order of a physician.

The HydroCoil® Embolic System (HES) and MicroPlex® Coil System (MCS) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae. The HES and MCS are also intended for vascular occlusion of blood vessels within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation and for arterial and venous embolizations in the peripheral vasculature.

The device should only be used by physicians who have undergone pre-clinical training in all aspects of HES/MCS procedures as prescribed by MicroVention.
DOTAREM®
gadoterate meglumine) Injection

Comparison of Dotarem® to Gadavist® for Overall Visualization and Characterization in the MRI Diagnosis of Primary Brain Tumors

Despite the difference in relaxivity between these 2 GBCAs

There Is No Measurable Difference in Clinical Benefit Observed Between Dotarem® and Gadavist®
as demonstrated by the REMIND Study, a multicenter, double-blind, randomized, controlled intraindividual crossover study.

This study “demonstrates the non-inferiority of gadoterate meglumine [Dotarem®] versus gadobutrol [Gadavist®] for overall visualization and characterization of primary brain tumors.” Additionally, there was no preference of the readers for either contrast agent, in most cases, regarding border delineation, internal morphology, and the qualitative degree of contrast enhancement, despite quantitative mean lesion percentage enhancement being higher with gadobutrol.2

- For all readers in the REMIND Study, more than 90% of patients presented with good or excellent overall lesion visualization and characterization with either Dotarem® or Gadavist®.2
- The REMIND Study also demonstrated a low incidence of immediate reported AEs with Dotarem® and with Gadavist®, as shown in multiple previous studies.2,3,4
- Dotarem® is the only imaging contrast with macrocyclic and ionic structure for high thermodynamic and kinetic stability.5,6
- Dotarem® is not only trusted for high molecular stability5,6; the REMIND Study demonstrates that it is as effective as Gadavist® for MRI diagnosis of primary brain tumors.2

Please see Important Safety information on opposite page. For more information on Dotarem®, please see Full Prescribing Information including Boxed Warning and Medication Guide.

Guerbet | COMMITTED

Learn more at RemindStudy.com
BRILLIANT HIGH-FLYER
ACCERO® Stent

- Self-expanding braided stent
- BlueXide® surface finishing
- Excellent opening behaviour & adaptability
- Brilliant visibility

www.acandis.com
The Woven EndoBridge Finally Coming Home across the Atlantic: What to Expect? W.J. van Rooij, et al.


Impact of Ischemic Lesion Location on the mRS Score in Patients with Ischemic Stroke: A Voxel-Based Approach M. Ernst, et al.


Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis R.R. Mattay, et al.

The Central Vein: FLAIR Signal Abnormalities Associated with Developmental Venous Anomalies in Patients with Multiple Sclerosis D.M. Rogers, et al.

Systematic Assessment of Multispectral Voxel-Based Morphometry in Previously MRI-Negative Focal Epilepsy R. Kotikalapudi, et al.

2027 Prospective Multicenter Study of Changes in MTT after Aneurysmal SAH and Relationship to Delayed Cerebral Ischemia in Patients with Good- and Poor-Grade Admission Status A. Murphy, et al.


2082 Low Wall Shear Stress Is Associated with Local Aneurysm Wall Enhancement on High-Resolution MR Vessel Wall Imaging W. Xiao, et al.

2088 Usefulness of Vessel Wall MR Imaging for Follow-Up after Stent-Assisted Coil Embolization of Intracranial Aneurysms S. Kim, et al.


2103 Facial Venous Malformations Are Associated with Cerebral Developmental Venous Anomalies W. Brinjikji, et al.


2114 MR Imaging in Menière Disease: Is the Contact between the Vestibular Endolymphatic Space and the Oval Window a Reliable Biomarker? G. Conte, et al.


2126 Expanding the Distinctive Neuroimaging Phenotype of ACTA2 Mutations F. D’Arco, et al.

2132 Cerebral Blood Flow and Narrow Diffusion Alterations in Children with Sickle Cell Anemia after Bone Marrow Transplantation and Transfusion M.T. Whitehead, et al.

2140 Aberrant Structural Brain Connectivity in Adolescents with Attentional Problems Who Were Born Prematurely O. Tymofiyeva, et al.


2161 Fluoroscopically Guided Facet Injections: Comparison of Intra-Articular and Periarticular Steroid and Anesthetic Injection on Immediate and Short-Term Pain Relief L.M. Kershen, et al.
ONLINE FEATURES


LETTERS


E119 Reply  J. Hodel, et al.

E120 MRI Findings Suggestive of Herpes Simplex Encephalitis in Patients with Anti-NMDA Receptor Encephalitis  M. Scheel, et al.

E121 Reply  T. Zhang, et al.

E123 Methodologic Issues on Interrater Reliability Regarding Structural and DTI-Based Corticospinal Tract Asymmetry  F. Jalalvandi, et al.

E124 Reply  O. Foesleitner, et al.

BOOK REVIEWS  R.M. Quencer, Section Editor

Please visit www.ajnrblog.org to read and comment on Book Reviews.

Sagittal T2- and contrast-enhanced T1-weighted images (left and center) show extensive congestive thoracic myelopathy and dilated perimedullary veins. Right, Spinal CE-MRA (MIP) shows an arterialized lumbar epidural pouch and thoracic arterialized perimedullary veins.
Title: Venice in Autumn. Venice is a group of 118 small islands surrounded by canals and connected by bridges, renowned for its languorous beauty, history, carnival, and architecture.

Karl Schaller and Maria Isabel Vargas. Neurosurgery Division and Neuroradiology Division of the Geneva University Hospitals, Geneva, Switzerland
The Woven EndoBridge Finally Coming Home across the Atlantic: What to Expect?

The Woven EndoBridge (WEB; Sequent Medical, Aliso Viejo, California) is an intrasaccular flow diverter primarily developed for wide-neck bifurcation aneurysms without the need for supporting stents and concomitant dual-antiplatelet therapy. The WEB consists of a self-expanding, oblong or spheric braid of platinum-cored nitinol wires intended to implant inside the aneurysmal sac, and it can be electrothermally detached. Since its introduction in 2010, the WEB has evolved from a high-profile dual-layer to a low-profile single-layer construction that can be delivered through a 0.017-inch microcatheter in sizes up to 7 mm. To date, more than 6000 WEBs have been implanted worldwide, most of these in Europe.

In the United States, FDA approval is expected soon, and our American colleagues will then have an exciting new tool available for endovascular treatment of intracranial aneurysms. The extensive European experience with the WEB provides for a flying start in the United States.

In this article, we share our personal experience with the WEB after having treated almost 300 aneurysms with the device.

How Did We Start?

In 2014, we evaluated our results of stent-assisted coiling and found that stent placement in 45 patients with acutely ruptured aneurysms resulted in permanent neurologic deficit or death in 10 (22%), in 5 due to thromboembolic complications and in 5 due to early rebleed in the postoperative period despite the aneurysms being adequately coiled. In February 2015, we considered an alternative for stent-assisted coiling in the new-generation WEB with a single layer, suitable for a 0.021-inch microcatheter. We started to use the WEB in wide-neck unruptured aneurysms without supporting stents or balloons, and our first results were encouraging. To further master the technique of the WEB, we gradually expanded the indication to all aneurysms suitable for the WEB; in general, small aneurysms from 3 to 10 mm, regardless of neck size or location.3–5

The Figure is a graphic display of the use of the WEB, coils, additional supporting devices, and flow diverters for endovascular treatment of intracranial aneurysms in our practice during 2013–2017.

Access and Periprocedural Anticoagulation

We use a biaxial approach with a short (11 cm) 6F sheath and a Benchmark (Penumbra, Alameda, California) guiding catheter positioned in the petrous carotid artery or V3 segment of the vertebral artery. Only with very tortuous vessels do we use a 90-cm-long sheath (Neuron Max; Penumbra) with a 6F or 5F distal-access guiding catheter.

In our hospital (St Elisabeth Hospital Tilburg, The Netherlands), all admitted patients receive subcutaneous heparin, 2500 U twice daily, as a thrombotic prophylaxis. In patients with ruptured aneurysms, we use no other anticoagulation than heparin in the pressure bags for flushing (5000 U/L). In patients with unruptured aneurysms, heparin, a 2500–5000 U bolus, is given at the beginning of the procedure. Antiplatelet medication is not routinely administered.

In case of a thromboembolic complication, we try to remove the thrombus with thrombectomy or a stent retriever, and for peripheral emboli, tirofiban is used. When antplatelet medication is considered necessary, aspirin, 500 mg, is given intravenously, later followed by prasugrel or clopidogrel (Plavix).

WEB Sizing and Technique of Implantation

The aneurysm is measured from 3D rotational images. Oversizing the WEB is imperative to assure anchoring the device to the aneurysm walls. In general, the WEB is oversized by 1–2 mm from the mean width of the aneurysm in 2 perpendicular planes. Because compression in the diameter results in increased height, the height is chosen 1–2 mm less than the actual aneurysm height. In regularly shaped aneurysms, WEB sizing is straightforward. In irregularly shaped aneurysms, some spatial awareness is helpful. Throughout our experience with WEB sizing, our sizing failure rate is about 25%, which has not improved with time.

In the sizes of 4–7 mm, there is overlap between the WEB 21 and 17 systems. In general, the WEB 17 performs better in tortuous and difficult anatomy and the WEB 21 is more stable. Our personal preference is WEB 17 in the smallest sizes, 3–4 mm, and WEB 21 in the larger sizes, 5–8 mm.

The VIA 17 and 21 Microcatheters (Sequent Medical) are specifically developed for the WEB. These catheters can be steamed and used when necessary (about 1 in 10 in our practice) and are stable during WEB delivery. The technique of WEB implantation is as follows: The tip of the microcatheter is positioned in the dome of the aneurysm. Then, the first part of the WEB is slowly unsheathed by microcatheter withdrawal until half of the WEB is deployed. At that point, the WEB has become soft, and puncture of the aneurysm wall with the distal marker has become highly unlikely. Next, the microcatheter is slightly pushed forward to ensure that the WEB is in the fundus of the aneurysm. At this point, the WEB can be completely deployed by further retracting the microcatheter while keeping the WEB in place.

The position of the WEB is checked with an angiographic run. Sometimes a rotational angiographic run may be helpful to eval-
The WEB can also be used in previously treated aneurysms. In wide-neck remnants, stents can be avoided. In large and giant partially thrombosed aneurysms, results with the WEB are as poor as with other techniques; the WEB will migrate into intraluminal thrombus just like coil meshes do.

**Clinical and Imaging Results and Implications for Practice**

Our published results with the WEB, both for ruptured and unruptured aneurysms, are good with a reopening/retreatment rate of 7%, about 95% adequate occlusion, and no bleeds or rebleeds during follow-up. We encountered only 1 procedural rupture without clinical sequelae. Most thromboembolic complications were due to catheterization and not to the WEB.

Clinical results in our practice have improved since the WEB replaced stent-assisted coiling, especially in ruptured aneurysms. The simple periprocedural anticoagulation protocol without antiplatelet medication is a great advantage.

The WEB procedure is a single-catheter treatment and is usually straightforward and quick. After gradually gaining confidence with the WEB, we now treat most aneurysms (about 70%) with this device (Figure). Only large aneurysms and shallow aneurysms are treated otherwise. In our practice, stents and flow diverters are never used in ruptured aneurysms and only rarely in unruptured aneurysms (Figure).

Although the use of the WEB has some technical issues, these can readily be learned by anyone with some experience with endovascular aneurysm treatment. The procedure is similar to simple coiling. Proper training on phantoms and proctoring of first cases can essentially avoid a learning curve. We recommend that first-time users start with simple aneurysms rather than with complex wide-neck aneurysms. Simple aneurysms can be wide-neck as long as there is sufficient height to accommodate oversizing in width. With growing confidence, more challenging aneurysms can be treated, sometimes surprisingly easily.

**Immunizations and Perspectives**

The development of the WEB is ongoing. More shallow sizes are being developed, and experiments are being performed with changes in the WEB shape; for example, a hybrid version between Single-Layer and Single-Layer Sphere. The larger WEB sizes, 9–11 mm, may become available in lower profiles suitable for a 0.038-inch instead of a 0.033-inch microcatheter.

To reduce the proportion of incorrect sizing of about 1 in 4, an automated 3D software program would be a valuable tool.

The WEB is now marketed as an expensive device, comparable with the price of stent-assisted coiling. With growing popularity, prices are likely to drop.

The WEB is now marketed as an expensive device, comparable with the price of stent-assisted coiling. With growing popularity, prices are likely to drop.

In summary, in our practice, the WEB has rapidly gained popularity and largely replaced the use of coils, stents, and flow diverters. The avoidance of dual antiplatelet medication is a great advantage over stents and flow diverters, resulting in fewer thromboembolic complications and fewer early rebleeds. The easy, quick, and safe technique has a convincing advantage over balloon- or stent-assisted coil treatments.
Disclosures: Willem Jan van Rooij—RELATED: Consulting Fee or Honorarium: Terumo, MicroVention; Other: Terumo, MicroVention, Comments: Proctoring WEB cases.* Sanne van Rooij—RELATED: Grants: Noordwest Ziekenhuisgroep Alkmaar, and unrestricted grant from MicroVention; Comments: 20% of resident salary during 2 years.* Jo P. Peluso—RELATED: Consultancy: Proctoring WEB cases.* *Money paid to individual.

REFERENCES
Neuroimaging Findings of Zika Virus–Associated Neurologic Complications in Adults


ABSTRACT

SUMMARY: When the first suspected cases of neurologic disorders associated with the Zika virus were noticed in Brazil in late 2015, several studies had been conducted to understand the pathophysiology of the disease and its associated complications. In addition to its well-established association with microcephaly in neonates, the Zika virus infection has also been suggested to trigger other severe neurologic complications in adults, such as Guillain-Barré syndrome, radiculomyelitis, and meningoencephalitis. Hence, the Zika virus should be deemed a global threat that can cause devastating neurologic complications among individuals in all age ranges. The aim of this review was to further describe neuroimaging findings of Zika virus infection and associated neurologic complications found in adults.

ABBREVIATIONS:

- ADEM = acute disseminated encephalomyelitis
- DENV = dengue fever
- ELISA = enzyme-linked immunosorbent assay
- GBS = Guillain-Barré syndrome
- IgM = immunoglobulin M
- PRNT = plaque-reduction neutralization test
- TM = transverse myelitis
- ZIKV = Zika virus

The Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) mainly transmitted by 2 species of mosquitoes, Aedes aegypti and Aedes albopictus. The virus was first identified in 1947 in Rhesus monkeys living in the Zika forest in Uganda. During the following decades, cases of human infection were subsequently reported in East and West Africa, Southeast Asia, and, finally, the Americas. Other modes of transmission of the virus have been described, such as sexual intercourse, blood transfusion, and vertical (mother-to-child) transmission. No other arboviruses are thought to be transmitted sexually, and the transmission can occur before, during, or after the onset of symptoms and from asymptomatic patients.

The first major reported outbreaks of ZIKV infection were described in French Polynesia in 2013 and 2015. At that time, some neurologic disabilities in infants of infected pregnant women were observed; however, the maternal-fetal transmission was not suspected at that time. Later, further evidence regarding the transmission of the virus was reported in addition to its possible connection to other neurologic complications in adults.

It has been speculated that 500,000–1.5 million people in Brazil have been infected with the ZIKV since the outbreak started. French Polynesian visitors are believed to have brought ZIKV to Brazil during the 2014 Fédération Internationale de Football Association World Cup. In Brazil, the first case of autochthonous transmission of ZIKV infection was reported in April 2015. By the end of 2016, across 1840 municipalities in Brazil, 161,241 cases of probable ZIKV infection were identified, 64,311 of which have been confirmed. In the first months of the outbreak, the diagnosis of ZIKV was challenging because its most commonly reported symptoms closely resemble those of other endemic, viral, and exanthematous diseases such as dengue fever (DENV) and chikungunya. Several reports of severe neurologic complications likely to be associated with ZIKV infection have been published during the past 3 years, culminating on February 1, 2016, with a declaration from the World Health Organization of a public health emergency of international concern.

In addition to its association with microcephaly, the ZIKV infection is also related to other neurologic complications mostly found in adults. Some authors have described a concomitant increase in the incidence of both Guillain-Barré syndrome (GBS) and ZIKV infection. Association with other neurologic complications in adults has also been suggested, including meningoencephalitis, transverse myelitis (TM), and ophthalmologic diseases.

MR imaging plays a key role in assessing the CNS and is, therefore, recommended for the diagnosis and follow-up of patients.
infected by the ZIKV. MR imaging involves no ionizing radiation and has the advantage of greater tissue differentiation, allowing a better evaluation of the CNS and providing useful data for eventual differential diagnoses.

The aim of this study was to describe the MR imaging findings of neurologic disorders in adult patients with ZIKV infection.

**Vectors, Transmission, and Laboratory Diagnosis**

The major vector of ZIKV worldwide is the mosquito *Aedes aegypti*, followed by *Aedes albopictus*. However, due to widespread distribution, the virus has been recently isolated from other mosquitoes, including the *Aedes furcifer*, *Aedes vittatus*, *Aedes taylori*, and *Aedes hirsutus*. The ZIKV is primarily transmitted between individuals through infected mosquito bites, establishing a transmission cycle between humans and mosquitoes. The transmission sources of ZIKV described so far are mosquito bites and human-to-human transmission (via body fluids).

It is extremely difficult to differentiate solely on the basis of clinical grounds the acute infections caused by ZIKV, DENV, and chikungunya virus. All of them might present in most patients with an acute exanthematous fever, usually associated with a maculopapular skin rash, conjunctivitis, and a painful syndrome, nor-
mally comprising headache, myalgia, and arthralgia, with subtle differences in the presentation.7 The rash might be more prominent with ZIKV, whereas DENV leads to more pronounced headaches and generalized pain, with chikungunya virus frequently causing incapacitating arthralgia and/or arthritis.7 Thus, laboratory diagnosis is essential during an outbreak of arbovirosis, even more so in places with endemic cases.

Since the ZIKV infection has become a global health problem, the World Health Organization has published several algorithms for an accurate diagnosis of the disease.13 The criterion standard for laboratory diagnosis of ZIKV infection relies mostly on the demonstration of the virus in body fluids by real-time reverse-transcription polymerase chain reaction analysis to detect the viral RNA; however, its positivity is very transient, usually persisting no longer than 5–7 days in the blood and CSF.14 Some studies have suggested a prolonged positivity in urine8 and semen15 for a few weeks to months.

The problem is that some of the neurologic manifestations in adults are considered postinfectious autoimmune phenomena (such as GBS, TM, and acute disseminated encephalomyelitis [ADEM]), and by the time of the development of clinical symptoms, viral RNA might already be undetectable. ZIKV immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay (ELISA) might remain positive in the blood and CSF samples for a longer period,13,14 but its use is further complicated in regions with endemic DENV because cross-reactivity is known to occur.13 The plaque-reduction neutralization test (PRNT) can be performed to help differentiate anti-ZIKV antibodies from cross-reacting antibodies, but with a low specificity, excessive cost, and performance only in specialized, experienced laboratories because no commercial kit is available.16 Consequently, since December 2016, the Centers for Disease Control and Prevention no longer recommend the use of the PRNT in areas with endemic presence of other flaviviruses, owing to its low accuracy.14

In an effort to improve diagnostic accuracy, a Brazilian study has shown that cross-reactivity might be overcome by using a ZIKV IgM antibody capture ELISA of both CSF and serum in cases of ZIKV-associated neurologic complications.17 This finding is based on the fact that the IgM pentamer is considered too large to cross the blood-brain barrier and its positivity in the CSF suggests recent intrathecal antibody synthesis and direct CNS penetration of ZIKV.18,19 As suggested by
this study, in areas with endemic DENV infection, a serum dengue IgM for serotypes 1–4 should be performed to check for cross-reactivity.17 If both the serum ZIKV and DENV IgM have positive findings, then CSF IgM for both viruses is tested; the results are considered diagnostic if they are positive for ZIKV alone.17 Another recent study from Brazil using CSF and blood samples from neonates with ZIKV-associated microcephaly has further supported these findings, showing a 100% correlation between positive CSF ZIKV serologies and PRNT.20

Neurologic Disorders Associated with Zika Virus Infection in Adults

Guillain-Barré Syndrome. Guillain-Barré syndrome is an acute, immune-mediated polyneuropathy affecting mainly the peripheral nerves and often following a prior infection. Several reports have described a probable, temporal association between the exponential increase in the number of GBS cases and ZIKV infection in areas of recent ZIKV outbreaks.5,8,17,21 Other arboviruses, especially the dengue and chikungunya viruses, have also been associated with an increased incidence of GBS in previous studies.

Parra et al8 described a series of patients with GBS and positive reverse-transcription polymerase chain reaction for ZIKV in Colombia and showed that most patients presented with an electrophysiologic pattern of acute inflammatory demyelinating polyneuropathy, which was similar to the pattern observed in a prospective cohort in Brazil.17 Conversely, in a case-control study conducted in the French Polynesia, the acute motor axonal neuropathy subtype was the most prevalent presentation.21 Some experts believe that the diverging findings might be explained by differences in performing electrophysiologic testing, rather than some major clinical phenomena.22

In some cases of ZIKV-related GBS, the temporal profile of neurologic symptoms is different from that observed in classic, postinfectious GBS. According to a report, neurologic symptoms are present in almost half of the cases during or immediately after the development of the clinical viral syndrome associated with ZIKV infection.8 Recently, cases of ZIKV-associated acute transient polyneuritis have been reported in Brazilian patients.23 Also, a case of chronic inflammatory demyelinating polyneuropathy has been reported.24 Nevertheless, GBS secondary to ZIKV seems to present with a similar clinical outcome and prognosis compared with more classic triggers for this polyneuropathy, with a fairly similar response to traditional therapies, such as intravenous immunoglobulin.7,8,17,21,25

MR imaging is mainly performed to rule out other clinical conditions presenting with acute flaccid paralysis. The findings on MR imaging are like those described in classic GBS, and nerve root enhancement of the cauda equina is often seen in postgadolinium T1-weighted imaging sequences. The involvement of the posterior nerve roots is commonly observed. However, in several cases, diffuse nerve root enhancement may also be observed (Fig 1). Spine MR imaging may also reveal bilateral abnormalities in the lumbar spinal ganglia, characterized by increased signal intensity in T2-weighted images and contrast enhancement. In addition, postcontrast enhancement of cra-

FIG 5. The same patient as in Fig 3. Zika virus-related Guillain-Barré syndrome associated with brain stem encephalitis and myelitis (encephaloradiculomyelitis). Brain MR imaging of a 35-year-old man positive for Zika infection with Guillain-Barré syndrome who presented with progressive ascending paralysis evolving to respiratory distress and decreased level of consciousness. The patient had skin rashes preceded by flu-like symptoms 1 week before the development of neurologic symptoms. Axial and coronal T2-weighted brain images show bilateral hyperintensity (arrows) in the middle cerebellar peduncles (A) and corticospinal tracts bilaterally (B and C). Brain and spine MR imaging performed 2 months after treatment demonstrate improvement of the middle cerebellar peduncle and corticospinal tract hyperintensity (D and E). An absence of contrast enhancement is seen in the conus medullaris and cauda equina nerve roots in the postcontrast sagittal fat-suppressed T1-weighted image (F). Axial T2-weighted spine image reveals improvement of the hyperintensity in the anterior horns of the thoracic spinal cord (G).

1970 Hygino da Cruz Jr Nov 2018 www.ajnr.org
nial nerves may also be noticeable, particularly in the facial and trigeminal nerves (Fig 2).

Myelitis. Despite the current absence of definitive evidence of an association between myelitis and ZIKV infection, a few reports have suggested that this association is likely to occur. Flaviviruses are neurotropic viruses, and DENV, Japanese encephalitis virus, and West Nile virus infections are often related to the occurrence of extensive transverse and longitudinal myelitis.26 Clinically, patients with these infections often present with fast-developing acute flaccid paralysis.

Spinal cord involvement in ZIKV can vary, and previous reports have described different forms of involvement.11,17,27,28 Clinical symptoms are diverse and depend on the location and extension of the lesion. We can speculate that ZIKV might also specifically affect the anterior horns of the spinal cord (Fig 3), leading to a motor neuron syndrome, similar to the West Nile virus.26 Other forms of spinal involvement have been

FIG 6. Zika virus–related brain stem encephalitis in a 40-year-old man. Axial fluid-attenuated inversion recovery image shows diffuse hyperintensity in the brain stem, especially in the pons and cerebral peduncle (A and B). Axial T2-weighted images show bilateral hyperintensity in the middle cerebellar peduncles (C, arrows). Hyperintensity is also seen in the corticospinal tracts bilaterally in axial (D) and coronal (E) T2-weighted images. These lesions showed no enhancement on postcontrast T1-weighted images (not shown).

FIG 7. Axial T2-weighted images of a 52-year-old man with Zika virus–related brain stem encephalitis and myelitis. Hyperintense lesions are seen in the upper portion of the lateral columns of the cervical spine (A, arrow) and anterior portion of the medulla bilaterally (B, arrow). The brain stem is diffusely involved (C–G), as are the middle cerebellar peduncles (C) and the bilateral corticospinal tracts (G, arrows).
described, such as those present in acute transverse myelitis, which usually involves the spinal cord in >3 segments lengthwise and more than two-thirds of its surface area.\(^1\)\(^7\),\(^2\)\(^8\) Myelitis can also be identified as diffuse lesions with varying sizes that may affect any portion of the spinal cord. Contrast enhancement may be seen in acute lesions. The spinal cord may be enlarged (Fig 4) due to edema.\(^1\)\(^1\),\(^2\)\(^7\)

Meningoencephalitis. Meningoencephalitis is a well-known and common presentation of Japanese encephalitis\(^2\)^9 and West Nile virus infections,\(^2\)\(^6\) but it is, surprisingly, a relatively rare complication involving other flaviviruses, including the ZIKV.\(^3\)\(^0\),\(^3\)\(^1\) The patients affected with meningoencephalitis present clinically with progressive somnolence, seizures, and focal deficits, and in rare cases, their condition may evolve into deep coma or brain death. As demonstrated in previous studies, cases of viral encephalitis (irrespective of the causing agent) may show no abnormalities on imaging examinations. Among a few available reports of ZIKV infection, no specific neuroimaging pattern has been found suggesting the occurrence of this condition.

Previous reports have revealed the presence of asymmetric subcortical hypointense lesions in meningoencephalitis, which may show restricted diffusion.\(^2\)\(^8\) Japanese encephalitis and West Nile viruses more commonly affect the deep gray matter, brain stem, and cerebellum; in contrast, a recent report has shown the involvement of the cortical and subcortical junctions, particularly the cingulate and superior frontal gyri.\(^2\)\(^8\) Cortical lesions in other infections by flaviviruses have also been demonstrated but are less frequent. In another study, diffuse and confluent lesions in the basal ganglia, thalamus, and white matter have been related to ZIKV infection–related encephalitis.\(^3\)\(^1\) Some patients may also present with bilaterally increased signal intensity in the middle cerebellar peduncles and corticospinal tracts (Fig 5). Other patients have been shown to present with brain stem involvement characterizing rhomboencephalitis (Figs 6 and 7).

Frequently, evidence of different forms of presentation may coexist in the same patient, including GBS, myelitis, and meningoencephalitis. In a prospective study conducted in Brazil, cases of concomitant central and peripheral nervous system involvement were observed in some adults with acute ZIKV infection.\(^1\)\(^7\)

Acute Disseminated Encephalomyelitis. Acute disseminated encephalomyelitis is an immune-mediated inflammatory demyelinating disorder targeting mostly the white matter of the brain and, less frequently, the gray matter and the spinal cord. It is characterized by an acute or subacute encephalopathy with multiple neurologic deficits and is typically monophasic and self-limiting. Although infrequent, recurrent and multiphasic forms may also

FIG 8. Brain and spine MR imaging of a 48-year-old woman with Zika virus infection and encephalitis and myelitis. Axial T2-weighted image of the brain shows hyperintensity of the middle cerebellar peduncles bilaterally (A, arrows). Short tau inversion recovery sagittal image (B) demonstrates a hyperintense lesion in the upper portion of the anterior spine without enhancement in the sagittal postcontrast T1-weighted image (C). Follow-up MR imaging was performed 2 weeks later.

FIG 9. The same patient as in Fig 8. Follow-up scans (2 weeks after infection) of the brain and spine MR imaging of a 48-year-old woman with Zika virus infection and encephalitis and myelitis. Improvement of the cerebellar lesions is seen (A, arrows). However, the anterior spinal cord is enlarged (B, arrow) and shows contrast enhancement (C, arrow).
occur. Clinical symptom onset generally develops within 3 weeks after a viral infection or vaccination. However, in some cases, it is not possible to prove such a relationship. The diagnosis is based on clinical and imaging findings, as well as on excluding other conditions that can mimic ADEM. Although it can occur at any age, it is more common in children and young adults.

Similar to observations of other viral infections, ZIKV infection may also be related to ADEM.\textsuperscript{32,33} The imaging findings described are like those observed in other related causes of ADEM, such as multifocal and asymmetric lesions, affecting the brain and the spinal cord. The clinical course of ADEM-ZIKV cases was very similar to that of the most typical ADEM cases, characterized as a self-limited and monophasic course, appearing weeks after the viral infection.

MR imaging findings reveal multiple ill-defined, asymmetric, hyperintense lesions on T2-weighted and FLAIR images (Fig 8), which demonstrate contrast enhancement in T1-weighted post gadolinium images.\textsuperscript{28} Figure 9 shows follow-up MR imaging performed 2 weeks after the infection.

**Differential Diagnoses**

Some MR imaging findings in ZIKV infection have an appearance like that of other flavivirus infections. The West Nile virus may also present with abnormalities resembling the ones described in ZIKV infections. Previous reports have demonstrated increased signal intensity in both the middle cerebellar peduncle and anterior horns of the spinal cord, as well as contrast enhancement of the lumbosacral nerve roots.\textsuperscript{26} These imaging features are identical to those observed in some cases of ZIKV infection.\textsuperscript{17,26} The same pattern may be observed in patients infected with the Japanese encephalitis virus.\textsuperscript{29} On the other hand, in this particular presentation of patients infected with ZIKV, a slight hyperintensity in bilateral cortical spinal tracts may also be seen (Figs 5–7). Thus, the differential diagnosis of the entities presenting with the imaging findings described above may only be established with further laboratory analysis.

Nerve root enhancement seems to be the most common imaging finding related to ZIKV infection, while it has been reported that involvement of the lumbosacral nerve roots is mostly related to GBS.\textsuperscript{8,17} In our opinion, the posterior nerve roots are equally involved in ZIKV infection, as are the anterior nerve roots. However, the anterior nerve roots are preferentially involved in GBS. In endemic areas, the identification of diffuse involvement of the cauda equina may be used to suggest the diagnosis of ZIKV.

**CONCLUSIONS**

In addition to the extensive congenital abnormalities previously described, ZIKV may be associated with a substantially increased incidence of a broad spectrum of life-threatening neurologic syndromes in adults. Unfortunately, no specific neuroimaging finding can be related to this viral infection. In addition, some observed abnormalities are very similar to those seen in other flavivirus infections. However, in combination with clinical information, neuroimaging can be used to suggest the possibility of ZIKV infection, especially in endemic areas. Thus, the MR imaging findings of these neurologic syndromes, in association with serum and CSF analysis as well as molecular and serologic testing, may play a significant role in the diagnosis of ZIKV infection.

**REFERENCES**


Characteristics of MR Neuroimaging Services Billed by Radiologists versus Nonradiologists

P.E. Sharp, N.U. Lall, D.R. Hughes, P.P. Harkey, and R. Duszak, Jr

ABSTRACT

BACKGROUND AND PURPOSE: Although most neuroimaging examinations are interpreted by radiologists, many nonradiologists provide interpretation services. We studied day of the week, site of service, and patient complexity differences for common Medicare MR neuroimaging examinations interpreted by radiologists versus nonradiologists.

MATERIALS AND METHODS: Using carrier claims files for a 5% sample of Medicare beneficiaries from 2012 to 2014, we identified all claims for brain and lumbar spine MR imaging examinations. Services were categorized by physician specialty, day of the week, and the site of service. Patient complexity was calculated using Charlson Comorbidity Indices. The \( \chi^2 \) was performed to test statistical significance.

RESULTS: A provider specialty could be identified for 568,423 brain and lumbar spine MR imaging examinations. Of weekday examinations, radiologists interpreted 475,288 (92.3%), and nonradiologists, 39,510 (7.7%). Of weekend examinations, radiologists interpreted 52,028 (97.0%) and nonradiologists 1597 (3.0%). Radiologists interpreted 145,904 (98.7%) examinations in the inpatient hospital and emergency department settings versus 1882 (1.3%) by nonradiologists. Of all examinations, 44,547 of those interpreted by radiologists (8.4%) were on the most clinically complex patients versus 2139 (5.2%) for nonradiologists. All interspecialty differences for day of the week, the site of service, and patient complexity were statistically significant (\( P < .001 \)).

CONCLUSIONS: Although radiologists interpret most common MR neuroimaging examinations for Medicare beneficiaries, in contrast to nonradiologists, they disproportionately render those services on weekends, in higher acuity sites, and on more complex patients. To optimize access and minimize disparities in necessary neuroimaging, quality metrics should consider such service characteristics.

ABBREVIATION: CCI = Charlson Comorbidity Index

Although radiologists interpret most neuroimaging examinations in the United States, a small-but-increasing proportion of those studies are interpreted by nonradiologists—notably by neurologists, neurosurgeons, and orthopedic surgeons.1-10 Writing about the changing provider marketplace in which imaging services are interpreted, Levin et al10 noted an increasing proportion of in-office imaging being performed by nonradiologists; all the while, radiologists continued to render interpretations in increasing volumes for more acutely ill hospital inpatients and patients in the emergency department. Anecdotally, others have similarly lamented that nonradiologists disproportionately render imaging services during daytime hours and on weekdays, leaving after-hours and weekend work for their radiologist counterparts.11 Recent work supports this anecdote, at least with regard to lower extremity venous duplex examinations.12 Although a large body of literature exists comparing the market share of interpretation by radiologists versus nonradiologists for a variety of diagnostic and interventional radiology services, little work, to date, has focused on how those specialty differences vary by time and location.13-16 Recent work suggests that emerging pay-for-performance models could unintentionally compromise patient access, particularly in areas where different specialty groups render similar services.17 Further investigation into potential specialist variation—and the drivers thereof—could potentially help inform policy initiatives to ensure consistent and equitable access of all patients to high-quality services, regardless of time, date, geography, or patient complexity.

Focusing on common MR neuroimaging examinations, the
purpose of this study was to compare differences in the frequency of interpretations by radiologists versus nonradiologists as a function of the day of the week (weekday versus weekend), the site of service, and patient complexity.

MATERIALS AND METHODS

Our retrospective use of Medicare administrative claims data was performed under an exemption from the institutional review board of the American College of Radiology.

Under a Data Use Agreement from the Centers for Medicare and Medicaid Services, we acquired carrier claims patient-level 5% Medicare Research Identifiable Files for 2011 through 2014. These datasets contain details associated with all fee-for-service claims for a 5% national sample of Medicare enrollees, representing approximately 2.5 million beneficiaries each year. Specifically included in the dataset is information about patient demographics (eg, age, sex), Current Procedural Terminology codes, and International Classification of Diseases codes associated with all services, as well as the date, site, and rendering provider of each service.18

All professional and global billed claims for brain MR imaging (Current Procedural Terminology codes 70551, 70552, and 70553) and lumbar spine MR imaging (Current Procedural Terminology codes 72148, 72149, and 72158) services were initially identified. For each claim, the date of interpretation as attested by the billing physician was mapped to a specific day of week (eg, Sunday, Monday). Using previously described methods for Medicare claims–based analyses, we then mapped provider specialty and the site of service using the respective identification codes.14,16,19-22 Radiologists were collectively identified using provider specialty codes for diagnostic radiology (n = 30), nuclear medicine (n = 36), and interventional radiology (n = 94). Some provider specialties could not be determined (eg, those billing using generic multispecialty clinic codes), and these were grouped into an “undetermined specialty” category. All other specialty codes were mapped to a “nonradiologist” category. Similarly, the site of service codes were used to map services to the private office (n = 11), inpatient hospital (n = 21), outpatient hospital (n = 22), and hospital emergency department (n = 23) settings. All far less frequent sites of service were grouped together.

Charlson Comorbidity Index (CCI) scoring is widely used in the health services research literature as a surrogate for patient complexity and is calculated by combining specific International Classification of Diseases–attributable diagnoses from the patient’s medical history from the prior year.23,24 Higher scores indicate higher mortality risk (eg, a score of zero indicates no co-morbid diagnoses for services during the previous year). Using each beneficiary’s claims data for a single year before each MR imaging claim (ie, 2011 through 2013), we calculated Charlson Comorbidity Index scores. These scores were grouped into 0, 1, 2, or 3+ (the latter to account for the relatively small number of patients with CCI values of >3 in our cohort).

We next compiled descriptive statistics for both brain and lumbar spine MR imaging services by specialty group in relation to the day of the week, the site of service, and the CCI. χ² testing was used to assess statistical significance. Because the first year of our data was required for calculation of CCI for subsequent years, these analyses span 2012–2014.

All analyses were performed using SAS, Version 9.3 for Windows (SAS Institute, Cary, North Carolina). Statistical tests were 2-sided with an α level of .05.

RESULTS

A total of 345,880 brain MR imaging examinations were identified within the Medicare Research Identifiable Files national 5% cohort between 2012 and 2014. Of these, 308,728 (89.3%) were interpreted by radiologists, 14,569 (4.2%) were interpreted by nonradiologists, and 22,583 (6.5%) were interpreted by providers whose specialties could not be identified. The former 2 groups formed the basis of our brain MR imaging analysis. A total of 279,073 lumbar spine MR imaging examinations were identified within our cohort. Of these, 218,588 (78.3%) were interpreted by radiologists, 26,538 (9.5%) were interpreted by nonradiologists, and 33,947 (12.2%) were interpreted by providers whose specialties could not be identified. The former 2 groups compose the basis of our lumbar spine MR imaging analysis.

When we considered brain and lumbar spine MR neuroimaging examinations together, radiologists interpreted 527,316 (84.4%) examinations and nonradiologists interpreted 41,107 (6.6%) examinations. There were 56,530 (9.0%) examinations for which a provider specialty could not be determined. Patients undergoing one or both of these services by a provider with an identifiable specialty composed our study cohort. Summary results are outlined in the Table.

Interpreting Provider by Day of Week

Of the 323,297 brain MR imaging examinations that could be attributed to unique provider specialties, 286,052 (88.5%) were performed on a weekday, and 37,245 (11.5%) on a weekend. Of brain MR imaging performed on weekdays, radiologists interpreted 272,282 (95.2%), while nonradiologists interpreted 13,770 (4.8%). For brain MR imaging performed on weekends, these proportions shifted to 36,446 (97.9%) by radiologists and 799 (2.1%) by nonradiologists (Fig 1A).

Of the 245,126 lumbar spine MR imaging examinations that could be attributed to unique provider specialties, 228,746 (93.3%) were performed on a weekday, and 16,380 (6.7%) on a
weekend. Of lumbar spine MR imaging performed on weekdays, radiologists interpreted 203,066 (88.7%), while nonradiologists interpreted 25,740 (11.3%). For lumbar spine MR imaging performed on weekends, these proportions shifted to 15,582 (95.1%) by radiologists and 798 (4.9%) by nonradiologists (Fig 1 B).

In total, for studies performed during the week, radiologists interpreted 475,288 (92.3%) and nonradiologists 39,510 (7.7%). Of weekend examinations, radiologists interpreted 52,028 (97.0%) and nonradiologists 1597 (3.0%). All of these differences were statistically significant (P < .001).

**Interpreting Provider by Site of Service**

Radiologists interpreted 98.4% (16,088) of all brain MR imaging examinations performed in the emergency department setting, 98.7% (105,145) of those performed in the inpatient setting, and 98.8% (119,920) of those performed in the outpatient hospital setting. Nonradiologists, in contrast, interpreted <2% of brain MR imaging examinations performed in any of these sites of service; they interpreted 1.6% (265) of studies performed in the emergency department setting, 1.3% (1395) in the inpatient setting, and 1.2% (1432) in the outpatient hospital setting. Conversely, nonradiologists interpreted 14.6% (11,447) of the brain MR imaging in the office setting. Those services rendered in private offices comprised 78.7% of all brain MR imaging interpreted by nonradiologists. The percentages of services by specialty group and sites of service are outlined in Fig 2A.

Radiologists similarly interpreted 99.3% (5305) of all lumbar spine MR imaging examinations performed in the emergency department setting, 99.1% (19,366) of those performed in the inpatient setting, and 99.3% (107,135) of those performed in the outpatient hospital setting. Nonradiologists, in contrast, interpreted <1% of lumbar spine MR imaging examinations performed in any of these sites of service: they interpreted 0.7% (38) of studies performed in the emergency department, 0.9% (184) in the inpatient setting, and 0.7% (748) in the outpatient hospital setting. Conversely, nonradiologists interpreted 22.9% (25,443) of the lumbar spine MR imaging in the office setting. Those services rendered in private offices comprised 96.3% of all lumbar spine MR imaging interpreted by nonradiologists. The percentages of services by specialty group and sites of service are outlined in Fig 2B.

In total, radiologists interpreted 145,904 (98.7%) examinations in the inpatient hospital and emergency department setting versus 1882 (1.3%) for nonradiologists. In contrast, nonradiologists interpreted 19.5% of examinations in the office setting versus 80.5% for radiologists. All of these differences were statistically significant (P < .001).

**Interpreting Provider by Patient Comorbidities**

We found statistically significant differences (P < .001) in the overall complexity of patients for whom brain MR imaging examinations were interpreted by radiologists versus nonradiologists. Specifically, 79.0% of patients whose brain MR imaging was interpreted by radiologists had a CCI of 0 (indicating an absence of any of the indexed comorbidities) versus 83.1% for nonradiologists. Conversely, 11.0% of patients whose brain MR imaging was interpreted by radiologists had a CCI of ≥3 versus 7.2% for nonradiologists. The results within each CCI subset were statistically significant as well (P < .001). Overall, the mean CCI was 0.67 for brain MR imaging interpretation services rendered by radiologists and 0.48 for those rendered by nonradiologists (P < .001). Comorbidity differences by specialty provider group are outlined in Fig 3A.

Similarly, we found statistically significant differences (P < .001) in the overall complexity of patients whose lumbar spine MR imaging was interpreted by radiologists versus nonradiolo-
Specifically, 83.3% of patients whose lumbar spine MR imaging was interpreted by radiologists had a CCI of 0 versus 85.6% for nonradiologists. Conversely, 7.1% of patients whose lumbar MR imaging was interpreted by radiologists had a CCI of ≥3 versus 5.1% for nonradiologists. The results within each CCI subset were statistically significant as well (P < .001). Overall, the mean CCI was 0.46 for lumbar MR imaging interpretation services rendered by radiologists and 0.36 for those rendered by nonradiologists (P < .001). Comorbidity differences by specialty provider group are outlined in Fig 3B.

In total, radiologists and nonradiologists rendered interpretations for a similar percentage of low-acuity patients with 80.8% of brain and lumbar spine MR imaging interpreted by radiologists performed on patients with a CCI of 0 versus 84.7% for nonradiologists. Of examinations interpreted by radiologists, 44,547 (8.4%) were for patients with a CCI of ≥3 versus 2139 (5.2%) by nonradiologists. All of these differences were statistically significant (P < .001).

**DISCUSSION**

Using individual claims data for a representative national sample of >2 million Medicare beneficiaries, we confirmed prior aggregate data-based observations that radiologists interpret most brain and lumbar MR imaging examinations in Medicare beneficiaries. The additional encounter-level nature of our analysis, however, allowed us to confirm temporal, location, and patient complexity differences in the services rendered by radiologists versus nonradiologists. Indeed, we found that radiologists disproportionately provide services to Medicare beneficiaries at less opportune times, in higher acuity settings, and on more complex patients compared with nonradiologists. Our observations regarding common MR neuroimaging studies comport closely with those reported recently by Prabhakar et al12 concerning lower extremity venous duplex examinations interpreted by radiologists versus nonradiologists.

The proportion of both brain MR imaging and lumbar spine MR imaging examinations interpreted by radiologists increased from weekdays to weekends (from 95.2% to 97.9% and 88.7% to 95.1%, respectively). As a result, there was a corresponding >50% relative decrease in the proportion of brain MR imaging (from 4.8% to 2.1%) and lumbar spine MR imaging (from 11.3% to 4.9%) interpreted by nonradiologists on weekends relative to weekdays. As our society continues to prioritize patient access as a health care reform imperative, radiologists appear to demonstrate value by providing services at less opportune times to individuals who fall ill on weekends or who may not be able to take time off work to seek elective imaging.10,11

Correspondingly, our results demonstrate that radiologists interpret the greatest share of brain and lumbar spine MR imaging examinations performed in 24/7/365 environments such as the hospital inpatient and emergency department settings, which are generally associated with a higher acuity of care. In contrast, most brain and lumbar spine MR imaging examinations interpreted by nonradiologists were performed in comparably lower acuity private office settings. Of note, the office environment was the only setting in which nonradiologists interpreted ≥1% of brain MR imaging or >1% of lumbar spine MR imaging. Although our dataset does not permit us to identify specific times of service (claims are only dated but not timed), the round-the-clock nature of the inpatient hospital and emergency department settings strongly suggests that radiologists likely provide a disproportionate fraction of services during late evening and overnight hours as well.

Although claims data do not permit us to definitively assert explanations for our observations, it is possible that self-referral plays a role in the disproportionate number of studies interpreted...
by nonradiologists in the office setting. Patients seen in the clinic environment by neurologists, neurosurgeons, or orthopedic surgeons have been shown more likely to be referred to the in-office imaging centers managed by themselves or their partners.25,26 This phenomenon could compound the effect that such office practices have on the overall proportion of in-office imaging examinations, but our analysis of administrative claims data does not permit us to assert causation—or even association.

Similar to differences in the day of week and site of services, our work highlights another area in which aggregate claims-based “turf battle” articles do not tell the entire story: patient complexity.5 When we compared the most complex patients (CCI of 3+) in Medicare with the least complex (CCI of 0), there was a 37% relative reduction in the interpretations provided by nonradiologists for brain MR imaging and a 27% relative reduction for lumbar spine MR imaging. Correspondingly, we found that as patient complexity increased, the proportion of examinations interpreted by radiologists increased. At present, Medicare Physician Fee Schedule rates are patient-complexity neutral (eg, pay for brain MR imaging is the same regardless of whether a patient presents with uncomplicated headache or follow-up for a tumor after surgery and radiation). Our findings suggest that as our society moves increasingly to value-based payments, complexity adjustments may be appropriate to ensure appropriate incentives for providers caring for our most vulnerable patients.

Our analysis, based on Medicare claims, has several limitations. First, our findings may not necessarily be generalizable to patients with commercial insurance or even to Medicare beneficiaries undergoing other types of imaging studies. Second, we acknowledge that we were unable to identify the time of day for individual services (eg, MR imaging performed at 1 AM versus 1 PM is indistinguishable in claims data). However, the drastically increased proportion of examinations interpreted by radiologists in round-the-clock environments suggests that specialty differences also exist after hours during the week as well. Additionally, the exclusion of examinations with non-specialty-specific provider codes (eg, a generic multispecialty clinic designation) precluded our ability to identify a provider specialty for 9.0% of relevant MR neuroimaging examinations. It is conceivable, though we believe unlikely, that this exclusion would introduce bias into our reported results. Finally, the nature of claims data prevented us from making any assessments on the quality of interpretations. Such an analysis would require institutional-level data.

CONCLUSIONS
Radiologists interpret most brain and lumbar spine MR imaging examinations performed on Medicare patients. Although some nonradiologists provide interpretation services as well, their work is disproportionately rendered on weekdays, in private office settings, and for less complex patients. Given that radiologists render the overwhelming majority of services on weekends, in sites of higher patient acuity, and to more complex patients, emerging quality metrics should consider such service characteristics to optimize equitable patient access to neuroimaging services.

REFERENCES


Optimization of Acquisition and Analysis Methods for Clinical Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object

N.B. Semmineh, L.C. Bell, A.M. Stokes, L.S. Hu, J.L. Boxerman, and C.C. Quarles

ABSTRACT

BACKGROUND AND PURPOSE: The accuracy of DSC-MR imaging CBV maps in glioblastoma depends on acquisition and analysis protocols. Multisite protocol heterogeneity has challenged standardization initiatives due to the difficulties of in vivo validation. This study sought to compare the accuracy of routinely used protocols using a digital reference object.

MATERIALS AND METHODS: The digital reference object consisted of approximately 10,000 simulated voxels recapitulating typical signal heterogeneity encountered in vivo. The influence of acquisition and postprocessing methods on CBV reliability was evaluated across 6912 parameter combinations, including contrast agent dosing schemes, pulse sequence parameters, field strengths, and postprocessing methods. Accuracy and precision were assessed using the concordance correlation coefficient and coefficient of variation.

RESULTS: Across all parameter space, the optimal protocol included full-dose contrast agent preload and bolus, intermediate (60°) flip angle, 30-ms TE, and postprocessing with a leakage-correction algorithm (concordance correlation coefficient = 0.97, coefficient of variation = 6.6%). Protocols with no preload or fractional dose preload and bolus using these acquisition parameters were generally less robust. However, a protocol with no preload, full-dose bolus, and low (30°) flip angle performed very well (concordance correlation coefficient = 0.93, coefficient of variation = 8.7% at 1.5T and concordance correlation coefficient = 0.92, coefficient of variation = 8.2% at 3T).

CONCLUSIONS: Schemes with full-dose preload and bolus maximize CBV accuracy and reduce variability, which could enable smaller sample sizes and more reliable detection of CBV changes in clinical trials. When a lower total contrast agent dose is desired, use of a low flip angle, no preload, and full-dose bolus protocol may provide an attractive alternative.

ABBREVIATIONS: ASFN.R = American Society of Functional Neuroradiology; A.P. = accuracy and precision index; B.S.W. = Boxerman-Schmainda-Weisskoff; B.T.I.P. = brain tumor imaging protocol; C.C.C = concordance correlation coefficient; C.V. = coefficient of variation; D.R.O. = digital reference object; F.A. = flip angle; G.V. = γ-variate fit; r.C.B.V. = relative CBV

Dynamic Susceptibility Contrast MRI Using a Population-Based Digital Reference Object

The accuracy of DSC-MR imaging CBV mapping has been used in the brain since the early 1990s\textsuperscript{1,2} with multiple neuro-oncology applications, including distinction of tumor from nontumor, glioma grading, biopsy guidance, and assessing response to treatment.\textsuperscript{3-17} However, disagreement persists about the best way to perform DSC-MR imaging and stems primarily from contrast agent extravasation through blood-brain barrier deficiencies characteristic of high-grade gliomas. This contrast agent extravasation introduces both pronounced T1 effects and magnetic susceptibility differences between tumor cells and the extravascular extracellular space, thereby rendering DSC-MR imaging signal a reflection not only of the vascular volume fraction but also cell volume fraction and the vascular permeability. Although sensitivity to these additional physiologic attributes has enabled appropriately acquired DSC-MR imaging to distinguish tumor types,\textsuperscript{18} it has confounded the accuracy of CBV measures, prompting the development of leakage-correction strategies including preload contrast agent administration, pulse sequence acquisition parameters balancing T1 and T2* sensitivities, and postprocessing techniques for correcting the leakage-contaminated signal.\textsuperscript{19-22}

QIBA/), and the National Brain Tumor Society (Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee; https://www.itnonline.com/content/new-standardized-brain-tumor-mri-recommendations-announced) have tried to standardize DCE-MR imaging methodology. The American Society of Functional Neuroradiology (ASFNR) published a white paper with a recommended DSC-MR imaging protocol based on practice patterns and literature data.23 Such effort is challenged by the relative paucity of data from systematic evaluations of the influence of DSC-MR imaging methodology on CBV accuracy and has relied on anecdotal evidence, including the correlation of CBV with glioma grade,24 fractional tumor burden in cases of postradiation enhancement,16 and patient survival in the setting of conventional and antiangiogenic therapies.12 Stereotactic biopsies with coregistered CBV maps have demonstrated general concordance between CBV estimates and histology. While prior in vivo studies evaluated the impact of DSC-MR imaging acquisition parameters and methodologies on CBV data in a small number of patients with high-grade gliomas,25 their influence on the underlying CBV accuracy has not been evaluated, likely due to the impracticality of multiple bolus injections in individual patients.

To facilitate the rigorous evaluation of the impact of DSC-MR imaging parameters on CBV accuracy, we recently developed and validated a population-based digital reference object (DRO) that recapitulates for glioblastoma the biophysical basis and inter- and intrasubject heterogeneity of DSC-MR imaging data.26 The DRO consists of DSC-MR imaging signals computed across a range of relevant physiologic and acquisition parameters, and clinical relevance was ensured through use of training and validation data-sets acquired from multiple patients with glioblastomas. Accordingly, the DRO provides a reliable ground truth for determining the impact of DSC-MR imaging acquisition and postprocessing methods on CBV accuracy. In this study, we used the DRO to evaluate the accuracy and precision of routinely used DSC-MR imaging protocols for glioblastoma, in which the choice of acquisition parameters, including preload and bolus dose, flip angle (FA), TE, and TR, can greatly impact the sensitivity of the acquired signals on T1 and T2* contrast agent leakage effects. Additionally, the accuracy of postprocessing leakage-correction methods24,27 may also depend on the degree of T1 and T2* contrast agent leakage effects, further affecting CBV accuracy. Given the interrelated nature of acquisition and postprocessing methods, we used the DRO to evaluate CBV accuracy across a range of commonly used DSC-MR imaging methods, identifying combinations of acquisition parameters yielding particularly high CBV accuracy and precision and potentially guiding future DSC-MR imaging consensus initiatives.

**MATERIALS AND METHODS**

We evaluated CBV fidelity across a range of relevant DSC-MR imaging parameters using a validated DRO that computes MR imaging signal intensities for heterogeneous 3D tissue structures, accounting for the relevant underlying DSC-MR imaging contrast mechanisms.26 Parameter inputs were ex-
tracted from voxelwise training data from 23 patients with glioblastomas (>40,000 voxels). To ensure that the simulated signals accurately represented the magnitude and distribution of contrast agent–induced T1 and T2* changes within typical glioblastomas, we chose model parameters so that the distribution of percentage signal recovery and the mean SD of signal intensities across the DRO matched those in the patient training dataset. The training process yielded approximately 10,000 DRO voxels that agreed with the in vivo data. The DRO was validated against a separate set of patients with glioblastomas imaged with pulse sequences and contrast agent dosing schemes differing from those in the training dataset.

Table 2: Comparison of the accuracy and precision index, coefficient of variation, and concordance correlation coefficient for all dosing schemes using intermediate and low flip angle protocols at 1.5T and 3T

<table>
<thead>
<tr>
<th>Dosing Scheme (Preload + Bolus)</th>
<th>Intermediate Flip Anglea</th>
<th>Low Flip Angleb</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1.5T</td>
<td>3T</td>
</tr>
<tr>
<td>(0 + 1)</td>
<td>0.30 21.7 0.08</td>
<td>0.55 12.4 0.43</td>
</tr>
<tr>
<td>(1/4 + 3/4)</td>
<td>0.51 13.3 0.38</td>
<td>0.74 8.8 0.65</td>
</tr>
<tr>
<td>(1/2 + 1/2)</td>
<td>0.61 12.7 0.48</td>
<td>0.76 9.2 0.67</td>
</tr>
<tr>
<td>(1/4 + 1)</td>
<td>0.86 7.9 0.78</td>
<td>0.93 6.8 0.86</td>
</tr>
<tr>
<td>(1/2 + 1)</td>
<td>0.90 7.7 0.82</td>
<td>0.96 6.8 0.89</td>
</tr>
<tr>
<td>(1 + 1)</td>
<td>0.94 7.4 0.86</td>
<td>0.97 6.6 0.91</td>
</tr>
</tbody>
</table>

a FA = 60°, TE = 30 ms, TR = 1.5 sec.
b FA = 30°, TE = 50 ms, TR = 1.5 sec, B0 = 1.5T; FA = 30°, TE = 30 ms, TR = 1.5 sec, B0 = 3T.

To investigate the influence of acquisition and postprocessing methods on the reliability of CBV measurements, we compared tumor CBV simulated with and without contrast agent leakage effects for the most commonly used DSC-MR imaging methods, including the following: 6 preload and bolus injection combinations, 3 flip angles, 3 TRs, 2 B0 values, 4 TEs, and 4 upper time limits for postprocessing integration (with a constant prebolus time). Furthermore, we compared the uncorrected CBV estimates with 4 postprocessing leakage-correction methods: Boxerman-Schmainda-Weisskoff (BSW),24 bidirectional,27 γ-variate fit, and postbolus baseline subtraction.25 Note that while baseline subtraction correction is typically applied to low flip angle data that predominantly exhibit T2* leakage effects, we implemented a version that corrects both T1 and T2* effects. Because baseline subtraction correction arbitrarily forces all signals to return to baseline, it was applied to both normal and tumor signals in the DRO. The investigated parameter space is summarized in Table 1. Across all parameter space, the concordance correlation coefficient (CCC) and the coefficient of variation (CV) between the simulated tumor CBV and the ground truth (the CBV values not confounded by leakage effects) were computed as a marker of accuracy and precision, respectively.

To aid in the identification of the optimal protocol, we computed an accuracy and precision index (API) that combines the CCC and CV:

\[ \text{API} = \frac{\text{CCC}}{100} \]

Accordingly, API values of 1 (CCC = 1, CV/100 = 0) reflect the ideal agreement. Protocols compliant with a recently published consensus brain tumor imaging protocol (BTIP)28 were highlighted because these can be most easily incorporated into clinical trial imaging protocols. Note that dosing schemes that are labeled “BTIP compliant” are those that align with the recommended dosing requirements and not necessarily the timing between the contrast agent injection and the postcontrast T1-weighted scan.
dosing schemes were not incorporated in the heat map, but their results are summarized in Table 2.

Several results can be observed from the heat map. First, at both field strengths, (1 + 1) contrast agent dosing provides the highest API and the least sensitivity (more consistent API values) to variations in TR, TE, and flip angle, compared with other dosing schemes. Across all parameter combinations, the top 1% of API values (>0.89) are derived from protocols that rely on (1 + 1) contrast agent dosing at both field strengths, as indicated by the black (1.5T) and red (3T) boxes. Although the top 1% of parameter combinations incorporate BSW leakage correction, both BSW and bidirectional leakage correction methods yielded similar APIs. Note that the top 1% is an arbitrary threshold, and the difference in utility of CBV maps derived from methods yielding slightly lower APIs (eg, top 1% versus the top 3%–5%) may not be clinically meaningful. Second, the API varies more substantially for acquisitions using (0 + 1) and (½ + ½) contrast agent dosing schemes, indicating greater sensitivity to contrast agent leakage effects and CNR losses related to low contrast agent dose. Third, for data acquired without or with small contrast agent preloads, a low flip angle (30°) maximizes the API. Fourth, the number of data points incorporated after the first pass into the CBV acquisition and analysis has minimal impact on API values, with a slight preference for shorter data lengths using the BSW correction.

Figures 2–5 compare the accuracy and precision of CBV measures using scatterplots (top) and Bland-Altman plots (bottom) for commonly used contrast agent dosing protocols [Fig 2: (1 + 1), Fig 3: (½ + ½), Fig 4: (½ + 1), Fig 5: (0 + 1)], field strengths (1.5T and 3T), and flip angles (low 30° versus intermediate 60°). The BSW leakage-correction method was applied to all data. For each flip angle, the TE was selected to maximize the API, yielding 4 parameter combinations: 1.5T, FA/TE = 30°/30 ms and FA/TE = 30°/50 ms; 3T, FA/TE = 30°/30 ms and FA/TE = 60°/30 ms. The first goal of this analysis was to evaluate CBV accuracy when data are acquired using the ASFNPR parameter recommendations (represented by the intermediate flip angle protocol) and variable dosing protocols and field strengths. The second was to compare this performance with that derived from the low flip angle case, which provided the overall highest CBV accuracy and precision.

Across the entire range of parameters, the highest CBV accuracy and precision (API = 0.91) was found for DSC-MR imaging data collected at 3T with a (1 + 1) dosing scheme and either an intermediate or low flip angle (Fig 2). At 1.5T, the CCC and CV

RESULTS

Figure 1 shows the API heat map across the parameter space in Table 1. The heat map in Fig 1 is segmented horizontally by $B_0$ (top half: $B_0 = 1.5T$; bottom half: $B_0 = 3T$). Within each $B_0$ segment, the heat map is further segmented vertically by the acquisition time limit (4 segments) and horizontally by TR (3 segments). For each acquisition time limit and TR combination, the heat map is further segmented, as shown in Fig 1A, horizontally by the leakage-correction method (2 segments for BSW and bidirectional; $\gamma$-variate fit, baseline subtraction, and uncorrected are excluded). Finally, each leakage-correction segment is split into 4 subplots (2 × 2) by contrast agent dosing (clockwise from top left: (0 + 1), (½ + ½), (1 + 1), (1⁄2 + 1⁄2), (0 + 1), (½ + ½)), where the first and second numeric values (eg, (1 + 1)) represent the preload and bolus-injection dose as a fraction of a total standard dose (0.1 mmol/kg). Each of these subplots shows the variation horizontally by TE (4 squares) and vertically by flip angle (3 squares). This singular figure demonstrates the API for 2304 possible parameter combinations (of the 8640 tested). The uncorrected $\gamma$-variate fit and baseline subtraction results are not included in Fig 1B (or in subsequent figures or tables) because their associated CCC, CV, and API values were substantially lower than those for BSW and bidirectional. For simplicity, the (½ + ½) and (½ + 1) contrast agent

FIG 3. Scatter- and Bland-Altman plots comparing CBV estimates for the (1⁄2 + 1⁄2) dosing scheme at 3T (A and B) and at 1.5T (C and D) using the intermediate (red) and low flip angle (blue) protocols. At both 3T and 1.5T, CBV values measured using an intermediate flip angle were consistently underestimated, yielding lower accuracy and precision (API = 0.67 and 0.48), respectively. The use of the low flip angle protocol improved both CBV accuracy and precision at 3T (API = 0.82) and 1.5T (API = 0.80). Leakage correction was applied using BSW.
values were only slightly lower than those at 3T, yielding similar API values (0.86 and 0.89 for intermediate and low flip angles, respectively).

For the (½ + ½) dosing scheme, illustrated in Fig 3, CBV measured using the intermediate flip angle protocol was consistently underestimated due to residual (uncorrected) T1 leakage effects, yielding moderately lower accuracy and precision (API = 0.67) at 3T and poor performance (API = 0.48) at 1.5T. The use of a low flip angle improved the API at both 3T (API = 0.82) and 1.5T (API = 0.80) due to reduced T1 sensitivity. However, the API for this dosing scheme was consistently lower than the (1 + 1) dosing scheme.

As illustrated in Fig 4, the use of an intermediate flip angle at 3T without a preload (0 + 1) dosing scheme substantially reduced both accuracy and precision (API = 0.43). This poor performance was exacerbated at 1.5T (API = 0.08). These results are consistent with previous studies demonstrating the necessity of preload when using moderate and high flip angles.25,29,30 By comparison, the use of the low flip angle protocol at 3T without preload introduces a relatively minor penalty (API = 0.83) compared with the (1 + 1) dosing scheme (API = 0.91). At 1.5T, CBV measured using the low flip angle protocol provided a substantial improvement compared with the intermediate flip angle in both accuracy and precision (API = 0.84).

Figure 5 shows CBV accuracy and precision for DSC-MR imaging acquired with (¼ + 1) contrast agent dosing. At 3T, both the intermediate and low flip angle protocols provide excellent accuracy (API values of 0.86 and 0.90, respectively), comparable with that for the (1 + 1) dosing scheme at 3T (API = 0.91). At 1.5T, the intermediate flip angle protocol yielded intermediate accuracy and precision (API = 0.78), whereas the low flip angle protocol yielded an API value (0.89) comparable with that for the (1 + 1) dosing scheme at 3T.

Table 2 compares CCC, CV, and API for the intermediate and low flip angle protocols at both field strengths and all dosing schemes. Across all dosing schemes and field strengths, the low FA provided equivalent or better API values compared with CBV data acquired with an intermediate FA. For BTIP-compliant dosing schemes, the (1⁄4 + ¼), (½ + ½), and (1 + 1), the (1 + 1) dosing scheme at 3T have poor performance, with moderately good performance for split-dose protocols (¼ + ¾) and (½ + ½) at 3T. For non-BTIP-compliant dosing schemes (¼ + 1) and (½ + 1), low and intermediate FA acquisitions yielded excellent results at 3T, and very good results at 1.5T, comparable with the optimal (1 + 1) dosing protocol.

DISCUSSION

The computational analysis presented herein confirms that it is possible to acquire highly accurate and precise relative CBV (rCBV) measurements in glioblastoma with proper selection of DSC-MR imaging methodology. To date, recommendations on optimal DSC-MR imaging acquisition protocols, such as the ASNR white paper,23 have relied on susceptibility contrast theory, clinical experience, and limited studies involving correlation with stereotactic biopsies.16,31 but this study establishes the limits of accuracy and precision using a computational approach across a wide range of parameters and, accordingly, may be used to inform the aforementioned standardization initiatives.

While the DRO used in this study can quantitatively assess rCBV accuracy for any combination of acquisition and postprocessing parameters, the overwhelming number of permutations makes identifying a single optimal approach challenging. For
example, the heat maps illustrate that there are many unique parameter combinations that yield reasonably accurate rCBV estimates. However, for many of these combinations, minor parameter modification (e.g., changing flip angles or TEs) yields substantially decreased accuracy and/or precision. Such isolated “local maximums” reflect specific parameter subsets that may suffice for singular distributions of T1 and T2* leakage effects but that are not broadly effective when those distributions are altered, such as greater sensitivity to T1 effects due to higher flip angles. While the DRO captures the full range of T1 and T2* leakage effects but that are not broadly effective when those distributions are altered, the distribution of these effects within a single patient could be unique. Accordingly, our strategy for identifying the most robust DSC-MR imaging protocol included accuracy, precision, and consistency across localized parameter space (e.g., a consistent API as the TE is varied), ensuring the identification of optimal methods both across and within patients.

Across all parameter space, the combination of preload scheme and acquisition parameters yielding the most robust rCBV estimates included full-dose preload and bolus (1 + 1), with either the recommended ASFNR (intermediate flip angle) or low flip angle pulse sequence parameters. This finding is consistent with a prior in vivo study that demonstrated that the (1 + 1) dosing scheme provided the most robust distinction between tumor and normal tissue rCBV. Most important, this dosing scheme maintained BTIP compliance because the postcontrast T1-weighted images can be acquired between preload and bolus contrast agent injections. The (1 + 1) dosing scheme requires double the standard dose of contrast agent (0.2 mmol/kg), and given the growing concern for long-term gadolinium deposition within the brain following repeat use of gadolinium-based contrast agents, we also investigated the accuracy of lower-dose schemes. Lower-dose, BTIP-compliant dosing schemes using the intermediate flip angle protocol introduced bias and lower precision compared with the (1 + 1) scheme. Lower preload doses yielded more error because they are not as effective at reducing T1 leakage effects before the primary bolus injection.

For dosing schemes using less than a full dose for the primary bolus, the relative magnitude of T1 leakage effects with respect to the expected T2* changes are larger than would be observed with the (1 + 1) scheme and appear to partially confound leakage-correction algorithms. A lower primary bolus dose scheme (e.g., (1/2 + 1/2)) also lowers the contrast-to-noise ratio and decreases precision. This reduction in precision could yield greater within- and across-subject rCBV variability, confounding the assessment of treatment response, determination of thresholds for clinical use (e.g., differentiating between tumor recurrence and radiation effects), and the sample size needed for clinical trials. These errors are magnified at 1.5T compared with 3T, which has further implications for clinical trial design. Although lower-dose protocols have reduced accuracy and precision, prior single-site studies have demonstrated their clinical utility for differentiating tumor recurrence and posttreatment radiation effects and detecting rCBV changes following bevacizumab therapy.

Another major finding of this work is that DSC-MR imaging data acquired with a low flip angle provide comparable or improved CBV accuracy across all dosing schemes and field strengths. As highlighted in Table 2, the acquisition protocol using a single total-dose contrast agent administration, [(1 + 1), (1/4 + 1/4), (1/2 + 1/2)], which yielded only a slighted reduced API, was a low flip angle scheme (FA = 30°, TR = 1.5 sec; TE = 30 ms at 1.5T and TE = 30 ms at 3T). The corresponding CCC values exceeded 0.9 at both 1.5T and 3T but exhibited slightly higher CV values due to a lower contrast-to-noise ratio compared with the (1 + 1) double-dose protocol. The similarity of the API values across
these single total-dose protocols, when combined with a low flip angle, indicates that the preload does not improve CBV fidelity and may not be needed in clinical practice. The use of a (0 + 1) dosing scheme with a low FA has the benefit of maintaining BTIP compliance and requiring only a single bolus injection, thereby simplifying perfusion scan protocols and increasing their consistency across patients and clinical trial sites. Given the potential ramifications of this finding on DSC-MR imaging recommendations, it would be highly relevant to compare, in the same patients, the agreement and CBV map quality from data acquired with this low flip angle alternative and the ASFN recommendations (using the double-dose protocol). Given that DSC-MR imaging data acquired with TE = 50 ms (the optimal TE at 1.5T) could be more sensitive to EPI-related artifacts and exhibit lowered contrast to noise, in vivo studies should be performed to confirm CBV map quality and interpretability. Paulson and Schmainda\(^a\) found that the use of a low flip angle and a 50-ms TE reduced the difference between tumor and normal tissue rCBV.

Similar to clinical results,\(^a\)\(^b\)\(^c\) leakage-correction models based on contrast agent kinetics, such as the BSW or bidirectional methods, provide the highest rCBV accuracy compared with no leakage correction or arbitrary curve fitting, like \(y\)-variate. While the latter provides curves that, in appearance, resemble traditional first-pass data, they cannot reliably correct the signal because of the underlying complexity of simultaneous and competing \(T1\) and \(T2\) leakage effects. The highest accuracy and precision were found when DSC-MR imaging data were corrected using the BSW approach. The bidirectional correction was similarly accurate but with lower precision. In future work, we will expand these studies to investigate model-independent and MTT-insensitive leakage-correction methods\(^b\)\(^c\)\(^d\) and methods that rely on biophysical models applied to multiecho data.\(^b\)\(^c\)

**CONCLUSIONS**

By leveraging a validated DRO, we characterized the influence of DSC-MR imaging methodology on CBV accuracy and precision and identified optimal protocols for clinical use. Our results support, to a large extent, the ASFN recommendations on DSC-MR imaging best practices,\(^b\) particularly at 3T and when paired with the (1 + 1) dosing protocol, which should encourage its broader acceptance and standardization. Taken together, the results indicate that for clinical trials, a (1 + 1) dosing scheme provides highly accurate and consistent CBV estimates, enabling smaller sample sizes for detecting treatment-related changes in CBV. For clinical surveillance scans, in which a lower total gadolinium dose is desirable, the low flip angle option without preload or the (1/4 + 1) dosing scheme is a viable alternative, providing reasonably robust CBV measures. An added advantage of these schemes is that they perform well at both 1.5T and 3T. Such considerations may inform standardization initiatives for the acquisition and analysis of DSC-MR imaging data in clinical trials and routine patient care.

Disclosures: Natenael B. Semmeneh—RELATED: Grant: National Institutes of Health, Arizona Biomedical Research Commission, and Barrow Neurological Foundation. Comments: This work was supported by National Institutes of Health/National Cancer Institute (R01 CA213158), the Arizona Biomedical Research Commission (ADHS16–16249), and the Barrow Neurological Foundation.* Christopher C. Quarels—RELATED: Grant: National Institutes of Health/National Cancer Institute.* Money paid to the institution.

REFERENCES


Impact of Ischemic Lesion Location on the mRS Score in Patients with Ischemic Stroke: A Voxel-Based Approach


ABSTRACT

BACKGROUND AND PURPOSE: Previous studies indicated that ischemic lesion volume might be a useful surrogate marker for functional outcome in ischemic stroke but should be considered in the context of lesion location. In contrast to previous studies using the ROI approach, which has several drawbacks, the present study aimed to measure the impact of ischemic lesion location on functional outcome using a more precise voxelwise approach.

MATERIALS AND METHODS: Datasets of patients with acute ischemic strokes from the Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands (MR CLEAN) were used. Primary outcome was functional outcome as assessed by the modified Rankin Scale 3 months after stroke. Ischemic lesion volume was determined on CT scans 3–9 days after stroke. Voxel-based lesion-symptom mapping techniques, including covariates that are known to be associated with functional outcome, were used to determine the impact of ischemic lesion location for outcome.

RESULTS: Of the 500 patients in the MR CLEAN trial, 216 were included for analysis. The mean age was 63 years. Lesion-symptom mapping with inclusion of covariates revealed that especially left-hemispheric lesions in the deep periventricular white matter and adjacent internal capsule showed a great influence on functional outcome.

CONCLUSIONS: Our study confirms that infarct location has an important impact on functional outcome of patients with stroke and should be considered in prediction models. After we adjusted for covariates, the left-hemispheric corticosubcortical fiber tracts seemed to be of higher functional importance compared with cortical lesions.

ABBREVIATIONS: FU-NCCT = follow-up noncontrast CT; ILV = ischemic lesion volume; VLSM = voxel-based lesion-symptom mapping

It is very desirable to improve prediction of functional outcome after an ischemic stroke to rapidly inform patients and their relatives and to optimize patient management, care, and rehabilitation strategies. Several studies aimed to forecast functional outcome of patients at an early stage after acute ischemic stroke using clinical and imaging data. With regard to stroke studies, it would be of major interest to replace clinical study end points with a validated surrogate end point. Within this context, image-based surrogate end points would be easier and more reliable to assess and would allow performing phase II stroke studies with a smaller sample size. Previous studies indicated that ischemic lesion volume (ILV) as a surrogate marker for functional outcome might be useful but should be considered in the context of lesion location.

Voxel-based lesion-symptom mapping (VLSM) techniques have been frequently used to investigate the relationship between lesion topography and functional outcome. VLSM compares functional outcome scores between patients with and without lesion...
sions on a voxelwise basis. In this approach, patients are divided for each voxel into 2 groups according to whether they have a lesion at that voxel location. VLSM methods have been used to examine motor recovery, spatial neglect, and aphasia in patients with chronic stroke, and the 1-month modified Rankin Scale score was used in patients with subacute stroke (2–3 days). These studies have provided insight into clinical deficits linked to lesions in particular brain regions but did not include important factors known to be associated with functional outcome after stroke such as age, sex, ILV, recanalization status, and treatment technique.

We aimed to investigate the impact of stroke lesion topography on functional outcome (3-month mRS) with and without accounting for factors known to be associated with functional outcome after stroke using a large data base of well-characterized patients with acute ischemic stroke.

**MATERIALS AND METHODS**

**Study Population**

The analyses are based on data from the Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands (MR CLEAN), which evaluated the effect of intra-arterial treatment versus usual care alone in patients with stroke with acute large-vessel occlusion in the anterior circulation. The main results and design of the study have been reported before.

**Inclusion and Exclusion Criteria**

We included all patients with a follow-up noncontrast CT (FU-NCCT) scan 3–9 days after stroke. Patients with FU-NCCT scans of poor quality due to motion or beam-hardening artifacts or technical errors precluding automatic registration or segmentation were excluded. Patients with decompressive hemicraniectomy and considerable brain shift secondary to mass effect were excluded as well. Moreover, we excluded patients with previous stroke, an mRS score of ≥0 at baseline, or mRS = 6 three months after stroke to remove potential confounds from death unrelated to the stroke. As a result, the patient population of this substudy differed from the total MR CLEAN population.

**Ethics Statement**

The MR CLEAN study protocol was approved by the Medical and Ethical Review Committee (Medisch Ethische Toetsings Commissie of Erasmus MC, Rotterdam, the Netherlands) and the research board of each participating center. All patient records and images were anonymized before analysis, and written informed consent was obtained from all patients or their legal representatives as a part of the original trial protocol.

**Ischemic Lesion Segmentation**

Binary masks of the ischemic lesions on 3- to 9-day FU-NCCT were created using a validated automatic method. An intensity-based region-growing algorithm implemented in Matlab (MathWorks, Natick, Massachusetts) iteratively examined all neighboring voxels of a segmented volume to determine whether these neighboring voxels should be included in the segmentation. A voxel was included if the difference in its intensity and the average intensity of the segmented volume was smaller than a predefined threshold. The region-growing was repeated for multiple thresholds. The range of thresholds was 1.5–4.5 HU with steps of 0.5 HU, resulting in 7 repeated segmentations. If needed, the segmentations were adjusted by an experienced observer with >5 years’ experience in neuroradiology (M.E.), blinded to clinical information and treatment as well as further imaging. Subsequently, the ILV was calculated.

**Functional Outcome**

Functional outcome was assessed by the mRS at 3 months after stroke onset. The mRS is one of the most widely used end points for stroke severity in clinical trials in acute stroke, shown to be valid and reliable. It captures the patient’s functional outcome on an ordinal scale that ranges from 0 to 6, where zero indicates no symptoms and 6 denotes a patient’s death.

**Statistical Analysis**

Two-tailed Wilcoxon rank sum tests were used to evaluate differences in continuous variables between patients with left-versus-right hemispheric strokes. Categoric variables were compared using the Pearson $\chi^2$ test. Backward stepwise regression was performed to investigate the relation among age, sex, ILV, admission National Institutes of Health Stroke Scale score, occlusion site, collateral score, pretreatment Alberta Stroke Program Early CT Score, time to treatment, treatment technique (intra-arterial treatment, intravenous administration of alteplase, or conservative treatment), and recanalization status with functional outcome. Successful recanalization was defined as a modified Arterial Occlusive Lesion score $\geq$2 or, if missing, as a modified Thrombolysis in Cerebral Infarction score of 2b–3. All analyses were performed in SPSS 21 (IBM, Armonk, New York).

**Voxel-Based Lesion-Symptom Mapping**

Voxelwise analysis requires that all images be in the same coordinate space to allow comparison of voxels between groups. Therefore, after ischemic lesion segmentation, each of the FU-NCCT images was coregistered to the standard Montreal Neurological Institute atlas space using an affine transformation and subsequent nonlinear transformation implemented in the NiftyReg toolkit (https://www.nitrc.org/projects/niftyreg/). The average CT atlas template described by Rorden et al served as a reference image. This template was based on healthy individuals with ages similar to those commonly seen in stroke (mean, 65 years of age). All coregistration results were visually checked for quality and adjusted if needed. Statistical maps of lesion contribution related to functional outcome were generated using VLSM, Version 2.55 (http://160.129.198.244/resources.html). For each voxel, patients were divided into 2 groups according to whether they had a lesion at that voxel location. In VLSM maps, high t-scores indicate that a lesion in that specific voxel has a very significant effect on functional outcome. We limited our analysis to voxels that were affected in ≥10 individuals (10%). Resulting t-score maps were thresholded ($P < .01$) on the basis of cluster size and permutation method (2000 permutations; $P < .05$) to correct for multiple comparisons. To evaluate the impact of predefined brain regions on mRS, we calculated median, mean, minimum, and maximum t-score values for each anatomic ROI provided by the Harvard-Oxford cortical and subcortical structural atlas and the Johns...
Hopkins University International Consortium of Brain Mapping Diffusion Tensor-81 white matter labels, distributed as part of the FMRIb Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl). In a second step, we repeated the VLSM and recalculated the t-score maps, adjusting for the variables found to be significantly associated with functional outcome in a backward stepwise regression analysis.

**RESULTS**

**Patient Characteristics**

Of the 500 patients included in MR CLEAN, 353 patients had a 3- to 9-day FU-NCTT scan (On-line Fig 1). Sixty-nine patients were excluded because of technical errors and insufficient scan quality precluding automatic registration or segmentation. Moreover, patients were excluded because of hemicraniectomy (21 patients), severe swelling (3 patients), previous stroke or mRS of >0 at baseline (22 patients), or mRS = 6 three months after stroke (22 patients).

All analyses were based on the final dataset comprising 216 patients. On-line Table 1 shows the baseline and follow-up characteristics of patients included in this study and of the original MR CLEAN population for comparison. The patients in this study had a mean age of 63 years, and 63% were men. The overall mean ILV was 73 mL.

**Backward Stepwise Regression Analysis**

The odds for a good outcome (lower mRS) were significantly higher given male sex and successful recanalization status (OR = 2.58; 95% CI, 1.16–6.01; 0.023; OR = 2.03; 95% CI, 1.05–4.04; 0.038, respectively) and significantly lower given a high ILV, older age, long time to treatment, and a high NIHSS score (OR = 0.71; 95% CI, 0.62–0.79; 0.001; OR = 0.64; 95% CI, 0.46–0.88; 0.007; OR = 0.78; 95% CI, 0.60–0.98; P = 0.043; OR = 0.79; 95% CI, 0.70–0.88; P < 0.001, respectively). Odds ratios and confidence intervals of the variables in the final model are shown in On-line Fig 2. These variables were used as covariates in subsequent VLSM analysis. The discriminative power of the final regression model was very good (area under the curve = 0.890; 95% CI, 0.846–0.933) (On-line Fig 3).

**Voxel-Based Lesion-Symptom Mapping**

Figure 1 shows the incidence of lesions within each voxel for all patients with stroke as well as the statistical power for α = 0.01 by
color-coded overlays. The distribution of stroke lesions was comparable for the left and right hemispheres, with a slightly higher incidence and higher power in the left hemisphere (maximum incidences, \( n = 98 \)) than the right hemisphere (maximum incidences, \( n = 80 \)). Table 1 shows the demographic differences between patients with left and right ischemic strokes. VLSM revealed a significant contribution of brain regions comprising the motor pathway, such as the left and right corticospinal tracts. Moreover, injury involving the opercular cortex, the left superior longitudinal fasciculus, and anterior thalamic radiation was associated strongly with mRS (Table 2). A full list of mean, median, minimal, and maximal \( t \)-score values of all template ROIs is provided in On-line Table 2.

After we included sex, age, and ILV as covariates, the left deep periventricular white matter and adjacent internal capsule showed a great influence on mRS (Fig 2 and Table 3). When we included sex and age as covariates, larger regions of brain tissue in the right hemisphere (245 versus 263 cm\(^3\)) and in the left hemisphere (267 versus 272 cm\(^3\)) were significantly associated with mRS (Fig 2). The volume of voxels significantly associated with mRS was 250 cm\(^3\) in the right hemisphere and 247 cm\(^3\) in the left hemisphere with sex, age, and time to treatment as covariates (On-line Fig 4). When we included sex, age, and the NIHSS as covariates, the volume of voxels significantly associated with mRS was reduced to 217 cm\(^3\) in the right hemisphere and 230 cm\(^3\) in the left hemisphere. When we included sex, age, and recanalization status as covariates, the volume of voxels significantly associated with mRS was reduced to 155 cm\(^3\) in the right hemisphere and 236 cm\(^3\) in the left hemisphere. When ILV was included as a covariate, only voxels defined by injury to the left deep periventricular white matter and adjacent internal capsule (31.6 cm\(^3\)) were associated with mRS.

**DISCUSSION**

By means of a voxelwise approach, our data demonstrate the influence of ischemic lesion location on functional outcome in patients with acute large-vessel-occlusion ischemic stroke. After we included covariates in the model, the left deep periventricular white matter and adjacent internal capsule showed a definite influence on mRS 3 months after stroke.

Our findings are in line with those in previous studies mapping corticospinal tract lesions to motor impairment and motor function recovery in patients with ischemic stroke. In a previous study analyzing the ILV in motor-related brain structures (primary motor cortex, putamen, supplementary motor area, corticospinal tract, and cerebellum), patients who achieved functional independence (mRS 0–2) had a higher rate of MCA recanalization at 24 hours, a smaller final infarct volume, and less infarct growth. However, the multivariable analysis showed that
the best predictor of outcome in terms of mRS was the degree of ischemic damage in the ipsilateral corticospinal tract, which classified the patients with 78% accuracy.26 In a following voxel-based analysis, the voxels of the brain linked to persistent disability were clustered in an area centered in the deep periventricular white matter and in the adjacent internal capsule.24. The strategic functional importance of this area might be because it represents an important crossroad for many cortico-subcortical and long-range intrahemispheric association fiber tracts, including the corticospinal tract. Our findings support the hypothesis of greater impact of the cortical spinal tract over cortical lesions because reorganization at the cortical level remains insufficient for the patient’s recovery in case of damage to the main motor outflow tract.26,27 Although the mRS is currently the most commonly used outcome scale in stroke studies, it is mainly determined by motor disability and is relatively insensitive to cognitive dysfunction. The analysis of other functional outcome parameters such as the NIHSS, Barthel Index, or Glasgow Outcome Scale should be examined in future studies using VLSM.

The voxelwise approach allowed a more precise analysis of lesion location compared with previous studies using the ROI approach,28 which is an intrinsic limitation implying an anatomic a priori localization of the supposed relevant brain area.

In contrast to previous studies that mirrored right-sided lesions onto left-sided ones to increase statistical power,5,25 our study distinguished brain areas of the right and left hemispheres. This distinction is important given that the association between lesion location and outcome in terms of mRS is likely to be influenced by the side of the lesion.2,29 Similar to the findings of Wu et al,7 lesion location in the right hemisphere was no longer significantly associated with poor mRS scores after including ILV as a covariate in the model. In contrast to Wu et al, including age and sex into our model increased the number of voxels associated with mRS not only in the right hemisphere but also in the left hemisphere. This finding suggests that for a given sex and age, ischemic lesion location influences the risk of disability.

An important strength of our study was the adjustment for factors known to be associated with functional outcome after stroke. We showed that even after we adjusted for these predictors of functional outcome, infarcted voxels in the motor pathways remained independently associated with functional outcome. This finding highlights the importance of taking both lesion location and ILV into account to augment stroke-outcome prediction models.

In contrast to previous studies that used acute MR imaging,5,7 the current study is the first to apply the voxel-based approach in FU-NCCCTs of patients with stroke. This is important because CT is still the most common and widely available diagnostic imaging technique. However, there are limitations to CT used for determining lesion size, and high-resolution MR imaging can provide more precise results.30

With regard to the acquisition time of the FU-NCCT, the current study measured ILV in imaging acquired at the subacute time point of 3–9 days after stroke onset because it shows better association with acute imaging. Thus, a recent MR CLEAN substudy reported that the growth of ILV was common 24 hours after symptom onset.31 Moreover, previous studies observed a good association between subacute and chronic ILV, as well as a similar correlation between mRS and chronic and subacute volume, and recommended assessing ILV 3–6 days after stroke onset.32–34 The exclusive use of FU-NCCCTs that were acquired after stroke treatment distinguishes our approach from a study that analyzed acute DWI in an inhomogeneous group of patients with stroke undergoing MR imaging partly before and partly after revascularization therapy.7

The use of FU-NCCT 3–9 days after stroke and the exclusion of patients with hemicraniectomy and brain shift as well as death before follow-up limit the generalizability of our study. However, these patients are generally known to have unfavorable functional outcome, while the analyzed patients with stroke are those whose outcome is more difficult to predict.

CONCLUSIONS

Our study confirms that infarct location has an important impact on the outcome of patients with acute ischemic stroke and should be considered in prediction models. In the presented voxelwise approach, lesions in the periventricular white matter and internal capsule showed a strong influence on functional outcome, measured by the mRS, which underlines the importance of white matter injury to stroke pathology.

References


References


Detection of Leukocortical Lesions in Multiple Sclerosis and Their Association with Physical and Cognitive Impairment: A Comparison of Conventional and Synthetic Phase-Sensitive Inversion Recovery MRI


ABSTRACT

BACKGROUND AND PURPOSE: Cortical lesions are common in multiple sclerosis and are included in the latest diagnostic criteria. The limited sensitivity of cortical MS lesions on conventional MR imaging can be improved by phase-sensitive inversion recovery. Synthetic MR imaging could provide phase-sensitive inversion recovery without additional scanning, but the use of synthetic phase-sensitive inversion recovery remains to be validated. We aimed to compare the ability and clinical value of detecting leukocortical lesions with conventional and synthetic phase-sensitive inversion recovery in MS.

MATERIALS AND METHODS: Twenty-one patients with MS prospectively underwent conventional and synthetic phase-sensitive inversion recovery, 3D T1-weighted, and T2 FLAIR imaging. Two neuroradiologists independently performed blinded phase-sensitive inversion recovery lesion assessments; a consensus rating with all sequences was considered the criterion standard. Lesion volumes were segmented. All participants underwent standardized cognitive and physical examinations and Fatigue Severity Scale assessment. Results were analyzed with multiple linear regressions.

RESULTS: Interrater and criterion standard agreement for leukocortical lesions was excellent for both conventional and synthetic phase-sensitive inversion recovery (intraclass correlation coefficient $r = 0.79–0.97$). Leukocortical lesion volumes for both sequences were associated with lower information-processing speed ($P = .01$) and verbal fluency ($P = .02$). Both phase-sensitive inversion recovery sequences showed a positive effect on the association when combining volumes of leukocortical lesions and white matter lesions with information-processing speed ($P = .005$) and verbal fluency ($P = .03$). No associations were found between leukocortical lesion volumes and physical disability or fatigue.

CONCLUSIONS: Synthetic and conventional phase-sensitive inversion recovery have a sensitivity similar to that of leukocortical MS lesions. The detected leukocortical lesions are associated with cognitive dysfunction and thus provide clinically relevant information, which encourages assessment of cortical MS involvement at conventional field strengths.

ABBREVIATIONS: DIR = double inversion recovery; EDSS = Expanded Disability Status Scale; ICC = intraclass correlation coefficient; LCL = leukocortical lesions; PSIR = phase-sensitive inversion recovery; $R_1$ = longitudinal relaxation rate; $R_2$ = transverse relaxation rate

Multiple sclerosis is a chronic inflammatory and degenerative disease affecting the central nervous system and is the leading nontraumatic cause of neurologic disability in young adults.1 In recent years, there has been an increased awareness of the gray matter involvement in MS. Cortical MS lesions are closely associated with cognitive impairment2-3 and contribute to cognitive deficits independent of white matter lesions.4-6 Cortical lesions are also an independent predictor of conversion from clinically isolated syndrome to MS.7 Thus, there is a need for feasible imaging techniques that can also monitor disease evolution and treatment response in the cerebral gray matter.8-9

While MS lesions in white matter are readily visualized with MR imaging, conventional MR imaging techniques have a low sensitivity for the detection of gray matter pathology, which hinders an accurate assessment of the total lesion burden.5 Newer MR imaging sequences such as double inversion recovery (DIR) and phase-sensitive inversion recovery (PSIR) are 1.5–5 times more sensitive than conventional MR imaging sequences in the

Received May 22, 2018; accepted after revision August 2.

From the Departments of Clinical Science, Intervention and Technology (Y.F., Å.B., F.H., J.M., S.S., M.K.W., T.G.) and Clinical Neuroscience (S.F.), Karolinska Institutet, Stockholm, Sweden; and Departments of Radiology (Y.F., F.H., J.M., S.S., M.K.W., T.G.) and Neurology (S.F.), Karolinska University Hospital, Stockholm, Sweden. This work was supported by Karolinska Institutet and Stockholm County Council through an ALF grant.

Please address correspondence to Yngve Forslin, MD, Department of Clinical Neuroscience, CI-46, Karolinska University Hospital, 141 86 Stockholm, Sweden; e-mail: yngve.forslin@ki.se

Indicates open access to non-subscribers at www.ajnr.org

Indicates article with supplemental on-line photo.

http://dx.doi.org/10.3174/ajnr.A5815

detection of cortical lesions. Leukocortical lesions (LCL) are located at the interface between the white matter and the cortex. LCL have the highest detection rate among cortical lesions and are thus a feasible potential imaging biomarker for cognitive deficits that could be readily available for clinical practice.\textsuperscript{10,11}

Synthetic MR imaging is a time-efficient MR imaging technique that provides simultaneous quantitative measurements of the longitudinal relaxation rate ($R_1$), the transverse relaxation rate ($R_2$), and proton-density with correction for field inhomogeneities.\textsuperscript{12} The technique is based on a double-echo saturation-recovery turbo spin-echo sequence applied with 4 repetitions in which the slice acquisition order is changed for each repetition. In practice, this provides 2 different TEs and 4 different TIs for each voxel. Both the magnitude and phase data are saved, providing a total of 16 complex images that are used to fit the T1- and T2-relaxation curves with a computationally efficient least-squares approach. From this simultaneous relaxometry, synthetic MR imaging can provide synthesized images with a wide range of TEs, TRs, and TIs. Thus, it is possible to obtain multiple spin-echo MR imaging weightings from a single acquisition. The technique has been shown to provide proton-density-, T1-, and T2-weighted images with diagnostic quality in MS.\textsuperscript{13-15} Furthermore, it is also possible to synthesize images with inversion pulses and by specifying the TRs, TEs, and TIs as a T1-weighted inversion recovery with phase-sensitive reconstruction; the technique makes it possible to obtain PSIR images from the same sequence without additional scanning time.\textsuperscript{14} This feature makes the technique attractive to apply in the monitoring of pathologies such as MS, in which the detection of cortical lesions on PSIR may be especially clinically important.

We aimed to compare the sensitivity of conventional and synthetic PSIR in detecting leukocortical MS lesions and to evaluate its clinical value in terms of their associations with clinical disability. We hypothesized that synthetic PSIR would have a sensitivity comparable with that of conventional PSIR and that the volume of LCL detected with synthetic PSIR would correlate with cognitive and physical disability.

**MATERIALS AND METHODS**

**Study Population**

We prospectively recruited a sample of 21 patients at the MS outpatient clinic at the Department of Neurology, Karolinska University Hospital in Huddinge, Stockholm, Sweden. The inclusion criterion was a diagnosis of MS according to the concurrent diagnostic criteria,\textsuperscript{16} and the exclusion criteria were contraindications for MR imaging, neurologic comorbidities, or a history of head trauma. The cohort was representative of the MS population in our region, represented by all clinical subtypes: 13 relapsing-remitting, 7 secondary-progressive, and 1 primary-progressive.\textsuperscript{17} The demography of the study population is further detailed in Table 1.

**Image Acquisition**

All participants were scanned on the same Magnetom Trio 3T MR imaging scanner (Siemens, Erlangen, Germany) using a 12-channel head coil. The imaging protocol included a multiecho multiechoturbo spin-echo sequence for synthetic MR imaging, conventional PSIR images, and additionally a 3D T1-weighted MPRAGE and T2-weighted FLAIR images. Synthetic PSIR images were achieved by applying a phase-sensitive reconstruction on the T1 inversion recovery parameters from synthetic MR imaging as specified in Table 2. The PSIR reconstruction is performed instantaneously in the synthetic MR imaging software after reading the DICOM images and fitting the quantitative maps (which takes <20 seconds on a standard workstation). All acquisition parameters are detailed in Table 2. None of the sequences were acquired with motion correction to accurately reflect clinical image acquisitions.

**Radiologic Evaluation**

The radiologic lesion assessments were performed independently by 2 neuroradiologists (F.H. and J.M.), blinded to all clinical information to avoid biased assessments. Using conventional and synthetic PSIR, the neuroradiologists identified juxtacortical lesions and assessed any adjacent cortical involvement, thus reclassifying the lesions as LCL. To compare the performance of conventional and synthetic PSIR and to avoid bias by the influence of other MR imaging sequences, the neuroradiologists initially assessed only these 2 sequences. For each patient, the conventional and synthetic PSIR images were assessed at 2 separate sessions separated by 12 weeks. For half of the participants (randomly assigned), the conventional PSIR image was presented in the first session, and the synthetic PSIR image, in the second session, and vice versa for the other half of the participants. A consensus agreement, considered to be the ground truth, was performed an additional 12 weeks later jointly by the 2 raters. For the consensus rating, both conventional and synthetic PSIR images were available, together with 3D T1-weighted MPRAGE and T2-weighted FLAIR images.

**Lesion Segmentations**

WM lesion volumes were segmented on conventional FLAIR images using the lesion probability algorithm in the Lesion Segmentation Toolbox 2.0.12 (Technische Universität München, Munich, Germany) for Statistical Parametric Mapping 12 (SPM12; http://www.fil.ion.ucl.ac.uk/spm/software/spm12).\textsuperscript{18} The resulting WM lesion probability masks were binarized in the FMRIB Software Library 5.0.9 (FSL; http://www.fmrib.ox.ac.uk/fsl) using a binarization threshold of 0.1.\textsuperscript{19} A resident in radiology (Y.F.) then performed manual corrections of the automatic WM lesion segmentations using ITK-SNAP, Version 3.4.0 (www.itksnap.org).\textsuperscript{20} On the basis of the identified LCL in the consensus agreement assessment, a neuroradiologist (F.H.) manually segmented the LCL in ITK-SNAP on both conventional and synthetic PSIR images separately.

### Table 1: Demography of the study population*

<table>
<thead>
<tr>
<th>Patients with MS</th>
<th>Female/male</th>
<th>Age (yr)</th>
<th>Disease duration (yr)</th>
<th>MS subtype (RR/SP/PP) (No.)</th>
<th>Disease-modifying therapy (No.) (%)</th>
<th>EDSS score (median) (interquartile range)</th>
<th>Symbol Digit Modalities Test, z scores (median) (interquartile range)</th>
<th>Verbal Fluency Test z scores</th>
<th>Fatigue Severity Scale score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>14:7</td>
<td>44.5 ± 12</td>
<td>14.5 ± 9.7</td>
<td>13/7/1</td>
<td>14 (67%)</td>
<td>2.0 (2.0)</td>
<td>−0.48 (1.46)</td>
<td>−0.37 ± 1.37</td>
<td>4.53 ± 1.79</td>
</tr>
</tbody>
</table>

*Note: RR indicates relapsing-remitting; SP, secondary-progressive; PP, primary-progressive.

*Values reported as mean ± SD unless otherwise specified.
Clinical Assessments

Physical disability was assessed with the Expanded Disability Status Scale (EDSS) by an experienced MS neurologist (S.F.). Cognitive testing was performed by an experienced neuropsychologist (Å.B.) with the Symbol Digit Modalities Test, the F-A-S Verbal Fluency Test, and the Fatigue Severity Scale. The testing was performed on the same day as the MR imaging. All cognitive scores were converted into z scores normalized to age and sex.

Statistics

Normality of data was assessed using the Shapiro-Wilk test. Lesion counts and volumes were positively skewed. Differences in lesion count/volume on conventional and synthetic PSIR images were therefore compared using the Wilcoxon signed rank test. Interrater agreement was evaluated using the intraclass coefficient (ICC); ICC ratings of <0.40, 0.40–0.59, 0.60–0.74, and 0.75–1.0 were considered weak, fair, good, or excellent according to statistical convention. Standard multiple linear regression was used to evaluate associations between the EDSS, Fatigue Severity Scale, Symbol Digit Modalities Test, and Verbal Fluency Test z scores (dependent variables) and LCL volume (independent variable). Fatigue and verbal fluency z scores were normally distributed, while Symbol Digit Modalities Test z scores were negatively skewed and therefore underwent a reflect and logarithmic transformation \([\text{Lg10} (\text{largest score in data} / 1) \text{data}]\) to obtain a normal distribution for the regression analysis; EDSS scores were positively skewed and underwent logarithmic transformation to achieve normal distribution. In a second step, WM lesion volumes were added to the analyses to look for any positive interaction between the 2 lesion metrics. P < .05 was considered statistically significant, which after correction for the false discovery rate according to the Benjamini-Hochberg method, corresponded to an adjusted level of P < .030.

RESULTS

Lesion Counts and Volumes

The ICC between the 2 raters was excellent for LCL for both conventional PSIR \((0.79, P < .001)\) and synthetic PSIR \((0.87, P < .001)\). Both raters also had excellent agreement with the consensus rating on both conventional \((\text{ICC} = 0.91 \text{ and } 0.97, \text{respectively, for each rater, } P < .001)\) and synthetic PSIR \((\text{ICC} = 0.92 \text{ and } 0.94, P < .001)\). There was no significant difference in the number of...
detected LCL between conventional and synthetic PSIR \((P = .47\) and \(P = .08\), respectively, for each rater). Figure 1 illustrates the relation of the individual lesion ratings and the consensus rating as well as the relation between conventional and synthetic PSIR. The 2 raters seemed to have relatively larger differences in their LCL counts in patients with fewer lesions. When we compared each individual rating with the consensus rating, one of the raters showed a small-but-significant difference between the individual and consensus rating in the LCL count on conventional PSIR \((P = .008, \text{by the Wilcoxon signed rank test})\). There was no significant difference between the manually segmented LCL volumes on conventional \((β = -0.55, P = .010, \text{adjusted } R^2 = 0.26)\). Similarly, higher volumes of LCL on conventional PSIR \((β = -0.51, P = .019, \text{adjusted } R^2 = 0.22)\) were associated with lower Verbal Fluency Test \(z\) scores, and a similar trend was seen for synthetic PSIR \((β = -0.43, P = .054, \text{adjusted } R^2 = 0.14)\). Using both the LCL and WM lesion volumes from conventional MR imaging, we saw a positive effect on the association for both the Symbol Digit Modalities Test \((β = -0.66, P = .001, \text{adjusted } R^2 = 0.41)\) and the Verbal Fluency Test \((β = -0.52, P = .015, \text{adjusted } R^2 = 0.24)\). An increased association was similarly observed for synthetic PSIR with the Symbol Digit Modalities Test \((β = -0.58, P = .005, \text{adjusted } R^2 = 0.31)\) and the Verbal Fluency Test \((β = -0.47, P = .030, \text{adjusted } R^2 = 0.18)\).

There were no statistically significant associations between EDSS scores and conventional PSIR \((β = 0.45, P = .18)\) or synthetic PSIR \((β = 0.60, P = .12)\). Neither were there any associations between fatigue and volumes of LCL on conventional PSIR \((β = 0.04, P = .88)\) or synthetic PSIR \((β = -0.03, P = .89)\).

**DISCUSSION**

In this prospective cohort of 21 patients with MS, we show that synthetic PSIR based on the multiparametric synthetic MR imaging technique shows a performance comparable with that of conventional PSIR in detecting leukocortical MS lesions. We further show that larger volumes of LCL on both synthetic and conventional PSIR are associated with lower cognitive performance, thus suggesting that the finding of LCL on PSIR is clinically valuable.

Visualization of cortical pathology in vivo improves the diagnostic accuracy in MS and its differential diagnoses. A single-center study and a larger multicenter study have demonstrated that including cortical lesions in the criteria for dissemination in space in clinically isolated syndrome increases the specificity in the prediction of those who later convert to MS. Our results support the potential clinical feasibility of including the combined term “cortical/juxta cortical lesions” in the evaluation of dissemination in space in the latest MAGNIMS criteria for MS diagnostics and the latest revision of the diagnostic criteria for MS.

Including cortical lesions in the diagnostic algorithms for MS has also been previously proposed, though a histopathologic validation study later showed a fairly low cortical lesion detection rate of merely 18% with double inversion recovery. However, PSIR has been suggested to be superior to DIR in detecting cortical MS lesions. The excellent agreement of LCL on both conventional and synthetic PSIR in the current study indicates that the proposed rating of LCL on PSIR may give a robust assessment of cortical disease involvement in MS. Nevertheless, we found that there was less difference in the LCL count between the 2 different PSIR sequences than between the raters and the consensus rating. This might be because the consensus rating generated a

---

**Table 3: Comparison of leukocortical lesion counts and volumes on conventional and synthetic PSIR**

<table>
<thead>
<tr>
<th></th>
<th>Conventional PSIR</th>
<th>Synthetic PSIR</th>
<th>Conventional vs Synthetic PSIR</th>
<th>Consensus Rating</th>
<th>P Value Conventional/ Synthetic PSIR vs Consensus Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocortical lesion count, Rater 1 (No.)</td>
<td>7 ± 17</td>
<td>5 ± 26</td>
<td>0.47</td>
<td>5 ± 30</td>
<td>.14/.06</td>
</tr>
<tr>
<td>Leukocortical lesion count, Rater 2 (No.)</td>
<td>7 ± 34</td>
<td>7 ± 29</td>
<td>0.08</td>
<td>5 ± 30</td>
<td>.008/.96</td>
</tr>
<tr>
<td>Leukocortical lesion volume (mL)</td>
<td>0.53 ± 2.46</td>
<td>0.32 ± 2.89</td>
<td>.17</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*All values are given as median ± interquartile range.

*P value by the Wilcoxon signed rank test.*
larger total lesion burden when the overall sensitivity and specificity increased with the combination of all available sequences. Combining different sequences, as performed for the criterion standard, was subjectively the preferred approach by the raters in the current study to accurately delineate cortical involvement, which supports previously proposed multimodal reading protocol approaches.4,29–31

Synthetic MR imaging has previously been shown to provide proton-density-, T1-, and T2-weightings in diagnostic quality (as illustrated in the On-line Figure)13–15 as well as automatic volumetrics,14 with a single acquisition. The image quality of synthetic FLAIR images has, however, been shown to be hampered by artifacts.17 We here show that it is possible to obtain diagnostic synthetic PSIR images from the same acquisition without additional scanning, thus providing a clinically feasible way to visualize leukocortical MS pathology, relevant for the latest revision of the MS criteria.23 Nevertheless, if the purpose would be to solely acquire a PSIR contrast, the conventional PSIR would be a faster approach (3 minutes and 32 seconds versus 7 minutes and 47 seconds) but without the additional imaging information provided with synthetic MR imaging.

In terms of the clinical importance of LCL, we found a significant association between higher LCL volume (measured on both synthetic and conventional PSIR) and lower cognitive scores. The good correspondence of both PSIR methods with the cognitive scores is expected because both sequences had similar detection rates and volumes of LCL. This association was increased when adding WM lesion volume to the analyses for both sequences, showing the clinical importance of also detecting LCL with the PSIR methods used here. However, no associations with physical disability or fatigue were found, suggesting that the LCL burden is more related to cognitive disabilities. To further expand our understanding of the pathologic meaning of the imaging findings on conventional/synthetic MR imaging, future studies may investigate the association with biofluid markers of interest in MS.

This study has some limitations: The sample size is relatively small, making it unfeasible to perform additional analyses within the different MS subtypes. The sparse number of raters makes the interrater assessment less robust. Furthermore, a histopathologic validation was not possible in this in vivo study. A comparison with an ultra-high-field strength MR imaging scanner for the ground truth would have been a more optimal validation, but that was, unfortunately, not available for the purpose of the study and synthetic MR imaging has yet to be applied at 7T. A slice distance factor of 0.5 was used to avoid interslice talk. A complementing 3D acquisition approach, as used for the consensus agreement, could be valuable to further increase the detection of smaller lesions such as purely intracortical lesions. With this in mind, we harmonized the spatial resolutions for conventional and synthetic PSIR so that the comparability of the LCL detection rate was not confounded by partial volume effects.

CONCLUSIONS

Synthetic MR imaging provides PSIR with a sensitivity similar to that of conventional PSIR in terms of the detection of leukocortical MS lesions. The leukocortical burden detected with synthetic PSIR is associated with cognitive deficits and, therefore, is of clinical relevance in MS. Our results highlight the value of evaluating leukocortical MS lesions, even without the use of ultra-high-field scanners and suggest that either synthetic or conventional PSIR could be a part of a multimodal approach with additional 3D-based sequences, applied to meet the new demands of the latest revision of the MS diagnostic criteria.

ACKNOWLEDGMENTS

We thank Russell Ouellette for valuable comments on the manuscript.

Disclosures: Yngve Forslin, Åsa Bergendal, Farouk Hashim, Juha Martola, Sara Shams, Tobias Granberg, Maria Kristoffersen-Wiberg—RELATED: Grant: ALF Grant* from Karolinska Institutet and Stockholm City Council. *Money paid to the institution. Sten Fredriksson—UNRELATED: Board Membership: Merck, Sanofi Genzyme, Teva Pharmaceutical Industries, Novartis, Roche; Consultancy: Merck, Sanofi Genzyme, Teva Pharmaceutical Industries, Novartis, Roche; Payment for Lectures Including Service on Speakers Bureaus: Merck, Sanofi Genzyme, Teva Pharmaceutical Industries, Novartis, Roche; Payment for Development of Educational Presentations: Merck, Sanofi Genzyme, Teva Pharmaceutical Industries, Novartis, Roche.

REFERENCES


Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis

R.R. Mattay, K. Davtyan, M. Bilello, and A.C. Mamourian

ABSTRACT

BACKGROUND AND PURPOSE: Patients with multiple sclerosis routinely have MR imaging with contrast every 6–12 months to assess response to medication. Multiple recent studies provide evidence of tissue deposition of MR imaging contrast agents, questioning the long-term safety of these agents. The goal of this retrospective image-analysis study was to determine whether contrast could be reserved for only those patients who show new MS lesions on follow-up examinations.

MATERIALS AND METHODS: We retrospectively reviewed brain MRIs of 138 patients. To increase our sensitivity, we used a previously described computerized image-comparison software to evaluate the stability or progression of multiple sclerosis white matter lesions in noncontrast FLAIR sequences. We correlated these findings with evidence of contrast-enhancing lesions on the enhanced T1 sequence from the same scan.

RESULTS: Thirty-three scans showed an increase in white matter lesion burden. Among those 33 patients, 14 examinations also demonstrated enhancing new lesions. While we found a single example of enhancement of a pre-existing white matter lesion that appeared unchanged in size, that same examination showed an overall increase in lesion burden with enhancement of other, new lesions. Thus, we found that all patients with enhancing lesions had evidence of progression on their noncontrast imaging.

CONCLUSIONS: Because all enhancing lesions were associated with new lesions on unenhanced imaging and progression was only evident in 24% of patients, in patients with relapsing-remitting MS, it is reasonable to consider reserving contrast for only those patients with evidence of progression on noncontrast MR images.

ABBREVIATIONS: GBCA = gadolinium-based contrast agents; RRMS = relapsing-remitting MS

Multiple sclerosis is a nervous system disease caused by immune-mediated myelin loss with an unpredictable course, usually characterized by clinical remission, relapse, and progression. Symptoms frequently correlate with a change in the number or volume of MS lesions in the central nervous system. Serial clinical assessments have underestimated disease activity and lesion burden when correlated with findings on serial brain MR imaging. According to the guidelines outlined in the Standardized MR Imaging Protocol for Multiple Sclerosis, MR imaging using standard FLAIR, T1-weighted, and T2-weighted pulse sequences with and without injection of gadolinium-based contrast agents (GBCA) is currently the preferred technique for the long-term monitoring of patients with MS.

Contrast-enhancing lesions indicate that there is acute active inflammatory disease and subsequent blood-brain barrier disruption, while noncontrast images identify progression of lesion burden. It has already been shown that new lesions typically enhance after administration of gadolinium-based contrast agents for approximately 3–4 weeks after their development, and after the resolution of enhancement, these lesions are radiologically defined as chronic. Although pathologic specimens have also shown evidence of perivascular inflammatory infiltrates in chronic lesions in patients with MS, the blood-brain barrier either remains intact or is only minimally damaged; therefore, the lesion no longer enhances on MR imaging. There has been recent evidence that noncontrast, susceptibility-based imaging can be used to detect a paramagnetic rim representing the presence of macrophages and other paramagnetic inflammatory species indicative of ongoing inflammation in some of these chronic lesions. However, these studies all used high-resolution imaging with a...
7T scanner, which currently is primarily limited to research protocols. 8-15

Considerable histopathologic evidence has linked leptomeningeal inflammation with subpial cortical demyelination in patients with MS. 16-21 While cortical lesions have been difficult to detect on in vivo MR imaging, recent studies have shown foci of leptomeningeal enhancement in patients with MS using specific delayed-acquisition postcontrast T2 FLAIR sequences. 23,24 These findings have also been correlated with cortical volume loss. 25 However, leptomeningeal enhancement has been shown to be unrelated to white matter lesion load and enhancement, 26 and the same study showed that 85% of foci of leptomeningeal enhancement persisted on follow-up with no change in morphology, shape, or size, despite the patient receiving disease-modifying therapy. While cortical volume loss and leptomeningeal enhancement are promising new biomarkers in understanding the progression and pathophysiology of this disease, they do not provide immediate information on response to currently available treatments, and MR imaging pulse sequences used for their detection and quantification are not routinely used in clinical practice.

Currently, the consensus is that follow-up scans can be ordered when clinically indicated; however, the standard of care followed in many large MS centers is to acquire regular, scheduled enhanced MR imaging. The intent is not only to analyze treatment effectiveness but also provide evidence for treatment decisions because these scans may reveal contrast-enhancing lesions in the absence of clinical symptoms. 26 These routine contrast-enhanced studies are performed as often as every 6 months. 5

MS typically presents in young adults between 20 and 50 years of age, with a peak onset around 30 years of age 27 and the median time to death of approximately 30 years from disease onset. 28 This means that in their lifetimes, patients with MS on a 6-month imaging schedule will have ≥60 contrast-enhanced MR images.

While there exists an accepted literature on gadolinium risk for patients with severely impaired renal function, there is now emerging evidence that retained intracranial gadolinium-related deposits appear after intravenous administration of GBCA in patients with normal renal function after contrast-enhanced MR imaging. This finding suggests that we explore avoiding unnecessary the use of MR imaging contrast agents. In light of recent studies that have shown that gadolinium tissue deposition takes place even in those without intracranial abnormalities and with normal renal function, 29-33 the FDA has recently issued a warning precaution on all GBCA. 34 Although we await the results of systematic studies to better characterize the nature of this tissue deposition from the use of GBCA and, more importantly, to determine whether it results in adverse effects, it seems prudent, in the meantime, to limit their use and develop new strategies to monitor disease progression in this potentially vulnerable population of patients with MS. One such proposed strategy is the use of additional noncontrast MR imaging techniques, such as DTI-based fractional anisotropy, which has been shown to be helpful in detection of MS lesion acuity without gadolinium. 35,36

To a similar end, we designed the current study to determine whether the nonenhanced MR imaging is reliable for selecting only those patients who need additional imaging with contrast when characterizing progression of MS. As previously mentioned, new lesions typically only enhance for approximately 3-4 weeks after their development. Therefore, even with imaging intervals as short as every 6 months, all new, enhancing lesions that develop in that timeframe are not captured. 5 Also, enhancing lesions are not sufficiently sensitive for a sole measure of disease activity. 30

We wondered, then, whether the findings on nonenhanced MS follow-up MR images could be used as a reliable predictor for the presence of enhancing lesions. If this were established with enough certainty, it would offer patients an option of forgoing gadolinium-based contrast agent administration in specific situations. While both enhanced and unenhanced sequences have proved useful together in maximizing the sensitivity and reliability in detecting a change in the stable disease state versus progression, we designed this study to examine whether there could be enhancing white matter lesions in patients when the unenhanced FLAIR sequence is stable—that is, no evidence of new or enlarging existing lesions. While we recognize that standard FLAIR imaging is imperfect for the detection of lesions, we re-examined this question using a 3D-FLAIR sequence along with computer-aided detection software, which we find increases the sensitivity of FLAIR to new lesions. 37

MATERIALS AND METHODS
After receiving institutional review board approval for the study, a list of 197 sequential, unique identifying numbers of follow-up brain MR images was generated from September 19, 2017, to October 31, 2017. All cases were available on our PACS for review, and the list contained cases that were imaged with MR imaging using a specific, proprietary multisequence MS protocol that was performed on one of several of our 3T scanners, Siemens Verio, Skyra, and Trio (Siemens, Erlangen, Germany). Our department 3D lab then processed the MR images obtained in this fashion using an in-house computer-assisted detection software system. 17 This program takes the 3D FLAIR images from the current and prior studies and applies an imaging-processing pipeline, including coregistration, skull stripping, and inhomogeneity correction. Then the program computes both forward and backward differences between the 2 time point datasets and subsequently creates composite images that display the coregistered current and prior studies, as well as a third image that shows new MS lesions in red and resolving lesions in green (Fig 1). The software is routinely run by our departmental 3D lab, and this program then sends the DICOM image files directly back to the PACS.

While this program has not received a formal FDA certification, the paired, matching source multiplanar reformats from each of the 3D-FLAIR scans are available to imagers at the time of interpretation along with the computer-processed composite images indicating change. These composite images together with the source images have been found helpful in clinical practice for identifying new lesions, particularly among confluent lesions, which are then confirmed or refuted on the source imaging. However, these synthetic composite images are not used in isolation for establishing the diagnosis.

Of the 197 patients imaged with our MS protocol, 53 were excluded because they did not have any prior studies or the prior examination was not acquired with the necessary 3D-FLAIR sequence used for image analysis, usually because the previous ex-
aminations were performed at an outside institution. An additional 2 patients were excluded because they did not receive or declined contrast for their scan. Another 2 were excluded due to nondiagnostic imaging or the absence of critical sequences. We eliminated, in total, 57 cases from consideration for these reasons.

The composite images of the remaining 140 patients were then reviewed independently by 2 investigators to determine the lesion burden of white matter lesions on the most recent scan compared with the prior one. This was characterized in terms of increase, decrease, or stability on the basis of the nonenhanced FLAIR sequence, often supported by proton-density sequences. The source images used to create the composite images were reviewed at the same time by the investigators to validate the computer-generated markings because artifactual lesions in the posterior fossa and parasellar region are commonplace. Then each of the investigators recorded their decision regarding lesion enhancement based on the contrast-enhanced T1-weighted sequence. The presence of any parenchymal enhancing lesions, with or without changes on the FLAIR scan, were recorded. The imaging findings of each of the study observers were then correlated with the report generated by the attending radiologist at the time of the initial interpretation, and agreement or differences with the final report were recorded.

The independent assessments of the 2 investigators were recorded on an Excel (Microsoft, Redmond, Washington) spreadsheet, and their findings for all variables were compared to determine whether there were any differences. Sixteen cases were identified with differences between the observers’ findings or that were discordant with the initial report. These were then reviewed by a third more senior investigator (a neuropathologist with a Certificate of Added Qualification with 27 years’ experience) to resolve any differences. The senior investigator agreed 14 times with investigator A and 2 times with investigator B.

Among these 140 cases, 3 were identified in which there was enhancement of a pre-existing lesion. All of these were also reviewed by the third, more senior investigator. Two of the 3 cases were excluded from the study because the findings indicated a pathologic process other than multiple sclerosis. In one case, the findings were most consistent with progressive multifocal leukoencephalopathy, and in the second, the findings were consistent with a low-grade brain tumor based on prolonged mass effect and persistent, stable enhancement.

Of the final 138 patients included in the data analysis, 39 were men and 99 were women, and the entire cohort had a mean age of 49.1 ± 13.3 years. Forty-one patients had specific mention of a clinical diagnosis of a certain type of MS in the electronic medical record at some point in their history. Four had secondary-progressive MS, 3 had possible primary-progressive MS, 33 had relapsing-remitting MS (RRMS), and one was thought to have secondary-progressive MS or RRMS. For the remaining 97 patients, we could not find a specific classification of MS mentioned in the clinical record. We assume that the overwhelming majority of these remaining patients had RRMS, in keeping with the expectation that 85% of patients will meet the criteria for this diagnosis.38

Data on 133 patients regarding whether they were on immune-modulating therapy was collected. Of these patients, 82 were on immune-modulating therapy at the time of their most recent scan (Table).

### RESULTS

Thirty-three scans (24%) showed an increase in white matter lesion burden, 102 scans (74%) showed stable lesion burden, and 3 scans (2%) showed a decrease in lesion burden. Of the scans that showed an increased lesion burden, 31 demonstrated new discrete...
lesions, while 2 demonstrated only enlargement of pre-existing lesions.

Fourteen scans (10%) demonstrated enhancing new lesions, all of which also demonstrated an increase in lesion burden. In 1 patient, there was enhancement of a single pre-existing lesion that appeared unchanged in size, but the same scan showed an overall increase in lesion burden with enhancement of other, new lesions (Fig 2). In short, we could not find, among the 138 follow-up studies reviewed, a single case that demonstrated abnormal parenchymal enhancement without increased lesion burden.

Of note, in the 1 instance of enhancement of a pre-existing lesion, no specific phenotype of MS was indicated in the clinical history.

DISCUSSION

While prudent use of contrast is a cornerstone of practice for every responsible radiology department, this still allows considerable latitude when risk is perceived as nearly nonexistent and the expected small gains in sensitivity support its use. With the emerging evidence of T1 shortening in brain tissue linked to contrast administration and recent FDA warnings regarding the use of MR imaging contrast, it is an appropriate time to consider an evidence-based approach to the use of MR imaging contrast in common clinical situations. In addition, there is also a responsibility to minimize cost because contrast agents add to the examination cost due to the price of the agent itself and the added time for administration, image generation, and interpretation.

We decided to focus on the imaging of patients with multiple sclerosis because their exposure to contrast agents can be substantial because their imaging often starts at a young age and continues for decades. While there have been a few other studies examining FLAIR signal characteristics of specific, individual lesions in patients with MS and their prediction of lesion enhancement, none of these studies examine our specific question regarding the relationship of enhancement based on each patient’s change in the entire white matter lesion load.39,40

On the basis of the results in our patient group reported here, enhancing lesions were found in 10% of the follow-up scans. This is well within the expected range for our patients based on clinical experience. Lesion burden progression was evident in 24% of our subjects, also not surprising on the basis of clinical experience, and all patients with enhancing lesions also had evidence of progression.

When considered from the perspective of minimizing contrast use, one could argue that contrast administration could be withheld in those patients with stable lesions on the basis of our results. Contrast could also be selectively administered to only those patients with evidence of progression on their noncontrast imaging. Additionally, this decision to administer contrast in those patients with progression may also be influenced by whether the additional findings of enhancing lesions would then alter the clinical management of the patient. In our experience, it is not currently feasible to complete the interpretation of the imaging with the processed imaging components while the patient waits in the scanner for a decision, so with this approach, patients would need to come back for their enhanced imaging.

Because our patient population consists almost entirely of patients with RRMS and there may be differences among the different phenotypes of MS, our findings may not be generalized to all types of MS. However, this approach could be reserved for patients with known RRMS, and that would still include >80% of patients with MS.

Adoption of this approach would then avoid unnecessary use of contrast. While we can only suggest this as a probability not proved by this study, it is likely that this proposed change in practice would provide a substantial cost savings to the health system and patients by shortening examination time, reducing examination complexity, and minimizing patients’ risks. However, to make a more definitive claim regarding cost savings, it would be necessary to systematically quantify the true cost and complexity required for the remaining one-quarter of patients with evidence of lesion progression returning for contrast administration.

While this proposed approach may be somewhat novel, we...
believe these findings at least offer patients with RRMS a choice: completing the MR imaging examination with contrast in 1 session or imaging without contrast with the awareness that additional imaging may be necessary at a later date. This choice may be influenced by personal concern regarding receiving contrast, difficulty in returning for contrast imaging based on factors such as distance and work schedule, as well as obtaining insurance approval. However, one would think that some agreement could be reached with insurers based on the assurance that the overall number of enhanced studies and accompanying additional costs would be reduced.

While a larger study with more patients and a larger proportion of patients with progressive MS would be ideal, this study population, we believe, provides evidence that supports a larger-but-anecdotal clinical experience that enhancement is seen only with progression. The number of cases reviewed (i.e., >100) is in keeping with other studies published in the literature. Furthermore, there are precedents for the use of imaging with marginally lower sensitivity to minimize overall risk and cost such as the use of MRA rather than CTA for aneurysm screening in patients with a family history of aneurysms.

There were 2 cases in the study group that appeared to have a disease process in addition to MS. One had imaging findings of a brain stem tumor; the other had findings of progressive multifocal leukoencephalopathy, which rarely occurs in patients with MS treated with immune modulators. Although excluded from the analysis, with our proposed approach, both patients would have received contrast had they been imaged initially with noncontrast MR imaging because of the new white matter findings in one and unresolving mass effect in the second.

One additional limitation of this study is the nature of our postcontrast imaging. We do not routinely use pulse sequences that maximize visualization of contrast enhancement, such as magnetization transfer or fat-suppressed T1-weighted postcontrast imaging mainly due to our choice of imaging all these patients at 3T, because that allows generation of high-quality FLAIR volume images for the postprocessing software to improve detection of progression. We also recognize that this type of software is not available at most imaging centers, but there are other, similar products available, and we were intent on maximizing detection of progression for this study. We believe that this approach improves detection of new white matter lesions and may have contributed to our overall finding that enhancement of lesions was only evident when there was progression. However, we cannot say that careful review of FLAIR, proton-density, and T2-weighted scans performed in a consistent manner using landmarks determined from sagittal scans such as the anterior/posterior commissure line without computer processing would not have provided identical results.

Finally, we did not include spine imaging in this study and recognize that many sites, including our own, include cervical and thoracic imaging on routine follow-up. On the basis of our experience that enhancing cord lesions are much less common than brain lesions and that there is considerable variability in the quality of spinal cord imaging between examinations, we elected to focus on brain imaging to evaluate a substantial number of cases with enhancing lesions. It seems very likely that this same approach (ie, enhancement only for patients with progression) could be used for spinal cord imaging because the underlying biology of MS in the brain and cord should be comparable. Nevertheless, we did not directly examine that question in this study. We also did not include findings of leptomeningeal enhancement or cortical lesions because these require specialized imaging sequences that are not routine at our institution and their significance is still being evaluated.

CONCLUSIONS

In our study of patients with MS undergoing routine MR imaging using a 3D-FLAIR acquisition and processed images that highlight new lesions, we found that all cases with enhancing brain lesions had evidence of progression on the noncontrast imaging. Because progression was only evident in 24% of our cases, approximately three-quarters of the patients having follow-up scans did not benefit from contrast enhancement. We believe that this has implications regarding the need for contrast enhancement in all follow-up scans in this patient population.

REFERENCES


34. FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm. Accessed March 5, 2018


The Central Vein: FLAIR Signal Abnormalities Associated with Developmental Venous Anomalies in Patients with Multiple Sclerosis

D. M. Rogers, L. M. Shah, and R. H. Wiggins III

ABSTRACT

BACKGROUND AND PURPOSE: Demyelination is a recently recognized cause of FLAIR hyperintensities associated with developmental venous anomalies. Our purpose was to quantify the prevalence of white matter signal abnormalities associated with developmental venous anomalies in patients with multiple sclerosis compared with controls.

MATERIALS AND METHODS: A retrospective, blinded, multireader study compared the prevalence of FLAIR hyperintense signal abnormalities adjacent to developmental venous anomalies in patients with MS compared with controls (patients with developmental venous anomalies without MS). Study findings were positive if a central vein was demonstrated using FLAIR and contrast-enhanced fat-saturated T1 sequences. Imaging parameters also included developmental venous anomaly location, developmental venous anomaly drainage, white matter lesion size, and depth of white matter lesions. Clinical parameters included age, sex, and the presence of confounding variables (hypertension, diabetes, migraines, and/or vasculopathy).

RESULTS: FLAIR signal abnormality was present around 47.3% (35/74) of developmental venous anomalies in patients with MS, and 13.5% (10/74) of developmental venous anomalies in the control group (P < .001). The multivariate logistic regression model controlling for covariates (including migraines, hypertension, diabetes mellitus, vasculopathy, age, sex, and drainage direction of developmental venous anomalies) showed that the odds of FLAIR hyperintensity around developmental venous anomalies was 6.7-fold higher in patients with MS (relative risk MS = 6.68; 95% CI, 2.79–15.97; P < .001).

CONCLUSIONS: The association of developmental venous anomalies and FLAIR hyperintensities was more common in patients with MS, which suggests that the underlying demyelinating pathologic process of MS may be the cause of this propensity in patients with MS. Impaired venous drainage in the territory of developmental venous anomalies may predispose to development of these lesions, and an associated central vein is helpful in understanding an atypical location of MS plaques.

ABBREVIATIONS: CCSVI = chronic cerebrospinal venous insufficiency; DVA = developmental venous anomaly
However, sequelae of demyelination have recently been recognized as another cause of signal abnormality surrounding DVAs in patients with multiple sclerosis. Two case series have described tumefactive demyelinating occuring adjacent to DVAs in patients with MS.\textsuperscript{14,17} MS plaques have long been known to occur in a perivenular distribution (eg, Dawson fingers), and the development of 3T FLAIR* and 7T MR imaging has demonstrated that almost all MS plaques have a central vein.\textsuperscript{16–18} Gaitán et al\textsuperscript{17} showed on dynamic contrast-enhanced 7T MR imaging that small MS plaques enhance centripetally from a central vein, and the “central vein sign” has been identified by the North American Imaging in Multiple Sclerosis Cooperative as an imaging feature with potential prospective diagnostic utility for the diagnosis of MS.\textsuperscript{18}

DVAs are a common incidental finding on contrast-enhanced brain MR imaging. Two prior studies reported the prevalence of DVAs in patients with MS as 12.1% and 12.6%, respectively.\textsuperscript{19,20} Our hypothesis is that demyelination is a pathologic cause of DVA-associated FLAIR hyperintensities in patients with MS. The purpose of this retrospective study was to compare the prevalence of DVA-associated FLAIR hyperintensities with a central vein in patients with MS and patients without MS who had incidentally detected DVAs. A greater prevalence of FLAIR signal abnormalities adjacent to DVAs in patients with MS compared with controls and/or the presence of other distinguishing features (such as lesion enhancement in patients with MS) would support the underlying demyelinating pathologic process of MS as the cause of this propensity in the MS group.

**MATERIALS AND METHODS**

This was an institutional review board–exempted retrospective study comparing the prevalence of white matter signal abnormalities on the FLAIR sequence adjacent to DVAs in patients with MS and patients without MS who incidentally found to have DVAs.

**Subjects and Imaging**

Using a radiology report search engine (Montage; Nuance Communications, Burlington, Massachusetts), we searched brain MR imaging studies obtained at an academic university hospital using the terms “developmental venous anomaly (or DVA)” AND “multiple sclerosis (or MS)” for the study group, and “developmental venous anomaly (or DVA)” for the control group.

For inclusion criteria, FLAIR and T1 postcontrast images of the FLAIR sequence adjacent to DVAs in patients with MS and patients without MS incidentally found to have DVAs. For the study group, our search resulted in 81 DVAs found in 78 patients with MS and 74 cases of disagreement, a second blinded neuroradiologist with 15 years of experience served as a tie-breaker. Criteria for a positive diagnosis is discussed later in the Materials and Methods section). These exclusions left 74 DVAs in the final MS study population.

For the control group, the 78 most recent brain MR imaging cases (from March to September 2017) with a DVA and without MS were analyzed, yielding 79 clearly delineated DVAs in 78 patients. Five cases were excluded due to the presence of an adjacent cavernous malformation for a final cohort of 74 DVAs. These scans were obtained for myriad reasons, most commonly to evaluate a neoplasm elsewhere in the brain or as a staging scan for possible malignancy.

Diagnostic MR imaging was performed on Prisma, Aera, Avanto, and Espree 1.5T scanners, or Prisma and Verio 3T scanners (Siemens, Erlangen, Germany). Most scans were obtained with a magnetic field strength of 1.5T (80.4%), and the remainder were obtained at 3T (19.6%). There was no significant difference in the number of studies performed at 1.5 T and 3T between the study and control groups (Table 1). While there was some mild variability, a typical 2D-FLAIR sequence had a TR of 9000 ms and TE of 110 ms with 5-mm slice thickness and no gap. FLAIR sequences were performed with chemical fat saturation. Typical contrast-enhanced 2D-T1 sequences had a TR of 600 ms and a TE of 10 ms with 5-mm slice thickness and no gap.

**Image Analysis and Chart Review**

Two radiologists, a senior neuroradiologist with 25 years of experience and a senior resident with 4 years of experience, performed a blinded and randomized review of the images on a PACS. In cases of disagreement, a second blinded neuroradiologist with 15 years of experience served as a tie-breaker. Criteria for a positive study were adapted from the central vein sign as described in the 2016 consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.\textsuperscript{18} In contrast to criteria used in the literature in which FLAIR hyperintensity in the vicinity of the DVA was used, we decided to use a stricter central vein criterion as subsequently described because it is more specific for demyelination. While Sati et al\textsuperscript{18} assessed the central vein and associated FLAIR hyperintense plaques on a single 3T FLAIR* sequence, we localized lesions with side-by-side comparison of conventional FLAIR and T1 postcontrast images.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Multiple Sclerosis (n = 74)</th>
<th>Controls (n = 74)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD) (yr)</td>
<td>45.1 (13.5)</td>
<td>50.7 (18.4)</td>
<td>.036</td>
</tr>
<tr>
<td>Sex: female</td>
<td>49 (66.2%)</td>
<td>37 (50.0%)</td>
<td>.045</td>
</tr>
<tr>
<td>MRI field strength 3T</td>
<td>18 (24.3%)</td>
<td>11 (14.9%)</td>
<td>.19</td>
</tr>
<tr>
<td>MRI field strength 1.5T</td>
<td>56 (75.7%)</td>
<td>63 (85.1%)</td>
<td>.25</td>
</tr>
<tr>
<td>DVA location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lobar</td>
<td>49 (66.2%)</td>
<td>51 (68.9%)</td>
<td>.81</td>
</tr>
<tr>
<td>Basal ganglia</td>
<td>6 (8.1%)</td>
<td>5 (6.7%)</td>
<td>.78</td>
</tr>
<tr>
<td>Cerebellum</td>
<td>18 (24.3%)</td>
<td>15 (20.3%)</td>
<td>.43</td>
</tr>
<tr>
<td>Brain stem</td>
<td>1 (1.4%)</td>
<td>3 (4.1%)</td>
<td>.36</td>
</tr>
<tr>
<td>DVA drainage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial</td>
<td>50 (67.5%)</td>
<td>46 (62.1%)</td>
<td>.75</td>
</tr>
<tr>
<td>Deep</td>
<td>21 (28.4%)</td>
<td>25 (33.8%)</td>
<td>.56</td>
</tr>
<tr>
<td>Both</td>
<td>3 (4.1%)</td>
<td>3 (4.1%)</td>
<td>.94</td>
</tr>
<tr>
<td>Hypertension</td>
<td>13 (17.6%)</td>
<td>15 (20.3%)</td>
<td>.78</td>
</tr>
<tr>
<td>Diabetes</td>
<td>3 (4.1%)</td>
<td>6 (8.1%)</td>
<td>.56</td>
</tr>
<tr>
<td>Migraines</td>
<td>10 (13.5%)</td>
<td>10 (13.5%)</td>
<td>.94</td>
</tr>
<tr>
<td>Intracranial vasculitis</td>
<td>1 (1.4%)</td>
<td>1 (1.4%)</td>
<td>.94</td>
</tr>
</tbody>
</table>
Criteria for positive FLAIR signal abnormality adjacent to a DVA with a central vein were the following:

1) The DVA vessel must pass through the FLAIR hyperintense lesion so that it is directly abutting it, approximately equidistant from the edges of the lesion and passing through it at no more than 2 locations.

2) The FLAIR hyperintense lesion is at least 3 mm in all planes.

3) Studies were excluded if the DVA-associated FLAIR hyperintense lesion merged with another parenchymal lesion (eg, a superficial DVA extending toward multiple large periventricular plaques). While these studies might represent DVA-associated lesions, they were not included to avoid the possibility of chance associations with adjacent lesions in patients with MS who may have an overall higher burden of white matter disease.

4) Care was taken not to count flow-related FLAIR signal within the vessel itself as a surrounding parenchymal abnormality.

Imaging parameters included DVA location (lobar, basal ganglia, cerebellum, or brain stem), DVA drainage direction (superficial, deep, or both), the presence of an associated white matter lesion meeting the aforementioned central vein criteria, width of the white matter lesion measured in millimeters, and depth of the white matter lesion (juxtacortical, subcortical, or periventricular). The DVA drainage direction was defined as the confluent draining vessel extending either toward the surface of the brain (superficial), toward the ventricles (deep), or both. “Juxtacortical” was defined as a lesion that directly abuts the cortex, while a “periventricular” lesion directly abuts the lateral, third or fourth ventricles.

Clinical electronic medical record chart review was performed to confirm that study group patients had been diagnosed with MS by a neurologist and met the revised 2017 McDonald criteria for the diagnosis of MS. Clinical parameters documented on the electronic medical record review included patient age and sex, duration since the time of diagnosis of MS, and potential confounding variables for white matter FLAIR hyperintensities such as hypertension, diabetes, migraines, and/or intracranial vasculitis.

### Table 2: Results

<table>
<thead>
<tr>
<th>Variable</th>
<th>Multiple Sclerosis (n = 74)</th>
<th>Controls (n = 74)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive FLAIR hyperintensity with a central vein</td>
<td>35 (47.3%)</td>
<td>10 (13.5%)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>FLAIR hyperintensity depth</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juxtacortical</td>
<td>13 (37.1%)</td>
<td>5 (50.0%)</td>
<td></td>
</tr>
<tr>
<td>Subcortical</td>
<td>12 (37.5%)</td>
<td>3 (30.0%)</td>
<td></td>
</tr>
<tr>
<td>Periventricular</td>
<td>10 (28.6%)</td>
<td>2 (20.0%)</td>
<td></td>
</tr>
<tr>
<td>Mean FLAIR hyperintensity width (SD) (mm)</td>
<td>8.5 (7.3)</td>
<td>8.0 (4.5)</td>
<td></td>
</tr>
<tr>
<td>Enhancing lesions</td>
<td>4 (11.4%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Location of DVA with associated FLAIR hyperintensity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lobar</td>
<td>29 (82.9%)</td>
<td>10 (100%)</td>
<td></td>
</tr>
<tr>
<td>Basal ganglia</td>
<td>2 (5.7%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Cerebellum</td>
<td>4 (11.4%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Brain stem</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Drainage of DVA with associated FLAIR hyperintensity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Superficial</td>
<td>23 (65.7%)</td>
<td>6 (60%)</td>
<td></td>
</tr>
<tr>
<td>Deep</td>
<td>12 (34.3%)</td>
<td>2 (20%)</td>
<td></td>
</tr>
<tr>
<td>Both</td>
<td>0 (0%)</td>
<td>2 (20%)</td>
<td></td>
</tr>
</tbody>
</table>

Data Analysis

Comparisons between the groups for dichotomous outcomes were performed using the chi-squared test if the minimum expected cell frequency assumption was met (80% of the cells have expected frequencies of at least 5 and no cell has an expected frequency of <1). The McNemar test was used for paired data. For comparison of paired groups on an interval-scaled variable, a t test was performed. Poisson regression was used for a binary outcome, with a robust variance estimate. A multivariate logistic regression model was created with positive FLAIR signal around DVAs as an outcome while controlling for covariates (including migraines, DVAs as an outcome while controlling for covariates (including migraines, hypertension, diabetes mellitus, vasculopathy, age, sex, and DVA drainage direction). Interrater reliability was measured using the κ coefficient, which is the proportion of agreement beyond expected chance agreement.

RESULTS

Study and control population characteristics are compared in Table 1. Of note, the MS study group was slightly younger than the control population (P = .036), with a female preponderance (P = .045). There were no significant differences in MR imaging field strength, DVA location, or DVA drainage in the study and control populations. Clinical parameters, including the presence of hypertension, diabetes, migraines, and/or intracranial vasculitis, were also not significantly different in the study and control populations.

FLAIR signal abnormality meeting the central vein criteria was present adjacent to 47.3% (35/74) of DVAs in patients with MS and adjacent to 13.5% (10/74) of DVAs in the control group (P < .001) (Table 2). A multivariate logistic regression model controlling for covariates (including migraines, hypertension, diabetes mellitus, vasculopathy, age, sex, and drainage direction of DVAs) showed that the odds of FLAIR hyperintensity around DVAs was 6.7-fold higher in patients with MS (relative risk MS = 6.68; 95% CI, 2.79–15.97; P < .001). In patients with MS, 11.4% (4/35) of the lesions demonstrated enhancement compared with none in the control group. There was no significant difference in FLAIR signal surrounding DVAs according to sex in the patients with MS (P = .504) or in the control subjects (P = .197). There was a 1.4-fold increase in FLAIR signal surrounding DVAs in controls for every 10-year increase in age (relative risk MS = 1.40; 95% CI, 1.01–1.94; P = .047). No such age-related association was present in the MS cohort. The mean number of years between the diagnosis of patients with MS and current imaging was 10.3 ± 8.6 years (range, 1–37 years). All except 4 patients with MS were on disease-modulating immunotherapy. Two of these patients had DVA-associated FLAIR hyperintensities, neither of which demonstrated enhancement. Examples of FLAIR hyperintense lesions adjacent to DVAs in patients with MS are shown in Fig 1, and...
FLAIR hyperintense lesions in the control group are shown in Fig 2.

For the cases of MS, the interrater reliability for the detection of FLAIR signal surrounding a DVA was 0.865 (95% CI, 0.748–0.979). For the control cases, the interrater reliability for detection of FLAIR signal surrounding a DVA was 0.874 (95% CI, 0.702–1). This corresponds to excellent agreement.22

**DISCUSSION**

In our study, FLAIR signal abnormalities adjacent to DVAs were found to be significantly more prevalent in patients with MS compared with the control group of patients without MS (47.3%–13.5%, \( P < .001 \)). Multivariate logistic regression accounting for multiple possible confounding variables found that white matter lesions are 6.7 times more likely around DVAs in patients with MS compared with controls (95% CI, 2.79–15.97; \( P < .001 \)). The underlying pathologic process in both the control group and in some of the patients with MS is likely perivenular gliosis secondary to vascular congestion, venous hypertension, and chronic hypoxia in the territory of the DVA, as described in the neuropathology literature and previously depicted with MR perfusion.9-13,23-25 However, the significantly higher proportion of DVA-associated FLAIR abnormalities in patients with MS combined with the presence of lesion enhancement in some cases suggests an additional underlying pathologic cause (eg, sequelae of demyelination caused by multiple sclerosis) of these signal abnormalities in patients with MS. To be clear, these results do not imply that demyelination is the underlying cause of the signal abnormalities in the control group or healthy patients with DVAs. The underlying cause of the leukoaraiosis on FLAIR sequences in each case is indistinguishable when they are chronic lesions (Figs 1 and 2). However, advanced MR imaging techniques such as perfusion MR imaging have the potential of distinguishing DVA-associated FLAIR hyperintensity due to demyelination prospectively, and are an exciting avenue for further research.

The association of DVAs with demyelination in patients with MS has clinical utility, particularly in cases in which there is imaging overlap between active demyelination and possible central nervous system neoplasms (Fig 3).14 A noninvasive diagnostic strategy in these cases is short-term follow-up imaging because the enhancement of an actively demyelinating lesion will fade with time, persisting chronically as a DVA-associated FLAIR hyperintensity. The association of DVAs and FLAIR hyperintensities in
patients with MS can also be useful to explain why demyelinating plaques may appear in atypical locations such as the basal ganglia. MS plaques classically appear along normally distributed veins (such as at the callososeptal interface) but also can be seen in areas of the brain where there is variant venous anatomy.

Previously reported theories may explain why FLAIR hyperintensities adjacent to DVAs are more common in patients with MS. The first is that patients with MS are predisposed to develop demyelination around DVAs due to their local inefficient venous drainage.9–13 MS plaques form when lymphocytes and monocytes cross the blood-brain barrier across venous channels, leading to perivenular cuffing.26,27 It is here that they react to autoantigens such as myelin basic protein, inciting an inflammatory response leading to perivenular demyelination.28,29 Jung et al9 previously showed on MR imaging perfusion that MTT and TTP are prolonged around most DVAs, suggestive of venous congestion in the parenchyma supplied by these DVAs. We hypothesize that the local venous congestion in the territory of a DVA predisposes to blood-brain barrier breakdown and lymphocytic infiltration, leading to demyelination in these regions. Previously published pathology-proved cases also support this hypothesis.14,30 It is unknown whether DVAs carry a greater risk for developing surrounding demyelination compared with normally distributed veins (such as callososeptal medullary veins). However, our finding that nearly half of DVAs in patients with MS have associated FLAIR hyperintensity, combined with the previously published findings supporting venous congestion in these regions, raises this possibility. Further investigation of DVA-associated signal abnormalities in patients with MS with MR imaging perfusion may help prove this theory.

It is critical that we address the controversial entity chronic cerebrospinal venous insufficiency (CCSVI), given the volume of medical literature and social media attention devoted to it. The CCSVI theory suggests that patients with MS are more likely to have stenosis of cerebrospinal venous outflow tracts, leading to intracranial venous reflux.31,32 In theory, a higher prevalence of global cerebral venous insufficiency in patients with MS superimposed on the impaired drainage of DVAs could lead to a higher rate of DVA-associated FLAIR hyperintensities in patients with MS compared with controls. However, CCSVI has largely been debunked as an underlying cause of MS lesions because there has been only a weak association between the CCSVI sonographic criteria proposed by Zamboni et al32 and MS, and multiple studies have found no statistically significant difference in venous drainage between patients with MS and controls.33–38 While global venous insufficiency in patients with MS seems unlikely on the basis of the current literature, this does not mean that local impairment of venous drainage in the territory of a DVA cannot be an exacerbating factor in MS.

There was an approximately 2:1 ratio of females to males in the MS group, while it was a 1:1 ratio in the control group. This ratio supports the previously reported epidemiology of MS.39 This difference was accounted for in the statistical analysis with a multivariate logistic regression model. We do not hypothesize that sex is an independent risk factor for the development of white matter lesions adjacent to DVAs, and sex predilection for these lesions has not been reported in the literature. In our study, of the 10 patients positive for DVA-associated FLAIR hyperintensity in the control group, 6 were male (60%). We found no statistical correlation of sex and FLAIR hyperintensity surrounding DVAs in patients with MS or controls.

In our study, the MS group was slightly younger than the control group. This is likely because patients with MS present for imaging due to symptoms at a younger age than the background population. This discrepancy was accounted for in the statistical analysis with a multivariate logistic regression model. Additionally, we are reporting a higher prevalence of DVA-associated signal abnormalities in the younger MS group; it has been reported in the literature that these signal abnormalities are more common in older patients.5 Similarly, univariate regression analysis showed that older control patients were more likely to have FLAIR hyperintensities adjacent to DVAs (P = .047). No association between patient age and the prevalence or size of DVA-associated signal abnormalities was seen in the MS group.

We acknowledge the limitations of this retrospective study. There may be a selection bias because a radiology report search tool was used for initial inclusion in the study. Cases in which smaller DVAs may not have been perceived by the prospectively interpreting radiologist or cases in which a DVA was identified but not included in a radiology report were not included in our study. We used a T1 postcontrast sequence to detect DVAs, which is potentially less sensitive compared with T2* sequences (such as SWI or 3T FLAIR*). Additionally, our 5-mm slice thickness may also be less sensitive compared with thinner slice techniques. However, being present in both cohorts of patients somewhat mitigates these biases. One might hypothesize that because patients with MS may have more white matter disease compared with controls, a chance association with DVAs is more likely. However, this was corrected for by adherence to our exclusion criteria, which specifically omitted cases in which there were confluent white matter lesions adjacent to the DVA.

CONCLUSIONS

Because statistically more FLAIR hyperintensities were found to surround DVAs in patients with MS compared with controls, our results suggest that the underlying demyelinating pathologic process of MS may be the cause of this propensity in patients with MS.
We hypothesize that impaired venous drainage in the territory of DVAs predisposes to the development of these lesions in patients with MS, and further prospective evaluation of these lesions with MR perfusion is a logical next step. This imaging feature is helpful in distinguishing tumefactive demyelinating lesions and central nervous system neoplasms and in understanding atypical locations of MS plaques at sites of variant venous anatomy.

REFERENCES

22. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–74 CrossRef Medline


Systematic Assessment of Multispectral Voxel-Based Morphometry in Previously MRI-Negative Focal Epilepsy

R. Kotikalapudi, P. Martin, J. Marquetand, T. Lindig, B. Bender, and N.K. Focke

ABSTRACT

BACKGROUND AND PURPOSE: Voxel-based morphometry is widely used for detecting gray matter abnormalities in epilepsy. However, its performance with changing parameters, smoothing and statistical threshold, is debatable. More important, the potential yield of combining multiple MR imaging contrasts (multispectral voxel-based morphometry) is still unclear. Our aim was to objectify smoothing and statistical cutoffs and systematically compare the performance of multispectral voxel-based morphometry with existing T1 voxel-based morphometry in patients with focal epilepsy and previously negative MRI.

MATERIALS AND METHODS: 3D T1-, T2-, and T2-weighted FLAIR scans were acquired for 62 healthy volunteers and 13 patients with MR imaging negative for focal epilepsy on a Magnetom Skyra 3T scanner with an isotropic resolution of 0.9 mm³. We systematically optimized the main voxel-based morphometry parameters, smoothing level and statistical cutoff, with T1 voxel-based morphometry as a reference. As a next step, the performance of multispectral voxel-based morphometry models, T1/FLAIR, T1/T2, and T1/T2/FLAIR, was compared with that of T1 voxel-based morphometry using gray matter concentration and gray matter volume analysis.

RESULTS: We found the best performance of T1 at 12 mm and a T-threshold (statistical cutoff) of 3.7 for gray matter concentration analysis. When we incorporated these parameters, after expert visual interpretation of concordant and discordant findings, we identified T1/FLAIR as the best model with a concordant rate of 46.2% and a discordant rate/discordant rate of 1.20 compared with T1 with 30.8% and 0.67, respectively. Visual interpretation of voxel-based morphometry findings decreased concordant rates from 38.5%–46.2% to 15.4%–46.2% and discordant rates from 53.8%–84.6% to 30.8%–46.2% and increased specificity across models from 33.9%–40.3% to 46.8%–54.8%.

CONCLUSIONS: Multispectral voxel-based morphometry, especially T1/FLAIR, can yield superior results over single-channel T1 in focal epilepsy patients with a negative conventional MR imaging.

ABBREVIATIONS: AUC = area under the curve; CR = concordant rate; DR = discordant rate; EEG = electroencephalography; GMC = gray matter concentration; GMV = gray matter volume; SP = specificity; VBM = voxel-based morphometry

In focal epilepsy, detection of a focal lesion in MR imaging increases the odds of seizure-free outcome after an operation by 2.5–3 times. A common epileptogenic lesion is focal cortical dysplasia, which has notable morphologic characteristics on MR imaging. However, pure visual analysis, especially in subtle cases, can be challenging. Also, many histopathologically proven focal cortical dysplasias escape visual detection. Failure to identify these lesions can often label patients as having negative MR imaging for focal cortical dysplasia. These patients have poor surgical outcomes or may not even be referred for a potential epilepsy surgery.

During the past decade, multiple MR imaging postprocessing methods have been applied to improve lesion detection in epilepsy, of which the most common applications are based on voxel-based morphology (VBM), usually using T1-weighted images (single-channel T1 VBM). VBM enables a voxelwise comparison between 2 groups of subjects and can highlight areas of statistically significant differences. This approach is commonly applied in the presurgical evaluation of epilepsy, comparing a single patient against a group of healthy controls. Martin et al, in 2015, reviewed various studies that have reported the potential use of VBM based on T1...
within a sensitivity range of 60%–100%, whereas its application in identifying structural abnormalities in cryptogenic epilepsy remains challenging, with a sensitivity between 10% and 38%. Also, past studies used variable smoothing (between 5 and 14 mm)7–9 and statistical cutoffs to elucidate VBM findings.10,11 Studies have shown that changing smoothing kernel size6 and statistical thresholds have a direct impact on the VBM findings,10 also affecting the specificity of the results.10

Recently, multispectral VBM (ie, the combination of multiple MR imaging contrast sequences) was proposed and made available in SPM8/SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12) within its unified segmentation framework (New Segment). This approach enables combining different MR image contrasts. Lindig et al, in 2018,12 showed that multispectral VBM improves tissue segmentation for gray matter, white matter, and CSF and improves lesion detection in MR imaging positive for focal epilepsy compared with T1 VBM. However, it is still unclear whether multispectral VBM is beneficial in the more challenging cohort of MR imaging negative for epileptogenic lesions.

In this study, we wanted to objectify the selection of smoothing and statistical cutoffs with reference to the established and frequently used T1 VBM. This enabled us to systematically compare the diagnostic value of T1 and multispectral VBM using multiple image contrast combinations, T1+T2, T1+FLAIR, and T1+T2+FLAIR, in patients with focal epilepsy, but negative conventional MR imaging (ie, previously MRI-negative).

MATERIALS AND METHODS

Subjects

We recruited 62 healthy volunteers (number of controls, Nc; 36 women, 26 men; mean age, 27.5 years) and 13 patients with MR imaging negative for cryptogenic epilepsy (number of patients, Np; 6 women, 7 men; mean age, 35.9 years) with a lobar clinical hypothesis of epilepsy origin. The clinical hypothesis was established through multie xpert consensus in the monthly epilepsy case conference, which uses all available clinical information in the presurgical epilepsy program (On-line Table 1). The multispectral VBM results analyzed in this work were not used in forming the clinical hypothesis. All patients had undergone video-electroencephalography (EEG) telemetry and neuropsychological assessment, and 6 of them had undergone PET/CT. After an epilepsy case conference for each of the 13 patients, 7 were identified as candidates for further intracranial EEG and possible subsequent epilepsy surgery due to medically refractory seizures (for clinical details see On-line Table 1). To date, intracranial EEG was performed in 5 patients and was offered to 2 patients who have not yet decided. Of the 5 patients with implants, 3 patients (patients 1, 2, and 6) had undergone an operation; in 2 patients with implants (patients 4 and 11), surgery was declined due to suspected multifocal epileptogenesis. In postsurgical patients, histopathology revealed evidence of hippocampal sclerosis in 1 patient (patient 2), but this patient did not achieve postoperative seizure freedom (Engel class II). The histopathologic tests of the other 2 operated patients (patients 1 and 6) were unremarkable, and to date, 1 patient (patient 1) is seizure-free without anticonvulsive medication (Engel I). The other patient (patient 6) had postoperative seizure freedom, but only for 1 year. All subjects were scanned on a 3T MR imaging scanner (Magnetom Skyra; Siemens, Erlangen, Germany) at the University Hospital Tübingen. The acquisition protocol was previously reported12 and consists of 0.9-mm3 isotropic 3D T1-weighted MPRAGE (= T1), 3D T2-weighted sampling perfection with application-optimized contrasts by using different flip angle evolutions (SPACE sequence; Siemens) (= T2), and 3D inversion recovery prepared SPACE sequence (= FLAIR).

Image Processing

At first, scans were converted from DICOM to NIfTI format using MRIConvert (https://knl.uoregon.edu/downloads/mricontvert). The postprocessing was performed with SPM12 in a Matlab R2016a (MathWorks, Natick, Massachusetts) environment and with an in-house Matlab code. We used VBM based on T1 images only (T1 VBM) as a reference. This was compared with multispectral VBM combinations based on multiple MR images (ie, T1+T2, T1+FLAIR, and T1+T2+FLAIR). For multispectral VBM, T2 images (T2 and FLAIR channels) were coregistered to their respective T1 images using linear coregistration with 12 df and a normalized mutual information cost function. Segmentation was performed with default settings of bias regularization of 0.001 and a bias cutoff full width at half maximum of 60 mm. As a next step, the segmented GM images were normalized to the Montreal Neurological Institute space by using the Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL, part of SPM) toolbox, with an isotropic resolution of 1.5 mm. To correct for regional volume changes in normalization, we modulated images to preserve the quantity of GM tissue (gray matter volume [GMV]) within a voxel and unmodulated images for preserving the concentration of GM tissue (gray matter concentration [GMC]). Finally, spatially normalized images were smoothed, using a Gaussian kernel with a range from 4- to 16-mm full width at half maximum in a step size of 2. The smoothed GMC and GMV images were further analyzed using SPM12.

Statistical Analysis

We used the general linear model from SPM12 to analyze regional increased differences in the smoothed GMC and GMV images. The general linear model analysis was performed using the factorial design specification (2-sample t test) in SPM12 to compare each patient against the control cohort (patient comparison) and each control in a leave-one-out cross-validation against the remainder of the controls after removing the subject in question (control comparison). We included age and sex as covariates for GMC. Total intracranial volume was also included as a covariate for GMV. The resulting statistical maps (t-contrast maps, subject > controls, ie, increase of GM) were thresholded with T-score cutoffs from 2.5 to 6 in step sizes of 0.1. The suprathreshold clusters at each smoothing level and each T-threshold were used for reporting the results.

Objective Diagnostic Performance Assessment

We created a brain mask by summation of normalized unmodulated GM and WM images from T1 segmentation. Voxel intensities <0.5 were excluded to remove nonbrain areas. On the basis of the expert clinical hypothesis, the lobes of the hypothesis were identified for each patient in the Montreal Neurological Institute structural atlas provided with FSL, Version 5.0.

(http://www.fmrib.ox.ac.uk/fsl). For each patient, “discordant lobes” were defined as the atlas lobes/regions (for example, left frontal lobe) that are identified as the lobes of clinical hypothesis. The lobes that are not a part of the clinical hypothesis for each patient were defined as “discordant lobes.” For controls, because no epileptogenic lesions are expected, all atlas regions were defined as discordant.

**Analysis**

Every suprathreshold cluster was considered as a concordant or a discordant finding provided one-third or greater of the suprathreshold cluster overlapped the respective lobar ROI (concordant or discordant). The concordant rate ($C_R$) was calculated as

$$C_R = \left( \frac{N_{CON}}{N_P} \right) \times 100,$$

The discordant rate ($D_R$) was calculated as

$$D_R = \left( \frac{N_{DIS}}{N_P} \right) \times 100.$$

For controls, each suprathreshold cluster was considered a non-epileptogenic finding provided one-third or greater of the cluster overlapped the control cortical mask (excluding likely artifactual findings outside the brain). Specificity ($S_P$) was calculated as

$$S_P = \left( \frac{N_{NF}}{N_C} \right) \times 100.$$

$N_{CON}$, $N_{DIS}$ and $N_{NF}$ in the above equations refer to the number of patients with concordant and discordant findings and the number of controls with no findings, respectively.

**Diagnostic Assessment**

To determine the ideal parameters (smoothing level and T-threshold), we generated receiver operating characteristic curves at each smoothing level by plotting 100-$S_P$ versus $C_R$ for all T-thresholds. The area under the curve (AUC) was calculated using a trapezoidal integration function in Matlab as a performance index for each smoothing kernel width. For comparing single-versus-multispectral VBM, we considered the smoothing level with the best performance (the highest AUC across all smoothing levels; 4–16 mm) for T1 as a reference.

**Determining T-Threshold, $S_p$, and $C_R$**

For this reference smoothing kernel, $S_P$ and $C_R$ values at T-thresholds of 2.5–6 were plotted. We considered the T-threshold in which the remainder of $C_R - S_P$ was the smallest but still positive. This point was referred to as the “optimized T-threshold.” At this threshold, a balanced trade-off between these 2 diagnostic indices ($C_R$ and $S_P$) can be achieved. At this defined T-threshold and the reference smoothing level, $S_P$, $C_R$, and $D_R$ values were reported for all VBM models. Later, the Euclidean distance (ED) of the pair $S_P$, $C_R$ from (100, 100) was calculated for all VBM models as

$$ED = \sqrt{(100 - S_P)^2 + (100 - C_R)^2}.$$

**Visual Interpretation of VBM Findings**

On the basis of the minimum Euclidean distance value across models and analysis, we selected analysis findings for visual interpretation. Visual analysis was performed to verify VBM findings in patients and controls. At the reference smoothing kernel and the optimized T-threshold, all findings across models were inverse-transformed to native space using the deformation utility in SPM12 for each subject separately (“back-normalization”). To group clusters in a close spatial relation, we applied a smoothing of 8-mm full width at half maximum to the transformed cluster maps and considered all clusters connected at a statistical value of >0.5 as a single cluster for the visual review process. Later, these clusters (native space findings) across all models were combined for each subject. Finally, native space findings were overlaid on corresponding patient native T1 and coregistered T2 and FLAIR scans. An expert board-certified neuroradiologist (B.B.) inspected each finding without prior knowledge of the lobar hypothesis and labeled each cluster as the following: 1, potentially epileptogenic and visible; 2, potentially epileptogenic but not visible; 3, nonepileptogenic; 4, unclear/not visible or ambiguous; and 5, artifacts. For visual inspection of controls, each cluster was categorized into the following: 1, visible and nonepileptogenic; 2, unclear/not visible; and 3, artifacts. The reviewer used the nonepileptogenic label when the finding was visible but likely not epileptogenic, such as microangiopathy or perivascular spaces. VBM clusters were rated as unclear when the finding was not sufficiently visible to confirm these findings as potentially epileptogenic, nonepileptogenic, or artifacts. As part of the visual analysis, we reviewed all clusters again to ascertain the correctness of the automated lobar classification and to flag them as either concordant or discordant clusters. This step was needed in only 1 case in which 63.2% of voxels were in the concordant lobar mask. Hence, this cluster was eventually marked as a discordant finding.

**RESULTS**

**VBM Automated Results: Smoothing Parameters in GMC and GMV**

For all models in the GMC analysis, the ideal smoothing was found to be 12 mm. T1+FLAIR showed the best AUC of 0.42 at 12 mm in comparison with T1 (0.35), T1+T2 (0.29), and T1+T2+FLAIR (0.36). For the GMV analysis, the ideal smoothing was also at 12-mm full width at half maximum of different smoothing levels as shown in Fig 1A, -B and On-line Table 2.

**T-Threshold, Concordant Rate, and Specificity**

We found the intersection of $C_R$ and $S_P$ across different T-thresholds at 3.7 for 12 mm in GMC analysis (Fig 1C). At this T-threshold, T1+T2 and T1+FLAIR showed $C_R$, $S_P$ at 46.2, 40.3 and 46.2, 37.1, respectively, compared with T1 at 38.5, 33.9. The ratio of $C_R/D_R$ was also higher for T1+T2 and T1+FLAIR at 0.86 and 0.75, respectively, compared with T1. The Euclidean distances for all models were in the range of 80.37–90.29. The performance details of all models are presented in Table 1. For the GMV analysis, a lower T-threshold of 3.0 was found at 12 mm as the intersection point for $C_R$ and $S_P$. The discordant rate across models was between 7.7% and 38.5%, with specificity between 9.7% and
21%. CR/DR across models was between 0.10 and 0.50. The Euclidean distances were in the range of 105.32–123.66. All details for GMV analysis are provided in Table 2.

### Visual Interpretation Results of VBM Findings

Visual interpretation was performed for GMC analysis at 12-mm full width at half maximum and a T-threshold of 3.7. The highest concordant rate was found for T1/H11001 FLAIR at 46.2% in comparison with T1 at 30.8%. Also, T1+FLAIR showed the highest CR/DR ratio at 1.20 compared with T1 (0.67) and the rest of the models. Only T1+FLAIR and T1+T2+FLAIR showed more or equal concordant-to-discordant findings. The discordant finding rate dropped from 53.8%–84.6% to 30.8%–46.2% after visual interpretation. All results for visual interpretation of patient findings are presented in Table 3. In the visual interpretation of controls, 14.5%–21% of findings were marked as nonepileptogenic, while

<table>
<thead>
<tr>
<th>Model</th>
<th>Concordant Rate (%)</th>
<th>Specificity (%)</th>
<th>Discordant Rate (%)</th>
<th>Euclidean Distance</th>
<th>Concordant Rate/Discordant Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>38.5</td>
<td>33.9</td>
<td>84.6</td>
<td>90.29</td>
<td>0.46</td>
</tr>
<tr>
<td>T1+T2</td>
<td>46.2</td>
<td>40.3</td>
<td>53.8</td>
<td>80.37</td>
<td>0.86</td>
</tr>
<tr>
<td>T1+FLAIR</td>
<td>46.2</td>
<td>37.1</td>
<td>61.5</td>
<td>82.77</td>
<td>0.75</td>
</tr>
<tr>
<td>T1+T2+FLAIR</td>
<td>46.2</td>
<td>35.5</td>
<td>76.9</td>
<td>84.00</td>
<td>0.60</td>
</tr>
</tbody>
</table>

*For VBM GMC automated analysis (prior to visual interpretation), values of concordant rate, specificity, discordant rate, Euclidean distance from CR = S = 100, and concordant/discordant ratio are provided for all models: namely, T1, T1+T2, T1+FLAIR, and T1+T2+FLAIR. The smoothing level and T-threshold are 12 mm and 3.7, respectively.
DISCUSSION

In this study, we identified ideal analysis parameters, namely smoothing and T-threshold (statistical cutoff), with reference to T1 VBM. Incorporating these parameters, we systematically compared T1 and multispectral VBM using a combination of T1, T2, and FLAIR images for detecting gray matter structural abnormalities in patients with MR imaging previously negative for focal epilepsy. We objectified the main VBM parameters, smoothing and statistical cutoffs, with reference to the classic T1 VBM. Furthermore, by systematically comparing multispectral VBM models against T1 VBM and using visual inspection of VBM findings, we found T1+FLAIR as the best performing model based on the discordant rate, specificity, and discordant-to-discordant ratio.

Table 2: GMV analysis for VBM models at 12 mm and a T-threshold of 3.0a

<table>
<thead>
<tr>
<th>Model</th>
<th>Concordant Rate (%)</th>
<th>Specificity (%)</th>
<th>Discordant Rate (%)</th>
<th>Euclidean Distance (Range, 0–141.14)</th>
<th>Concordant Rate/Discordant Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>23.1</td>
<td>21.0</td>
<td>84.6</td>
<td>110.25</td>
<td>0.27</td>
</tr>
<tr>
<td>T1+T2</td>
<td>7.7</td>
<td>17.7</td>
<td>76.9</td>
<td>123.66</td>
<td>0.10</td>
</tr>
<tr>
<td>T1+FLAIR</td>
<td>38.5</td>
<td>9.7</td>
<td>84.6</td>
<td>109.25</td>
<td>0.46</td>
</tr>
<tr>
<td>T1+T2+FLAIR</td>
<td>38.5</td>
<td>14.5</td>
<td>76.9</td>
<td>105.32</td>
<td>0.50</td>
</tr>
</tbody>
</table>

45.2%–53.2% were marked as unclear (Table 4); 17.7%–25.8% of controls also had findings that were classified as artifacts. The overall specificity after visual interpretation across models was between 46.8% and 54.8%.

Table 3: Patients—visual analysis results for GMCa

<table>
<thead>
<tr>
<th>Model</th>
<th>Potentially Epileptogenic (and Visible)</th>
<th>Potentially Epileptogenic (and Not Visible)</th>
<th>Potentially Epileptogenic (Combined)</th>
<th>Nonepileptogenic</th>
<th>Unclear</th>
<th>Artifacts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concordant lobe (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>15.4</td>
<td>15.4</td>
<td>30.8</td>
<td>7.7</td>
<td>15.4</td>
<td>0</td>
</tr>
<tr>
<td>T1+T2</td>
<td>15.4</td>
<td>0</td>
<td>15.4</td>
<td>7.7</td>
<td>15.4</td>
<td>0</td>
</tr>
<tr>
<td>T1+FLAIR</td>
<td>15.4</td>
<td>30.8</td>
<td>46.2</td>
<td>7.7</td>
<td>23.1</td>
<td>0</td>
</tr>
<tr>
<td>T1+T2+FLAIR</td>
<td>15.4</td>
<td>15.4</td>
<td>30.8</td>
<td>7.7</td>
<td>23.1</td>
<td>0</td>
</tr>
<tr>
<td>Discordant lobe (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>7.7</td>
<td>38.5</td>
<td>46.2</td>
<td>7.7</td>
<td>30.8</td>
<td>15.4</td>
</tr>
<tr>
<td>T1+T2</td>
<td>7.7</td>
<td>23.1</td>
<td>30.8</td>
<td>7.7</td>
<td>30.8</td>
<td>7.7</td>
</tr>
<tr>
<td>T1+FLAIR</td>
<td>7.7</td>
<td>30.8</td>
<td>38.5</td>
<td>7.7</td>
<td>30.8</td>
<td>7.7</td>
</tr>
<tr>
<td>T1+T2+FLAIR</td>
<td>7.7</td>
<td>23.1</td>
<td>30.8</td>
<td>7.7</td>
<td>30.8</td>
<td>7.7</td>
</tr>
</tbody>
</table>

Visual interpretation results of GMC analysis of patients are provided. The results contain percentages of patients scored by the reviewer as potentially epileptogenic and visible, potentially epileptogenic and not visible, potentially epileptogenic (number of patients with potentially epileptogenic and visible/not visible or both), nonepileptogenic, unclear, and artifacts. The results are reported for both concordant and discordant lobes.

Table 4: Controls—visual analysis results for GMCa

<table>
<thead>
<tr>
<th>Models</th>
<th>All Lobes (%)</th>
<th>Nonpileptogenic</th>
<th>Unclear</th>
<th>Artifacts</th>
<th>Corrected Specificity (Excluding Artifacts and Nonepileptogenic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td></td>
<td>14.5</td>
<td>53.2</td>
<td>22.6</td>
<td>46.8</td>
</tr>
<tr>
<td>T1+T2</td>
<td></td>
<td>21.0</td>
<td>45.2</td>
<td>17.7</td>
<td>54.8</td>
</tr>
<tr>
<td>T1+FLAIR</td>
<td>16.1</td>
<td>50.0</td>
<td>19.4</td>
<td>50.0</td>
<td></td>
</tr>
<tr>
<td>T1+T2+FLAIR</td>
<td>16.1</td>
<td>48.4</td>
<td>25.8</td>
<td>51.6</td>
<td></td>
</tr>
</tbody>
</table>

Visual interpretation results of GMC analysis for controls are presented. The results contain the percentage of controls scored by the reviewer as potentially epileptogenic and visible, potentially epileptogenic and not visible, potentially epileptogenic (number of patients with potentially epileptogenic and visible/not visible or both), nonepileptogenic, unclear, and artifacts. The results are reported for all lobes.

Smoothing and Statistical Cutoff

There is a wide variation in parameters in VBM studies for lesion detection in epilepsy for smoothing kernel sizes ranging from 5 to 14 mm7-9,16-18and for a statistical cutoff from P < .001 uncorrected (corresponding to a statistical cutoff T of approximately 3.2 in our sample) to P < .05 family wise error–corrected (corresponding to a statistical cutoff T of approximately 5.1 in our sample)10 as well as comparisons at multiple statistical cutoffs.3 We provide a systematic comparison of the 2 main parameters focused on patients with focal epilepsy, but negative conventional MRI, given that this is the main target cohort for advanced lesion detection in epilepsy. For the most frequently used T1-only approach, we found that a smoothing of 12-mm full width at half maximum and a threshold of T = 3.7 provide the highest AUC and best diagnostic balance between concordant rate and specificity. Most interesting, our recommendation of a 12-mm smoothing kernel is similar to that in a previous study conducted by Salmond et al.15 In line with this study, we found a low specificity with decreased diagnostic performance (AUC, Fig 1A and On-line Table 2) at 4 mm across all models.

Second, as expected, the concordant rate decreased and specificity increased with respect to increasing statistical cutoffs (Fig 1C). This finding is in agreement with a previous study on a lesional cohort based on Z-scores.8 We aimed for a balance between sensitivity/Cs and specificity (maximal AUC, intersection of Cs and Sp). It is debatable whether a different approach with maximized sensitivity could also be clinically useful, dealing with little or no specificity. However, in our view, a VBM approach should have at least some
degree of specificity to be informative in the difficult context of MRI-negative patients, in which invasive diagnostics and invasive EEG are commonly performed and carry low-but-non-negligible risks for patients. Martin et al.10 found that the best odds ratio for predicting postoperative seizure freedom was achieved by the VBM variant with the best specificity, namely the normalized FLAIR signal. Nonetheless, our results will also provide guidance if other groups want to select their analysis parameters with a different intention, either maximizing sensitivity or specificity (On-line Figs 1 and 2).

**Gray Matter Concentration versus Volume Analysis**

We found that gray matter concentration analysis revealed better results for both single- and multispectral models in comparison with volume analysis. This is in agreement with a previous study in a different cohort in which gray matter concentration was found to be better in detecting epileptogenic lesions in MRI-negative and MRI-positive patients.10 The only difference between the 2 analyses is the additional step of modulation, which is intended to preserve the original tissue volume.6 The exact reason for this diagnostic difference remains speculative. It is possible that epileptogenic lesions and focal cortical dysplasias are better characterized by local changes of tissue composition, and global volume effects attenuate the effect size (eg, “compensating” gray matter increase in the lesions with atrophy in the surrounding area). Whether superiority of GMC over GMV analysis remains true for different MR imaging pulse sequences with different tissue contrasts needs to be determined.

**Visual Interpretation of VBM Findings**

After visual interpretation of control findings, we found a specificity range between 46.8% and 54.8% across all models. We cannot draw a direct comparison with previous studies because our VBM models, smoothing and statistical cutoffs, are different from those in past studies.10,16,20 However, we are in line with our previous study on 50 controls, in which a specificity of 42% was reported for T1 gray matter concentration analysis10 at P < .05 (family-wise error). Moreover, 12.9%–16.1% of controls had only visible (nonepileptogenic/artifacts) findings (ie, controls who had visible findings but no unclear findings). This finding contributed to an increase in specificity after visual analysis (Table 4). In a previous study based on the morphometric analysis program, approximately 25% of findings in controls (13 of 52) were marked as nonepileptogenic normal variants,20 similar to our results. Across models, after visual analysis, we observed a drop in concordant and discordant rates (Tables 1 and 3). In a previous study based on an MR imaging cohort negative for epileptogenic lesions, after visual analysis, the concordant rate for FLAIR and T1 VBM dropped from 28.6% and 14.3% to 14.3% and 0%, respectively.7 This result shows that visual interpretation of VBM findings is needed before considering these for epilepsy surgery. Nevertheless, we and others have previously shown that VBM findings carry a positive odds ratio for a good outcome after epilepsy surgery and are, thus, clinically relevant.10,20

**Effect of Multispectral VBM**

After visual inspection, the highest concordant rate was confirmed for multispectral T1 + FLAIR at 46.2% in comparison with T1 (30.8%) and the other models. This is in line with a previous study in patients with lesional epilepsy, in which multispectral T1 + FLAIR also showed a superior performance compared with T1.12 Similarly, the enhanced performance of FLAIR-VBM (concordant rate, 14.3%) over T1 (0%) was also found in a study cohort of children with cryptogenic epilepsy.7 Additionally, intensity-normalized FLAIR-VBM11 showed positive odds of 7.3 for a successful surgical outcome in comparison with T1 VBM in 129 patients with MR imaging negative for epilepsy.10 This finding indicates that inclusion of a new channel, FLAIR in this case, can contribute to increasing discordant rates in a cohort with MR imaging negative for focal epilepsy. Overall these results show that multispectral VBM is superior to T1 VBM, but there still is a need for new modalities and approaches to be explored (eg, based on [resting-state] functional imaging, alternative tissue contrasts like MP2RAGE/diffusion imaging, and higher magnetic fields).

**Discordant Findings in Patients**

All VBM variants had a relevant number of findings discordant with the primary clinical hypothesis, but these differed substantially among the variants. Only T1 + FLAIR showed more concordant-than-discordant findings, with the highest concordant-to-discordant ratio among all models and approximately 2 times more than in T1. In a previous study, Martin et al.10 showed that only normalized FLAIR-VBM had more discordant than discordant findings in MRI-negative patients against T1. In the same study, only normalized FLAIR-VBM had no discordant findings in the group of 15 patients with MR imaging positive for focal cortical dysplasia. We are not aware of any other VBM-based study addressing discordant findings in the cryptogenic epilepsy cohort; 30.8%–46.2% of patients still had discordant findings that were marked as potentially epileptogenic. In this most challenging epilepsy surgery cohort (MR imaging negative for focal epilepsy), the definition of an epileptogenic zone is often limited because fast propagation of epileptogenic activity can be difficult to detect in scalp video-EEG.22,23 Furthermore, patients can have >1 epileptogenic zone/lesion, and our hypotheses were derived from noninvasive data (especially video telemetry EEG) in many cases (On-line Table 1). Thus, VBM findings initially considered discordant may still be real and clinically relevant. We also provided the discordant and discordant findings in patients for all VBM models that were visually confirmed as potentially epileptogenic as in On-line Table 3.

**Nonvisible Findings**

Patients and controls also had findings marked as not visible (Table 5). The biologic meaning of these findings that are not visible, is difficult to assess. They can be due to subtle artifacts beyond the visible threshold (eg, field inhomogeneities or movement) or minor differences in cortical morphology without direct pathologic mean-

---

### Table 5: Nonvisible findings—visual analysis results for GMC

<table>
<thead>
<tr>
<th>Models</th>
<th>All Lobes (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>53.2</td>
</tr>
<tr>
<td>T1 + T2</td>
<td>45.2</td>
</tr>
<tr>
<td>T1 + FLAIR</td>
<td>50.0</td>
</tr>
<tr>
<td>T1 + T2 + FLAIR</td>
<td>48.4</td>
</tr>
</tbody>
</table>

*All Lobes (%) are reported.*
In patients, these findings can also represent subtle epileptogenic lesions that escape visual detection. In a direct comparison, the frequency of detecting a nonvisible finding was only slightly higher in patients than in controls (for some models), making it likely that these findings are largely nonspecific. However, more clinical data and follow-up are needed to draw further conclusions from such nonvisible findings.

**Diagnostic Value of Multispectral FLAIR-VBM in Focal Epilepsy**

A major advantage of multispectral VBM lies in simultaneously including FLAIR along with T1. It takes only an extra 5–7 minutes to acquire 3D-FLAIR. Additionally, processing time for T1 and T1+FLAIR VBM differs only in the extra step of coregistration for the latter. Second, many lesions in focal epilepsy (focal cortical dysplasia, hippocampal sclerosis, tumors) have a prolonged T2-relaxation, resulting in hyperintense signal and increased visibility on a FLAIR image. Thus, it is not surprising that FLAIR-based methods could detect those lesions better than T1 alone. For example, Fig 2 shows the presumed lesion to be more visible on FLAIR than on T1 images. All VBM models eventually detect this abnormality, but the coverage and effect size were best in VBM models that include FLAIR. The finding is in concordance with the clinical lobar hypothesis, which was in the right frontal lobe, indicated by noninvasive and intracranial EEG.

Another example is shown in Fig 3, where only T1+FLAIR VBM detects a subtle structural abnormality in the left temporopinsular region. In comparison with the right side, a subtle blurring of GM-WM is visible at the left temporal operculum/posterior insula. This finding is in concordance with the clinical lobar hypothesis of bilateral temporal onset. In both cases, it is likely that the suspected abnormalities are segmented as gray matter and, consequently, increase the gray matter probability when the FLAIR image is added. Furthermore, the improved tissue classification by multimodal segmentation may improve the lesion detection. Of the 3 patients with operations, 1 patient (patient 6) had findings concordant with the lobar clinical hypothesis in the left temporal region detected by T1...
and T1+FLAIR but not coinciding with the resected area. The patient was seizure-free for only 1 year before seizures resumed, raising the possibility of a partial resection and prompting further clinical investigations.

**Limitations**

Five of six patients with concordant findings did not have surgical resection; the one patient with a resection did not have the finding in the resection area and later had seizure relapse. Hence, a histopathologic confirmation was not possible. Low rates of surgical resection as well as reduced chances of seizure freedom are typical for patients with MR imaging negative for epilepsy. Nonetheless, a visual review of the findings by an expert radiologist blinded to the clinical hypothesis shows clear improvement in the concordant/discordant ratio for multispectral VBM. This indicates that these findings can be of diagnostic relevance. However, our study cannot assess whether multispectral VBM will eventually improve the surgical outcome. This will require longitudinal multimodal studies by large multicenter collaborations. Our results can guide the choice of sequences and analysis parameters for such projects.

**CONCLUSIONS**

We provide optimized VBM parameters, specifically smoothing and statistical cutoff (T-threshold), for lesion detection in MR imaging previously negative for focal epilepsy with T1 VBM as a reference. We systematically compared multispectral VBM with T1 VBM. We found a smoothing level of 12 mm and a T-threshold of 3.7 for GMC analysis as ideal parameters. With these parameters, after we visually confirmed VBM findings, multispectral VBM T1+FLAIR yielded results superior to those of all other models. We also found VBM an important computational advancement, which, after a careful visual interpretation, can aid the presurgical evaluation of focal epilepsy. We recommend multispectral VBM, especially T1+FLAIR, as currently the best VBM model in detecting increased gray matter structural abnormalities in patients with MR imaging previously negative for focal epilepsy.

Disclosures: Benjamin Bender—UNRELATED: Expert Testimony; Medtronic*. Niels K. Focke—RELATED: Grant: Deutsche Forschungsgemeinschaft/Deutsche Forschungsgemeinschaft. Comments: Deutsche Forschungsgemeinschaft grant FO750/5-3; UNRELATED: Consultancy: Bial, Eisai; Payment for Lectures Including Service on Speakers Bureau: UCB; Payment for Development of Educational Presentations: Bial. *Money paid to the institution.

**REFERENCES**

Does the Presence or Absence of DESH Predict Outcomes in Adult Hydrocephalus?


ABSTRACT

BACKGROUND AND PURPOSE: The DESH (disproportionately enlarged subarachnoid-space hydrocephalus) pattern of “tight high-convexity and medial subarachnoid spaces, and enlarged Sylvian fissures with ventriculomegaly” is used to determine which patients undergo an operation for adult hydrocephalus at many centers. Our aim was to review adult hydrocephalus cases when DESH has not been a criterion for an operation to determine the prevalence of DESH among the cohort and compare the surgical outcomes in the presence or absence of DESH.

MATERIALS AND METHODS: A retrospective cohort study was conducted at a single institution (Johns Hopkins Hospital) to include patients surgically treated for adult hydrocephalus between 2003 and 2014 drawn from a data base of patients who had undergone standardized hydrocephalus protocol MR imaging. Preoperative imaging was reviewed by 2 blinded neuroradiologists to characterize the presence of DESH. Preoperative and postoperative clinical symptomatology was recorded. Frequencies were compared using the Fisher exact test, and nonparametric means were compared using the Mann-Whitney U Test.

RESULTS: One hundred thirty-three subjects were identified and included (96 DESH absent, 37 DESH present). Shunting led to significant improvement in gait and urinary and cognitive symptoms for the overall cohort and for patients with and without DESH (P < .05). The Fisher exact test did not demonstrate any significant differences in either gait or urinary or cognitive symptom improvement between patients with or without DESH (P > .05).

CONCLUSIONS: The current study demonstrated symptom improvement in patients with adult hydrocephalus following shunting, with no significant differences between subjects with and without DESH. Thus, shunt insertion for patients with adult hydrocephalus should not rely solely on the presence of preoperative DESH findings.

ABBREVIATIONS: DESH = disproportionately enlarged subarachnoid-space hydrocephalus; iNPH = idiopathic normal pressure hydrocephalus; MMSE = Mini-Mental State Examination; NPH = normal pressure hydrocephalus; TUG = Timed Up and Go test

Adult hydrocephalus, the communicating form known as normal pressure hydrocephalus (NPH) in the elderly population, is associated with the classic triad of gait, cognitive, and urinary disturbances.1,2 Shunting is the mainstay of treatment, but the accurate neuroradiologic diagnosis of shunt-responsive adult hydrocephalus may be difficult. As described by the NPH guidelines study group, there is no single standard for the imaging evaluation of idiopathic NPH (iNPH).3-5

The Study of Idiopathic Normal Pressure Hydrocephalus on Neurologic Improvement (SINPHONI) developed MR imaging–based diagnostic criteria for adult hydrocephalus, termed “disproportionately enlarged subarachnoid-space hydrocephalus” (DESH).2 DESH is defined as “tight high-convexity and medial subarachnoid spaces, and enlarged Sylvian fissures with ventriculomegaly.” Hashimoto et al2 reported that the DESH criteria, on coronal MR imaging, are a defining characteristic for iNPH. The DESH pattern is used to aid in the surgical selection of patients in some centers and is given particular weight in some geographic areas.6

The aim of the present study was to review adult hydrocephalus cases at a single institution (Johns Hopkins Hospital), where the presence or absence of DESH has not been used as a surgical criterion, to determine the prevalence of DESH among the cohort, characterize adult hydrocephalus cases by the presence of DESH criteria, and compare the outcomes of patients with and without DESH following shunting treatment.
MATERIALS AND METHODS

Study Design and Inclusion Criteria
A retrospective chart review was conducted, following institutional review board approval (NA_00067508), which included patients who underwent treatment for adult hydrocephalus at a single institution from 2003 to 2014 selected from a data base of patients who have undergone a standardized hydrocephalus protocol clinical high-resolution MR imaging, including sagittal MPRAGE (TR, 2300 ms; TE, 1.88 ms; inversion recovery, 900; 144 partitions; 0.9-mm isotropic voxels). Patients undergoing an operation had a preoperative Evans index of >0.3 and symptoms of potential hydrocephalus. The inclusion criteria for screening consisted of patients 18–80 years if age with symptomatic and radiographically confirmed adult hydrocephalus treated by surgical shunting, with sufficient preoperative imaging and a detailed medical record describing preoperative and postoperative symptoms. All included patients underwent high-resolution imaging through the hydrocephalus center for evaluation of potential adult hydrocephalus.

Hydrocephalus Classification
All preoperative images were de-identified and reviewed by 2 neuroradiologists blinded to clinical features, with discrepancies resolved through consensus, and scored for the presence or absence of all DESH criteria, based on the previously published criteria. However, previous reports did not include cutoff measurements for Sylvian fissure enlargement according to the DESH criteria. Consistent with the literature definition of DESH, the presence of Sylvian fissure enlargement was a qualitative observation made after thorough review of the relevant literature. The authors chose not to classify Sylvian fissure enlargement by measurement, to avoid inconsistencies with previous reports describing the DESH classification. In an effort to include a pure sample of DESH cases and controls negative for DESH, we excluded patients who had partial features of DESH without fulfilling all criteria from this study. Excluded patients were those with either tight high-convexity and medial subarachnoid spaces without enlarged Sylvian fissures or patients with enlarged Sylvian fissures in the absence of tight high-convexity and medial subarachnoid spaces.

Recorded Data
Following retrospective review of medical records for adult patients surgically treated for hydrocephalus, demographic (age at treatment and sex) data, symptomatology, and treatment were recorded. Imaging, gait, urinary dysfunction, dementia, Mini-Mental State Examination (MMSE) scores, Timed Up and Go test (TUG) scores, Tinetti scores, and depression status were recorded preoperatively and postoperatively. Baseline gait was recorded on a scale of 0–4: 0, no gait abnormality; 1, minor gait abnormality on uneven surfaces or with regard to pace; 2, recent history of falls; 3, requiring cane or walker assistance; and 4, wheelchair-bound. Urinary function was recorded as the following: 0, no urinary dysfunction; 1, urinary urgency, hesitancy, ambiguous dysfunction, or noted by others; 2, rare urinary dysfunction; 3, frequent urinary dysfunction; and 4, incontinent. Cognitive symptoms were recorded as the following: 0, no cognitive symptoms; 1, infrequent forgetfulness or ambiguous cognitive symptoms; 2, mild cognitive symptoms; 3, frequent cognitive symptoms; and 4, severe cognitive impairment in activities of daily living.

Because many studies of adult hydrocephalus suggest 1 year of follow-up, postoperative clinical outcomes were recorded close to the 1-year postoperative follow-up visit and at the last known clinical follow-up. Postoperative gait, and urinary and cognitive symptoms were graded by 3 criteria: 1, worsening of symptoms; 2, no improvement (ie, same as baseline); or 3, improvement in symptoms at the last known clinical follow-up.

Statistical Analysis
Frequencies were compared using the Fisher exact test, and non-parametric means were compared using the Mann-Whitney U test. A P value < .05 was considered significant. Analysis was performed by using STATA SE 12 (StataCorp, College Station, Texas).

RESULTS
Patient Demographics and Baseline Characteristics
Patients surgically treated for adult hydrocephalus during an 11-year period (2003–2014) were included. Following blinded neuroradiology review of preoperative imaging for 162 adult patients surgically treated for hydrocephalus, 29 patients had partial features of DESH without fulfilling the complete DESH criteria and were excluded from this study. Of the remaining 133, ninety-six (72.2%) did not meet any DESH criteria and 37 (27.8%) had all DESH features present (Figure and Table 1). Of the 133 patients included in this study, 68.4% were men. The mean age at shunting was 71.7 years (range, 53–80 years) (Table 1).

Clinical Presentation
Preoperatively, 14 (10.5%) patients presented with a normal gait, 18 (13.5%) presented with gait abnormalities on an uneven surface or slow pace, 54 (40.6%) had a history of falls, 39 (29.3%) required an assisted gait, and 8 (6%) were wheelchair-bound. Of the 133 patients, those with preoperative findings of DESH (n = 37) had greater preoperative gait dysfunction compared with those without DESH (n = 96) (P < .05). Of those with preoperative DESH findings, only 2.7% had a normal gait compared with 13.5% of those without DESH (Table 2).

Of the cohort of 131 patients in whom urinary function was known, 43 (32.8%) had no preoperative urinary dysfunction; 18 (13.7%) had urgency, anxiety, or ambiguous symptoms; 43 (32.8%) had rare or intermittent symptoms; 16 (12.2%) had urinary dysfunction often; and 10 (7.6%) had urinary incontinence at presentation. There were no significant differences between patients with or without DESH, regarding preoperative urinary dysfunction (P > .05).

Similar to urinary dysfunction, there were no significant differences between patients with and without DESH with respect to preoperative dementia. In both groups, 15.8% had no dementia, preoperatively (P > .05) (Table 2).

The mean score for the MMSE was 26.5 (95% CI, 7–30); for the Tinetti, it was 21.4 (95% CI, 6–28); and for the TUG, it was 19.07 (95% CI, 4.5–82); 55.3% of patients presented with depression and 56.4% presented with headaches. MMSE, Tinetti, TUG,
The Fisher exact test did not demonstrate any significant difference in the proportion of either urinary or dementia symptom improvement between patients with or without DESH ($P > .05$) (Table 3). The Fisher exact test also did not demonstrate any demographically significant differences with respect to sex or age for patients with known baseline and postoperative gait, urinary, and dementia symptoms ($P > .05$ for all).

The number of patients with known postoperative status for the MMSE, Timed-Up-and-Go (TUG) test, and Brief Cognitive Function Inventory (BCFI) was limited. Therefore, it is not found to be statistically significant compared with preoperative values.

**DISCUSSION**

The communicating form of adult hydrocephalus in the elderly, NPH, is associated with the classic triad of gait, cognitive, and urinary disturbances. A third of NPH cases are classified as idiopathic, not secondary to trauma, surgery, meningitis, or other abnormalities of the arachnoid mater. Ventricular shunting may provide symptom relief in cases of NPH, which can be difficult to distinguish from vascular dementias and neurodegenerative diseases of the elderly. Thus, the treatment of NPH relies partly on accurate neuroimaging diagnosis and characterization.

Kitagaki et al demonstrated that the Sylvian fissure CSF volume and ventricular volume were greater in patients with iNPH compared with other dementias (ie, Alzheimer disease). Patients with iNPH also had decreased CSF in the superior convexity and medial subarachnoid spaces. This study supported enlarged basal cisterns and Sylvian fissures, with focally dilated sulci, as responsive to shunting. Narita et al showed that presurgical high-convexity tightness, callosal angle, and Sylvian fissure dilation were significantly associated with clinical improvement. Following multiple linear regression, high-convexity tightness alone predicted clinical improvement at 1 year. However, 92% of patients had high-convexity tightness (rated as ≥2), and 100% had Sylvian fissure dilation (rated as ≥2). Similar to findings in the current study, findings in patients with DESH did improve following shunting, but the study of Narita et al excluded patients with no DESH findings who were treated by shunting.

In a study by Mostafa et al, 72 patients negative for DESH and 31 patients positive for DESH with adult hydrocephalus were assessed for shunt responsiveness—compared with 96 and 37 patients in the current study, respectively. In this study of the 103 patients included, 78 demonstrated symptomatic improvement at 1 year after shunting. Most interesting, of those who improved, 69% were negative for DESH findings and only 31% were positive for DESH with significance between both groups ($P < .001$). The positive and negative predictive values for DESH findings predicting shunt responsiveness were 77% and 25%, respectively. This finding suggests that though the presence of DESH may predict shunt responsiveness, its absence does not preclude symptom improvement following shunting. The authors did not directly compare surgical outcomes of patients positive and negative for DESH, leaving open the possibility that DESH features were significant contributors to prognosis.

In the current study, patients positive for DESH had improvement in urinary, gait, and dementia symptoms following shunt...
treatment. However, the data also demonstrated shunt responsiveness in the absence of DESH findings. Unlike previous literature, in our study, gait, dementia, and urinary symptoms improved in groups with DESH and without DESH following shunting, with no significant differences between groups. The DESH findings of tight high-convexity and medial subarachnoid spaces and enlarged Sylvian fissures with ventriculomegaly may therefore encompass only a portion of shunt-responsive adult hydrocephalus.

Limitations of this work include a sample size from a single institution, and those inherent in retrospective studies. In particular, outcome data available in the medical record for subjects in the study were limited and not homogeneous among all subjects. Because patients who fulfilled only partial features of DESH were

<table>
<thead>
<tr>
<th>Table 2: Preoperative clinical presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
</tr>
<tr>
<td>Gait (No.)</td>
</tr>
<tr>
<td>Normal gait</td>
</tr>
<tr>
<td>Gait abnormality with uneven surfaces or pace</td>
</tr>
<tr>
<td>History of falls</td>
</tr>
<tr>
<td>Assisted gait (ie, walker)</td>
</tr>
<tr>
<td>Wheelchair-bound</td>
</tr>
<tr>
<td>Urinary dysfunction (No.)</td>
</tr>
<tr>
<td>No dysfunction</td>
</tr>
<tr>
<td>Urgency, anxiety, or ambiguous symptoms not otherwise classified</td>
</tr>
<tr>
<td>Rare or intermittent symptoms</td>
</tr>
<tr>
<td>Urinary symptoms often</td>
</tr>
<tr>
<td>Urinary incontinence (requiring adult diapers)</td>
</tr>
<tr>
<td>Dementia (No.)</td>
</tr>
<tr>
<td>No dementia</td>
</tr>
<tr>
<td>Forgetfulness</td>
</tr>
<tr>
<td>Mild dementia</td>
</tr>
<tr>
<td>Moderate dementia</td>
</tr>
<tr>
<td>Severe dementia</td>
</tr>
<tr>
<td>MMSE (mean) (95% CI)</td>
</tr>
<tr>
<td>Tinetti (proportion)</td>
</tr>
<tr>
<td>TUG (mean) (95% CI)</td>
</tr>
<tr>
<td>Depression (proportion)</td>
</tr>
<tr>
<td>Headache (proportion)</td>
</tr>
</tbody>
</table>

* The MMSE score was available for 26/96 patients with preoperative findings without DESH and 34/37 patients with DESH.

<table>
<thead>
<tr>
<th>Table 3: Outcomes following treatment for adult hydrocephalus at last known follow-up (1248.3 ± 103.3 days following surgery)a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
</tr>
<tr>
<td>Gait (No.)</td>
</tr>
<tr>
<td>Improvement</td>
</tr>
<tr>
<td>No improvement</td>
</tr>
<tr>
<td>Worse</td>
</tr>
<tr>
<td>Normal findings at baseline</td>
</tr>
<tr>
<td>P valueb</td>
</tr>
<tr>
<td>Improvement compared with baseline</td>
</tr>
<tr>
<td>Urinary dysfunction (No.) (%)</td>
</tr>
<tr>
<td>Improvement</td>
</tr>
<tr>
<td>No improvement</td>
</tr>
<tr>
<td>Worse</td>
</tr>
<tr>
<td>Normal findings at baseline</td>
</tr>
<tr>
<td>P valueb</td>
</tr>
<tr>
<td>Improvement compared with baseline</td>
</tr>
<tr>
<td>Dementia (No.) (%)</td>
</tr>
<tr>
<td>Improvement</td>
</tr>
<tr>
<td>No improvement</td>
</tr>
<tr>
<td>Worse</td>
</tr>
<tr>
<td>Normal findings at baseline</td>
</tr>
<tr>
<td>P valueb</td>
</tr>
<tr>
<td>Improvement compared with baseline</td>
</tr>
<tr>
<td>MMSE</td>
</tr>
<tr>
<td>Tinetti</td>
</tr>
<tr>
<td>TUG</td>
</tr>
</tbody>
</table>

a Columns compare the proportion improved among a cohort (ie, overall, DESH, No DESH); rows compare proportional improvement between those with and without DESH.

b The Fisher exact test was performed for those with preoperative symptoms, excluding those with normal findings at baseline. Findings are significant.
excluded from this study, the findings presented cannot be generalized to all patients with adult hydrocephalus. The exclusion of patients with poor clinical documentation or insufficient follow-up is unavoidable when collecting meaningful data but introduces the potential for bias in the inclusion of subjects. Our data suggest that if there is prognostic significance for the DESH pattern below the power of our study, it is not of sufficient magnitude to warrant significant weighting for the selection of individual patients for an operation. Future prospective studies in this area are required, including rigorous preoperative and postoperative clinical and radiographic evaluation.

CONCLUSIONS

Normal-pressure hydrocephalus, a communicating form of adult hydrocephalus, is associated with the classic triad of gait, cognitive, and urinary disturbances in elderly patients. The DESH findings of tight high-convexity and medial subarachnoid spaces and enlarged Sylvian fissures with ventriculomegaly can be used for the diagnosis of NPH but may only encompass a portion of shunt-responsive adult hydrocephalus. The current study demonstrated urinary and dementia symptom improvement in both the presence and absence of DESH following shunting, with no significant differences between groups. Thus, shunt insertion for patients with adult hydrocephalus should not rely solely on the presence of preoperative DESH findings.


REFERENCES

7. Mendes GAS, de Oliveira MF, Pinto FCG. The Timed Up and Go Test as a diagnostic criterion in normal pressure hydrocephalus. World Neurosurg 2017;105:456–61 CrossRef Medline
Prospective Multicenter Study of Changes in MTT after Aneurysmal SAH and Relationship to Delayed Cerebral Ischemia in Patients with Good- and Poor-Grade Admission Status


ABSTRACT

BACKGROUND AND PURPOSE: Patients with aneurysmal SAH and good clinical status at admission are considered at a lower risk for delayed cerebral ischemia. Prolonged MTT may be associated with an increased risk. It is unclear whether this is dependent on clinical status. Our purpose was to determine whether increased MTT within 3 days of aneurysmal SAH compared with baseline is associated with a higher risk of delayed cerebral ischemia in patients with good (World Federation of Neurosurgical Societies I–III) versus poor (World Federation of Neurosurgical Societies IV–V) admission status.

MATERIALS AND METHODS: This prolonged MTT was a multicenter, prospective cohort investigation of 87 patients with aneurysmal SAH. MTT was measured at admission before aneurysm treatment (MTT1) and following repair (MTT2) within 3 days of admission; MTTdiff was calculated as the difference between MTT2 and MTT1. Changes in MTT across time were assessed with repeated measures analyses. Risk of delayed cerebral ischemia or death was determined with multivariate logistic regression analysis.

RESULTS: In patients with a good grade (n = 49), MTT was prolonged in patients who developed delayed cerebral ischemia, with MTTdiff significantly greater (0.82 ± 1.5) compared with those who did not develop delayed cerebral ischemia (−0.14 ± 0.98) (P = .03). Prolonged MTT was associated with a significantly higher risk of delayed cerebral ischemia or death (OR = 3.1; 95% CI, 1.3–7.4; P = .014) on multivariate analysis. In patients with poor grades (n = 38), MTTdiff was not greater in patients who developed delayed cerebral ischemia; MTT1 was significantly prolonged compared with patients with a good grade.

CONCLUSIONS: Patients in good clinical condition following aneurysmal SAH but with increasing MTT in the first few days after aneurysmal SAH are at high risk of delayed cerebral ischemia and warrant close clinical monitoring.

ABBREVIATIONS: aSAH = aneurysmal SAH; DCI = delayed cerebral ischemia; GCS = Glasgow Coma Scale; ICP = intracranial pressure; MTT = MTT before aneurysm treatment; MTT2 = MTT after repair; MTTdiff = the difference between MTT before aneurysm treatment and after repair; WFNS = World Federation of Neurosurgical Societies

Identifying patients at high risk of delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH) is important for guiding medical and endovascular management and could help improve disposition planning. Management algorithms are largely based on admission clinical status and the volume of SAH. The World Federation of Neurosurgical Societies (WFNS) has a commonly used scale to assess presentation clinical status. Higher WFNS grades (IV–V) are associated with a higher risk of DCI and death, while a good grade (WFNS I–III) at admission indicates lower risk. Early perfusion abnormalities before DCI symptoms could help identify patients at risk. Specifically, delayed MTT measured with CTP may be associated with higher risk. Absolute thresholds have been cited but depend on physiologic variability between individuals and technical aspects of acquisition and post-

Received March 25, 2018; accepted after revision July 26.
From the Division of Diagnostic and Interventional Neuroradiology (A.M., T.R.M., A. Bharatha), Department of Medical Imaging, Division of Neurosurgery (R.L.M.), Departments of Anesthesia and Critical Care Medicine (A. Baker), Labatt Family Centre of Excellence in Brain Injury and Trauma Research (R.L.M.), Keenan Research Centre for Biomedical Science (R.L.M.), St. Michael’s Hospital, Toronto, Ontario, Canada; Lawson Health Research Institute and Robarts Research Institute (T.-Y.L.), University of Western Ontario, London, Ontario, Canada; Division of Neurosurgery (T.R.M., J.S., A. Bharatha), Department of Surgery, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; Departments of Physiology and Surgery (R.L.M.) and Medical Imaging (A. Bharatha), University of Toronto, Toronto, Ontario, Canada; and Department of Medical Imaging (R.I.A.), Sunnybrook Hospital, Toronto, Ontario, Canada.

A.M. was supported by an RSNA Research Fellow Grant. Portions of this work were supported by the Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario (St. Michael’s Hospital, Sunnybrook Hospital) to A. Bharatha and R.I.A.

http://dx.doi.org/10.3174/ajnr.A5844
The purpose of this study was to determine whether prolonged MTT within 3 days of aSAH is associated with a higher risk of DCI in patients with good (WFNS I–III) and poor (WFNS IV–V) clinical status on admission. Secondarily, we assessed the pattern of MTT changes before and after aneurysm treatment in patients with good and poor grades.

MATERIALS AND METHODS

Study Population
This was a prospective multicenter cohort investigation of patients with aSAH between 2015 and 2017. Power analysis performed for logistic regression analysis with DCI as a binary response variable showed that 83 patients were required to achieve 80% power at .05 significance. Inclusion criteria were aSAH and age older than 18 years. Exclusion criteria were the following: no aneurysm, prior aneurysm treatment, poor scan quality, no baseline CTP, severe renal dysfunction, or contrast allergy. Consecutive patients presenting with aSAH at 2 institutions (St. Michael’s Hospital and Sunnybrook Hospital, Toronto, Ontario, Canada) were screened. Institutional ethics approval and informed consent were obtained.

Clinical Data
Patient demographics, WFNS grade (good grade = I–III; poor grade = IV–V), Glasgow Coma Scale (GCS) score, hypertension, and smoking status were recorded at admission. The type of aneurysm treatment (clipping or coiling) was documented. Intracranial pressure (ICP) measurements were obtained at scanning when available.

DCI was defined according to a previously published consensus statement and considered present with new focal neurologic impairment or a decrease of at least 2 points in the GCS score not apparent immediately after aneurysm treatment and not attributed to other causes.9 Death within 2 weeks of admission was additionally noted. Timing of medical and endovascular treatment for DCI was reviewed to confirm occurrence after the onset of symptoms.

CT
Each patient had a noncontrast CT, CTA, and CTP on admission (before aneurysm treatment) and within 3 days of admission (after aneurysm treatment). Admission noncontrast CT images were assessed to determine the Modified Fisher Scale grade10 and for hydrocephalus and intraparenchymal hematoma. CTAs were assessed for angiographic vasospasm (the presence of large-artery vessel narrowing at baseline or on a subsequent study compared with baseline).

CTP was performed on either 256-slice or 64-slice scanners (Revolution or VCT; GE Healthcare, Milwaukee, Wisconsin) (256-slice: 14 cm of coverage with 80 kV; 75–150 Smart mA dose modulation; noise index, 8; rotation time, 1 second; and Adaptive Statistical Iterative Reconstruction (ASIR), 50%; 64-slice: shuttle mode, 16 × 5 mm slices [8 cm of coverage] with 80 kV and 100 milliamperere second (mA)).

CTP cine images were analyzed on CT Perfusion 5 (Prototype of CTP 4D; GE Healthcare) by research assistants with expertise in CTP analysis blinded to clinical data. Arterial input ROIs were chosen to maximize the slope of the arterial time-density curve, usually the anterior cerebral artery or MCA. Venous ROIs were placed on the superior sagittal sinus to maximize the area under the venous time-density curve.11 CTP functional maps for each slice, including MTT, CBF, and an average map (average of all the cine images of the same slice), were generated.

Slices with extensive coil artifacts were excluded. ROIs were drawn to define the anterior cerebral artery, MCA, and posterior cerebral artery vascular territories and the basal ganglia and thalamus on each slice, avoiding hematomas and External ventricular drain (EVD) tracts (Fig 1). Segmentation of gray and white matter was achieved using a threshold range of Hounsfield units. Blood flow and blood volume thresholding was performed to exclude vascular structures by eliminating pixels with blood flow of >100 mL/min/100 g and blood volume of >8 mL/100 g from the segmented gray and white matter masks.12 The ROIs were automatically propagated to MTT maps, and MTT was calculated as the weighted average of the gray matter volume from all ROIs on all slices. MTT on the CTP performed at admission before aneurysm treatment was MTT1, and at 3 days after treatment, it was MTT2.

Statistical Analysis
Characteristics of the study population were compared using an independent t test for continuous variables or χ² analysis for categorical variables.

To study the interaction between MTT changes associated with DCI and clinical grade, we dichotomized patients into 2 groups (good grade, WFNS I–III; and poor grade, WFNS IV–V) at presentation. Repeated measures linear regression analysis was performed to assess differences between MTT1 and MTT2 and the interaction between temporal changes in MTT and grade. Post hoc analysis was
Table 1: Characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>All (n = 87)</th>
<th>Good Grade (n = 49)</th>
<th>Poor Grade (n = 38)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean) (SD) (yr)</td>
<td>58.5 (13.2)</td>
<td>57.5 (12.8)</td>
<td>59.4 (13.9)</td>
<td>.554</td>
</tr>
<tr>
<td>Female (No.) (%)</td>
<td>58 (67)</td>
<td>34 (69)</td>
<td>24 (63)</td>
<td>.541</td>
</tr>
<tr>
<td>Smoking (No.) (%)</td>
<td>28 (32)</td>
<td>15 (31)</td>
<td>13 (34)</td>
<td>.722</td>
</tr>
<tr>
<td>Hypertension (No.) (%)</td>
<td>41 (47)</td>
<td>19 (39)</td>
<td>22 (58)</td>
<td>.076</td>
</tr>
<tr>
<td>GCS score (mean) (SD)</td>
<td>11.2 (4.6)</td>
<td>14.5 (0.8)</td>
<td>6.8 (3.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>mFisher grade (No.) (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;.001</td>
</tr>
<tr>
<td>1</td>
<td>7 (8)</td>
<td>7 (14)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>26 (30)</td>
<td>21 (43)</td>
<td>5 (13)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>6 (7)</td>
<td>6 (12)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>58 (55)</td>
<td>15 (31)</td>
<td>33 (87)</td>
<td></td>
</tr>
<tr>
<td>Aneurysm treatment (No.) (%)</td>
<td></td>
<td></td>
<td></td>
<td>.015</td>
</tr>
<tr>
<td>Clip</td>
<td>11 (13)</td>
<td>7 (14)</td>
<td>4 (11)</td>
<td></td>
</tr>
<tr>
<td>Coil</td>
<td>70 (81)</td>
<td>42 (86)</td>
<td>28 (74)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>6 (6)</td>
<td>0 (0)</td>
<td>6 (16)</td>
<td></td>
</tr>
<tr>
<td>Intracerebral hematoma (No.) (%)</td>
<td>64 (74)</td>
<td>16 (16)</td>
<td>15 (40)</td>
<td>.03</td>
</tr>
<tr>
<td>Hydrocephalus (No.) (%)</td>
<td>57 (66)</td>
<td>27 (55)</td>
<td>30 (79)</td>
<td>.02</td>
</tr>
<tr>
<td>Intracranial pressure (mean) (SD)</td>
<td>28.7 (28.0)</td>
<td>15.3 (7.9)</td>
<td>36.8 (31.1)</td>
<td>.005</td>
</tr>
<tr>
<td>Angiographic vasospasm (No.) (%)</td>
<td>38 (44)</td>
<td>16 (33)</td>
<td>22 (58)</td>
<td>.377</td>
</tr>
<tr>
<td>CT 1</td>
<td>10 (11)</td>
<td>1 (2)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CT 2</td>
<td>10 (11)</td>
<td>6 (12)</td>
<td>4 (11)</td>
<td></td>
</tr>
<tr>
<td>DCl (No.) (%)</td>
<td>13 (15)</td>
<td>9 (18)</td>
<td>4 (11)</td>
<td>.309</td>
</tr>
<tr>
<td>Death (No.) (%)</td>
<td>12 (14)</td>
<td>0 (0)</td>
<td>12 (34)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>DCl or death (No.) (%)</td>
<td>25 (28)</td>
<td>9 (18)</td>
<td>16 (42)</td>
<td>.015</td>
</tr>
</tbody>
</table>

Note: mFisher indicates modified Fisher Scale; CT 1, before aneurysm treatment; CT 2, after aneurysm treatment.

Table 2: Mean MTT values

<table>
<thead>
<tr>
<th></th>
<th>Good Grade</th>
<th>Poor Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All</td>
<td>No DCI</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>No DCI</td>
</tr>
<tr>
<td>MTT 1 (SD)</td>
<td>6.3 (1.4)</td>
<td>6.2 (1.3)</td>
</tr>
<tr>
<td></td>
<td>7.3 (1.7)</td>
<td>6.4 (1.9)</td>
</tr>
<tr>
<td>MTT 2 (SD)</td>
<td>6.3 (1.7)</td>
<td>6.1 (1.5)</td>
</tr>
<tr>
<td></td>
<td>7.3 (1.7)</td>
<td>6.5 (2.1)</td>
</tr>
<tr>
<td>MTTdiff (SD)</td>
<td>0.03 (1.2)</td>
<td>-0.14 (0.98)</td>
</tr>
<tr>
<td></td>
<td>-0.75 (1.8)</td>
<td>-0.78 (1.6)</td>
</tr>
</tbody>
</table>

* Significantly greater than MTTdiff in patients with good grades (P < .05).

RESULTS

Characteristics of Study

Eighty-seven patients were included. One hundred two were screened, and 15 were excluded for the following indications: no baseline CTP (n = 6), rebleed of previously coiled aneurysm (n = 2), nonaneurysmal SAH (n = 5), CTP of insufficient quality (n = 1), and no SAH on baseline (n = 1) (Table 1).

Forty-nine of 87 (56%) had good grades on admission, and 38/87 (44%) had poor grades. Patients with poor grades had lower GCS scores, higher Modified Fisher Scale scores, higher ICP, and higher incidences of intraparenchymal hematoma, hydrocephalus, and untreated aneurysm. Death within 2 weeks occurred in 12 patients, all of whom had poor grades. While the rate of DCI was similar between patients with good and poor grades, patients with poor grades had significantly higher rates of death and DCI when considered together.

Temporal Trends in MTT

There was a significant interaction between MTT and clinical grade (P = .009), indicating that changes between MTT1 and MTT2 are different for patients with poor and good grades. MTT1 was significantly higher in patients with a poor grade compared with patients with a good grade with and without DCI or death (P < .05). There was no difference in MTT2 (Table 2 and Figs 2 and 3).

In patients with a good grade, different trends were observed between MTT1 and MTT2 in patients with and without DCI (P = .03) (Table 2). The mean difference between MTT2 and MTT1 was positive in patients who developed DCI (0.82 ± 1.6), indicating increasing (worsening) MTT in the first few days after aSAH. This difference was significantly greater than the MTTdiff in patients without DCI (−0.14 ± 0.98, P = .03), which showed an average decrease (improvement) in MTT.

In patients with a poor grade, similar trends were observed between MTT1 and MTT2 in patients with and without DCI (P = .969). MTT significantly decreased between MTT1 and MTT2 in patients who developed DCI or death and those who did not (MTT1, 8.3 ± 3.0 seconds; MTT2, 6.0 ± 0.8 seconds; P = .03). In pooled analysis combining patients with good and poor grades, we did not find a statistically significant trend in the change in MTT between patients who did or did not develop DCI.

Univariate Analysis: Predictors of DCI or Death

Univariate analysis showed that WFNS, ICP, GCS, and intraparenchymal hematoma were significant predictors of DCI or death (Table 3). In patients with a good grade, MTTdiff was associated with a higher risk of DCI (OR = 2.1; 95% CI, 1.0–4.1; P = .04). Patients with poor grades had no significantly increased risk of DCI or death with increasing MTT (OR = 0.99; 95% CI, 0.6–1.6; P = .97).

Multivariate Analysis: Predictors of DCI or Death

Increasing MTT between MTT1 and MTT2 (higher MTTdiff), intraparenchymal hematoma, and higher WFNS scores remained
significant predictors of DCI or death on multivariate analysis (Table 4). Subgroup analysis of patients with good and poor grades showed that higher MTT$_{\text{diff}}$ (worsening MTT between MTT1 and MTT2) was significantly associated with an increased risk of DCI in patients with a good grade (OR $\sim 3.1$; 95% CI, 1.3–7.4; $P = .014$).

**MTT Thresholds**

In patients with a poor grade, there was a higher baseline MTT threshold (MTT1, $>9.6$ seconds) compared with patients with a good grade (MTT1, $>6.3$ seconds), whereas the MTT2 thresholds are similar regardless of clinical grade. MTT$_{\text{diff}}$ thresholds also differed depending on the clinical grade, with patients with a good grade showing a positive threshold (MTT$_{\text{diff}} > 0.2$) and patients with a poor grade showing a negative threshold (MTT$_{\text{diff}}$ more than $-0.33$) (Table 5).

**DISCUSSION**

In this study, we showed that increasing (worsening) MTT in the first few days after aSAH was associated with an increased risk of DCI or death in patients with a good grade. Roughly every 1-second increase in global MTT was associated with a $3 \times$ greater risk of DCI in patients with a good clinical status, and this risk remained significant on multivariate analysis. In contrast, patients with a poor grade (WFNS IV–V) tended to show decreasing (improving) MTT in the first few days after aSAH in those with and without subsequent DCI or death.

Some management algorithms rely on clinical status for triaging patients to high or low risk for DCI and poor outcome. Patients in good clinical condition may undergo less frequent neurologic monitoring and may be transferred out of intensive care units earlier. Consensus statements have identified CTP as a potential screening tool, though specific recommendations for its integration are lacking. Our data support the use of CTP in the first few days after aSAH before the typical onset of DCI, to identify patients who, despite good clinical status, remain at an elevated risk of DCI. Multivariate analysis showed that increasing MTT remained a significant risk factor for DCI in patients with a good grade.

MTT changes that we observed occurred before DCI symptoms. This “therapeutic window” could allow optimization of therapy in high-risk patients. Effective options for the prevention of DCI are currently limited to nimodipine and maintenance of euvolemma. Once DCI has been established, hypertensive therapy is considered first-line treatment in many centers, though there is a lack of evidence showing clinical benefit. Targeted application of therapies in individuals at higher risk might improve the clinical efficacy, though currently evidence is lacking. In addition, new prophylactic treatment studies might incorporate MTT$_{\text{diff}}$ as a biomarker for imaging selection or for monitoring treatment efficacy.

While MTT on admission was significantly higher in patients with a poor-versus-good grade, it was not a significant predictor of DCI or death in either univariate or multivariate models. This finding may reflect the limitations of a single-measurement MTT compared with temporal changes of MTT in an individual. Technical differences may also have an impact. In our study, CTP data were acquired at 2 different tertiary care centers.
with different CT scanners, though all postprocessing was performed at the same core laboratory with standardized methodology.

We chose to analyze MTT because it has been previously shown to be a sensitive perfusion parameter for prediction and detection of DCI,\textsuperscript{23-25} and it takes into account fluctuations in CBV.\textsuperscript{23-25} In our cohort, EVDs were present in 60% of patients with a poor grade at MTT1, and an additional 8 patients (21%) had interval EVD insertion before MTT2. In both groups, we observed improving MTT between MTT1 and MTT2, suggesting that corrected hydrocephalus is not the only explanation for MTT improvement in these patients.

In patients with a poor grade, high MTT at admission of >9.6 seconds (as determined by the Youden Index threshold analysis; Table 5) portends increased risk of subsequent DCI or death. Elevated ICP can lead to delayed MTT. As ICP normalizes (for untreated ICP/hydrocephalus, both of which could result in prolonged MTT1.\textsuperscript{24} In our cohort, EVDs were present in 60% of patients with a poor grade at MTT1, and an additional 8 patients (21%) had interval EVD insertion before MTT2. In both groups, we observed improving MTT between MTT1 and MTT2, suggesting that corrected hydrocephalus is not the only explanation for MTT improvement in these patients.

In patients with a poor grade, high MTT at admission of >9.6 seconds (as determined by the Youden Index threshold analysis; Table 5) portends increased risk of subsequent DCI or death. Elevated ICP can lead to delayed MTT. As ICP normalizes (for example, following CSF diversion), MTT decreases as cerebral perfusion improves; this change could lead to improvement or reperfusion injury that exacerbates early brain injury.

With respect to early within-individual changes in MTT, there are other limited published data. In a study by Rodriguez-Régent et al,\textsuperscript{30} CTP between day 0 and day 4 was analyzed in 47 patients with aSAH. Early deterioration in perfusion parameters was significantly correlated with an increased risk of delayed infarct burden on CT/MR imaging. However, their study focused on imaging outcome, whereas ours focused on clinical deterioration of DCI. Because therapeutic maneuvers may prevent patients with DCI from developing infarction, we think that our study provides important evidence about the relationship of early deterioration in MTT to the development of clinical DCI, which is the current target for clinical intervention. Our study also included a larger

<table>
<thead>
<tr>
<th>Table 3: Univariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All</strong></td>
</tr>
<tr>
<td>---------</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>Hypertension</td>
</tr>
<tr>
<td>Hydrocephalus</td>
</tr>
<tr>
<td>Hematoma</td>
</tr>
<tr>
<td>GCS score</td>
</tr>
<tr>
<td>WFNS score</td>
</tr>
<tr>
<td>mFisher Scale score</td>
</tr>
<tr>
<td>Intracranial pressure</td>
</tr>
<tr>
<td>MTT1</td>
</tr>
<tr>
<td>MTT2</td>
</tr>
</tbody>
</table>

**Note:** \( ^{a} \)mFisher indicates modified Fisher Scale.

**Table 4: Multivariate analysis**

<table>
<thead>
<tr>
<th><strong>All</strong></th>
<th><strong>Good Grade</strong></th>
<th><strong>Poor Grade</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OR</strong></td>
<td><strong>95% CI</strong></td>
<td><strong>P Value</strong></td>
</tr>
<tr>
<td>WFNS grade</td>
<td>3.08</td>
<td>1.03–9.22</td>
</tr>
<tr>
<td>GCS score</td>
<td>1.2</td>
<td>0.87–2.8</td>
</tr>
<tr>
<td>Hematoma</td>
<td>0.35</td>
<td>0.03–0.72</td>
</tr>
<tr>
<td>MTTdiff</td>
<td>1.67</td>
<td>1.01–2.86</td>
</tr>
</tbody>
</table>

**Table 5: Optimal MTT thresholds and sensitivity and specificity (determined by the Youden Index) for DCI/death**

<table>
<thead>
<tr>
<th><strong>Clinical Grade</strong></th>
<th><strong>MTT1</strong></th>
<th><strong>MTT2</strong></th>
<th><strong>MTTdiff</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>All</strong></td>
<td>9.5 (26, 95)</td>
<td>5.5 (67, 48)</td>
<td>0.05 (47, 75)</td>
</tr>
<tr>
<td><strong>Good</strong></td>
<td>6.5 (56, 73)</td>
<td>5.0 (100, 35)</td>
<td>0.2 (73, 37)</td>
</tr>
<tr>
<td><strong>Poor</strong></td>
<td>9.6 (64, 90)</td>
<td>5.4 (88, 46)</td>
<td>0.33 (43, 65)</td>
</tr>
</tbody>
</table>

\( ^{*} \)MTT values in seconds with corresponding sensitivity and specificity (%).
cohort of patients and explored the influence of clinical grade on early perfusion changes.

Limitations include a relatively low percentage of DCI in this cohort compared with the literature, which, in the context of the sample size, could influence the power of the results. In addition, the clinical teams were not blinded to the results of CTA/CTP; however, they did not have access to quantitative CTP data, only qualitative color maps. This is mitigated by the fact that this study included strict clinical definitions of DCI, which were not influenced by imaging results. There was a relatively high rate of patients with poor grades in this study, likely due to the prospective study design in which patients with poor presentation of clinical status were not excluded. Clinical detection of DCI in patients with poor grades is challenging, and this issue could introduce errors in the diagnosis of DCI in these patients. We chose to include death in combination with DCI in patients with a poor grade because this is a measurable outcome in patients with a comatose or nearly comatose state, but this could also introduce error. Finally, CT perfusion includes iodinated contrast (risks for renal injury and allergic reaction) and ionizing radiation (risk of radiation injury and induced cancer); however, these risks are low using optimal imaging protocols.

CONCLUSIONS

In patients with a good grade (WFNS I–III), increased MTT in the early period after SAH (around day 3) compared with a baseline study performed at presentation is associated with a significantly higher risk of subsequent development of DCI. Patients with a poor grade (WFNS IV–V) did not show an increased risk of DCI with increasing MTT. Early changes in MTT may be a useful imaging biomarker for the risk of DCI in patients with a good grade.

ACKNOWLEDGMENTS

The authors thank the following individuals for their contributions to this investigation: Kyle Burgers, Elton Law, Feng Su, Marjorie Ho, Rita Vittorino, Vy Nguyen, Yang-mei Li, Pascal Tyrrell, Kuan Liu, and Yaeshe Randeree.

Disclosures: Amanda Murphy—RELATED: Grant: RSNA Research Fellow Grant.* Ting-Yin Lee—UNRELATED: Grants/Grants Pending: GE Healthcare. Comments: research study on dual-energy CT scanning of metal objects in the extremities*. Royalties: GE Healthcare, Comments: for the CT perfusion license agreement*. Thomas R. Marotta—UNRELATED: Consultancy: Medtronic; Comments: proctor for the Pipeline Embolization Device; Patents (Planned, Pending or Issued): eCLIPS; Stock/Stock Options: Evac; Robert L. Macdonald—UNRELATED: Board Membership: Brain Aneurysm Foundation, Canadian Institutes of Health Research; Employment: Edge Therapeutics; Stock/Stock Options: Edge Therapeutics. Richard I. Aviv—RELATED: Grant: Sunnybrook Alternate Funding Plan; Comments: grant is for 46,000; grant was peer reviewed.* Aditya Bhartaha—RELATED: Grant: Ontario Alternate Funding Plan Innovation Grant.* *No money paid to the institution.

REFERENCES

20. Hanggi D, Etminan N, Macdonald RL, et al. NEWTON: nimodip-
ine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage. *Neurocrit Care* 2015;23:274–84 CrossRef Medline
Vessel Wall MRI for Targeting Biopsies of Intracranial Vasculitis

S.R. Zeiler, Y. Qiao, C.A. Pardo, M. Lim, and B.A. Wasserman

ABSTRACT
SUMMARY: Central nervous system vasculitides are elusive diseases that are challenging to diagnose because brain biopsies have high false-negative rates. We sought to test the ability of contrast-enhanced, high-resolution 3D vessel wall MR imaging to identify vascular inflammation and direct open biopsies of intracranial target vessels and adjacent brain parenchyma. Eight of 9 specimens revealed vascular inflammation. We conclude that vessel wall MR imaging can identify inflamed intracranial vessels, enabling precise localization of biopsy targets.

ABBREVIATIONS: CNSV = CNS vasculitis; VWMRI = vessel wall MR imaging

We operationally define central nervous system vasculitis (CNSV) as any inflammatory vasculopathy producing nonatheromatous inflammation of intracranial vessels either directly (eg, primary CNS vasculitis) or indirectly via inflammation of CNS parenchyma with secondary vascular involvement (eg, as seen with infections, tumors, and certain autoimmune conditions). A variety of pathogenic processes leading to CNSV may have similar or overlapping clinical presentations and can mimic noninflammatory vasculopathies on conventional MR imaging or CT (eg, atherosclerosis, dissection, and reversible cerebrovascular vasoconstriction syndrome). Thus, a biopsy should be performed for a definitive diagnosis and to identify the cause of the underlying inflammation, especially because immunosuppressive therapy has adverse effects.

Unfortunately, despite MR imaging and digital subtraction angiography (DSA) having high sensitivities for CNSV (60%–100%), specificity estimates range from 14% to 60% and 19% to 36% for DSA and MR imaging, respectively. For MR imaging, this sensitivity is likely secondary to flow artifacts and partial volume averaging constraints.

Furthermore, intracranial blood vessel biopsy has a high false-negative rate (<50%) because of patchy involvement of relevant pathology.

We hypothesized that vessel wall MR imaging (VWMRI) can identify inflamed intracranial vessels and precisely localize biopsy targets, thus aiding in the diagnosis of CNSV and its attendant pathology.

MATERIALS AND METHODS
Patients
We present 9 patients (On-line Tables 1 and 2) consecutively admitted to the Johns Hopkins stroke service between 2012 and 2016 for ischemic stroke with clinical concern for CNSV and no reasonable explanation for a noninflammatory cause. Work-up for hypercoagulable state, rheumatologic disease, malignancy, cardiac dysfunction, and infection was unremarkable for all patients except patient 6, which revealed Varicella zoster virus immunoglobulin G in the CSF. All 9 patients referred with intent to biopsy underwent VWMRI and subsequent biopsy and were therefore included in this prospective study and consecutively entered into our data base. The institutional review board approved this study and provided an exemption to allow the inclusion of de-identified data for patients from whom we did not receive written consent because the VWMRI was performed as part of clinical care.

MR Imaging Examination Protocol
VWMRI examinations were performed up to 7 days before biopsy (mean, 2.2 days) on a 3T MR imaging scanner (Magnetom Skyra; Siemens, Erlangen, Germany) using a 32-channel head coil. Fiducial markers were placed, and a standardized MR imaging protocol was implemented for all patients that included a 3D time-
flight MRA (acquired resolution, 0.5 × 0.5 × 0.55 mm³), pre- and postcontrast 3D VWMRI (acquired resolution, 0.5 × 0.5 × 0.5 mm³), and a 3D contrast-enhanced MRA (acquired resolution, 0.52 × 0.52 × 1.04 mm³) of the intracranial vessels (On-line Fig 1). Diffusion-weighted images of the brain were obtained for all patients, and susceptibility-weighted images (acquired resolution, 0.70 × 0.70 × 1.50 mm³) were obtained for 5 of the 9 examinations. Postcontrast T1 echo-spoiled gradient-echo images were obtained for surgical navigation.

The 3D-VWMRI sequence design was previously described, and T1-weighting was implemented to highlight contrast enhancement (TR/TE, 800/25 ms; turbo factor, 30; echo spacing, 5.6 ms; generalized autocalibrating partially parallel acquisition acceleration, 2; FOV, 160 × 160 mm²; number of averages, 1,4). VWMRI was acquired in a coronal plane (112 slices [56 mm]; 9.5-minute acquisition time) and, after contrast administration, was oriented in multiple planes (axial [80 slices, 40 mm; 7.5-minute acquisition time], coronal, and in some cases, sagittal) to enable greater coverage of intracranial vessels, including distal branches. Contrast-enhanced MRA images were acquired during the intravenous administration of gadobutrol (Gadavist; Bayer Schering Pharma, Berlin, Germany; 0.1 mmol/kg) with arterial and venous phase acquisitions, and postcontrast VWMRI acquisitions began 5 minutes after contrast administration.

MR Imaging Analysis

All MR imaging examinations were analyzed by a neuroradiologist (B.A.W.) using a PACS. 3D-VWMRI was reconstructed in multiple obliquities and was used to visually identify vascular inflammation (present/absent) based on segmental, concentric enhancement of the vessel wall and/or circumferential, periventricular enhancement following a vessel segment. Evidence of atherosclerotic features including calcification, a fibrous cap and lipid core, or focal, noncircumferential wall thickening excluded the diagnosis of vasculitis. The 3D-TOF MRA and contrast-enhanced MRA acquisitions were reconstituted and coregistered with the VWMRI sequence to isolate the vessel of interest in long and short axes. Because the lumen of very small vessels could not always be identified on VWMRI, small-vessel involvement was suspected on the basis of the linear configuration of inflammatory enhancement (Figure) and was corroborated by the identification of a lumen on the reconstructed contrast-enhanced MRA and TOF MRA source images or the susceptibility-weighted images when available. Diffusion-weighted imaging (on present and prior examinations) was used to exclude foci of enhancement due to subacute infarction. The inflamed vessel segments were then reviewed with the neurology and neurosurgical services to reach a consensus on a vessel target that avoided eloquent areas, was superficial, and was preferably venous.

Biopsy Procedure

Open biopsy was performed with the patient under general anesthesia using fiducial markers. The target vessel and adjacent brain parenchyma were biopsied with the aid of an image-guidance system (Brainlab Cranial Navigation Systems; Brainlab, Feldkirchen, Germany). M.L. was able to identify and biopsy a vessel at the identified coordinates.

RESULTS

Biopsy Results

The targeted blood vessel and surrounding brain tissue were obtained from each patient (On-line Table 2). Blood vessel biopsy analysis from 8 of the 9 patients revealed vascular inflammation via direct tissue examination (Figure and On-line Fig 2). The etiology of CNSV for patients 1, 2, 3, and 9 was primary CNS angitis; for patient 4, it was amyloid-β-related angitis; and for patient 6, it was Varicella zoster virus vasculitis. Although we confirmed perivascular inflammation for patients 7 and 8, we were unable to find a cause. Brain biopsy specimens showed no evidence of parenchymal inflammation in all except patient 7. The vessel specimen from patient 5 did not reveal inflammation but instead a multitude of thickened blood vessels with amyloid deposition. There were no postoperative complications.

Standard MR imaging T1 postcontrast studies (Figure and On-line Fig 2) as well as MRA, CTA, and DSA studies (On-line Table 1) did not prospectively identify the target pathology that was identified by VWMRI and eventually biopsied.16

DISCUSSION

We present the first reported study to use 3D-VWMRI at 3T for identifying CNSV. Notably, we show that VWMRI can be used to direct biopsies of inflamed intracranial vessels with high accuracy.
(89% in our series), which is a substantial improvement over the standard approach (sensitivities as low as 36% in prior studies). The success of our study was largely attributable to our ability to implement a 3D high-resolution VWMRI sequence that enables evaluation of a large volume of intracranial vessels, maximizing the number of potential targets that could then be reviewed for accessibility and safety.

There are several limitations of this study: 1) Although the VWMRI sequence was acquired using a TR of 800 ms to produce T1-weighting, some inherent proton-density weighting could not be eliminated, and this issue accounted for areas of mild hyperintense signal from remote white matter ischemic injury. We acquired precontrast VWMRI to help distinguish this hyperintensity from true enhancement surrounding small parenchymal vessels. Consequently, we confirmed vascular enhancement only when postcontrast signal was unequivocally high, so vessels with milder postcontrast signal were excluded from consideration. 2) The 3D-VWMRI sequence can result in inadequate flow suppression, depending on the size and orientation of the vessel. We acquired the 3D-VWMRI sequence in multiple planes, so most vessels were captured in the long axis relative to the scan orientation. Furthermore, we used contrast-enhanced MRA images to confirm patency of the lumen. 3) Shifting of vascular structures from the craniotomy and opening of the dura could lead to false-negative specimen analyses. Nevertheless, in our cohort, every patient except patient 5 was confirmed to have CNSV on biopsy. VWMRI was unable to distinguish inflammation located in the transmural or perivascular space.

**CONCLUSIONS**
Our data indicate that VWMRI can be used to target and improve the yield of biopsy in patients with CNSV. We suggest that biopsy remains instrumental in tailoring therapy because VWMRI was unable to distinguish among primary, infectious, and/or any etiology leading to perivascular inflammation.


**REFERENCES**
Hemodynamic Impairment Measured by Positron-Emission Tomography Is Regionally Associated with Decreased Cortical Thickness in Moyamoya Phenomenon


ABSTRACT

BACKGROUND AND PURPOSE: Impaired cerebrovascular reactivity has been associated with decreased cortical thickness in patients with arterial occlusive diseases. This study tests the hypothesis that severe hemodynamic impairment, indicated by increased oxygen extraction fraction ratios on positron-emission tomography with $^{15}$O tracers, is associated with decreased cortical thickness in patients with Moyamoya phenomenon.

MATERIALS AND METHODS: Patients with unilateral or bilateral idiopathic Moyamoya phenomenon were recruited. Oxygen extraction fraction ratio maps were generated from cerebral images of $^{15}$O counts divided by H$_2^{15}$O counts with normalization by corresponding cerebellar counts. The normal range of the oxygen extraction fraction ratio was estimated from historically available healthy control subjects. Cortical thickness was estimated from T1-weighted MR imaging and FreeSurfer. Regional samples of oxygen extraction fraction ratios and cortical thicknesses were drawn using FreeSurfer parcellations, retaining only parcellations from the vascular territory of the middle cerebral artery.

RESULTS: Complete MR imaging and PET datasets were available in 35 subjects, including 23 women; the mean age at scanning was 44 years. Patients with Moyamoya phenomenon had a significantly increased regional oxygen extraction fraction ratio compared with 15 healthy control subjects ($P < .001$). Regional oxygen extraction fraction ratio and age were significant predictors of cortical thickness ($P < .001$ for each) in a generalized linear mixed-effects model. Using hemisphere averages and patient averages, we found that only age was a significant predictor of cortical thickness ($P < .001$).

CONCLUSIONS: Chronic hemodynamic impairment, as indicated by a higher regional oxygen extraction fraction ratio, was significantly predictive of reduced cortical thickness in mixed-effects analysis of FreeSurfer regions. This phenomenon may be related to reversible metabolic down-regulation.

ABBREVIATIONS: OEF — oxygen extraction fraction; OEFR — oxygen extraction fraction ratio; SEM — standard error of measurement

Chronic hemodynamic impairment from basal artery occlusive disease may lead to regional reductions in cortical thickness. Fierstra et al$^1$ examined patients with unilateral occlusive cerebrovascular disease using CO$_2$ reactivity and diminished blood oxygen level–dependent responses as a marker for regional hemodynamic impairment. They demonstrated that regions with steal physiology and a reduced blood oxygen level–dependent response to CO$_2$ had cortical thickness (2.40 ± 0.03 mm standard error of measurement [SEM]) that increased 5.1% after successful surgical revascularization (2.53 ± 0.03 mm SEM).

The content of this work is solely the responsibility of the authors and does not necessarily represent the official view of the National Center for Research Resources or the National Institutes of Health. Clinical trial registration information: http://www.clinicaltrials.gov. Unique identifier: NCT00629915.

Please address correspondence to John J. Lee, MD, PhD, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4525 Scott Ave, Campus Box 8225, St Louis, MO 63110; e-mail: jjlee@wustl.edu; @jjleeWustlEdu

@Indicates open access to non-subscribers at www.ajnr.org

Indicates article with supplemental on-line tables.

http://dx.doi.org/10.3174/ajnr.A5812

Methods to categorize hemodynamic impairment are based on the response of the cerebrovasculature to vasodilatory challenges, measurements of increased blood volume, mean transit time, or measurements of an increased oxygen extraction fraction (OEF).\textsuperscript{2} The diminished blood oxygen level–dependent response to CO\textsubscript{2} is likely a response of pre-existing autoregulatory vasodilation in response to reduced perfusion pressure.\textsuperscript{2} OEF measurement uses \textsuperscript{15}O radiotracers to quantify oxygen extracted from blood by the brain. When cerebral blood flow falls, the OEF can increase from a normal baseline of \textoplus40\% to \textoplus80\% to maintain normal oxygen metabolism and brain function.\textsuperscript{3,4} Increased OEF has been shown to be a powerful predictor of stroke in patients with atherosclerotic carotid artery occlusion.\textsuperscript{2,5,7}

Quantitative OEF requires radial artery cannulation, multiple levels of calibrations, and the assumption that first-passage of the bolus of radiolabels along the radial artery is an accurate proxy for first-passage of the bolus through the cerebral circulation. For chronic carotid occlusive disease, methods of OEF estimation using emission counts and normalization against reference values have had comparable predictive values for clinical outcomes and improved receiver operating characteristics.\textsuperscript{8,9} In this work, we used the ratio of count-based OEF (OEFR) in the cerebral regions to count-based OEF in the cerebellum for all analyses.\textsuperscript{10}

This study sought to test the hypothesis that chronic hemodynamic impairment, as identified by an OEFR, is associated with decreased cortical thickness in patients with Moyamoya phenomenon.\textsuperscript{1}

\section*{MATERIALS AND METHODS}

\subsection*{Patients}

Technically sufficient MR imaging, PET imaging, and clinical data were obtained from 35 patients enrolled in a prospective, blinded adjudicated study of hemodynamic factors and stroke risk.\textsuperscript{11} Inclusion criteria were unilateral or bilateral Moyamoya phenomenon by angiography. Patients with prior surgical revascularization were included if the contralateral hemisphere was affected and untreated or if there were recurrent symptoms in the treated hemisphere. In analyses, data were excluded if the encompassing hemisphere demonstrated cortical infarction or hemorrhage. These inclusion and exclusion criteria and their applicability to cerebral hemispheres as well as individual patients were based on criteria used in previous cortical thickness studies of Moyamoya phenomenon by Fierstra et al.\textsuperscript{1} On enrollment, patients traveled to Washington University Medical Center for a detailed neurologic history, physical examination, interviews for baseline demographics and stroke risk factors, MR imaging, and PET imaging.

The present data are a subset of data from a prospective natural history study by Derdeyn et al.\textsuperscript{11} Of the 50 subjects in the previous study, 15 were excluded from this study because of the following: technically incomplete imaging necessary for this study, bilateral infarctions, bilateral hemorrhages, or surgical treatment with improvement. Methodologic differences between the prior study and this one included the following: use of FreeSurfer (http://surfer.nmr.mgh.harvard.edu)\textsuperscript{12-14} automated cortical parcellations, classification of regions most likely to be in the MCA vascular territory, granular identification of regional peaks of OEFR, and use of generalized linear mixed models.

Solely for purposes of estimating the range of normal values for OEFR, technically sufficient, historically available PET data from Grubb et al\textsuperscript{16} were gathered from 15 subjects, including 8 women, who had previously been recruited for healthy control PET measurements; the mean age for this cohort was 48 \textpm18 years. All control subjects had normal neurologic examination findings and normal brain MR imaging findings. Cortical thickness assessments were not technically feasible in the historical data. Written, informed consent was obtained for all patients and healthy subjects according to guidelines of the Washington University institutional review boards.

\subsection*{PET Imaging}

All PET imaging was performed at a single ECAT EXACT HR+ scanner (Siemens, Erlangen, Germany). Scanning began with transmission acquisitions from \textsuperscript{68}Ge/[\textsuperscript{68}Ga] sources for attenuation correction. Subjects inhaled 1 or 2 breaths from tubing connected to a shielded canister containing room air and 100 mCi (nominal) of O\textsubscript{15}O. Emission scanning began simultaneously, lasting 120 seconds. After waiting at least 15 minutes, a bolus of 75 mCi (nominal) of H\textsubscript{2}\textsuperscript{15}O was injected through an antecubital intravenous cannula, and emissions were scanned for 120 seconds. Following filtered back-projection reconstruction with corrections for normalization, attenuation, and scatter, reconstructed images had 2.0 \texttimes 2.0 \texttimes 2.4 mm resolution in an FOV of 128 \texttimes 128 \texttimes 63 voxels. Dynamic oxygen and water image frames were temporally summed over 40 seconds starting from the time of tracer arrival into the FOV; then they were Gaussian-filtered to the measured point-spread function of the scanner, 7.3 \times 7.3 \times 5.3 mm full width at half maximum.\textsuperscript{15,16}

\subsection*{MR Imaging}

All MR imaging studies used the same 3T system (Magnetom Tim Trio; Siemens). MR imaging was performed within 24 hours of PET scanning, in most cases within 1 hour after the conclusion of PET studies. All except 4 patients were scanned by MPRAGE series (TR, 2000 ms; TE, 2.97 ms) with a sagittal orientation, 1 \times 1 \times 1 mm resolution, and 208 \times 256 \times 144 FOV. Some MPRAGE scans had 1.25 \times 1.25 \times 1.3 mm resolution. For detecting white matter lesions, FLAIR series (TR, 4000 ms; TE, 294 ms) 0.9 \times 0.9 \times 5 mm resolution; 256 \times 256 \times 26 FOV) and T2-weighted imaging (TR, 3200 ms; TE, 319 ms; turbo spin-echo; 0.45 \times 0.45 \times 5 mm resolution; 416 \times 512 \times 26 FOV) were also obtained.

\subsection*{Analysis of OEFR and Cortical Thickness}

All ROIs made use of the Destrieux parcellations, aparc.a2009s+aseg, obtained from recon-all in FreeSurfer (Linux GNU stable, Version 5 20130513).\textsuperscript{12-14,17} Fully regional analyses used cortical regions numbered 11101–11175 and 12101–12175 and cerebellar regions 7, 8, 46, and 47 as discovered by recon-all and using additional selection criteria detailed below. The FMRIB Linear Image Registration Tool (FLIRT, Version 5; http://www.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT)\textsuperscript{18} created coregistrations of all tracer studies from PET onto FreeSurfer-generated T1.mgz images us-
ing mutual information cost functions. The mri_segstats application from FreeSurfer provided statistical results for all regions. The regions provided sampling of emission counts directly from O\(^{15}\)O and H\(_2\)\(^{15}\)O, both cortical and cerebellar, and OEFRs were calculated from regional mean counts normalized by the corresponding measurements in the cerebellum. All cerebellar regions were bilaterally pooled according to patient identity to avoid possible artifacts from crossed cerebellar diaschisis.

To increase the specificity of analysis, we manually classified the Destrieux regions\(^17\) according to vascular territories previously reported by van der Zwan et al.\(^17\) van der Zwan et al had empirically determined estimates of the volumetric extent of the anterior, middle, and posterior cerebral arterial circulations by injecting colored Araldite F mixtures (Kirkside Products, Osborne Park, Western Australia) into arterial sources of unfixed human brains obtained at routine postmortem. The largest volumetric extent of the middle cerebral artery territory was identified by visual inspection with Destrieux parcellations on the Montreal Neurological Institute 305 atlas. By submitting a subset of Destrieux region numbers 11101–11175 and 12101–12175 to mri_segstats, we obtained estimates of OEFRs for 60 parcellations per hemisphere most likely to correspond to the MCA territories. All OEFR measurements were matched with cortical thickness measurements from identical, coregistered sampling volumes in the images; the correspondence was ensured throughout analyses of regions, hemispheres, and patients. The PET data from historical, healthy control subjects did not include high-resolution MPRAGE; consequently, the Montreal Neurological Institute 305 atlas was coregistered to the historical PET images, and mapped Destrieux regions were subsequently sampled to obtain OEFRs.

Analysis with granularity for hemispheres facilitates comparison of this work with the limited number of existing cortical thickness reports. Granularity for patient identity facilitates comparison with existing Moyamoya phenomenon case series. Thus, measurements made on Destrieux regions for MCA territories within a hemisphere were pooled by hemispheres and patient identities and analyzed separately.

All registration results and OEFR calculations were individually reviewed as maps coregistered to T1.mgz anatomy as well as surface inflation maps. Regions of cortical infarction noted in clinical histories and MR imaging were marked for exclusion from further analyses. Most artifacts identified in quality-control reviews were associated with infarcted areas previously identified by exclusion criteria. All processing pipelines and analyses were coded in Matlab (Mathworks, Natick, Massachusetts) for reproducibility.

**Statistical Analyses**

The historical healthy control data solely provided confidence intervals for estimating normal OEFR. T tests for differences of regional OEFR between controls and patients with Moyamoya phenomenon were 2-tailed and heteroscedastic because these measurements were drawn from distinct studies, clinical categories, and subjects (ttest2 from Matlab R2017a). Generalized linear mixed-effects models used normal priors without link functions (fitglm from Matlab). Mixed-effect models appropriately describe the hierarchic covariance structures of measurements made by regions, hemispheres, and subjects and the repeated measurements necessarily made on hierarchic data. In this work, mixed-effects models tested the OEFR, age, and sex as predictors of cortical thickness.\(^5,20\) Intercepts, OEFR, age, and sex always had fixed effects. Intercepts and OEFR were explored using Akaike and Bayesian information criteria as random effects and grouped by patient identity to account for covariance structures between regions for a given patient. There were no other adjustments for multiple measurements. The significance level was always 95%. Analyses computed joint covariances of fixed effects and covariance parameters and assessed the Hessian of the objective function at convergence. The maximum pseudolikelihood algorithm estimated model parameters with 10–100 iterations.

**RESULTS**

On-line Table 1 lists demographic, clinical, diagnostic, and treatment results both from Derdeyn et al\(^3\) and this study. The natural history study of 50 patients by Derdeyn et al used OEFRs in hemispheres as a biomarker. This study examined a subset of 35 patients with technically adequate imaging, after imposing additional inclusion and exclusion criteria described in the Materials and Methods, to enable FreeSurfer-based regional analyses. The elevated regional OEFR in this study is defined to exceed the upper 95% confidence limit of regional OEFR measured in the control group of healthy subjects described in the Materials and Methods and quantified below. Characteristics listed in On-line Table 1 indicate the generalizability of these study results.

On-line Table 1 reports partitioning of patient census and measurements into unilateral and bilateral Moyamoya phenomenon in the category of vasculopathy on angiography. Of 10 patients with unilateral Moyamoya phenomenon, only 1 patient did not have an elevated regional OEFR; however, the hemisphere with Moyamoya phenomenon was excluded because of resolved symptoms after surgical revascularization. Of 25 patients with bilateral Moyamoya disease, 3 had an elevated regional OEFR.

Thirteen hemispheres in 13 patients were excluded from analyses in accordance with predetermined criteria, described in the Materials and Methods, applied to hemispheres. Of the remainder, 9 hemispheres in 9 patients were excluded for cortical infarction in the middle cerebral artery territory. Three hemispheres in 3 patients were excluded for basal ganglia hemorrhage. Three patients had prior surgical unilateral revascularization procedures. One of these revascularized hemispheres was excluded for basal ganglia hemorrhage; another hemisphere was excluded for absence of recurrent symptoms after surgical treatment. A total of 57 hemispheres in 35 patients were included in analyses.

**Imaging OEFR and Cortical Thickness**

Figure 1A–D shows regional OEFRs fused with T1 anatomy and cortical thickness embedded in inflated surface maps for 4 patients randomly sampled from the patient cohort. Matlab function random-sampled patient identities following inclusion and exclusion selections. Higher regional OEFR was associated with a thinner cortex on visual inspection. However, venous sinuses and adjacent regions with partial volume averaging have artificially elevated OEFRs arising from venous tracer activities because the
OEFR method does not correct for cerebral blood volumes. Restricting analyses to MCA regions mitigates these artifacts. Figure 1E, -F demonstrates confounding artifacts in hemispheres with infarction or hemorrhage. Anatomic pathology such as encephalomalacia presented challenges to the parcellation algorithms in FreeSurfer. Consequently, automated identifying of regions be-
comes unreliable, and partial volume averaging with adjacent nonviable tissues made OEF estimates uninterpretable.

Distributions of OEF and Cortical Thickness
A historical dataset of 15 healthy subjects provided 900 Destrieux regions from MCA territories for use in estimating confidence intervals for the normal range of OEFs. The distribution of OEFs is shown in Fig 2A in blue. The mean OEF was 0.995 with 95% CI, 0.776–1.213, and values above 1.213 were considered elevated. For patients with Moyamoya phenomenon, after inclusion and exclusion selections, 3420 Destrieux MCA regions had OEFs distributed as shown in Fig 2A in orange. The mean OEF was 1.076 with 95% CI, 0.805–1.357. The two-tailed t test rejects the null hypothesis of equal means with unequal variances between healthy controls and patients with Moyamoya phenomenon, 0.07–0.09. For all patients with Moyamoya phenomenon, the 3420 regions had cortical thicknesses distributed according to Fig 2B with a mean of 2.49 ± 0.01 mm SEM and 95% CI, 1.57–3.41. There were 376 hemodynamically impaired Moyamoya regions with elevated OEFs of >1.213; their cortical thicknesses had a mean of 2.34 ± 0.02 mm SEM and 95% CI, 1.47–3.21. On-line Table 1 enumerates how demographics, categoric clinical presentations, and angiographic confirmation of unilateral Moyamoya phenomena or bilateral Moyamoya disease varied with respect to OEF and nominal elevations of OEF.

Mixed-Effects Models
Figure 3 and On-line Table 2 detail results from generalized linear mixed-effects models. For measurements with granularity for hemispheres, 57 hemispheres had OEFs from 0.917 to 1.32 and cortical thickness from 1.94 to 2.81 mm. The best model had 35 random-effects coefficients for the intercept for each patient grouping and an isotropic covariance pattern with 2 parameters. Only age was a significant predictor of cortical thickness, regardless of whether OEF or time to scanning was included in the mixed model.

For measurements with granularity for patients (1 or 2 hemispheres), 35 patients had an OEF from 0.932 to 1.32 and cortical thickness from 2.01 to 2.81 mm. In numeric analyses, the data did not support any random effects. Only age was a significant predictor of cortical thickness regardless of inclusions of OEF or time to scanning in the mixed model.

DISCUSSION
The present data support the observation that cortical thickness is reduced in chronic hemodynamic impairment. This study aimed to maintain continuity with the larger body of cortical thickness research, including the study of Moyamoya phenomenon by Fierstra et al. Patients with Moyamoya phenomenon from Fierstra et al, with steal phenomena before surgical revascularization, had a hemispheric mean thickness of 2.40 ± 0.03 mm SEM. Patients with Moyamoya phenomenon in this study had FreeSurfer regions characterized by increased OEF, and their mean thickness was 2.34 ± 0.02 mm SEM. However, this work differs from the prior studies of Fierstra et al, in 3 important ways. First, hemodynamic impairment in the previous studies was identified by regions that demonstrated paradoxically reduced blood oxygen level–dependent signal after CO2 challenge (steal phenomenon). Hemodynamic impairment in the present work was identified by increased OEFs. These 2 physiologies are fundamentally different, though both likely reflect responses to reduced perfusion pressure or blood flow. Second, in the original 2010 study of Fierstra et al, all patients had unilateral occlusive disease, and the comparison was made between brain regions with steal...
phenomenon on the affected hemisphere and unaffected contralateral regions with each patient serving as his or her own control.\textsuperscript{21} In the present analysis, we included patients with bilateral and unilateral disease and idiopathic Moyamoya phenomenon. Third, we used mixed-effects models to examine OEFR and cortical thickness with explicit considerations for the hierarchy of FreeSurfer regions, hemispheres, and patient identities. We also selectively examined MCA territories, and included age, sex, and time between symptom onset and scanning in our models.

We used values of OEFR from Destrieux parcellation regions confined to MCA territories. Distal internal carotid occlusive disease was most likely to affect flow to these regions. We recognize that patients in this series may have had greater flow reduction to one or the other territory and some may have had posterior cerebral artery involvement. Averaging over entire hemispheres shifted the significance of regressions from OEFR and age to only age, a well-studied predictor for cortical thickness.\textsuperscript{20} Diagnosis and surgical treatment options for patients with Moyamoya phenomenon may benefit from FreeSurfer-based regional measurements of OEF, OEFR, or cortical thickness.

**FIG 3.** Plots of data arranged by granularity of measurements (FreeSurfer regions, hemispheres, patients) in columns and mappings of predictors (OEFR, age, sex, and time from symptom onset to scanning) of cortical thickness in rows. For sex, male $= 0$ and female $= 1$. The color map indicates patient identities. Lines of regression between model parameters and cortical thickness correspond to significant predictors. $\rho$ denotes the partial correlation coefficient between the plotted parameter and cortical thickness. The top-left panel excludes a data point with OEFR $= 0.479$ and 4 data points with an OEFR of $>2$ to clarify the distribution of regional data with respect to OEFR and thickness. All plots exclude regions and hemispheres ipsilateral to infarctions or hemorrhages as detailed in the Materials and Methods.
Carotid disease and chronic hemodynamic impairment are associated with reduced cognitive function. Subclinical stroke represents the major potential confound for this association. In baseline data from the Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) study, Marshall et al. reported a strong association between increased OEF and reduced baseline neurocognitive status. Patients with increased OEF on study entry were much more likely to have neurocognitive impairment than patients with a normal OEF.

Finally, there is good evidence that cortical thickness is dynamic. Increases in gray matter volume and cortical thickness have been reported with learning new functions. These changes can be measured within days and are postulated to reflect neuronal changes, such as spine and synapse turnover, given the time course. Changes in the microvasculature are possible (eg, reduced capillary density, vasoconstriction), but difficult to explain. The associations of cortical thickness with age that we observed are well-described and provide further evidence of the external validity of our methods and observations; however, associations of cortical thickness with sex are likely confounded by the predominance of women with Moyamoya phenomenon in our study. The alternative explanations for reduced cortical thickness would generally not be reversible. These would include selective neuronal loss, submillimeter cortical infarctions, and white matter infarction leading to reduced cortical activity.

CONCLUSIONS
Our data support the hypothesis that chronic hemodynamic impairment measured by PET is regionally associated with reduced cortical thickness. The effects of regional chronic hemodynamic impairment are significant and comparable with age for explaining reduced cortical thickness; age is a well-studied predictor of cortical thickness in healthy adults. Given the evidence from other studies that cortical thickness decreases are reversible, it is possible that decreases reflect metabolic down-regulation that may, in turn, be associated with reversible cognitive impairment. Future studies that incorporate serial measurements of oxygen metabolism and neuropsychological testing will be required to test these hypotheses.

For enhanced reproducibility, analysis software, unit tests, and summary data are provided at https://github.com/jjleewustledu/Hemodynamic-Impairment-Measured-by-PET-is-Regionally-Associated-with-Cortical-Thickness-in-Moyamoya.

Disclosures: John J. Lee—RELATED: Grant: National Institutes of Health, Comments: Supported by National Institute of Neurological Disorders and Stroke ROI NS053631. Support for the research imaging center where the MR imaging studies were performed was provided by 1UL1RR024992-01, 1T1LR024995-01, and 1K12 RR024994-01 from the National Center for Research Resources, a component of the National Institutes of Health, and the National Institutes of Health Roadmap for Medical Research and P30NS048056*. Joshua S. Shimony—UNRELATED: Expert Testimony: expert testimony in regard to the use of DTI in the diagnosis of traumatic brain injury; Grants/Grants Pending: National Institutes of Health.* Gregory R. Zifpel—UNRELATED: Consultancy: Gerson Lehrman Group, Comments: consulting on a medical topic outside that discussed in the present article; Expert Testimony: Wais, Vogelstein, Forman and Offutt; Darby & Ganza, Zeigler Cohen & Koch; Hyde, Love, and Overby, Boyle Brasher LLC, Comments: expert witness for a variety of medical conditions; Grants/Grants Pending: National Institutes of Health.* Money paid to institution.

REFERENCES


C. Zamora, S.-C. Hung, C. Tomingas, C. Atkinson, and M. Castillo

ABSTRACT

SUMMARY: We describe the prevalence and potential significance of deep medullary vein engorgement on SWI in patients with neurosarcoidosis, a finding that has not been described previously. Engorgement was evaluated for possible associations with meningeal or perivascular disease, intracranial hemorrhage, and venous thrombosis, as well as with modified Rankin Scale scores at the time of MR imaging and at follow-up. Deep medullary vein engorgement was seen in 7 of 21 patients and was more common in men. Patients with venous engorgement had a significantly increased incidence of microhemorrhages, perivascular disease, and hydrocephalus. There was no association with the degree of leptomeningeal disease, venous dural sinus thrombosis, or modified Rankin Scale scores. In conclusion, deep medullary vein engorgement was common in our patients with neurosarcoidosis. Although its pathophysiology remains uncertain, it could be related to venous or perivenous abnormalities and may represent a useful secondary finding of cerebrovascular disease.

ABBREVIATION: DMVE = deep medullary vein engorgement

Sarcoidosis is a multisystem disease characterized by formation of noncaseating granulomas. Neurologic manifestations occur in 5% of patients, and mortality can be as high as 11% in the 10 years after initial diagnosis. Neurosarcoidosis has an predilection for perivascular dissemination but can also lead to parenchymal, leptomeningeal, or pachymeningeal disease and may result in a granulomatous angiitis. CNS complications can be diverse and are a function of the nature and extent of tissues involved. Patients can have cranial neuropathies, neuroendocrine dysfunction due to involvement of the pituitary-hypothalamic axis, aseptic meningitis, and myelopathy, among other symptoms. A relatively rare-but-ominous complication is hydrocephalus, which is associated with high mortality. Intracranial hemorrhage is also associated with a poor prognosis and has been reported as a possible sequela of vascular disease.

We have noted that some patients with neurosarcoidosis show a characteristic pattern of deep medullary vein engorgement (DMVE) on SWI, which, to our knowledge, has not been previously described. Our purpose was to report the prevalence of this finding and to establish whether there may be an association with an increased frequency of intracranial hemorrhage, hydrocephalus, or worse neurologic outcomes.

Case Series

Subjects. This retrospective study was approved by our institutional review board, which waived the requirement for informed consent. We searched our electronic medical records system between January 2013 and December 2017 and included all consecutive adult patients (n = 21; 10 men; mean age, 46 ± 14 years) diagnosed with probable or definite neurosarcoidosis based on the criteria of Zajic et al. We only included patients after 2013 because that was the year when we started using SWI routinely at our institution.

Clinical Variables

General demographic information and clinical characteristics were extracted from the patients’ charts at the time of initial MR imaging. Modified Rankin Scale scores were determined from neurology consults and/or clinical visits at the time of initial MR imaging and at last follow-up.

Imaging Evaluation

Routine multisequence pre- and postcontrast MR imaging scans were evaluated by a neuroradiologist with a Certificate of Added Qualification for the presence of DMVE, leptomeningeal or dural disease, discrete perivascular nodular enhancement (distinct from the engorged vessel), venous thrombosis, hydrocephalus,
and hemorrhage. Microhemorrhages were defined as \(<1\) cm, and macrohemorrhages were \(\geq 1\) cm. Imaging was performed on 1.5T or 3T MR imaging scanners (Avanto, Trio, Skyra, or Aera, Siemens, Erlangen, Germany). Typical parameters for SWI were the following: TE, 40 ms; TR, 49 ms at 1.5T; and TE, 20 ms; TR, 28 ms at 3T; section thickness, 2 mm; flip angle, 15°; FOV, 220 × 220 mm; and matrix size, 256 × 256. Venous thrombosis was evaluated using contrast-enhanced MPRAGE, with the following parameters: TE, 2.54 ms; TR, 1900 ms; section thickness, 1 mm; flip angle, 9°; FOV, 250 × 250 mm; matrix size, 256 × 256. Minimum and maximum intensity projections were postprocessed at slice thicknesses of 16 and 12 mm for SWI and MPRAGE, respectively. The median time (interquartile range) from symptom onset to the first MR imaging that included SWI was 36.4 months (9–47 months) in the group with DMVE and 28.5 months (3–47 months) in the group without DMVE.

**Statistical Analysis**

The normality of data distribution was evaluated with the Shapiro-Wilk test. Distributions were summarized using the mean ± SD or median (interquartile range). Categoric data were expressed as counts or percentages. We used the \(\chi^2\) and Fisher exact tests for categoric variables and the independent 2-sample \(t\) test to compare means of normally distributed data. The Mann-Whitney \(U\) test was used to compare variables that were not normally distributed. \(P\) values < .05 were considered significant. Statistical analysis was performed with SPSS, Version 24 (IBM, Armonk, New York).

**Deep Medullary Vein Engorgement**

DMVE was present in 7 (33%) of 21 patients and appeared as enlarged and tortuous medullary veins in a parallel configuration at the level of the corona radiata and a radial orientation around the frontal horns and atria (Fig 1A and Fig 2A, B). This was bilateral and symmetric in all except 1 patient and showed corresponding enhancement on the postcontrast MPRAGE MIP image (arrowheads). There is also ventriculomegaly.

**Intracranial Hemorrhage**

Microhemorrhages were present in 7 (33%) of 21 patients and were more prevalent with DMVE (\(P = .009\)). Five (71%) of 7 patients with DMVE and 2 (14%) of 14 patients without DMVE had microhemorrhages. There was a single macrohemorrhage in a patient with DMVE who also had microhemorrhages (Fig 3); however, the presence of macrohemorrhage per se was not significant (\(P = .147\)). Thirteen patients had MR imaging follow-up at a mean of 803 ± 549 days.
patients with and without DMVE and there was no significant difference ($P = .707$).

**Hydrocephalus**

Hydrocephalus was present in 6 (29%) of 21 patients and was significantly more common in patients with DMVE (4 of 7 patients, 57%) than in those without (2 of 14 patients, 14%; $P = .04$). There was no significant association between hydrocephalus and patient age ($P = .222$), leptomeningeal enhancement ($P = .201$), or perivascular nodular enhancement ($P = .844$). A summary of imaging variables is presented in the Table.

**Clinical Characteristics and Neurologic Status**

As can be seen in the Table, symptoms were similar in both groups: Patients without DMVE presented with headaches ($n = 4$), vision loss ($n = 4$), seizures ($n = 3$), extremity weakness ($n = 2$), cranial neuropathies ($n = 2$), gait instability ($n = 1$), hypopituitarism ($n = 1$), memory issues ($n = 1$), and word-finding difficulties ($n = 1$).

Modified Rankin Scale scores were obtained at the time of first MR imaging in 20 of 21 patients. In 1 patient, information on neurologic status was not available. Mean scores were higher (worse) in patients with DMVE (3.2 ± 0.75) compared with those without DMVE (2.1 ± 1.5), but the difference was not significant ($P = .125$). Of 18 patients available for clinical follow-up (mean follow-up duration, 725 ± 551 days), mean scores were also higher in those with DMVE; however, the difference was not significant ($P = .167$).

**Laboratory Findings**

Because this was a retrospective study, laboratory results at the time of scanning were limited. CSF analysis in 3 patients with DMVE and 5 patients without DMVE showed no significant differences in angiotensin-converting enzyme ($P = .393$) or protein ($P = .786$) levels or pleocytosis ($P = .464$). The CSF angiotensin-converting enzyme level was elevated in 1 patient with DMVE and 1 patient without DMVE, and the CSF protein level was elevated in 2 of 3 patients in the first group and 4 of 5 patients in the second group. The serum angiotensin-converting enzyme was available for 2 patients with DMVE and 7 patients without DMVE and was within normal limits except for 1 patient in each group.

**DISCUSSION**

Deep medullary veins constitute the major draining route of cerebral white matter. They have a typical perpendicular arrangement relative to the long axis of the lateral ventricles and a radial

---

**Basic demographics, symptoms, MRI findings, and modified Rankin Scale scores of patients with neurosarcoidosis**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (%)</th>
<th>DMVE (+) (%)</th>
<th>DMVE (−) (%)</th>
<th>$P$ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>21</td>
<td>7</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Age (mean ± SD) (yr)</td>
<td>46 ± 14</td>
<td>45 ± 13</td>
<td>47 ± 16</td>
<td>.813</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>10/11</td>
<td>6/1</td>
<td>4/10</td>
<td>.013*</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>8 (38%)</td>
<td>4 (57%)</td>
<td>4 (29%)</td>
<td>.346</td>
</tr>
<tr>
<td>Vision loss</td>
<td>5 (24%)</td>
<td>1 (14%)</td>
<td>4 (29%)</td>
<td>.624</td>
</tr>
<tr>
<td>Seizure</td>
<td>3 (14%)</td>
<td>0 (0%)</td>
<td>3 (21%)</td>
<td>.521</td>
</tr>
<tr>
<td>Extremity weakness</td>
<td>3 (14%)</td>
<td>1 (14%)</td>
<td>2 (14%)</td>
<td>.1</td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>2 (10%)</td>
<td>0 (0%)</td>
<td>2 (14%)</td>
<td>.533</td>
</tr>
<tr>
<td>Gait instability</td>
<td>3 (14%)</td>
<td>2 (29%)</td>
<td>1 (7%)</td>
<td>.247</td>
</tr>
<tr>
<td>Bowel/bladder dysfunction</td>
<td>4 (19%)</td>
<td>3 (43%)</td>
<td>1 (7%)</td>
<td>.088</td>
</tr>
<tr>
<td>Others</td>
<td>4 (19%)</td>
<td>1 (14%)</td>
<td>3 (21%)</td>
<td></td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Microhemorrhage</td>
<td>7 (33%)</td>
<td>5 (71%)</td>
<td>2 (14%)</td>
<td>.009*</td>
</tr>
<tr>
<td>Macrohemorrhage</td>
<td>1 (5%)</td>
<td>1 (14%)</td>
<td>0 (0%)</td>
<td>.147</td>
</tr>
<tr>
<td>Enhancing disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leptomeningeal</td>
<td>13 (62%)</td>
<td>4 (57%)</td>
<td>9 (64%)</td>
<td>.751</td>
</tr>
<tr>
<td>Pachymeningeal</td>
<td>8 (38%)</td>
<td>3 (43%)</td>
<td>5 (36%)</td>
<td>.751</td>
</tr>
<tr>
<td>Perivascular</td>
<td>3 (14%)</td>
<td>3 (43%)</td>
<td>0 (0%)</td>
<td>.089*</td>
</tr>
<tr>
<td>Venous thrombosis</td>
<td>2 (10%)</td>
<td>1 (14%)</td>
<td>1 (7%)</td>
<td>.599</td>
</tr>
<tr>
<td>Hydrothrombosis</td>
<td>6 (29%)</td>
<td>4 (57%)</td>
<td>2 (14%)</td>
<td>.040*</td>
</tr>
<tr>
<td>Modified Rankin Scale score</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At initial MRI (n = 20)</td>
<td>3.2 ± 0.75</td>
<td>2.1 ± 15</td>
<td>.125</td>
<td></td>
</tr>
<tr>
<td>At follow-up (n = 18)</td>
<td>2.4 ± 11</td>
<td>15 ± 11</td>
<td>.167</td>
<td></td>
</tr>
</tbody>
</table>

* Statistically significant.
distribution along the atria and frontal horns, with a fine and uniform caliber and several zones of convergence that lead to the subependymal veins and ultimately the dural sinuses.13

In this study, we found that DMVE is a common finding in neurosarcoidosis, though not as yet recognized as a distinct cerebrovascular manifestation.5 It was significantly more common in men, consistent with cerebrovascular manifestations of sarcoidosis being more frequent in this group.5 DMVE came to our attention owing to its conspicuousity on SWI, a sequence that is now widely available and was originally developed as a means for MR venography.14 A recent review showed 1 case with mild periatrial DMVE in a typical radial configuration on SWI; however, the presence of engorgement itself was not described.5

The pathophysiology of engorgement is uncertain but does not appear to be directly caused by downstream venous occlusion because dural sinuses and deep cerebral veins were patent in almost all our patients. Although there was no evident cortical thrombosis, we did notice a relative paucity of cortical veins along the cerebral hemispheres in some patients from both groups, which raised the question of whether abnormalities in the cortical veins could explain the appearance of DMVE. We did not find a significant difference in the number of visualized cortical veins between groups, but this could be an effect of sample size, and a difference may manifest itself in a larger population. Previous studies have proposed congestion of deep medullary veins as a potential indirect sign of dural sinus thrombosis.12,15-17 However, other than 2 cases published by Taoka et al12 and D’Amore et al,17 most reports do not convincingly demonstrate the characteristic parallel or radial anatomy seen in our patients. Comparison with such studies is limited because they lacked SWI. In our cohort, 1 patient with DMVE had chronic nonocclusive thrombus in the torcular, and we do not know whether it may have contributed to vascular engorgement. Thrombus can also show prominent hypointense signal on SWI18 and could potentially be difficult to distinguish from venous engorgement solely on the basis of that sequence. Although attributing our finding to venous engorgement rather than thrombosis was relatively straightforward based on its SWI appearance and lack of “blooming” artifacts, we also confirmed it by the corresponding contrast enhancement.

There was a higher incidence of perivascular space involvement in the group of patients with DMVE than in those without. Neurosarcoidosis is thought to spread to the CNS via the hematogenous route and has a tendency to disseminate along perivascular spaces, though the reason for this particular distribution is unknown.19 Recent studies have drawn attention owing to its conspicuity on SWI, a sequence that is now widely available and was originally developed as a means for MR venography.14 A recent review showed 1 case with mild periatrial DMVE in a typical radial configuration on SWI; however, the presence of engorgement itself was not described.5

Histopathologically, granulomatous infiltration of arterial and venous walls and perivascular tissues in neurosarcoidosis can be indistinguishable from primary CNS angiitis.5 Notably, venous involvement is more common around the ventricles,27 territory drained by the medullary veins. In some cases, there may be an inflammatory infiltrate with extensive endothelial damage in the absence of granulomas.28 These pathologic alterations may result in narrowing or obliteration of the vessel lumina19 and may possibly contribute to the engorged appearance of deep medullary veins through some degree of venous impedance.

Previous reports of primary CNS angiitis have shown a similar pattern of radial enhancement of deep medullary veins.29,30 However, it is difficult to assess how much of the linear enhancement in those patients was related to venous engorgement versus perivascular disease because no SWI was performed and findings resolved after treatment. In our study, contrast enhancement was likely a combination of perivascular disease superimposed on engorged vessels. While most patients with DMVE did not show discrete perivascular nodular enhancement, small intramural or transmural changes may have been present but beyond the capabilities of conventional MR imaging to resolve. Furthermore, there was no difference in leptomeningeal enhancement between patients with and without DMVE, and those with marked leptomeningeal disease burden were not more likely to fall into either category.

Deep medullary veins can also be prominent in ischemic stroke, in which mild prominence of deep medullary veins has been linked to hypoperfusion and poor outcomes.31,32 In that setting, they are presumed to be a manifestation of an increased regional oxygen extraction fraction leading to elevated deoxyhemoglobin in the draining veins. Studies have also suggested that this finding may be a predictor of hemorrhagic transformation in patients treated with intravenous tissue plasminogen activator.33,34 A similar appearance has also been described in Moyamoya disease, in which it has been correlated with severity.35 However, this so-called “brush sign” is relatively subtle, and none of the published cases have shown the degree of tortuosity and engorgement that was evident in our patients, in whom the process appears to be longstanding and potentially irreversible. Therefore, it is unlikely that the presence of DMVE is a direct result of perfusion changes in neurosarcoidosis. Nevertheless, we did not perform perfusion imaging, and additional research may be worthwhile.

Intracranial hemorrhage is rare in neurosarcoidosis and typically presents as microhemorrhages, likely a reflection of small-vessel disease.5,7,36 Hemorrhage is thought to result from destruction of the vessel wall by granulomatous inflammation, and previous report documented venous rupture on histopathology.36 In our study, most patients with DMVE had microhemorrhages. These were significantly more common in this group and did not seem to be an effect of patient age. Notably, there was 1
instance of macrohemorrhage that occurred in a patient with DMVE.

Hydrocephalus is seen in 10% of patients with neurosarcoidosis and is associated with high mortality.\textsuperscript{6,15} It can result from decreased CSF resorption, obstruction from meningeal or subependymal disease, or adhesions with ventricular entrapment.\textsuperscript{2,38,39} We found that hydrocephalus was much more frequent in patients with DMVE, and it is possible that these are manifestations of a more aggressive sarcoid phenotype. We did explore whether patients with DMVE had worse neurologic outcomes, but there was no significant difference in modified Rankin Scale scores at initial evaluation or follow-up.

The main limitations of this study are inherent in its retrospective nature, with heterogeneity in follow-up times and treatment paradigms. Studies were performed on different field magnets, which likely had an effect on the conspicuity of DMVE. Additionally, conventional postcontrast MR imaging likely underestimates vascular/perivascular disease in the background of engorged enhancing vessels. Finally, sample size was relatively small, and it is possible that specific clinical associations may come to light in larger studies.

In conclusion, DMVE is a frequent manifestation of neurosarcoidosis and was seen in about one-third of patients. It does not appear to be secondary to venous thrombosis in most patients and could be an indirect effect of venous and perivenous inflammation resulting in increased venous impedance. In our cohort, this finding was associated with an increased prevalence of microhemorrhages and hydrocephalus, but patients with this finding did not have worse neurologic outcomes. Being a relatively common finding, DMVE might prompt the reader to consider a diagnosis of neurosarcoidosis in challenging cases.


REFERENCES


Subtraction CTA: An Alternative Imaging Option for the Follow-Up of Flow-Diverter-Treated Aneurysms?


ABSTRACT

BACKGROUND AND PURPOSE: This was a pilot study to explore the diagnostic accuracy and safety of subtraction CTA combined with a single-energy metal artifact reduction algorithm (SEMAR) compared to DSA for the evaluation of intracranial aneurysm occlusion after flow diverter treatment.

MATERIALS AND METHODS: We included patients treated with a flow diverter for an unruptured intracranial aneurysm between November 2015 and November 2016. The patient cohort comprised 2 groups: those who underwent follow-up imaging 1 month after flow-diverter treatment and those with a known residual intracranial aneurysm after flow diverter treatment who underwent imaging at regular follow-ups. Full-brain subtraction CTA was performed on a 320-detector row CT system. A low-dose non-enhanced volume acquisition was followed by a contrast-enhanced volume CTA. Iterative and noise-reduction filters, SEMAR, andSURESubtraction algorithms were applied. DSA was performed on a flat panel C-arm angiography system. Standard posteroanterior, lateral, 3D, and detailed 2D acquisitions were performed. Imaging was independently scored by 2 clinicians. Aneurysm occlusion (Raymond scale) was our primary outcome parameter.

RESULTS: Thirteen intracranial aneurysms were evaluated with subtraction CTA and DSA. Nine aneurysm remnants were demonstrated by both subtraction CTA and DSA. The sensitivity and specificity of subtraction CTA for the detection of aneurysm occlusion were 100% (95% CI, 82.41%–100%) and 100% (95% CI, 67.55%–100%), respectively. Agreement between readers was perfect (κ = 1.0). The smallest neck remnant detected on subtraction CTA was 1.2 mm. No complications occurred.

CONCLUSIONS: Subtraction CTA with single-electron metal artifact reduction is effective in the reduction of metal artifacts of flow diverters and might therefore be a viable alternative in the assessment of intracranial aneurysm occlusion after flow diverter treatment.

ABBREVIATIONS: IA = intracranial aneurysm; FD = flow diverter; sCTA = subtraction CTA; SEMAR = single-electron metal artifact reduction

Flow diverters (FDs) are being increasingly used to treat complex intracranial aneurysms (IAs). These stentlike implants initially disrupt the blood flow into the IA and eventually facilitate parent artery reconstruction through endothelialization of the FD. Ideally this will lead to IA occlusion and rupture prevention.

Although complete IA occlusion is the goal of the FD treatment, it is only achieved in around 75%–80% of cases. Identification of aneurysm remnants after FD treatment is therefore important because remnants can still rupture and cause a subarachnoid hemorrhage. Digital subtraction angiography is considered the criterion standard to assess IA occlusion and IA remnants after FD treatment. However, this technique is invasive and has a low but not negligible complication rate. Subtraction CT angiography (sCTA), in which a noncontrast acquisition is subtracted from a contrast-enhanced acquisition, might be a good alternative to DSA in the follow-up of patients treated with FDs. This technique has already been shown to produce results comparable with those of DSA in the detection and classification of IAs in the preoperative setting. Detection of small IAs and IAs adjacent to bony structures is even more accurate in sCTA. Additional advantages of sCTA compared with DSA are lower costs, a less invasive procedure, and a lower radiation dose for the patient. One major disadvantage of using sCTA in the follow-up of patients treated with FDs is that the metal wires of the implant can produce artifacts, which can hamper IA assessment.

With the introductions of new metal artifact–reduction algo...
The goal of our study was to answer the following question: Can sCTA combined with a SEMAR algorithm effectively reduce metal artifacts of FDs, making it a viable alternative to DSA in the postoperative follow-up of patients treated with FDs? To answer our research question, we performed a pilot study to evaluate the diagnostic accuracy of sCTA compared with DSA for the evaluation of IA occlusion after FD placement.

**MATERIALS AND METHODS**

**Study Population**

A pilot study was performed at our Department of Neurosurgery. Ethics committee approval was obtained, and all patients gave written informed consent. Patients treated with a FD for an unruptured IA were included in our series. The patient cohort comprised 2 groups: those who were treated between November 2015 and November 2016 receiving follow-up imaging 1 month after FD treatment and those with a known residual IA after earlier FD treatment who received imaging at regular follow-ups (which was between November 2015 and November 2016).

Exclusion criteria were the following: younger than 18 years of age, retreatment for a previously coiled IA, the presence of a SAH, a known allergy or contraindication to the use of contrast agents, renal insufficiency, pregnancy, or the current clinical condition not allowing inclusion. Renal function was checked before (<3 months) and 3 days after the procedure. sCTA and DSA were performed within 24 hours of each other.

3D reconstructions were generated and analyzed on a workstation (XtraVision; Philips Healthcare). 3D reconstructions were used to assess the best working projections for following detailed 2D acquisitions. At the end of the procedure, the arterial puncture wound was closed with an Angio-Seal (St. Jude Medical, Minnetonka, Minnesota) or by manual compression. An average of 50 mL of contrast material (300 mg of iodine/mL, iomeprol, Iomeron; Bracco, Milan, Italy) was used per procedure. The estimated radiation dose for the entire DSA (all acquisitions) was 10 mSv.

**Digital Subtraction Angiography**

DSA was performed on a flat panel C-arm angiography system (Allura Xper FD20; Philips Healthcare, Best, the Netherlands). Before all acquisitions, a system-specific air calibration of the C-arm system was performed. Standard posteroanterior and lateral acquisitions were obtained using a diagnostic catheter via the transfemoral route. After standard 2D acquisitions, a 3D rotational acquisition was performed using a cerebral soft-tissue protocol (XperCT; Philips Healthcare) with selective contrast bolus injection via the ICA using a power injector (Angiomat Illumena; Covidien/Mallinckrodt, Lake Forest, California).

The estimated radiation dose was 2.6 mSv as reported by the scanner after each acquisition.

**Image Analysis**

Studies were independently scored by 1 neuroradiologist (F.J.A.M., reader 1 with 12 years experience) and 1 neurosurgeon (M.P.D.C., reader 2 with 3 years experience). Neither of these 2 readers were involved in the treatment of the patients. Both sCTA and DSA studies were reviewed on a dedicated clinical workstation (Impax, Version 6.6; Agfa HealthCare, Mortsel, Belgium).

All variables were dichotomized to assess the diagnostic accuracy of sCTA compared with DSA as the reference standard. Intracranial aneurysm occlusion rate, based on the Raymond scale, was used as the primary study parameter and was categorized as either completely occluded (Raymond grade 1) or incompletely occluded (Raymond grade ≥2).

We assessed the following secondary outcome measures: Device deployment, wall apposition, and neck coverage were scored as “complete” or “incomplete.” Proximal and distal vessel patency

**FIG 1.** A patient with 3 aneurysms treated with either a flow diverter or coils. Axial view in which both a flow diverter (arrows) and coils are visible to illustrate the effect of single-energy metal artifact reduction. Non-SEMAR CTA (left), CTA with SEMAR (middle), and subtraction CTA with SEMAR (right) demonstrate the effects of SEMAR on metal artifacts.
was compared with pretreatment vessel diameter and scored as either "nonstenotic" (≤25% stenosis) or "stenotic" (>25% stenosis). Side-branch patency was scored as "unchanged" or "changed" compared with pretreatment DSA.

Statistical analysis was performed on initial scoring. In case of discrepancies, readers were asked to re-evaluate these specific cases in a second reading to see whether consensus between sCTA and DSA scoring could be reached. These consensus readings were used solely for descriptive analysis and not for statistical analysis because of the great bias after the initial reading.

Statistical Analysis

Statistical analyses were performed using SPSS statistical software (Version 22.0; IBM, Armonk, New York). The sensitivity and specificity of sCTA compared with DSA regarding the primary outcome measure were calculated. \( \kappa \) statistics were calculated for interrater reliability regarding the primary outcome measure. \( \kappa \) values were scored according to the method of Fleiss et al\(^\text{20}\): <0.4, poor but fair agreement; 0.41–0.75, good agreement; and >0.75 excellent agreement. Descriptive statistics were used for patient and aneurysm characteristics and secondary parameters.

RESULTS

Included Patients

Between November 2015 and November 2016, twenty-three patients were treated with a flow diverter at our Department of Neurosurgery. Thirteen patients (8 women and 5 men) were enrolled in this study (Fig 2). Seven patients were newly treated and underwent early follow-up imaging 1 month after treatment to assess IA closure. The remaining 6 patients had a known IA remnant and were included at their regular follow-up moment. Five patients declined to participate in the study, and 2 patients were excluded due to their renal function. Three patients were excluded due to their clinical condition. These patients had neurologic deterioration after FD treatment either due to mass effect or ischemic events.

The average age of patients was 60 ± 8 years (range, 44–76 years). Treated IAs originated from the internal carotid artery (54%, \( n = 7 \)), middle cerebral artery (23%, \( n = 3 \)), posterior communicating artery (8%, \( n = 1 \)), vertebral artery (8%, \( n = 1 \)), and posterior inferior cerebellar artery (8%, \( n = 1 \)).

All patients had been treated previously with a Surpass FD (Stryker Neurovascular, Kalamazoo, Michigan). Eleven patients were treated with 1 FD and 2 patients were retreated with an additional FD due to persistent IA filling after the initial FD treatment. sCTA and DSA were performed within 24 hours of each other in every patient. No complications occurred.
Primary Outcome
In all cases, sCTA and DSA provided adequate images for diagnostic evaluation. Nine incomplete IA occlusions were demonstrated by both sCTA and DSA (Figs 3–5).

The sensitivity and specificity of sCTA for the detection of IA occlusion were 100% (95% CI, 82.41%–100%) and 100% (95% CI, 67.55%–100%), respectively (Table). Agreement between readers was perfect ($\kappa = 1.0$). The smallest neck remnant detected on sCTA was 1.2 mm (Fig 6).

Secondary Outcomes
Agreement between sCTA and DSA regarding the secondary parameters is presented in the Table. Five disagreements in 4 secondary parameters occurred.

DISCUSSION
We strived to answer the following question: Can sCTA, combined with a SEMAR algorithm, effectively reduce metal artifacts of FDs, making them a viable alternative to DSA in the postoperative follow-up of patients treated with FDs? In this pilot study, we showed that sCTA in combination with a SEMAR algorithm was effective in the reduction of metal artifacts of FDs and that the diagnostic accuracy of sCTA with a SEMAR was similar compared with DSA for the evaluation of IA occlusion after FD placement.

To our knowledge, this is the first study in which an alternative imaging technique has been shown to be comparable with DSA after FD treatment; in recent studies, contrast-enhanced MRA,21–23 3D TOF-MRA,21,22 C-arm conebeam CT,24,25 and CTA22 were all inferior to DSA due to metal artifacts originating from the FD wires. Although a recent study comparing contrast-enhanced MRA with DSA demonstrated good imaging of the aneurysm sac after FD treatment, the assessability of the stent lumen, however, remained difficult due to metal artifacts.23

Besides IA occlusion, we also assessed several secondary parameters such as device deployment, device malapposition, parent artery stenosis, and side-branch patency. Although 5 disagreements between DSA and sCTA occurred in these secondary parameters (Table), none would have led to discrepancies in clinical decision-making. Disagreements were not clearly in favor of 1 of the 2 modalities. For example, in 1 case, a side branch was missed by 1 reader on sCTA but not on DSA. However, in another case, both readers scored wall apposition as incomplete on sCTA but complete on DSA in 1 subject. A second reading of this case confirmed incomplete wall apposition on DSA, which demonstrated the potential of sCTA in the follow-up of patients treated with FDs.

The SEMAR algorithm has been an important addition to the sCTA technique. Despite only recently becoming commercially available, it has already led to successful results in several fields of medicine. The algorithm was able to reduce metal artifacts in

---

**Table 1**

<table>
<thead>
<tr>
<th>Intracranial Aneurysm Feature</th>
<th>Discrepancies between sCTA and DSA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysm closure (Raymond I)</td>
<td>Reader 1: 0</td>
<td>NA</td>
</tr>
<tr>
<td>Complete device deployment</td>
<td>Reader 2: 1</td>
<td>Device deployment was scored complete on sCTA but incomplete on DSA; a second reading of this case confirmed complete device deployment on DSA</td>
</tr>
<tr>
<td>Complete wall apposition</td>
<td>Reader 1: 1</td>
<td>In 1 patient, both readers scored wall apposition incomplete on sCTA but complete on DSA; a second reading of this case confirmed incomplete wall apposition on DSA</td>
</tr>
<tr>
<td>Complete neck coverage</td>
<td>Reader 1: 0</td>
<td>NA</td>
</tr>
<tr>
<td>Vessel patency distal (nonstenotic)</td>
<td>Reader 2: 1</td>
<td>Vessel patency was scored nonstenotic on sCTA but stenotic on DSA; in 1 case; a second reading confirmed nonstenosis on DSA</td>
</tr>
<tr>
<td>Vessel patency proximal (nonstenotic)</td>
<td>Reader 1: 0</td>
<td>NA</td>
</tr>
<tr>
<td>Side branch patency (no change)</td>
<td>Reader 2: 1</td>
<td>In 1 case, a side branch was missed on follow-up sCTA; a second reading of the case confirmed a patent side branch on sCTA</td>
</tr>
</tbody>
</table>

Note: NA indicates not applicable.
patients with dental implants\textsuperscript{26} and hip prostheses.\textsuperscript{17} Additionally, the SEMAR was also able to improve image quality in patients treated with coils for IA aneurysms and abdominal aneurysms (Fig 1).\textsuperscript{16,18} These results demonstrate the importance of SEMAR when using sCTA, and we think it might also be a useful tool for follow-up imaging when patients with IAs have been treated with surgical clips or detachable coils. This should be studied in future research.

This study has several limitations. First, because this was a pilot study, we used a small patient cohort and thus gathered limited data. However, we were able to collect a relatively high number of nonoccluded IAs by selecting patients with either a known aneurysm remnant as well as by performing a short follow-up after FD implantation. A large, prospective study is necessary to confirm the results of this pilot study.

Second, blinded scoring of sCTA and DSA studies would have improved the methodology of this study. However, with a limited study population, it will remain extremely difficult for readers to be completely blinded because they will likely recognize individual cases by the size, shape, and location of the IA.

Third, we only included patients treated with a Surpass FD device and results may not translate to other FDs because not all FDs are made from the same material. However, the cobalt chromium wires of the Surpass FD are expected to result in more pronounced metal artifacts compared with nitinol stents, which would make this a worst-case scenario.

**CONCLUSIONS**

Subtraction CTA with the SEMAR is effective in the reduction of metal artifacts of FDs and might, therefore, be a viable alternative in the assessment of IA occlusion after FD treatment.


**REFERENCES**

Flow-Diversion Effect of LEO Stents: Aneurysm Occlusion and Flow Remodeling of Covered Side Branches and Perforators


ABSTRACT

BACKGROUND AND PURPOSE: Flow diversion with intermediate-porosity stents (braided stents) has been recently reported for distally located small aneurysms. The aim of this study was to evaluate the flow-diversion effect of LEO stents on covered vessels and for aneurysms treated with sole stent-placement therapy.

MATERIALS AND METHODS: We retrospectively evaluated the following outcomes: 1) remodeling of covered side branches and perforators (extra-aneurysmal flow remodeling), and 2) the occlusion rate of aneurysms treated with sole stent-placement therapy (intra-aneurysmal flow remodeling).

RESULTS: Seventy-six patients with 98 covered vessels were studied. Overall, 89 covered arteries (91%) were normal, 7 showed narrowing (7%), and 2 (2%) were occluded (1 posterior communicating artery and 1 MCA) without related complications (mean DSA follow-up, 14 months). Univariate and multivariate analyses highlighted smoking (P = .03) and the length of follow-up (P = .002) as factors associated with arterial remodeling. Of the 17 Sylvian (lenticulostriate arteries) and 7 basilar perforators, 1 (4%) group of Sylvian perforators covered with double stents had asymptomatic remodeling. Ten aneurysms (mean size, 3.5 mm) were treated with LEO stents as stent monotherapy (5 recanalized after coiling and 5 directly treated with the LEO). Complete occlusion (Raymond-Roy I) was achieved in 70% of aneurysms (mean follow-up, 14 months). The Raymond-Roy I occlusion rate among recanalized aneurysms and those directly treated with LEO stents was 80% and 60%, respectively (P = .9).

CONCLUSIONS: The rate of flow remodeling on the covered arteries and perforators was 9% and 4%, respectively, and was clinically irrelevant in all cases. Complete occlusion of aneurysms treated with sole stent-placement therapy was 70%. These data stress the flow-diversion properties of LEO stents.

ABBREVIATIONS: PcomA = posterior communicating artery; RR = Raymond-Roy; SAC = stent-assisted coiling

LEO stents (Balt Extrusion, Montmorency, France) are self-expanding closed-cell stents produced by braiding individual strands of nitinol onto a mandrel. Based on the braided morphology, LEO stents have a relatively small pore size (cell size of approximately 0.9 mm) that gives a higher metal coverage ratio compared with other self-expandable stents, allowing a certain grade of flow-diverting hemodynamic effect. Accordingly, LEO stents have been recently reported as stent monotherapy for the treatment of small and complex intracranial aneurysms based on their flow-modification capacity and their biologic effects. The deployment of low-porosity flow-diverter stents across side branches or perforators has a potential risk of occlusion and related symptomatic ischemic lesions. Because of their intermediate porosity, braided stents could provide flow-change patterns similar to those provided by conventional flow-diverter devices, both on the aneurysm and covered side branches and perforators. However, the extra-aneurysmal flow modifications, the fate of vessels covered by LEO stents, and the related clinical sequelae have been poorly investigated in the literature.

We present a retrospective series of 76 intracranial aneurysms and 98 side branches covered by LEO stents with the aim of investigating the following: 1) the flow-diversion effect on the aneurysms treated with LEO stents as a stent monotherapy, 2) the flow remodeling of the covered side branches and perforators, and 3) the clinical events related to the flow changes on the investigated vessels.
MATERIALS AND METHODS

Patient Selection
Our hospital institutional review board (Centre Hospitalier Universitaire de Montpellier) approved this retrospective study. Our institutional prospectively maintained data base (January 2011 to January 2018) was retrospectively reviewed by 2 and, in case of inconsistency, by 3 investigators independently. The inclusion criteria were the following: 1) intracranial aneurysms treated with a LEO placed across side branches or perforators, and 2) intracranial aneurysms treated with stent monotherapy in which LEO devices were used as intermediate-porosity flow diverters. Only patients examined with DSA at follow-up were included in this series. Flow diversion with the LEO as stent monotherapy was performed to treat the following: 1) small aneurysms with a complex morphology not amenable to simple coil embolization, balloon remodeling, or stent-assisted coiling (SAC); 2) distally located recanalized aneurysms requiring retreatment and difficult to treat with conventional coiling (for the unstable position of the microcatheter) or with flow diversion (for the presence of important branches or perforators); and 3) dissecting aneurysms not amenable to different treatments. The treatment strategy was chosen by multidisciplinary consensus (vascular neurosurgeons and interventional neuroradiologists).

Antiplatelet Therapy
For unruptured aneurysms, antiplatelet therapy included daily dual-antiplatelet medication with aspirin (Kardegiec), 75 mg, and clopidogrel (Plavix), 75 mg, starting 5 days before treatment. The therapy was maintained for 3–6 months. Thereafter, based on the clinical and radiologic evaluation, the patients were switched to aspirin. VerifyNow P2Y12 assay (Accumetrics, San Diego, California) was used to test the platelet inhibition: both P2Y12 reaction unit and aspirin reaction units were tested. When LEO stents were used in patients with acutely ruptured aneurysms, an intravenous bolus of abciximab (0.125 mg/kg) was administered a few minutes before stent deployment, and standard dual-antiplatelet therapy was started the day after. Concurrent with the procedure, in both unruptured and ruptured aneurysms, intravenous heparinization was performed (activated clotting time maintained above 250 seconds).

Description of Technique
All patients were treated under general anesthesia via a transfemoral approach. Through a long femoral sheath (triaxial approach), a 6F guiding catheter was advanced into the carotid or vertebrobasilar system. Vessels and aneurysms were analyzed via biplane and 3D rotational angiography. The LEO stent was unsheathed under roadmap guidance through the dedicated Vasco microcatheter (Balt). VasoCT (Philips Healthcare, Best, the Netherlands) with diluted iodinated contrast medium was used to assess stent apposition to the arterial wall. ⁷,⁸

Clinical and Imaging Assessment
Usually, the angiographic follow-up was performed with MRA at 6 months and DSA at 12 and 24 months. Flow remodeling was examined with DSA. Flow remodeling was examined on the following arteries covered by LEO stents (On-line Table 1): ophthalmic artery, anterior choroidal artery, posterior communicating artery (PcomA), A1 segment (stent from the ICA to M1), A2 segment (stent from the A1 to the contralateral A2, or stent from the A1 to the ipsilateral A2 in cases of an absent or hypoplastic contralateral A1), callosomarginal and orbitofrontal arteries, middle cerebral artery (M2), superior cerebellar artery, anterior inferior cerebellar artery, and posterior cerebral artery. Covered anterior communicating arteries and related perforators were not considered in this study. Perforator arteries covered by the LEO were divided into 2 groups: Sylvian perforator (lenticulostriate arteries) and basilar artery perforators. Perforating arteries were grouped as 1 entity per case (group of perforators) and were counted accordingly. The native arterial configuration was based on preoperative angiography. The flow remodeling was recorded as follows: 1) normal artery (no change in flow or caliber), 2) reduced in caliber/narrowing, and 3) occluded. Parent vessel stenosis was not considered as extra-aneurysmal flow remodeling. The ischemic complications related to covered vessels were detected on MR imaging at follow-up. Clinical follow-up information was obtained at the time of the follow-up clinic visits at 6, 12, and 24 months.

The aneurysm occlusion rate was defined on the basis of the Raymond-Roy (RR) classification: complete occlusion (class I), residual neck (class II), and incomplete occlusion or residual aneurysm (class III).⁹

Statistical Analysis
Categoric data were described by frequency, whereas quantitative data were described by mean and SD. The dependent variable was the angiographic outcome of the covered artery, and it was divided into “normal” and “occlusion/narrowing.” The χ² test was used to evaluate the qualitative risk factors for occlusion/narrowing (location, hypertension, smoking, number of stents, covered artery arising from the inner or outer curve or from a linear stent, and sex). The t test (2-tailed) was applied to assess quantitative risk factors (length of follow-up and age). Although the number of events was <20, two variables (smoking and length of follow-up) were significantly associated with arterial occlusion/narrowing in univariate analysis and were analyzed together in a binary logistic regression (multivariate analysis) to assess the independent contribution of each risk factor. The results of the regression model were calculated by the Wald test and expressed using P values and related odds ratios. All statistical analyses, descriptive and inferential, were performed with SPSS, Version 24 (IBM, Armonk, New York).

RESULTS

Population Characteristics
In the 7-year period, 76 consecutive patients (51 women, 25 men; mean age, 54.5 ± 10.5 years) with 98 side branches and 24 groups of perforators (17 Sylvian perforators and 7 basilar perforators) covered with LEO stents were included in this study (details in On-line Tables 2 and 3).
Treatment-Related Complications
Successful stent deployment was observed in all except 2 cases. A minor misopening of the proximal part of the stent was seen on plain x-rays and confirmed by the VasoCT. Due to the minor malapposition of the stents, no additional maneuvers were performed and there were no related complications. Overall, in-stent acute thrombosis was seen in 9 cases and was completely resolved after abciximab injection in all except 1 case. Small and asymptomatic ischemic lesions in the basal ganglia were reported in 2 patients (1 case is described in Fig 1). Finally, there were 2 cases of asymptomatic ICA dissections.

Two cases of asymptomatic mild stent stenosis (<50%) were observed and were related to in-stent intimal hyperplasia (1 case of mild stent stenosis is depicted in the On-line Figure).

Angiographic Outcome of Covered Arteries and Perforators
All of the included patients underwent DSA at follow-up (mean DSA follow-up, 14 months; median, 13.5 months; range, 11–24 months, IQR, 13–14 months). Overall, 76 (77.5%) anterior circulation and 22 (22.5%) posterior circulation side branches were covered with LEO stents (On-line Table 1). Among 15 patients, the superimposition of other arteries or bone structures hampered the angiographic visualization of some branching vessels that were not included in the analysis. During follow-up, 89 covered arteries (91%) were normal, whereas 7 showed a reduction in diameter (7%) (Figs 2 and 3) and 2 arteries (2%) were occluded (Fig 3). There were no symptomatic or asymptomatic associated complications.

All except 1 group of perforators (17 Sylvian perforators and 7 basilar perforators) were patent at the last follow-up. One patient (4%) with an MCA aneurysm treated with Y-stent placement had asymptomatic occlusion of some of the M1 perforators during 13 months of follow-up (Fig 1). The M1 perforators were covered with 2 overlapped LEOs.

Factors Associated with Arterial Remodeling
The factors tested as predictors of arterial occlusion/narrowing are reported in On-line Table 4. There was a trend toward lower mean age among patients presenting with flow remodeling (47.8 vs 54.7 years, \( P = .06 \)). However, the univariate analysis showed that the only factors associated with an increased risk of arterial narrowing/occlusion were the length of radiologic follow-up (\( P < .001, \text{OR} = 1.85 \)) and smoking (\( P < .001, \text{OR} = 18.4 \)), which were confirmed with multivariate analysis (smoking: \( \text{OR} > 20, P = .03 \)) (length of follow-up: \( \text{OR} = 1.99, P = .002 \)).

Angiographic Outcome of Aneurysms Treated with LEO Stents as Stent Monotherapy
Overall, the LEO stent was used as flow-diversion treatment among 10 aneurysms (On-line Table 5). Five of them were recanalized after coiling (3 previously ruptured and 2 unruptured); the others were directly treated with LEO stents (4 unruptured aneurysms and 1 dissecting ruptured aneurysm) (Fig 3 and On-line Figure). Reasons behind the treatment with the sole stent-placement technique are detailed in On-line Table 5. The mean size of this group of aneurysms was 3.5 mm (median, 3.5 mm; range, 2–5 mm). Complete occlusion (RR I) was achieved in 70% of aneurysms. There were no differences in the size of aneurysms completely and incompletely occluded (RR III) (\( P = .33 \)). RR I occlusion was 60% and 80% among lesions directly treated with LEO stents versus aneurysms previously coiled, respectively (\( P = .9 \)). The mean length of follow-up was 14 months; the mean length of follow-up of the groups of completely occluded and incompletely occluded aneurysms was 22 months and 15 months, respectively (\( P = .6 \)).
DISCUSSION

Compared with laser-cut stents, LEO devices are braided from a single nitinol wire with closed cells that can change size on the basis of the stent deployment. The braided stents have relatively higher pore density (0.979 and 0.782 pore/mm²) than the laser-cut stents (0.276 pore/mm² for both Enterprise [Codman & Shurtleff, Raynham, Massachusetts] and Neuroform [Stryker Neurovascular, Kalamazoo, Michigan] stents), giving greater metal coverage (14% for LEO stents versus 5%–10% for Enterprise and Neuroform stents). These characteristics may have important therapeutic implications. Indeed, although their metal surface coverage is lower than that in a flow diverter (30% for the Pipeline Embolization Device; Covidien, Irvine, California), LEO stents have been successfully used as stent monotherapy, especially for distal and complex small aneurysms. In addition, computational fluid dynamics studies revealed that a double-overlapped braided stent resulted in greater flow diversion than a single Pipeline device, supporting the flow-diversion capacity of these stents. However, while the hemodynamic effect of flow diveters has been largely studied, the potential flow remodeling of LEO stents on the aneurysm, covered side branches, and perforator arteries has been poorly investigated.

Angiographic Outcome of Covered Side Branches and Perforators

To the best of our knowledge, our series is the first study that provides angiographic and clinical data about the peri-aneurysmal flow remodeling of LEO devices. The rates of arterial narrowing and occlusion were close to 7% and 2%, respectively. Among series of flow diverters covering ICA branches, the rate of arterial occlusion and related symptoms ranged widely in relation to the type of covered artery. The rate of PcomA occlusion is reported between 7% and 50% without related symptoms and with lower rates of occlusion in the fetal variant (due to the major supply to the posterior cerebral artery). The rate of ophthalmic artery occlusion ranged from 0% to 17%, with <1% associated symptoms. Finally, occlusion of the anterior choroidal artery has been described between 0% to 5%, without neurologic sequelae in most of the reported series.

FIG 2. A, Procedural angiogram of a 49-year-old male patient with a 7-mm unruptured aneurysm on the right MCA bifurcation (black arrow). B, A nonsubtracted angiographic image obtained during treatment demonstrates the successful SAC embolization of the aneurysm with a LEO stent (2.5 × 18 mm) deployed from the M1 to the inferior M2 segment (red arrows). The M2 superior branch is covered by the stent (short white arrow). C, A 20-month follow-up DSA reveals complete aneurysm occlusion and asymptomatic narrowing of the covered superior M2 branch. D, Blood flow compensation is provided by the collateral circulation (white star).

Most interesting, in our series, the mean follow-up time among patients with arterial narrowing and occlusion was higher (19 and 21 months, respectively) compared with the group of normal arteries (13 months). Indeed, multivariate analysis confirmed the length of radiologic follow-up as an independent factor associated with arterial remodeling. Accordingly, it is likely that a longer follow-up time would demonstrate a higher incidence of vessel remodeling. In addition, arterial narrowing and occlusion were strongly related to smoking. Data regarding the influence of smoking on arterial occlusion after flow diversion are scant. In a series of 30 PcomAs covered with Pipeline devices, smoking was not a risk factor for occlusion in the multivariate analysis. Rouchaud et al. in a series of nearly 600 patients treated with the Pipeline, demonstrated that tobacco does not affect aneurysm occlusion or thromboembolic complications after flow diversion. However, other studies have shown that smoking is associated with worse clinical outcomes after stent treatment in other locations. In a study of 9000 patients undergoing percutaneous coronary implantation of drug-eluting stents, Matteau et al. found that smoking was an independent risk factor for ischemic events and bleeding. Similarly, after percutaneous cor-
onary intervention, Yeo et al. found that active smoking was associated with a higher risk of in-stent thrombosis. After stent deployment, the cellular responses related to the mechanical vascular injury included the following: 1) platelet activation and inflammation, 2) granulation tissue and smooth-muscle cell proliferation, and 3) tissue remodeling and neoendothelialization. Smoking negatively influences the coagulation system, stimulating platelet aggregation, promoting a precoagulatory state, and causing endothelial dysfunction. These factors potentially stimulate an exuberant healing response leading to intimal hyperplasia at the level of the ostium of the branching arteries. Theoretically, this mechanism can explain the higher rate of occlusion of covered arteries in smoking patients found in our series.

Contrariwise, location, age, and sex were not statistically associated with arterial flow changes. Although few patients were treated with double LEO stents, multiple stents were not related to a higher risk of arterial occlusion. Similarly, multiple flow diverters were reported to be associated with greater occlusion in some series, while in other studies, the number of devices was not a significant predictor of sluggish flow. This result highlights the complexity of the flow-remodeling process, which involves the mechanical properties of the stent as well as biologic (neoendothelialization) and hemodynamic factors (collateral circulation).

In case of tortuous parent arteries (carotid siphon or bifurcations), the local stent deformation can influence the density of the pores, resulting in tighter mesh in the inner curves, with higher flow density and lower density of the pores in the outer curve. Rouchaud et al. reported 75% optic nerve atrophy when the ophthalmic artery originated from the inner curve of the flow diverter, probably based on the higher local density of the stent. However, in our series, there was no statistically significant correlation between the different origins of the covered artery (from the inner or outer curve or from a linear stent) and the angiographic outcome.

Another important factor associated with flow diverters is the risk of perforating injury due to coverage of lenticulostriate or basilar perforators. Accordingly, flow-diversion treatment of MCA or posterior circulation aneurysms is associated with higher complications, mostly related to perforating injury. In our series, we observed only 1 case (4%) of asymptomatic flow remodeling of lenticulostriate arteries covered with 2 overlapped LEO stents (Fig 1). Similarly, Aydin et al. reported 1 patient with a small and clinically transient lacunar infarct in the basal ganglia due to Sylvian perforator occlusion during follow-up.

Angiographic Outcome of Aneurysms Treated with the LEO Stent as Stent Monotherapy

The first experience of flow-diverter treatment with LEO stents was described by Pumar et al., reporting 75% complete occlusion after treatment of 20 intracranial fusiform aneurysms. Recently, Aydin et al. reported 73% complete occlusion of complex and small aneurysms located behind the circle of Willis and treated with braided stents as stent monotherapy. In our series, 70% of aneurysms treated with the LEO as a flow diverter showed complete occlusion (RR I) during 14 months of follow-up, showing the flow-diversion capacity of these stents. We reported a slightly higher occlusion rate among aneurysms previously coiled (80%) compared with lesions directly treated with sole stent-placement therapy (60%). Stent monotherapy has also been reported with open-cell laser-cut stents. Fiorella et al. reported 10 ruptured uncoiled aneurysms treated with Neuroform stents, showing 50% and 40% complete and near-complete occlusion, respectively. Comparable results reported by Nyberg and Larson showed a 45% complete or near-complete occlusion of small sac-
cular aneurysms treated with a single low-porosity stent. Indeed, aneurysm occlusion is influenced by both the flow disruption of the intra-aneurysmal flow and the endothelialization of the stent with subsequent intravascular remodeling. The main factor influencing neoendothelialization is the vessel wall apposition of the stent; LEO devices, with their braided morphology, provide high conformability and wall apposition, promoting, together with their flow-diversion effect, thrombosis of the aneurysm. As with in vitro studies showing good conformability and vessel wall apposition, in our series, successful stent deployment and wall apposition were achieved in 97% of cases and were confirmed by the VasoCT. This outcome is in accordance with other recent series of LEO stent embolization reporting rates of successful stent delivery ranging from 90% to 100%,\textsuperscript{3,4,38}

**Limitations of the Study**

Our study has limitations intrinsic to single-center series. The data were analyzed retrospectively. The imaging outcome was assessed by operators and not independently. Although all patients received the same dual-antiplatelet therapy, the influence of the platelet responsiveness of each patient was not assessed in the univariate and multivariate analyses. Accordingly, we were not able to establish whether the platelet responsiveness was a risk factor of arterial narrowing/occlusion after stent coverage.

**CONCLUSIONS**

The rate of flow remodeling on the covered arteries and perforators was 9% and 4%, respectively, and was clinically irrelevant in all cases. Flow changes on the covered side branches were directly related to the length of follow-up and influenced by smoking habits. Complete occlusion of aneurysms treated with sole stent-placement therapy was 70%. These data stress the flow-diversion properties of LEO stents.

**ACKNOWLEDGMENTS**

We thank Beth De Felici for the English revision.


**REFERENCES**

24. Cagnazzo F, Mantilla D, Lefevre PH, et al. Treatment of middle ce-
rebral artery aneurysms with flow-diverter stents: a systematic re-
CrossRef Medline
25. Rouchaud A, Brinjikji W, Cloft HJ, et al. Smoking does not affect oc-
clusion rates and morbidity-mortality after Pipeline emboliza-
tion for intracranial aneurysms. AJNR Am J Neuroradiol 2016;37:
1122–26 CrossRef Medline
26. Matteau A, Yeh RW, Camenzind E, et al. Balancing long-term risks of ischemic and bleeding complications after percutaneous coro-
mary intervention with drug-eluting stents. Am J Cardiol 2015;116:
686–93 CrossRef Medline
27. Yeo KK, Armstrong EJ, Soni K, et al. Long-term outcomes of angi-
ographically confirmed coronary stent thrombosis: results from a multicentre California registry. EuroIntervention 2015;11:188–95
CrossRef Medline
thrombosis. JACC Cardiovasc Inter 2011;4:1057–66 CrossRef Medline
919–22 CrossRef Medline
31. Makoyeva A, Bing F, Darsaut TE, et al. The varying porosity of braid
35. Fiorella D, Albuquerque FC, Deshmukh VR, et al. Endovascular re-
construction with the Neuroform stent as monotherapy for the treat-
36. Nyberg EM, Larson TC. Beneficial remodeling of small saccular in-
tracranial aneurysms after staged stent only treatment: a case se-
37. Valdivia y Alvarado M, Ebrahimi N, Benndorf G. Study of conform-
ability of the new LEO Plus stent to a curved vascular model using flat-panel detector computed tomography (DynaCT). Neurosurgery 2009;64:ons130–134; discussion ons134 CrossRef Medline
38. Machi P, Costalat V, Lobotesis K, et al. LEO Baby Stent use following balloon-assisted coiling: single- and dual-stent technique—imme-
diate and midterm results of 29 consecutive patients. AJNR Am J
Neuroradiol 2015;36:2096–103 CrossRef Medline
Treatment of Intracranial Aneurysms with Self-Expandable Braided Stents: A Systematic Review and Meta-Analysis


ABSTRACT

BACKGROUND: The safety and efficacy of treatment with self-expandable braided stents (LEO and LVIS) required further investigation.

PURPOSE: Our aim was to analyze the outcomes after treatment with braided stents.

DATA SOURCES: A systematic search of 3 databases was performed for studies published from 2006 to 2017.

STUDY SELECTION: According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included studies reporting patients treated with LEO or LVIS stents.

DATA ANALYSIS: Random-effects meta-analysis was used to pool the following: aneurysm occlusion rate, complications, and neurologic outcomes.

DATA SYNTHESIS: Thirty-five studies evaluating 1426 patients treated with braided stents were included in this meta-analysis. Successful stent delivery and complete aneurysm occlusion were 97% (1041/1095; 95% CI, 95%–98%) (I² = 44%) and 88.3% (1097/1256; 95% CI, 85%–91%) (I² = 72%), respectively. Overall, treatment-related complications were 7.4% (107/1317; 95% CI, 5%–9%) (I² = 44%). Ischemic/thromboembolic events (48/1324 = 2.4%; 95% CI, 1.5%–3.4%) (I² = 27%) and in-stent thrombosis (35/1324 = 1.5%; 95% CI, 0.6%–1.7%) (I² = 0%) were the most common complications. Treatment-related morbidity was 1.5% (30/1324; 95% CI, 0.9%–2%) and was comparable between the LEO and LVIS groups. Complication rates between the anterior (29/322 = 8.8%; 95% CI, 3.4%–12%) (I² = 41%) versus posterior circulation (10/84 = 10.5%; 95% CI, 4%–16%) (I² = 0%) and distal (30/303 = 8%; 95% CI, 4.5%–12%) (I² = 48%) versus proximal aneurysms (14/153 = 9%; 95% CI, 3%–13%) (I² = 46%) were comparable (P > .05).

LIMITATIONS: Limitations were selection and publication biases.

CONCLUSIONS: In this analysis, treatment with the LEO and LVIS stents was relatively safe and effective. The most common complications were periprocedural thromboembolisms and in-stent thrombosis. The rate of complications was comparable among anterior and posterior circulation aneurysms, as well as for proximal and distally located lesions.

ABBREVIATIONS: IQR = interquartile range; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SAC = stent-assisted coiling

The development of self-expandable stents has progressively changed the treatment strategy for most intracranial aneurysms, creating a mechanical scaffold that prevents coil protrusion and promoting neointimalization of the neck. Several self-expandable stents were introduced in the past years, including laser-cut open-cell stents (such as the Neuroform; Stryker Neurovascular, Kalamazoo, Michigan) and laser-cut closed-cell stents (such as the Enterprise; Codman & Shurtleff, Raynham, Massachusetts). The third generation of self-expandable closed stents was produced by braiding individual strands of nitinol onto a mandrel (LVIS, MicroVention, Tustin, California; and LEO, Balt Extrusion, Montmorency, France). In addition to providing mechanical support, the braided morphology gives a relatively higher pore density than the laser-cut stents, theoretically improving the flow-diverting hemodynamic effect of these devic-
es. Recently, the low-profile design of the braided stents (LEO Baby and LVIS Jr) allowed delivery through a 0.0165-inch microcatheter and navigation in small vessels, with the possibility of treating distally located aneurysms. Improved understanding of treatment-related outcomes of braided stents can help practitioners in the selection of lesions amenable to being effectively treated with these devices. Our meta-analysis examined occlusion rates and procedure-related complications after treatment with braided stents, focusing on the influence of aneurysm features, location, and treatment characteristics on the studied outcomes.

MATERIALS AND METHODS

Literature Search

A comprehensive literature search of PubMed, Ovid MEDLINE, and Ovid EMBASE was conducted for studies published from January 2006 to February 2018. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The key words and the detailed search strategy are reported in On-line Table 1. The inclusion criteria were the following: studies reporting series of intracranial aneurysms treated with LEO and LVIS stents. Exclusion criteria were the following: 1) review articles, 2) studies published in languages other than English, 3) in vitro studies, and 4) animal studies. In cases of overlapping patient populations, only the series with the largest number of patients or the most detailed data was included. Two independent readers screened articles in their entirety to determine eligibility for inclusion. A third author solved discrepancies.

Data Collection

From each study, we extracted the following: 1) treatment-related complications, 2) occlusion rate, and 3) clinical outcome. Occlusion and complication rates were analyzed on the basis of the influence of the following parameters: 1) unruptured-versus-acute ruptured aneurysms, 2) distal-versus-proximal location, 3) anterior-versus-posterior circulation, 4) first treatment versus retreatment, 5) stent alone versus stent-assisted coiling (SAC), and 6) single-versus-multiple stents. A subgroup analysis was performed for aneurysms treated with small low-profile braided stents (LEO Baby and LVIS Jr). Distal location was considered for lesions arising distal to the circle of Willis or located in small vessels: A2–3 segments, middle cerebral artery, posterior cerebral artery, posterior inferior cerebellar artery, anterior inferior cerebellar artery, and superior cerebellar artery. The occlusion rate was defined on the basis of the Raymond-Roy classification. Accordingly, we used the following terms: complete occlusion (class I), residual neck or near complete occlusion (class II), and incomplete occlusion or residual aneurysm (class III). Treatment-related complications were divided into 2 groups: periprocedural/early events (within 30 days after treatment) and delayed events (after 30 days). Finally, good outcome was defined as a modified Rankin Scale score of 0–2 or a Glasgow Outcome Score of 4–5, or it was assumed if the study used terms such as “no morbidity,” “good recovery,” or “no symptoms.”

Outcomes

The primary objectives of this meta-analysis were to define the safety (treatment-related complications, neurologic outcomes, mortality rate) and the efficacy (aneurysm occlusion rate) of the treatment of intracranial aneurysms with self-expanding braided stents (LEO and LVIS). The secondary objectives were to define the influence of aneurysm location, aneurysm characteristics, and factors related to the treatment on the analyzed outcomes.

Quality Scoring

A modified version of the Newcastle-Ottawa Scale was used for quality assessment of the included studies. The details are reported in On-line Tables 2 and 3. The quality assessment was performed by 2 authors independently, and a third author solved discrepancies.

Statistical Analysis

We estimated, from each cohort, the cumulative prevalence (percentage) and 95% confidence interval for each outcome. Percentages were calculated with a random-effects meta-analysis. Heterogeneity across studies was evaluated using the I² statistic: An I² value of >50% suggests substantial heterogeneity. To compare the percentages and to calculate the P values, we used the Z-test for 2 proportions. Meta-regression was not used in this study. Statistical analysis was performed using OpenMeta[Analyst] (http://www.cebm.brown.edu/openmeta/).

RESULTS

Literature Review

Studies included in our meta-analysis are summarized in On-line Table 4. The search flow diagram is shown in the On-line Figure. A total of 35 studies and 1426 patients with 1518 intracranial aneurysms treated with LEO or LVIS stents were included in our review.

Quality of Studies

Overall, 14 studies (40%) were rated “high quality” (On-line Tables 2 and 3). Three articles were prospective multicentric series, 5 studies were obtained from a prospectively maintained database, 3 studies were retrospective multicentric, and 24 articles were single-center retrospective.

Patient Population

Overall, 510 aneurysms (33.5%) were treated with LEO stents and 948 aneurysms (62.5%) were treated with LVIS devices. One study with 60 aneurysms (4%) reported patients treated with LEO and LVIS stents (On-line Table 5). The mean age of patients (54.5 years; range, 7–79 years) and the male/female ratio (0.47) were comparable between the 2 groups. Overall, 83% (1172/1410; 95% CI, 81%–84%) of aneurysms were located in the anterior circulation. The mean aneurysm size was 7.2 mm (range, 2–65 mm). Most aneurysms were found incidentally (572/954 = 60%; 95% CI, 56%–63%). The mean radiologic and clinical follow-up was 10.4 months (interquartile range [IQR], 6–12 months; median, 6.5 months) and 12 months (IQR, 6–13 months; median, 8 months), respectively.
**Angiographic Outcomes**

Overall, the devices were successfully delivered in 97% (1041/1095; 95% CI, 95%–98%) (I² = 44%) of cases (On-line Table 6). The technical success rate was 97.5% (379/396; 95% CI, 95%–98%) (I² = 42%) and 97% (662/699; 95% CI, 95%–99%) (I² = 58%) for LEO and LVIS stents, respectively. During a mean angiographic follow-up of 10.4 months (median, 6.5 months; IQR, 6–12 months), the overall rate of complete/near-complete occlusion was 88.3% (1097/1256; 95% CI, 85%–91%) (I² = 72%); Complete/near-complete occlusion was achieved in 88.6% (410/463; 95% CI, 83%–93%) (I² = 69%) and 87.8% (687/793; 95% CI, 83%–92%) (I² = 74%) of aneurysms treated with LEO and LVIS stents, respectively.

**Treatment-Related Complications**

The overall complication rate was 7.4% (107/1317; 95% CI, 5%–9%) (I² = 44%). Complications were higher among LEO stents (46/391 = 10.5%; 95% CI, 7%–13%) (I² = 0%) compared with LVIS stents (54/867 = 5.3%; 95% CI, 3%–7%) (I² = 34%) (P = .001). The overall rate of permanent complications was 1.5% (30/1324; 95% CI, 0.9%–2%) (I² = 0%). Permanent complications were 2.7% (17/398; 95% CI, 1%–4%) (I² = 3%) and 1.3% (12/867; 95% CI, 0.6%–2.2%) (I² = 0%) after LEO and LVIS stent treatment, respectively (P = .002).

Most complications were periprocedural or early events (85/1324 = 5%; 95% CI, 3%–6%) (I² = 36%), whereas delayed complications were 1% (27/1324; 95% CI, 0.5%–1.6%) (I² = 0%). Both periprocedural and delayed complications were higher in the LEO group (On-line Table 6). Overall, the most common complications were ischemic/thromboembolic events (48/1324 = 2.4%; 95% CI, 1.5%–3.4%) (I² = 27%), followed by in-stent thrombosis (35/1324 = 1.5%; 95% CI, 0.6%–1.7%) (I² = 0%). After treatment with LEO stents, there was a higher incidence of ischemic/thromboembolic events (21/398 = 5.3%; 95% CI, 1.8%–5% versus 24/867 = 1.6%; 95% CI, 0.6%–1.5% (P = .03) and in-stent thrombosis (19/398 = 3.2%; 95% CI, 1.5%–5% versus 15/867 = 0.8%; 95% CI, 0.2%–1.5%) (P = .003). Ischemic complications were related to the following events: thromboembolism (44/48 = 91%; 95% CI, 79%–97%), perforating injury due to stent coverage of lenticulostriate arteries (1/48 = 2%; 95% CI, 0.1%–10%), and platelet aggregation in the side branches covered with the stent (3/48 = 6.5%; 95% CI, 1.5%–17%). The rate of aneurysm perforation/vessel dissection during treatment and the rate of intraparenchymal hemorrhage (unrelated to aneurysm rupture) were 1.3% (22/1324; 95% CI, 0.7%–1.8%) (I² = 0%) and 0.5% (1/1324; 95% CI, 0.1%–1.1%) (I² = 0%), respectively, without differences between the 2 groups. The incidence of aneurysm rupture after treatment was 0.7% (3/1324; 95% CI, 0.3%–1.1%) (I² = 0%). Treatment-related mortality was 0.7% (3/1357; 95% CI, 0.3%–1.2%) (I² = 0%), whereas the rate of good neurologic outcome was 98% (770/78; 95% CI, 97%–99%) (I² = 0%), respectively (P = .001) (On-line Table 7). Complete/near-complete occlusion in the anterior circulation (149/174 = 88.5%; 95% CI, 82%–94%) (I² = 34%) was higher compared with the posterior circulation (26/37 = 70%; 95% CI, 53%–86%) (I² = 47%) (P = .003). Occlusion after retreatment with braided stents of aneurysms recalibrated after previous treatments was lower (31/42 = 75%; 95% CI, 54%–94%) (I² = 57%) compared with the occlusion rate of the first treatment (179/203 = 88.9%; 95% CI, 83%–94%) (I² = 23%) (P = .01). Differences in occlusion rates were not statistically significant in relation to single-versus-multiple overlapping devices. SAC was more effective compared with treatment with a stent alone: a complete/near-complete occlusion rate of 90% (807/898; 95% CI, 86%–93%) (I² = 67%) versus 63% (19/26; 95% CI, 40%–90%) (I² = 48%), respectively (P = .0001). In the stent-alone group, 58% (15 aneurysms) and 42% (11 aneurysms) of patients were treated with single and double stents, respectively.

**Factors Related to Complications after Treatment**

The complication rate was higher for ruptured aneurysms treated in the acute phase (12/75 = 14.5%; 95% CI, 7%–21%) (I² = 0%) compared with unruptured lesions (54/675 = 6.6%; 95% CI, 4.8%–4%) (I² = 0%) (P = .01). There was no statistically significant difference in complication rates among distal-versus-proximal locations and anterior-versus-posterior circulation. Similarly, treatment-related complications were comparable among first treatment versus retreatment, SAC versus stent alone, and single-versus-multiple stents.

**Angiographic Outcomes and Treatment-Related Complications for Low-Profile Braided Stents (LEO Baby and LVIS Jr)**

Low-profile braided stents were successfully delivered in 96% (601/638; 95% CI, 94%–98%) (I² = 41%) of cases, without differences between the LEO Baby and LVIS Jr (On-line Table 8). Overall, 61% (318/521; 95% CI, 56%–65%) of low-profile braided stents were deployed in small and distal vessels, whereas 39% (203/521; 95% CI, 34%–43%) were used to treat proximally located aneurysms. In addition, LEO Baby and LVIS Jr were mostly used for the treatment of anterior circulation aneurysms (296/399 = 74%; 95% CI, 69%–78%) compared with posterior circulation lesions (103/399 = 26%; 95% CI, 21%–30%). Overall, complete/near-complete occlusion was 88.6% (507/580; 95% CI, 84%–92%) (I² = 63%) and was higher with the LEO Baby (135/143 = 96.3%; 95% CI, 93%–99%) (I² = 0%) compared with LVIS Jr (372/437 = 86%; 95% CI, 80%–91%) (I² = 65%) (P = .005). The overall complication rate was 7.2% (54/636; 95% CI, 5%–9%) (I² = 0%) with 1.9% (13/636; 95% CI, 0.9%–2.9%) (I² = 0%) permanent events. LEO Baby devices were associated with a 3.7% (4/1148; 95% CI, 0.7%–6%) (I² = 0%) permanent complication rate, whereas LVIS Jr stents had 1.6% (9/488; 95% CI, 0.5%–2.8%) (I² = 0%) (P = .7). The most common complications were ischemic/thromboembolic (22/636 = 1.8%; 95% CI, 0.7%–2.8%) (I² = 0%) and in-stent thrombosis (21/636 = 1.6%; 95% CI, 0.6%–2.6%) (I² = 4%). In-stent thrombosis was higher among LEO Baby (9/148 = 5%; 95% CI, 2%–8%) (I² = 0%) compared with LVIS Jr (12/488 = 1.1%; 95% CI, 0.2%–2%) (I² = 0%). Treatment-related mortality and good neurologic outcome
were 0.8% (1/636; 95% CI, 0.4%–1.5%) ($I^2 = 0\%$) and 98.3% (406/415; 95% CI, 96%–99%) ($I^2 = 0\%$), respectively.

**Study Heterogeneity**
Analysis of the angiographic outcomes and treatment-related complications showed high heterogeneity in 10% of the reported results (4 of 39 studied outcomes) (On-line Table 6). The analysis of the factors related to complications and occlusion (On-line Table 5) showed high heterogeneity in 18% of the studied events (4 of 22 reported outcomes). The rate of high heterogeneity among complications and angiographic outcomes after LEO Baby and LVIS Jr (On-line Table 7) was 9% (3 of 33 reported results).

**DISCUSSION**
With the advent of the SAC technique, most complex, wide-neck intracranial aneurysms can be efficiently treated endovascularly. Compared with other intracranial stents that are laser-cut from nitinol hypotubes, LEO and LVIS stents are braided from a single nitinol wire with a closed-cell design. Because of the increased use of these devices, understanding the safety and efficacy of treatment with braided stents is important in the management of lesions amenable to SAC treatment.

**Angiographic Outcomes**
In combining aneurysmal occlusion rates from 35 series, our analysis provides more representative data on angiographic outcomes than any single study. We demonstrated high rates of complete/near-complete occlusion for both LEO (88.6%; 95% CI, 83%–93%) and LVIS devices (87.8%; 95% CI, 83%–92%). Meta-analysis of aneurysms treated with SAC using different devices showed 61% long-term occlusion. The high rates of occlusion after treatment with braided stents can be related to the smaller cell size, higher metal coverage and flow-diversion effect than other conventional self-expandable stents. Computational fluid dynamics studies showed that LVIS stents allowed more flow reduction than laser-cut devices, and double LVIS stents resulted in a better flow-diverting effect than the Pipeline Embolization Device (PED; Covidien, Irvine, California). Aydin et al, investigating the flow-diversion effect of low-profile braided stents used as stent monotherapy, reported 75% complete occlusion during follow-up. In the subgroup of aneurysms treated with double stents, the authors showed a slightly higher rate of complete occlusion (82%). In our study, braided stents used as stent monotherapy allowed a 63% (95% CI, 40%–90%) complete occlusion rate, which was significantly lower compared with the treatment with stent plus coiling (90%; 95% CI, 86%–93%) ($P = .0001$). Most interesting, lesions treated with SAC with single or multiple stents had comparable rates of occlusion, showing that in most cases, a single stent is enough to achieve complete aneurysm occlusion, avoiding the ischemic complications related to the higher metal density in the vessel.

**Treatment-Related Complications**
In general, treatment-related complications and morbidity after SAC are 12% and 5%, respectively. In our analysis, treatment with braided stents was relatively safe, with overall rates of complications and morbidity of 7.4% (95% CI, 5%–9%) and 1.5% (95% CI, 0.9%–2%), respectively. This is in accordance with a recent prospective, multicentric study of LVIS devices that reported approximately 5% treatment-related morbidity. Most interesting, the overall complication rate was higher after treatment with LEO (10.5%; 95% CI, 7%–13%) compared with LVIS stents (5.3%; 95% CI, 3%–7%). The higher rate of complications was related to higher ischemic/thromboembolic events (3.6%; 95% CI, 1.5%–5% versus 1.6%; 95% CI, 0.6%–2.5%) and in-stent thrombosis (3.2%; 95% CI, 1.5%–5% versus 0.8%; 95% CI, 0.2%–1.5%). After we investigated the literature, the rate of in-stent thrombosis after treatment with laser-cut stents was 1%, which is lower compared with the overall rate of both braided stents and low-profile braided stents (1.5% and 1.6%, respectively). Similar to that in flow-diverter stents, the higher incidence of acute occlusion of braided stents compared with laser-cut devices can be explained, at least in part, by the higher mesh density and more condensed pores of these devices. However, in our meta-analysis, LVIS and LVIS Jr had a low incidence of acute in-stent occlusion (0.8% and 1.1%, respectively), which appears quite comparable with that in the laser-cut stents.

Knowledge of the safety of braided stents in relation to the location and characteristics of the aneurysms has important therapeutic implications. Most interesting, we found comparable rates of complications between proximal (ICA and circle of Willis) and distal aneurysms beyond the circle of Willis or in small vessels. The rate of complications for distal aneurysms treated with flow-diverter stents ranges between 15% and 20%. Feng et al reported 5% complications after SAC of MCA aneurysms with LVIS Jr stents. Similarly, Aydin et al reported a high occlusion rate and a low incidence (5%) of complications after flow-diversion treatment of aneurysms at or distal to the circle of Willis, with low-profile braided stents used as stent monotherapy.

Although the occlusion rate was lower in the posterior circulation (70%; 95% CI, 53%–86% versus 88.5%; 95% CI, 82%–94%), treatment-related complications were comparable between anterior (8.8%; 95% CI, 3.4%–12%) and posterior circulation aneurysms (10.5; 95% CI, 4%–16%) ($P = .7$). Similarly, Johnson et al, in a large series of 486 aneurysms treated with Neuroform and Enterprise stents, reported comparable rates of complications among anterior (11.5%) and posterior circulation lesions (12.7%). Contrariwise, flow diversion in the posterior circulation is associated with not negligible rates of ischemic complications related to perforators infarcts. In the International Retrospective Study of Pipeline Embolization Device, the rates of morbidity and mortality after flow diversion treatment were higher among posterior circulation (16.5%) compared with anterior circulation lesions (5%–9%).

Finally, our subgroup analysis of >600 aneurysms treated with low-profile braided stents (LEO Baby and LVIS Jr) demonstrated comparable results in terms of the safety (complication rate = 7.2%; 95% CI, 5%–9%) and efficacy (complete/near-complete occlusion = 96.3%; 95% CI, 93%–99%) of these devices usually used in smaller and distal vessels because of the possibility of being delivered through a 0.0165-inch microcatheter.
Strength and Limitations
Our study has limitations. Most series are retrospective studies and single-institution experiences. Details of the antipatelet therapy were infrequently specified. The smaller number of cases in some subgroup analyses may not provide sufficient power to demonstrate a statistically significant difference among the studied outcomes. However, although retrospective data are low in quality, our meta-analysis is the best available evidence to guide the treatment management of aneurysms with braided stents.

CONCLUSIONS
In our study, treatment with the LEO and LVIS stents was relatively safe and effective. Most of the complications were related to periprocedural thromboembolic events and in-stent thrombosis. We found comparable rates of treatment-related complications among anterior-versus-posterior circulation aneurysms and for proximal-versus-distally located lesions. These findings can guide practitioners in the treatment, management, and selection of aneurysms amenable to treatment with braided stents.

ACKNOWLEDGMENTS
We thank Beth De Felici for the English revision.


REFERENCES
32. Negrotto M, Crosa R, Casagrande W.


22. Gao BL, Li TX, Li L, et al. Tiny cerebral aneurysms can be treated safely and effectively with Low-Profile Visualized Intraluminal Support stent-assisted coiling or coiling alone. World Neurosurg 2018;113:e426–30 CrossRef Medline

Outcomes of Stent Retriever versus Aspiration-First Thrombectomy in Ischemic Stroke: A Systematic Review and Meta-Analysis


ABSTRACT

BACKGROUND: There is ongoing debate regarding the optimal first-line thrombectomy technique for large-vessel occlusion.

PURPOSE: We performed a systematic review and meta-analysis of comparative studies on stent retriever–first and aspiration-first thrombectomy.

DATA SOURCES: We searched Ovid MEDLINE, PubMed, and EMBASE from 2009 to February 2018.

STUDY SELECTION: Two reviewers independently selected the studies. The primary end point was successful reperfusion (TICI 2b/3).

DATA ANALYSIS: Random-effects meta-analysis was used for analysis.

DATA SYNTHESIS: Eighteen studies including 2893 patients were included. There was no significant difference in the rate of final successful reperfusion (83.9% versus 83.3%; OR = 0.87; 95% CI, 0.62%–1.27%) or good functional outcome (mRS 0–2) at 90 days (OR = 1.07; 95% CI, 0.80–1.44) between the stent-retriever thrombectomy and aspiration groups. The stent-retriever thrombectomy–first group achieved a statistically significant higher TICI 2b/3 rate after the first-line device than the aspiration-first group (74.9% versus 66.4%; OR = 1.53; 95% CI, 1.14%–2.05%) and resulted in lower use of a rescue device (99.9% versus 32.5%; OR = 0.36; 95% CI, 0.14%–0.90%). The aspiration-first approach resulted in a statistically shorter groin-to-reperfusion time (weighted mean difference, 7.15 minutes; 95% CI, 1.63–12.67 minutes). There was no difference in the number of passes, symptomatic intracerebral hemorrhage, vessel dissection or perforation, and mortality between groups.

LIMITATIONS: Most of the included studies were nonrandomized. There was significant heterogeneity in some of the outcome variables.

CONCLUSIONS: Stent-retriever thrombectomy–first and aspiration-first thrombectomy were associated with comparable final reperfusion rates and functional outcome. Stent-retriever thrombectomy was superior in achieving reperfusion as a stand-alone first-line technique, with lower use of rescue devices but a longer groin-to-reperfusion time.

ABBREVIATIONS: ADAPT = A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT = randomized controlled trial; SRT = stent-retriever thrombectomy

Endovascular thrombectomy is recommended as a standard of care for anterior circulation acute ischemic stroke secondary to large-vessel occlusion.¹ This treatment was established in 2015 when multiple randomized controlled trials (RCTs) established the clinical efficacy and safety of modern stent-retriever thrombectomy (SRT) in removing the obstructing thrombus in acute ischemia.²–⁶ A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke (ADAPT) is an alternative thrombectomy technique that has become the standard of care at many centers.⁷ This is performed by advancing a large-bore catheter (typically with an inner diameter of ≥0.060 inch) to the face of the thrombus, followed by its removal by aspiration alone or withdrawal of the catheter while aspirating. Previous observational studies focusing on ADAPT reported a higher rate of com-
plete revascularization and potentially a shorter time from groin puncture to reperfusion compared with stent-retriever thrombectomy. However, recent randomized trials comparing SRT with ADAPT have failed to demonstrate the superiority of ADAPT in technical or clinical outcomes. To address the ongoing debate of the optimal first-line thrombectomy technique, we performed a meta-analysis of comparative studies reporting outcomes on SRT versus ADAPT as a first-line approach.

**MATERIALS AND METHODS**

**Search Strategy and Selection Criteria**

A systematic literature review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The English literature was searched with Ovid MEDLINE, PubMed, and EMBASE from January 2009 to February 2018. The following terms and their combinations were used as keywords or Medical Subject Headings terms: “mechanical thrombectomy,” “endovascular,” “stroke,” “ADAPT,” “aspiration,” “stent retriever,” and “first-pass.” We also searched the references of relevant articles and contacted experts in the field to identify additional studies pertaining to the outcome of different thrombectomy techniques that were not included in the initial literature search.

Studies identified were then evaluated to meet the following inclusion criteria: 1) studies comparing the outcomes of the SRT-first and aspiration-first strategies; 2) studies reporting separately the clinical and technical outcomes of the SRT and aspiration groups; and 3) studies with at least 10 patients each in the SRT or aspiration group. The exclusion criteria were the following: 1) noncomparative studies reporting outcomes only on 1 group (SRT or aspiration); 2) studies that predominantly used the first generation of aspiration catheters (eg, Penumbra Separator 0.041 [Penumbra, Alameda, California] or smaller catheters, with or without the Separator) in the aspiration arm; and 3) studies that did not separate outcomes by the first-line thrombectomy technique adopted. Both randomized and observational studies were included.

**Data Items and Extraction**

Patients were divided into 2 groups: SRT-first and aspiration-first. For this study, patients were considered to have SRT-first if any stent retriever was used in the first thrombectomy attempt, with or without balloon-guiding catheters or simultaneous distal aspiration (ie, Solumbra technique). Those receiving only direct aspiration with large-bore distal-access catheters in the first thrombectomy attempt were considered aspiration-first.

The primary end point was the rate of successful reperfusion defined as the final Thrombolysis in Cerebral Infarction score of 2b/3. Other clinical outcomes included the following: good functional outcome defined as a modified Rankin Scale 0–2 at 90 days, 90-day mortality, symptomatic intracerebral hemorrhage, and complications of vessel dissection or perforation. Other technical outcomes studied included the following: the rate of complete reperfusion (TICI 3), the rate of TICI 2b/3 achieved with only the first device, the use of a rescue device, the number of thrombectomy passes, and the time from groin puncture to reperfusion.

**Risk of Bias Assessment**

The included studies were assessed for risk of bias by 2 independent readers (A.C.O.T. and I.H.W.C.) with the Newcastle Ottawa Scale. This is an 8-item tool for nonrandomized studies included in systematic reviews and meta-analyses, in which the selection, comparability, and ascertainment of outcomes of the study groups are assessed. The scale ranges from 0 to 9, with the higher score indicating lower risk of bias. Studies that used well-defined selection criteria, with comparable baseline stroke severity; patient demographics; onset-to-groin puncture time, with contemporaneous use of SRT; and aspiration thrombectomy and those that had an independent assessment of clinical and technical outcomes are considered to have a low risk of bias.

**Statistical Analysis**

We extracted from each study a 2×2 table for binary outcomes and the mean group sample size and a variability measure for continuous outcomes. The pooled outcomes were meta-analyzed using a random-effects model. Heterogeneity of the studies not attributable to chance was quantified with the I² statistic. The 95% confidence intervals of the odds ratios for binary outcomes and the weighted mean differences for continuous outcomes were reported. Some included studies reported continuous outcomes with median and interquartile range; these were converted to a mean and SD value based on the assumption of a log-normal distribution of the original measure. When the SD or the interquartile range for a specific outcome was not reported in the article, it was extrapolated from other studies when such data were available. If >10 studies were identified, a funnel plot was constructed to explore the impact of publication bias.

Only 3 of the 18 included studies were randomized by the first thrombectomy strategy. To address the potential heterogeneity between the 2 study groups, we conducted meta-regression to test the influence of moderators, including baseline stroke severity measured by the National Institutes of Health Stroke Scale and age. Sensitivity analyses were performed by studying the comparative outcomes, including only those studies that were RCTs, those that included predominantly (>90%) anterior circulation thrombectomy, and those that used balloon-guiding catheters with SRT consistently. Meta-analysis and meta-regression were performed with OpenMeta[Analyst] (http://www.cebm.brown.edu/openmeta/).

**RESULTS**

**Literature Search**

The initial literature search yielded 862 articles. The titles and abstracts of these were read, and 818 articles were excluded for irrelevance. Of the remaining 44 articles, 14 were excluded because they were conference abstracts, and 7 were excluded because they were review articles or editorials. After review, 2 articles were excluded for overlapping patient populations, and 4 studies were excluded for predominantly using a previous generation of thrombectomy devices. One additional study was identified by contacting experts in the field, yielding a total of 18 studies eligible for analysis. The PRISMA flow diagram is provided in Fig 1.
Clinical Outcomes

There was no statistical difference in the rate of good functional outcome (mRS 0–2) at 90 days between groups (OR = 1.07; 95% CI, 0.80–1.44). There was also no significant difference in the mortality rate, the rate of symptomatic intracerebral hemorrhage, emboli to new territories, vessel dissection, or perforation between the 2 groups. These results are summarized in Tables 2 and 3.

Publication Bias and Study Heterogeneity

Funnel plot analysis did not suggest publication bias (Fig 3). There was low heterogeneity (I² < 50%) for the following outcomes: the TICI 2b/3 rate after the first-line approach (I² = 31%), mortality rate (I² = 28%), risk of symptomatic intracerebral hemorrhage (I² = 0%), emboli to new territories (I² = 0%), and vessel dissection or perforation (I² = 26%). There was moderate substantial heterogeneity (I² >50%) for the following outcomes: final rate of TICI 2b/3 (I² = 54%), final rate of TICI 3 (I² = 79.5%), mRS 0–2 at 90 days (I² = 62%), the need for a rescue device (I² = 93%), groin-to-reperfusion time (I² = 79%), and the number of passes required (I² = 77%).

Sensitivity Analysis

We performed a subgroup analysis to determine whether the outcomes were different in anterior circulation stroke versus posterior circulation stroke. In the 9 studies that included predominantly (>90%) anterior circulation stroke, there was no statistically significant difference in the final TICI 2b/3 rate between groups (OR = 0.892; 95% CI, 0.59–1.35). Four studies reporting posterior circulation stroke only were included. The use of the SRT-first approach in posterior circulation stroke was associated with a statistically significant lower successful reperfusion (OR = 0.47; 95% CI, 0.25–0.91).

When we included only the 3 randomized controlled trials, we found no difference in the final TICI 2b/3 rate (OR = 1.05; 95% CI, 0.58–1.90) and good functional outcome (OR = 1.04; 95% CI, 0.79–1.37). There was a non-statistically significant higher chance in the SRT-first group of achieving TICI 2b/3 after the first-line approach (OR = 1.26; 95% CI, 0.85–1.86).

When including only the 5 studies that consistently used balloon-guiding catheters with SRT, we again found no difference in the final TICI 2b/3 rate (OR = 0.95; 95% CI, 0.54–1.67) and good functional outcome (OR = 1.22; 95% CI, 0.91–1.64). There was a non-statistically significant higher chance in the SRT-first group of achieving TICI 2b/3 after the first-line approach (OR = 1.26; 95% CI, 0.92–1.73).

When we excluded the study that used the Penumbra 3D Separator device, which was different in design from other conventional stent retrievers, there were no differences in the final TICI 2b/3 rate (OR = 0.88; 95% CI, 0.62–1.25). When we included only the 3 studies that reported TICI 2c/3 outcomes, there were no differences in the final TICI 2c/3 rate (OR = 1.10; 95% CI, 0.61–1.89) between groups.
DISCUSSION

Our meta-analysis of 2893 patients from 18 studies found no significant difference in terms of the final revascularization rate and functional outcome between aspiration-first and SRT-first thrombectomy for large-vessel occlusion stroke. Notably, stent retriever use was superior in achieving successful reperfusion as a stand-alone technique, compared with aspiration. The need for a rescue device was also significantly less when SRT was adopted as a first approach instead of aspiration. The comparable final reperfusion rate in the aspiration group was achieved with the use of a rescue device after the initial failed attempts with contact aspiration, which was necessary in 32.5% of patients. These findings are important because they suggest that despite SRT and aspiration-first strategies being able to achieve similar final revascularization rates and functional outcomes, SRT appears to be more effective than aspiration as a primary treatment technique for achieving TICI 2b/3 revascularization.

Endovascular thrombectomy with stent retrievers for large-vessel occlusion stroke has been established as the standard of care since 2015.32 The use of direct-contact aspiration thrombectomy

Table 1: Studies included in the meta-analysis

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>No. of Patients, SRT/Asp</th>
<th>Mean Age (yr), SRT/Asp</th>
<th>Mean Baseline NIHSS, SRT/Asp</th>
<th>Mean Baseline ASPECTS, SRT/Asp</th>
<th>Anterior Circulation (%)</th>
<th>Study Design</th>
<th>Risk of Bias (NOS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delgado Almandoz et al17</td>
<td>2016</td>
<td>55/45</td>
<td>69.6/66.1</td>
<td>16.8/19.2</td>
<td>NA</td>
<td>8.2/9.1</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Turk et al16</td>
<td>2015</td>
<td>30/64</td>
<td>62.5/68.5</td>
<td>17.6/16.5</td>
<td>NA</td>
<td>90%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Son et al16</td>
<td>2016</td>
<td>13/18</td>
<td>68.9/64.4</td>
<td>27.3/21.3</td>
<td>NA</td>
<td>0%</td>
<td>Retrospective, single-center, case-control</td>
<td>6</td>
</tr>
<tr>
<td>Kim et al12</td>
<td>2017</td>
<td>16/25</td>
<td>76.5/71</td>
<td>10.5/15</td>
<td>7/8</td>
<td>100%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Lapergue et al12</td>
<td>2016</td>
<td>119/124</td>
<td>65.5/64.3</td>
<td>15.9/15.9</td>
<td>8/9</td>
<td>100%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Mokin et al12</td>
<td>2016</td>
<td>58/42</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>0%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Gerber et al12</td>
<td>2017</td>
<td>13/20</td>
<td>63.2/62.8</td>
<td>25/18</td>
<td>6.5/7.5</td>
<td>0%</td>
<td>Retrospective, single-center, case-control</td>
<td>6</td>
</tr>
<tr>
<td>Hentschel et al15</td>
<td>2017</td>
<td>67/69</td>
<td>66.2/64.1</td>
<td>NA</td>
<td>NA</td>
<td>90%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Hesse et al13</td>
<td>2018</td>
<td>286/164</td>
<td>74/72</td>
<td>15.5/15.3</td>
<td>NA</td>
<td>8/8</td>
<td>Retrospective, multicenter, case-control</td>
<td>5</td>
</tr>
<tr>
<td>Jadhav et al14</td>
<td>2017</td>
<td>195/112</td>
<td>69/66</td>
<td>17/17</td>
<td>9/9</td>
<td>87%</td>
<td>Retrospective, single-center, case-control</td>
<td>6</td>
</tr>
<tr>
<td>Lapergue et al16</td>
<td>2018</td>
<td>398/192</td>
<td>68.1/71.7</td>
<td>16/16.3</td>
<td>7/7</td>
<td>100%</td>
<td>Randomized controlled trial, multicenter</td>
<td>9</td>
</tr>
<tr>
<td>Maegerlein et al</td>
<td>2017</td>
<td>63/51</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>89%</td>
<td>Retrospective, multicenter, case-control</td>
<td>5</td>
</tr>
<tr>
<td>Mokin et al14</td>
<td>2018</td>
<td>70/47</td>
<td>69.4/63.5</td>
<td>16.5/16.5</td>
<td>8.3/8</td>
<td>100%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Gory et al17</td>
<td>2018</td>
<td>54/46</td>
<td>67/61</td>
<td>20/14</td>
<td>8/7</td>
<td>0%</td>
<td>Retrospective, multicenter, case-control</td>
<td>7</td>
</tr>
<tr>
<td>Mocco et al17</td>
<td>2018</td>
<td>136/133</td>
<td>71/71.8</td>
<td>7/6</td>
<td>NA</td>
<td>100%</td>
<td>Randomized controlled trial, multicenter</td>
<td>9</td>
</tr>
<tr>
<td>Nogueira et al18</td>
<td>2018</td>
<td>95/97</td>
<td>67.3/66.5</td>
<td>18/18</td>
<td>8/8</td>
<td>98%</td>
<td>Randomized controlled trial, multicenter</td>
<td>9</td>
</tr>
<tr>
<td>Nishi et al19</td>
<td>2018</td>
<td>45/44</td>
<td>73/77.8</td>
<td>19/17</td>
<td>88%</td>
<td>100%</td>
<td>Retrospective, single-center, case-control</td>
<td>7</td>
</tr>
</tbody>
</table>

Note:—NOS indicates Newcastle-Ottawa Scale; NA, not available; Asp, aspiration.

Table 2: Summary of meta-analysis outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>I²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Final TICI 2b/3</td>
<td>0.87</td>
<td>0.62–1.27</td>
<td>53.6%</td>
</tr>
<tr>
<td>Final TICI 3</td>
<td>0.82</td>
<td>0.49–1.37</td>
<td>79.5%</td>
</tr>
<tr>
<td>First-line approach, TICI 2b/3</td>
<td>1.53</td>
<td>1.14–2.05</td>
<td>31.1%</td>
</tr>
<tr>
<td>mRS 0–2 at 90 days</td>
<td>1.07</td>
<td>0.80–1.44</td>
<td>61.8%</td>
</tr>
<tr>
<td>Mortality</td>
<td>0.91</td>
<td>0.69–1.20</td>
<td>28.1%</td>
</tr>
<tr>
<td>Rescue device</td>
<td>0.36</td>
<td>0.14–0.90</td>
<td>93.0%</td>
</tr>
<tr>
<td>Dissection or perforation</td>
<td>1.26</td>
<td>0.52–3.08</td>
<td>26.3%</td>
</tr>
<tr>
<td>ENT</td>
<td>1.11</td>
<td>0.70–1.74</td>
<td>0%</td>
</tr>
<tr>
<td>sICH</td>
<td>1.20</td>
<td>0.78–1.84</td>
<td>0%</td>
</tr>
</tbody>
</table>

Note:—ENT indicates emboli to new territories; sICH, symptomatic intracranial hemorrage.

FIG 2. Forest plot of meta-analysis results. A, Final successful reperfusion was TICI 2b/3. B, Good functional outcome mRS 0–2 at 90 days. Successful reperfusion TICI 2b/3 after the first-line approach (C) and the use of a rescue device (D).
is another common technique but was not supported by class I evidence. Nevertheless, aspiration thrombectomy as a first-line approach is widely practiced in the United States, Hong Kong, and Italy despite the availability of the proved and efficacious stent-retriever thrombectomy.33–35 The THERAPY (The Randomized, Concurrent Controlled Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke; NCT01429350) trial, which compared aspiration thrombectomy with best medical therapy, was halted early and did not demonstrate efficacy.36 While recent meta-analyses of uncontrolled observational studies focusing solely on the aspiration technique reported higher complete reperfusion rates and shorter procedure times than SRT,8,37 these conclusions were confounded by the different patient-selection criteria and baseline stroke severity in the included single-arm studies. The published RCTs on this subject demonstrated noninferiority of aspiration thrombectomy compared with SRT in the final reperfusion rate but were underpowered to compare other clinical outcomes such as functional status and complication rates.8,37 To address these limitations, the present review included only studies that compared both SRT-first and aspiration-first approaches in the same patient cohort, as well as the 3 recently published/presented RCTs investigating these 2 groups.

One of the notable findings from our study is that SRT could achieve higher rates of TICI 2b/3 reperfusion without the help of rescue therapy than aspiration thrombectomy alone. This is important because the literature has focused more on the first-pass effect during thrombectomy for acute ischemic stroke, defined as achieving complete recanalization with a single pass. In a recently published post hoc analysis of the North American Solitaire Acute Stroke Registry, Zaidat et al38 found that patients who achieved TICI 2b/3 on a first pass had significantly better clinical outcomes than those who did not. Independent predictors of a first-pass effect included the use of a balloon-guiding catheter and noninternal carotid artery terminus occlusion. While we were not able to examine first-pass recanalization rates between SRT and aspiration in this meta-analysis, SRT alone achieved higher recanalization rates than aspiration alone. Ultimately, the fact that SRT was used as a rescue therapy in nearly one-third of aspiration cases while aspiration was needed as rescue therapy in nearly one-fifth of SRT cases suggests that SRT has some technical advantages in clot retrieval.

There are a number of advantages to aspiration thrombectomy compared with SRT. With contact aspiration thrombectomy, it is not necessary to traverse the occluding thrombus, thus theoretically reducing the risk of vessel perforation and downstream emboli. While cases of catastrophic vessel perforation with the use of SRT have been reported, the incidence was low.39 Our review did not show any significant difference in the safety profiles between the 2 groups. Rates of vessel perforation, dissection, and symptomatic ICH were comparable. Another proposed advantage of aspiration over SRT is the shorter procedural time. The aspiration-first approach was associated with a 7-minute advantage in groin-to-reperfusion time in the meta-analysis. In the 3 randomized studies comparing the 2 approaches, the aspiration-first approach also resulted in a shorter procedural time of 10–13 minutes.9,27,28 Nevertheless, this advantage in rapidity did not translate to improved patient outcome in any of those trials.

While the overall final reperfusion rate is comparable, there remain uncertainties about whether SRT or aspiration is superior in selected vessel locations or the etiology of stroke. Subgroup analysis of the 4 posterior circulation stroke studies including 264 patients showed that SRT was inferior to aspiration in terms of reperfusion rates. However, the sample size was too small to draw any definitive conclusions. None of the included studies reported the comparative efficacy of aspiration and SRT stratified by the specific occluded vessel to allow subgroup analysis. The etiology of large-vessel occlusion may also affect the efficacy of thrombectomy. In large-vessel occlusion secondary to intracranial artery stenosis, early experience with stent retrievers in this group of patients resulted in a lower reperfusion rate and poorer outcome. In addition, rescue therapy with balloon angioplasty or intra-arterial thrombolytic infusion was frequently required.40 The shearing force exerted over the atherosclerotic plaque during stent retrieval may be the culprit, and the optimal first-line thrombectomy strategy in this group of patients needs further investigation. Techniques combining SRT and aspiration have been increasingly used, but their superiority over SRT or aspiration alone remains to be defined in randomized studies.17,41,42 Future studies on the optimal thrombectomy technique should also adopt more robust outcome variables, including TICI 2c/3 angiographic outcome and the first-pass success rate,38,43 and should consider other aspects such as delayed effects on the vessel wall and the relative cost-effectiveness of different techniques.

**Limitations**

Our study has limitations. Apart from the 3 RCTs, most of the included studies were nonrandomized, thus introducing selection bias. Furthermore, we had to include single-arm studies. The published post hoc analysis of the North American Solitaire Acute Stroke Registry, Zaidat et al38 found that patients who achieved TICI 2b/3 on a first pass had significantly better clinical outcomes than those who did not. Independent predictors of a first-pass effect included the use of a balloon-guiding catheter and noninternal carotid artery terminus occlusion. While we were not able to examine first-pass recanalization rates between SRT and aspiration in this meta-analysis, SRT alone achieved higher recanalization rates than aspiration alone. Ultimately, the fact that SRT
bias. When performing subgroup analysis on only the 3 recent RCTs, we found results similar to those in our meta-analysis. We limited the review to comparative studies with control groups to compare the relative efficacy of SRT and aspiration and excluded those studies that used predominantly previous generations of thrombectomy catheters or devices. There was significant statistical heterogeneity in some of the outcome variables that can impact the validity of our results. Another limitation is that in some cases SRT was performed with simultaneous aspiration (ie, Solumbra technique) and we could not perform subgroup analyses of Solumbra versus SRT-alone versus aspiration. While TICI 2c/3 is increasingly recognized as a better angiographic outcome measure and correlates better with clinical outcome, only 3 of the included studies reported TICI 2c/3 rates and the subgroup analysis on these studies showed similar results.

CONCLUSIONS
This systematic review and meta-analysis of 18 studies and 2893 patients found that SRT-first and aspiration-first thrombectomy were associated with comparable final reperfusion rates and functional outcomes. SRT was superior in achieving reperfusion as a stand-alone first-line technique, with lower use of rescue devices but a longer groin-to-reperfusion time. There were no significant differences in complication rates and mortality. The optimal first-line thrombectomy approach for specific location or stroke etiology remains unclear.

Disclosures: Chun On Anderson Tsang—RELATED: Grant: Health and Medical Research Fund of Hong Kong (01550027), Comments: a peer-reviewed medical research grant provided by the Hong Kong government through the Food and Health Bureau.* David F. Kallmes—UNRELATED: Consultancy: Medtronic, Comments: clinical trials; Grants/Grants Pending: Medtronic, Neuravi, Comments: preclinical and clinical research; Patents (Planned, Pending or Issued): Mayo Clinic, Comments: balloon-guided devices; Stock/Stock Options: Marblehead Medical, Comments: stroke access device development. *Money paid to the institution.

REFERENCES


ABSTRACT

BACKGROUND AND PURPOSE: Blood flow management in the carotid artery during mechanical thrombectomy is crucial for safety and effectiveness. There is an ongoing discussion about whether balloon-guide catheters or large-bore sheaths are needed for effective flow management. We compared general flow characteristics of proximal aspiration through a large-bore sheath and a balloon-guide catheter in a porcine in vivo model.

MATERIALS AND METHODS: We investigated blood flow in a porcine common carotid artery with and without aspiration (VacLok syringe and Penumbra pump, Pump MAX) through an 8F-long sheath and an 8F balloon-guide catheter. Blood hemodynamics were assessed via continuous duplex sonography.

RESULTS: Average vessel diameter and baseline blood flow were 4.4 ± 0.2 mm and 244 ± 20 mL/min, respectively. For the 8F sheath, pump aspiration resulted in a significant flow reduction (225 ± 25 mL/min, \( P < .001 \)), but with a persisting antegrade stream. Manual aspiration resulted in collapse of the vessel in 2 of 7 measurements and oscillatory flow with antegrade systolic and retrograde diastolic components in the remaining 5 measurements. Net flow was antegrade (52 ± 44 mL/min) in 3 and retrograde (−95 ± 52 mL/min) in the remaining 2 measurements. For balloon-guide catheters, balloon inflation always resulted in flow arrest. Additional pump or manual aspiration resulted in significant flow reversal of −1100 ± 230 and −468 ± 46 mL/min, respectively (both, \( P < .001 \)).

CONCLUSIONS: Only balloon-guide catheters allow reliable blood flow arrest and flow reversal in combination with aspiration via syringes or high-flow pump systems. Aspiration through an 8F sheath results in either collapse of the vessel or oscillatory flow, which can result in a net antegrade or retrograde stream.

ABBREVIATIONS: BGC = balloon-guide catheter; CCA = common carotid artery

Endovascular mechanical thrombectomy has been established as the standard treatment option for acute ischemic stroke caused by large-vessel occlusion.\(^1\) Even though the basic principle of mechanical thrombectomy is established, actual procedures differ in many ways, ranging from the choice of stent retrievers to the choice of access catheters.\(^2\)–\(^4\) Recent clinical studies imply better procedural and clinical outcomes for patients who are treated with balloon-guide catheters (BGCs) compared with other carotid-access catheters such as large-bore sheaths.\(^5\)–\(^6\) Zaidat et al\(^5\) found, in their analysis of the Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRA-TIS) Registry data, that BGCs are associated with higher rates of good clinical outcome (mRS ≤ 2), successful revascularization, a trend toward higher rates of complete first-pass revascularization, and a lower number of overall passes.\(^7\) Because these data are not derived from randomized prospective trials, it is possible that the superiority of BGCs simply reflects their being used by more experienced interventionalists. Nonetheless, it is reasonable that blood flow management in the carotid artery is crucial for safety and effectiveness during mechanical thrombectomy.\(^8\) It has been shown that thrombectomy maneuvers produce thousands of small clot fragments that may occlude small arterioles and capillaries.\(^9\) The result can be small infarctions that can have a relevant clinical impact despite being invisible on MR imaging.\(^9\)–\(^10\) Hence, flow arrest is important regardless of the specific thrombectomy technique (eg, classic stent-retriever thrombectomy, A Direct Aspiration First Pass Technique [ADAPT], Solumbra, or other techniques). Antegrade blood flow should be reversed during mechanical thrombectomy to prevent embolization of clot frag-
ments. This is usually attempted via blood aspiration through an access catheter in the internal carotid artery. There is a variety of access catheters, ranging from small (5F–7F) guiding catheters to large-bore sheath catheters (8F) and BGCs, but there is no consensus about which access catheter is most suitable.

Mechanical thrombectomy is becoming more common, and many interventionalists must decide which technique to choose. Because empiric data are lacking and large randomized prospective studies are needed to resolve this issue from a clinical point of view, we addressed this question with a simple technical approach. To reflect basic principles of flow management in real-life settings, we quantified and compared flow characteristics and aspiration volumes of proximal aspiration through a large-bore sheath and a BGC with both manual and pump aspiration. Because it is practically impossible to quantify blood flow during mechanical thrombectomy in the ICA, let alone in the cerebral arteries, we decided to investigate flow characteristics in an in vivo porcine model.

MATERIALS AND METHODS
All experiments were performed on 4 female Landrace swine (weight, 50–60 kg) with peri- and intrainterventional management as reported previously. The experiments were performed in accordance with the German legislation governing animal studies following the “Guide for the Care and Use of Laboratory Animals” (https://grants.nih.gov/grants/olaw/Guide-for-the-Care-and-use-of-laboratory-animals.pdf) and the “Directive 2010/63/EU on the Protection of Animals Used for Scientific Purposes” (https://www.researchgate.net/publication/233428185_DIRECTIVE_201063EU_on_the_protection_of_animals_used_for_scientific_purposes). Official permission was granted from the governmental animal care and use office, Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, Recklinghausen, Germany.

We investigated flow in a porcine common carotid artery (CCA) with and without aspiration through a large-bore sheath and a BGC. We chose the CCA because its diameter is comparable with that of the human ICA. We adapted flow in the CCA, which has a physiologic blood flow that is twice as high as the human ICA blood flow, by injecting blood clots into the subsequent arteries. This procedure was repeated until a blood flow between 200 and 280 mL/min was achieved in the target vessel. We assessed blood flow via duplex sonography (LOGIQ S8; GE Healthcare, Milwaukee, Wisconsin) by measuring vessel diameter and flow speed using the built-in software and GraphClick software (Arizona Software, Neuchâtel, Switzerland).

Instead of testing all possible access catheters ranging from 5F guide catheters to large-bore sheaths, we chose 1 large-bore sheath and 1 large-bore BGC to investigate flow characteristics in 2 setups that supposedly allow maximum flow control. We used an 8F-long sheath, Shuttle Select (Cook, Bloomington, Indiana; outer diameter, 3 mm; inner diameter, 2.87 mm) and an 8F Flow-Gate II BGC (Concentric Medical, Mountain View, California; outer diameter, 2.7 mm; inner diameter, 2.1 mm), which are currently the largest of the most commonly used proximal access catheters. Sheaths and BGCs were introduced through a femoral access and placed 5–7 cm behind the CCA origin. Blood flow was assessed 7–10 cm distal to the sheath/BGC tips (Fig 1). We did not measure immediately behind the catheter tips to avoid measuring blood flow in areas of turbulent flow. After quantifying the baseline blood flow in the CCA, we quantified blood flow with and without aspiration through the sheath and the inflated BGC. Aspiration was performed manually with a 60-mL VacLok syringe (Merit Medical Systems, South Jordan, Utah) and with a Penumbra pump, Pump MAX (Penumbra, Alameda, California), which is the most common aspiration pump, with the recommended vacuum pressure of −25.5 Hg. All experiments were performed at least 7 times, and all measurements were included in our final
analysis. Because our experiments resulted in considerable blood loss, not all experiments were repeated in all swine. However, every setup was performed in at least 2 swine to increase the variance. To restrict aspirated blood volume, we performed only 3 aspiration experiments with an inflated BGC as a proof of principle. Blood flow was assessed regularly between experiments to anticipate unnoticed shifts of baseline values.

**Statistical Analysis**

Student t tests were used for comparison of flow volumes after testing our data for normal distribution with a Shapiro-Wilk test. P values of an α level of ≤0.05 were significant. All statistical analyses were performed with SPSS 23 software (IBM, Armonk, New York).

**RESULTS**

The average diameter of the CCA and baseline blood flow were 4.4 ± 0.2 mm and 244 ± 20 mL/min, respectively (Fig 1). The 8F sheath resulted in an average reduction of vessel diameter and cross-sectional area of 61% and 37%, respectively, and the sheath did not significantly reduce blood flow (236 ± 25 mL/min, P = .19). Pump aspiration resulted in a significant flow reduction with a net flow of 225 ± 25 mL/min (P < .001) (Fig 2). However, flow always remained antegrade, and there was no flow arrest or reversal. Manual aspiration through the 8F sheath resulted in collapse of the vessel in 2 of 7 measurements. In the remaining 5 measurements, there was an oscillatory flow with antegrade flow in systole and retrograde flow in diastole (Fig 3). Net flow was antegrade (52 ± 44 mL/min) in 3 of 5 measurements and retrograde (−95 ± 52 mL/min) in the remaining 2 measurements.

The noninflated 8F BGC in the CCA led to an average reduction of vessel diameter and cross-sectional area of 61% and 37%, respectively, and slightly reduced blood flow (from 244 ± 20 to 228 ± 22 mL/min, P = .02). Balloon inflation always resulted in arrest of antegrade flow (Fig 4). Additional pump aspiration and manual aspiration through an inflated BGC resulted in a constant and significant flow reversal with a flow of −1100 ± 230 and −468 ± 46 mL/min, respectively (both, P < .001) (Fig 4). Net flow in the carotid artery was significantly lower when blood was aspirated through an inflated BGC compared with the 8F sheath, regardless of pump or syringe aspiration (both, P < .001).

**DISCUSSION**

Ever since mechanical stroke treatment has been established as a standard treatment technique, the focus of neurointerventional stroke research has shifted to finding the optimal treatment techniques. Proximal aspiration in the ICA to achieve flow reversal has been established as a standard technique for mechanical thrombectomy. In an average patient and without application of a balloon-guide catheter, which restricts antegrade flow, the amount of aspirated blood in the ICA should surpass its normal flow of 240 mL/min to achieve reliable flow reversal. There is an ongoing discussion of whether BGCs or large-bore sheaths are needed for effective flow management. Large-bore sheaths allow aspiration of high-flow volumes up to approximately 1000 mL/min. However, the handling of these sheaths is rather complicated because their stiffness necessitates additional guiding catheters for placement. BGCs allow reliable occlusion of the respective artery and consecutive reduction of antegrade flow. However, rather difficult handling and their comparably small inner diameters, which restrict the choice of catheters/devices that can be introduced through the BGC, prevent many interventionists from using BGCs.

Our results show that the choice of carotid access catheter has an important impact on blood flow in the target vessel. We have
found that only BGCs allow reliable flow arrest in our in vivo porcine model. In a patient, this does not mean that balloon inflation results in arrest of cerebral perfusion because collaterals may maintain cerebral blood flow distal to the occlusion site. As long as the clot is located above the circle of Willis, flow from the posterior and anterior communicating arteries and the ophthalmic artery can sustain the full physiologic flow volume of the ICA and may cause embolization of clot fragments. Consequently, aspiration of blood through an inflated BGC is necessary for reliable retrograde flow and control of peripheral embolization. Aspiration through the BGC with the syringe and with the Penumbra pump resulted in constant retrograde flow. However, only the syringe achieved high flow that surpassed the required antegrade flow rate of 240 mL/min for reliably reverting blood flow at the level of the terminal segment of the internal carotid artery. Therefore, we discourage using the Penumbra pump if flow reversal during mechanical thrombectomy is intended.

Surprisingly, aspiration with large-bore sheaths did not necessarily result in flow arrest or reversal, despite high-aspiration flow volumes. Aspiration through an 8F sheath with a syringe or a Penumbra pump results in flow volumes of ~800 and ~240 mL/min, respectively. By simply adding antegrade and retrograde flow, we would have expected a net backward flow of >500 mL/min with the syringe and flow arrest with the Penumbra pump. However, aspiration through an 8F sheath did not result in reliable flow reversal. At best, there was oscillatory flow with small net backward flow volumes, which would not suffice to reverse blood flow above the circle of Willis. This behavior is likely because aspiration results in an additional pressure gradient that mobilizes additional flow from the aortic arch into the CCA along the catheter while antegrade flow in the ICA is maintained (Fig 2). In the worst-case scenario, aspiration resulted in vessel collapse, which coincides with our clinical experience: During our interventions, we have found that when too much suction is applied, blood cannot be aspirated until the suction is decreased either because the catheter tip has engaged the vessel wall or—as we surmise—the vessel collapsed. Vessel collapse in perfused vessels is mainly due to the Bernoulli effect, which causes the vessel walls to collapse during aspiration of high flow volumes. This issue is relevant in clinical practice because it is almost impossible to predict vessel collapse: Many factors such as flow volume, position of the catheter, occlusion site, and the diameter of the vessel and its rigidity have an impact on the applied forces that cause vessel collapse. Given that aspiration with large-bore sheaths did not reliably result in flow arrest or reversal, we discourage using large-bore catheters or sheaths for flow arrest in the ICA, regardless of syringe or pump aspiration. Furthermore, we specifically discourage using smaller guiding catheters (5F–7F), which are very common because of their easy handling and low cost but face the same issue of insufficient aspiration like the larger sheath tested in our experiment. Notably, even under ideal conditions (perfect vacuum and no external resistors), aspiration flow through a 6F catheter with a stent retriever in its lumen does not reach 240 mL/min.

Such an experiment would need transcranial Doppler measurements in patients during thrombectomy, which is impossible due to the artifacts caused by the microcatheter and stent retriever in place. As an approximation, we estimated the following: Physiologic blood flow in an internal carotid artery is approximately 240 mL/min. It has been shown that aspiration flow through an 8F BGC with pump and syringe aspiration can surpass 350 mL/min (pump) and 500 mL/min (syringe), which again should be sufficient to allow flow arrest despite collateral flow. Nonetheless, there remains the possibility that collateral flow through the circle of Willis may be enough to maintain antegrade cerebral blood flow despite high-aspiration flow volumes. Also, due to the nature of our study, we could not investigate whether flow reversal has an effect on clinical outcome, but our results may serve as a foundation for future research that specifically addresses this question. Also, even though the porcine cardiovascular system serves as an excellent model, it may be arguable whether our quantitative results can be translated to patients without restrictions. Nonetheless, because it is impossible to conduct such an experiment in patients the porcine model is the best approximation to real life. Last, flow volume measurements based on duplex sonography may not always reflect actual flow volumes and are a minor limitation of our study. However, even if flow volumes are over- or underestimated, our results remain valid on a qualitative level because the direction of flow is unaffected by the measuring method.

**CONCLUSIONS**

Only BGCs allow reliable flow reversal and should be used with syringes or high-flow pump systems. Aspiration through an 8F sheath in the ICA results in either collapse of the vessel or oscillatory flow with antegrade flow in flow diameter, which can result in a net antegrade or retrograde flow.

**Limitations**

A major limitation of our study is that it does not allow assessing whether cerebral blood flow above the circle of Willis is reversed.

Disclosures: Martin Wiesmann—UNRELATED: Consultancy: Stryker Neurovascular; Payment for Lectures Including Service on Speakers Bureau: Bracco, Medtronic, Siemens, Stryker Neurovascular; Payment for Development of Educational Presentations: Abbott, Ab medica, Accanis, Bayer HealthCare, Bracco, B. Braun, Codman Neurovascular, Kaneka Pharma Europe, Medtronic, Dahnhausen Mediotechnik, MicroVention, Penumbra, phenox, Philips Healthcare, Route 92, Siemens, Silk Road Medical, St. Jude, Stryker Neurovascular. **Money paid to the institution.

**REFERENCES**


Low Wall Shear Stress Is Associated with Local Aneurysm Wall Enhancement on High-Resolution MR Vessel Wall Imaging

W. Xiao, T. Qi, S. He, Z. Li, S. Ou, G. Zhang, X. Liu, Z. Huang, and F. Liang

ABSTRACT

BACKGROUND AND PURPOSE: Some retrospective studies have found that the aneurysm wall enhancement on high-resolution MR vessel wall postgadolinium T1WI has the potential to distinguish unstable aneurysms. This study aimed to identify hemodynamic characteristics that differ between the enhanced and nonenhanced areas of the aneurysm wall on high-resolution MR vessel wall postgadolinium T1WI.

MATERIALS AND METHODS: TOF-MRA and high-resolution MR vessel wall T1WI of 25 patients were fused to localize the enhanced area of the aneurysm wall. Using computational fluid dynamics, we studied the aneurysm models. Mean static pressure, mean wall shear stress, and oscillatory shear index were compared between the enhanced and nonenhanced areas.

RESULTS: The aneurysmal enhanced area had lower wall shear stress \( (P < .05) \) and a lower oscillatory shear index \( (P = .021) \) than the nonenhanced area. In addition, the whole aneurysm had lower wall shear stress \( (P < .05) \) and a higher oscillatory shear index \( (P = .007) \) than the parent artery.

CONCLUSIONS: This study suggests that there are hemodynamic differences between the enhanced and nonenhanced areas of the aneurysm wall on high-resolution MR vessel wall postgadolinium T1WI.

ABBREVIATIONS: HR-VWI = high-resolution MR vessel wall imaging; OSI = oscillatory shear index; \( P \) = mean static pressure; WSS = wall shear stress

An intracranial aneurysm is regarded as the most common culprit for nontraumatic subarachnoid hemorrhage, a devastating clinical situation that is usually followed by the risks of aneurysm rebleeding, cerebral vascular spasm, and hydrocephalus. Imaging examinations, one of which is high-resolution MRI, have been used to discover, diagnose, estimate, and evaluate aneurysms. For instance, as a noninvasive examination, high-resolution MRI can be used as a screening method and a tool for follow-up visits, and it can help visualize dissecting aneurysms. Moreover, it can be used to evaluate the depth of aneurysm location before open surgery such as the clipping of middle cerebral bifurcation aneurysms. In patients with subarachnoid hemorrhage and multiple aneurysms, MR imaging can help discriminate the responsible aneurysm. Fu et al2 proposed that circumferential aneurysmal wall enhancement on high-resolution MR vessel wall imaging (HR-VWI) is correlated with headaches and third nerve palsy caused by unruptured aneurysms. Two previous studies indicated that as an indicator of inflammation, the aneurysm wall enhancement on HR-VWI postgadolinium T1WI has the potential for discriminating unstable aneurysms from stable ones.3,4 Wang et al5 found that all partial wall enhancement of 16 aneurysms was in the irregularly shaped portions or daughter sacs in their study. Computational fluid dynamics has been used to investigate hemodynamic parameters that are linked with cerebral aneurysm formation, progression, and rupture, one of which is wall shear stress (WSS), the most highlighted but controversial parameter.6–8 However, to our knowledge, no published investigations have revealed the association between hemodynamic characteristics and aneurysm wall enhancement on HR-VWI postgadolinium T1WI.

Therefore, we designed a retrospective study into hemodynamic parameters on aneurysm models with local wall enhancement on HR-VWI postgadolinium T1WI, to provide a new idea for the future investigation into wall enhancement.
MATERIALS AND METHODS

Patient Selection
This retrospective study protocol was approved by the ethics committees of the First Affiliated Hospital, Sun Yat-sen University, and informed consent was exempted. Patients with aneurysms who underwent an HR-VWI examination before an operation or conservative treatment from January 2015 to March 2016 were reviewed. The inclusion criteria were as follows: 1) intracranial aneurysms diagnosed by CTA, MRA, or DSA; 2) anterior circulation aneurysms; 3) HR-VWI postgadolinium T1WI revealing wall enhancement; and 4) available HR-VWI and DSA 3D rotational angiography data. The exclusion criteria were the following: 1) fusiform, dissecting aneurysms or pseudoaneurysms; 2) anterior communicating artery aneurysms or posterior circulation artery aneurysms; and 3) HR-VWI and 3D rotational angiography data unavailable.

Imaging Analysis
Two experienced neurovascular radiologists (with >5 years’ experience in neurovascular imaging) analyzed pre- and postcontrast T1-weighted images, retrospectively and respectively, to determine whether there was local enhancement. They were blinded to the patients’ clinical data and other sequences except for 3D-TOF imaging before the analysis. Discordance between 2 readers was resolved by consensus. One of the readers performed a second analysis after 3 weeks. By comparing pre- and postcontrast T1WI, we defined the wall enhancement as circumferential when the whole aneurysm wall was enhanced after contrast agent infusion; otherwise, it was defined as partial when only part of the aneurysm wall was enhanced. Only aneurysms with local enhancement were enrolled into this study. Protocols of HR-VWI and 3D rotational angiography are provided in the On-line Appendix.

Location of Aneurysm Wall Enhanced Area
DICOM files of HR-VWI were imported into iPlan cranial 3.0 (BrainLab, Munich, Germany). Then, in the projection of Image Fusion, the HR-VWI T1WI and TOF-MRA images were chosen and paired (Fig 1C and Fig 2C). They were then merged using the function of Auto Fusion. After Auto Fusion, merged images were checked on the axial view and fine manual fusion was performed for tiny adjustments, which ensured the precision of Image Fusion. Aneurysm models were reconstructed with TOF-MRA using Auto Segmentation. Irrelevant arteries were cut off manually, with aneurysms, parent arteries, and the important branches preserved. Aneurysm wall enhanced areas were also reconstructed using manual segmentation with T1WI (Fig 1D and Fig 2D). The aneurysm models and aneurysm wall enhanced area were displayed simultaneously to locate the enhanced area (Fig 1E, -F and Fig 2E, -F).

Aneurysm Modeling
The patients’ 3D rotational angiography DICOM files were imported into Mimics 17.0 (Materialise, Leuven, Belgium) for a rough model reconstruction by threshold segmentation. Then the unconnected regions were manually removed with the region-
growing algorithm. Meanwhile, branches extending from the parent artery and the aneurysm were preserved. Then, the vascular models were converted to a stereolithography format and imported into Geomagic Studio 2013 (Geomagic, Research Triangle Park, North Carolina) and SolidWorks 2012 (Dassault Systemes, Waltham, Massachusetts) successively for smoothing, surface construction, cutting off distal redundant arteries along with cutting out vascular inlets and outlets, and keeping the proximal parent artery at least 2 cm long to ensure the numeric stability.

**Computational Fluid Dynamics Analysis**
All the aneurysm models were loaded into Fluent Software 17.0 (ANSYS Corporation, Canonsburg, Pennsylvania) for meshing. In addition, the aneurysm wall-enhanced area and the whole aneurysm area were calculated, and the enhanced area ratio was defined as aneurysm wall enhanced area divided by the whole aneurysm area. The enhanced area, nonenhanced area, parent artery, inlets, and outlets of the aneurysm models were selected and defined. Computational fluid dynamics simulations were performed under the transient status, by setting the solver type as pressure-based, the velocity formulation as absolute, and the solver time as transient. The vessel was disposed as a rigid wall with no-slip boundary conditions, neglecting the gravity effect. A laminar and incompressible blood flow, with density and viscosity set as 1060 kg/m$^3$ and 0.004 Pa·s, respectively, was used in the calculation. The pulsatile velocity profile of the ICA, which was obtained from a middle-aged female patient with carotid duplex sonography, was imposed at the inlets, with all the vascular outlets defined as zero pressure boundary conditions. Time-step size was set at 0.02 seconds; the number of time-steps was set at 40. In addition, maximum iterations ranged from 40 to 100. Detailed information about pulsatile ICA velocity can be seen in the Online Appendix.

**Hemodynamic Analysis**
Three hemodynamic parameters, which were time-averaged over a cardiac cycle of enhanced area, nonenhanced area, the whole aneurysm, and parent artery, respectively, were calculated, namely mean static pressure ($P$), mean wall shear stress, and oscillatory shear index (OSI). To compare hemodynamic differences between ruptured and unruptured aneurysms, we calculated the $P$ and WSS of the enhanced area and the whole aneurysm normalized by the parent artery $P$ and WSS.

**Statistical Analysis**
Statistical analysis was performed using SPSS 20.0 (IBM, Armonk, New York). The agreement between 2 observers for the presence of local enhancement was evaluated by a $\kappa$ value. Normally distributed variables were expressed as mean ± SD and analyzed with a paired-samples $t$ test. Non-normally distributed variables were expressed as the median (interquartile range) and analyzed using a nonparametric paired Wilcoxon rank sum test. Statistical significance was indicated at the .05 level.
Table 1: Hemodynamic comparison between enhanced and nonenhanced areas

<table>
<thead>
<tr>
<th>Variables</th>
<th>Enhanced Area</th>
<th>Nonenhanced Area</th>
<th>P Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>P (Pa)</td>
<td>183.2600 (97.4000–242.9950)</td>
<td>158.8200 (103.5900–220.2000)</td>
<td>.115</td>
</tr>
<tr>
<td>WSS (Pa)</td>
<td>7.5342 (4.6062–11.1105)</td>
<td>7.3255 (4.8478–8.3533)</td>
<td>.0629</td>
</tr>
<tr>
<td>OSI</td>
<td>0.2288 ± 0.0918</td>
<td>0.3008 ± 0.0890</td>
<td>.021</td>
</tr>
</tbody>
</table>

a Data are expressed as means for normally distributed continuous variables, and as the median for non-normally distributed variables. Numbers in parentheses are interquartile range.

DISCUSSION

To our knowledge, our study is the first to reveal the association between hemodynamic characteristics and aneurysm wall enhancement on HR-VWI postgadolinium T1WI. High-resolution MRI has been used for intracranial aneurysm evaluation and assessment in the past few years. Several studies have reported the predicting role of high-resolution MRI in distinguishing unstable intracranial aneurysms. As previously reported, the aneurysm wall enhancement on HR-VWI postgadolinium T1WI could serve as an independent risk factor for the prediction of aneurysm rupture. On the other hand, hemodynamic forces are believed to act as a prominent factor in aneurysm initiation, progression, and rupture but are poorly understood. Specifically, WSS, one of the most frequently explored but still controversial and puzzling hemodynamic parameters, either high or low, has been shown to be correlated with aneurysm progression and rupture.

However, the hemodynamic characteristics correlated with the enhanced area of the aneurysm wall on HR-VWI postgadolinium T1WI have still not been investigated. Therefore, in this study, computational fluid dynamics was performed on aneurysm models generated from 25 patients with local aneurysm enhancement on HR-VWI postgadolinium T1WI, for hemodynamic simulation and parameter calculation.

In our study, the WSS and OSI of the aneurysmal enhanced area were both significantly lower than those of the nonenhanced area (Fig 1H–J and Fig 2H–J). In addition, higher WSS was found in the parent artery in contrast to the whole aneurysm sac due to arterial curvature and tortuosity. The abrupt geometric change caused aneurysm blood turbulence, thus resulting in higher aneurysmal OSI. There were no statistically significant hemodynamic differences between the ruptured and unruptured aneurysms, either at the enhanced region or in the whole aneurysm.

Because WSS is the tangential force exerted by the horizontally moving fluid on the surface and OSI denotes WSS fluctuation magnitude and the tangential force oscillation in a cardiac cycle, low WSS with low OSI may reflect a concentrated blood inflow jet at the enhanced area. We assume that a regional concentrated inflow jet is likely to damage the endothelial cell layer and lead to inflammation, thus changing the aneurysm geometry and promoting its tendency to grow or rupture. In fact, local enhancement of 17 aneurysms in our study was present in the irregularly shaped portions or in daughter sacs, both of which are normally regarded as risk factors for aneurysm rupture. The endothelial damage could possibly cause contrast agent adhesion or uptake or leakage.

Exposure to low WSS has been demonstrated to promote vascular permeability in some studies. Conkin et al performed porcine experiments and proposed that low WSS could decrease occludin expression and thus increase vascular permeability. Hinburg et al also discovered that being exposed to high WSS, the endothelial permeability to albumin decreased in porcine models. Thus, intra-aneurysmal sites being exposed to low WSS are likely to exhibit elevated permeability to contrast agent, which is presented as local enhancement on HR-VWI postgadolinium T1WI. More advanced studies are needed to confirm this hypothesis.

Several studies also suggested that applying directly to the en-
dothelial cells and acting as a mechanobiological trigger, low WSS may predispose the region to the dysfunction of flow-induced nitric oxide, upgrade endothelial surface adhesion molecules, promote the permeability of endothelial cells, and, thus, facilitate atherosclerotic and inflammatory cell infiltration.10,14,19–21 Edjlali et al10 proposed the potential of low WSS in monitoring the aneurysm wall inflammatory process. Hu et al14 collected a specimen of the aneurysm wall from a patient intraoperatively, which had exhibited local wall enhancement on the high-resolution MRI, and the following histologic study revealed phagocyte and lymphocyte invasion. In our study, we found that the whole aneurysm wall had lower mean WSS than the parent artery. In addition, the enhanced area had lower WSS than the nonenhanced region in the aneurysm as a whole. Low WSS may, therefore, underlie the aneurysm wall local enhancement on HR-VWI postgadolinium T1WI hemodynamically, which is summarized in On-line Fig 4. Future larger studies and further histologic investigation are needed to support this hypothesis.

In an unruptured aneurysm study, low WSS was found to colocalize with thin, easily visualized translucent regions of the aneurysm sac.22 These regions were thought to be fragile locations of the aneurysm wall that lead to rupture. In addition, in studies on ruptured aneurysms, low WSS was associated with the aneurysm rupture point.10,20,22–23 In our study, low WSS was also associated with a local enhanced area of the aneurysm wall; the association indicates that the enhanced area may also be the weak part of aneurysm wall. In addition, there were no statistically significant hemodynamic differences between the ruptured and unruptured aneurysms, which indicates that these unruptured aneurysms with local wall enhancement may have a potential risk similar to that of ruptured aneurysms.

Limitations

In our study, all the aneurysm models were analyzed using the same pulsatile velocity profile of the ICA instead of patient-specific analysis because carotid duplex sonography is not a clinical routine examination. However, it may be able to reflect the hemodynamic differences in various areas of the same model, which we are trying to find. Moreover, we have normalized the aneurysmal values by the parent vessel values to reduce the influence of inlet boundary conditions when making comparisons between different aneurysms.

Moreover, the small number of the patients enrolled into this study may also introduce bias. This may be partly due to the difficulties and risks for patients with unstable and ruptured aneurysms undergoing time-consuming MR imaging examinations. The developing technique discussed here will shorten the examination time and help solve this problem to some extent.

CONCLUSIONS

The results of this study indicate that hemodynamic differences exist between the enhanced and nonenhanced areas of the aneurysm wall on HR-VWI postgadolinium T1WI. The mean WSS of the aneurysm enhanced area is lower than that of the nonenhanced area, suggesting that low WSS may be an important hemodynamic factor that contributes to the aneurysm wall local enhancement. In addition, the OSI of the aneurysm enhanced area was lower than that of the nonenhanced area, reflecting a comparatively concentrated inflow jet.

REFERENCES


Usefulness of Vessel Wall MR Imaging for Follow-Up after Stent-Assisted Coil Embolization of Intracranial Aneurysms

S. Kim, M. Kang, D.W. Kim, and J.-H. Choi

ABSTRACT

BACKGROUND AND PURPOSE: Follow-up with MRA for intracranial aneurysms after stent-assisted coiling is complicated by imaging artifacts. We evaluated the usefulness of an alternative method: vessel wall MR imaging.

MATERIALS AND METHODS: We conducted a single-center, retrospective review of medical records of 47 patients who underwent 3D TOF-MRA, vessel wall MRI, and DSA after stent-assisted coiling between March 2016 and January 2018. We evaluated the mean value of the signal intensity in the stented artery and the contralateral normal artery on vessel wall MRI. The quality of visualization was further compared between TOF-MRA and vessel wall MRI. Furthermore, we evaluated the diagnostic accuracy and concordance rate of TOF-MRA and vessel wall MRI for assessing the patency of the stented parent artery. DSA was used as a reference test.

RESULTS: The mean signal intensities of the stented and normal arteries on vessel wall MRI were not significantly different (P = .133). The mean scores for the visualization of the stented parent artery on vessel wall MRI were significantly superior to those of TOF-MRA images (P < .001). Vessel wall MRI reached an excellent positive predictive value (100%). However, TOF-MRA had a poor positive predictive value (11%; 95% CI, 9%–12%). The likelihood ratios of vessel wall MRI and TOF-MRA were 27.36 (P < .001) and 2.98 (P = .225), respectively. The concordance rate of vessel wall MRI and TOF-MRA with DSA for evaluating the state of the stented artery was 100% (κ = 1) and 28% (κ = 0.038), respectively.

CONCLUSIONS: Vessel wall MRI may be useful in evaluating the patency of stented arteries after stent-assisted coil embolization for intracranial aneurysms.

ABBREVIATIONS: SI = signal intensity; VWMRI = vessel wall MRI

Endovascular coil embolization has become an established treatment method for intracranial aneurysms. Intracranial stents are used to treat wide-neck aneurysms using the neck-remodeling technique. However, stents cause endothelial hyperplasia and thrombosis, which can lead to stenosis or stented artery occlusion. The incidence of in-stent stenosis is approximately 1%. In-stent thrombosis may be more common—reported to be as high as 4% in 1 series—and may account for as much as 29% of thromboembolic complications. The criterion standard for evaluating this complication and the outcome of aneurysm treatment is DSA. There has been a move toward noninvasive follow-up using MR imaging due to the risks inherent in the invasive DSA procedure.

A widely used noninvasive alternative to DSA is 3D TOF-MRA. However, it is difficult to interpret the patency and/or degree of stenosis on TOF-MRA because of susceptibility artifacts and radiofrequency shielding of intracranial nitinol stents. Contrast-enhanced MRA has been reported to yield better results than TOF-MRA for the evaluation of aneurysm occlusions, but the ability of contrast-enhanced MRA to evaluate stented-artery status remains unclear. Furthermore, the use of contrast materials in contrast-enhanced MRA is associated with anaphylactic shock and nephrogenic systemic fibrosis; the frequency of all acute, adverse events after an injection of 0.1 or 0.2 mmol/kg of gadolinium chelate ranges from 0.07% to 2.4%. To reduce this risk, we attempted to find a useful imaging technique to evaluate the stented parent artery as an alternative to both contrast agents and DSA.

Vessel wall MR imaging (VWMRI) has been increasingly used to study intracranial vascular lesions, such as atherosclerosis, vasculitis, and aneurysms. In practice, the signal loss caused by the
stent on TOF-MRA makes evaluation of the parent artery difficult. However, VWMRI is closely related to fast spin-echo techniques with variable flip angle refocusing pulses, which use radio-frequency refocusing pulses to return a T2' decay of transverse magnetization to a longer T2 decay, thus reducing signal loss. We hypothesized that even without contrast administration, VWMRI could provide good image quality for evaluating stented parent arteries. Thus, the present study evaluated the usefulness of VWMRI after stent-assisted coil embolization for intracranial aneurysms and compared its efficacy with that of TOF-MRA.

**MATERIALS AND METHODS**

**Patients**

This study was approved by our institutional review board, and the requirement for written informed consent was waived. We retrospectively reviewed the medical records of patients who had an intracranial aneurysm treated by stent-assisted coiling between March 2016 and January 2018. Before patient discharge, our institution performs an initial MR imaging with TOF-MRA and VWMRI after stent-assisted coil embolization. Follow-up is performed by MR imaging with TOF-MRA and VWMRI. Conventional angiography is performed if there is suspicion of aneurysm recanalization or stent-related complications (eg, thromboembolism, stenosis, or occlusion).

**MR Imaging Protocol**

MR imaging was performed with a 3T MR imaging system (Discovery MR750; GE Healthcare, Milwaukee, Wisconsin) using a 32-channel head coil. The VWMRI consisted of 3D fast spin-echo proton-density imaging with variable flip angles (Cube; GE Healthcare) and motion-sensitized driven equilibrium. The imaging parameters for 3D proton-density images were as follows: TR, 1500 ms; TE, 21.3 ms; bandwidth, 62.5 kHz; FOV, 190 × 190 mm; matrix, 384 × 384; in-plane resolution, 0.49 × 0.49 mm; slice thickness, 0.8 mm (interpolated to 0.4 mm); NEX, 1; Auto-calibrating Reconstruction for Cartesian imaging acceleration factor, 1.5; scan time, 7 minutes, 53 seconds. We obtained 3D TOF-MRA with the following parameters: TR, 23 ms; TE, 2.5 ms; flip angle, 20°; bandwidth, 50 kHz; FOV, 210 × 180 mm; matrix, 416 × 224; slice thickness/slice overlap, 1.2 mm/16%; 3 slabs using multiple overlapping thin-slab acquisition; asset factor, 2; scan time, 4 minutes, 32 seconds. For 3D TOF-MRA, maximum-intensity-projection reconstructions and source images were used. For VWMRI, minimum-intensity-projection reconstructions and source images were used.

**DSA**

Intra-arterial DSA was performed with a biplane neuroangiographic system (AXIOM Artis dBA; Siemens, Erlangen, Germany). Using transfemoral catheterization, selective injections of the internal carotid or vertebral arteries were performed according to the aneurysm location. All DSA examinations included anteroposterior, lateral, and working views.

**Image Analysis**

We performed quantitative analyses of relative signal intensity (SI) and visualization of the stented parent arteries on the images obtained by VWMRI after the procedures.

One observer manually drew an ROI of at least 1 mm² on the single-slice source images (On-line Figure). An ROI was placed at the stented artery adjacent to the aneurysm neck on the basis of the assumption that an aneurysm would be located in the middle of the stented artery in most cases because we consistently placed the center of the stent at the aneurysm neck site during stent-assisted coiling. DSA and VWMRI are different imaging modalities, and it is difficult to match the exact position of the stent by comparing the VWMRI with DSA. Moreover, the stent strut is not visible on VWMRI.

The mean value of the SI in the stented artery was compared with that in the contralateral normal artery. The relative SI of the stented artery was calculated as follows: SI of the Stented Artery/SI of the Contralateral Normal Artery. In the case of the basilar artery, the proximal normal artery was referred to as the contralateral normal artery.

The image quality of the stented parent artery was graded subjectively on a 3-point scale: 1 = poor (evaluation could not be made), 2 = moderate (evaluation could be made but information was lacking compared with the DSA), and 3 = good (image could be evaluated similar to DSA).

Furthermore, we evaluated the status of the stented parent artery by comparing the VWMRI, TOF-MRA, and the DSA. The patency status of the parent artery was evaluated on a 3-point scale: 1 = patent (no change in the parent artery diameter), 2 = stenosis (narrowing of the parent artery), 3 = parent artery occlusion. A simplified 2-grade scale was used to assess the diagnostic accuracies for parent vessel patency: normal and pathologic (stenosis, occlusion, or thrombosis).

Two interventional neuroradiologists (one with 10 years of experience and the other with 5 years) independently evaluated all images in a random order. In case of disagreement, a third experienced neuroradiologist with 17 years of experience helped to establish consensus. DSA findings were considered the standard reference and were interpreted independently by 1 neurosurgeon who was unaware of the MR imaging findings.

**Statistical Analysis**

A Wilcoxon signed rank test was used to analyze the subjective scores for the quality of the stented artery images. P values < .05 were considered statistically significant. The Mann-Whitney U test was used to compare the mean relative SI value for the stented arteries with those of the contralateral normal arteries. The weighted κ statistic was used to evaluate interobserver agreement for each technique and the concordance rate for evaluating the patency of the parent vessel using the results of DSA as a standard of reference. Statistical analyses were performed with MedCalc for Windows, Version 18.2.1 (MedCalc Software, Mariakerke, Belgium). Diagnostic accuracy was calculated with SPSS software, Version 11.5 (IBM, Armonk, New York).

**RESULTS**

Before discharge, 84 patients underwent stent-assisted coiling and an initial MR imaging; 2 patients were excluded from our study because the intraluminal signal intensity was too high, even in normal arteries, due to motion or flow artifacts; and 35 patients were excluded because the follow-up DSA was not available after discharge.
discharge. The sample of the present study, therefore, totaled 47 patients (female/male ratio, 33:14; mean age, 57.2 ± 8.9 years; age range, 39–78 years) who underwent TOF-MRA, VWMRI, and DSA after their respective procedures. A Neuroform 3 stent (Stryker Neurovascular, Kalamazoo, Michigan) was used for 31 aneurysms, while a Solitaire AB stent (Covidien, Irvine, California) was used for 16. The clinical characteristics of the patients are shown in Table 1.

All 47 parents underwent both follow-up MR imaging and DSA with an interval gap of <7 days. The mean period between coil embolization and follow-up DSA was 266 ± 98 days; the interval between the follow-up MR imaging and follow-up DSA was 3.3 ± 1.8 days.

### Relative Signal Intensity in the Stent

We performed quantitative analyses of relative SI of the arteries in the images obtained by initial VWMRI after the procedures in 46 of the 47 patients; 1 patient was excluded due to signal intensity contamination in the parent artery by acute in-stent thrombosis. The mean SIs for the stented artery and normal artery were 167 ± 20 and 174 ± 20, respectively, and were not significantly different (P = .133). The mean relative SIs for the stented arteries using the Neuroform and Solitaire stents was 0.97 ± 0.04 and 0.94 ± 0.05, respectively; the mean relative SI of the stented artery fitted with Solitaire stents was lower than that of stented arteries fitted with Neuroform stents (P < .013).

### Image Quality

For the Neuroform stent cases, the image quality of the stented parent artery on VWMRI was significantly superior to that obtained by TOF-MRA (P < .001). The average scores were 3 ± 0 for VWMRI and 2.2 ± 0.69 for MRA. In cases of Solitaire stents, the image quality was equally poor for the stented parent artery on VWMRI and MRA. A proximal marker near the detachment zone of the Solitaire stent caused significant signal loss of the lumen due to susceptibility artifacts in both imaging modalities. When the evaluations were performed in the Solitaire stents and the proximal portion of the stented artery was excluded, the mean scores for the stented artery were 3 ± 0 and 1.7 ± 0.7 for VWMRI and TOF-MRA, respectively (P < .001). Therefore, the quality for the stented artery images obtained by VWMRI was significantly superior to that observed in 3D TOF-MRA images. With the exception of the proximal portion in the Solitaire stent, this finding was consistent regardless of the type of stent used. The overall mean scores for image quality, in terms of visualization of the stented artery, were 3 ± 0 and 2 ± 0.7 for VWMRI and 3D TOF-MRA, respectively (P < .001).

### Patency of the Parent Vessel

It was difficult to evaluate the patency of the parent artery near the detachment zone in Solitaire stents due to signal loss on VWMRI and MRA. However, apart from the marker region in the Solitaire stent, VWMRI showed results consistent with those of DSA. The statuses of the parent vessel artery assessed with VWMRI, TOF-MRA, and DSA are shown in Table 2.

Interobserver agreement was very good for VWMRI (κ = 1) and good for TOF-MRA (κ = 0.64). The concordance rate of VWMRI and TOF-MRA with DSA for evaluating the state of the stented artery was 100% (κ = 1) and 28% (κ = 0.038), respectively. The likelihood ratios of VWMRI and TOF-MRA were 27.36 (P < .001) and 2.98 (P < .225), respectively. By means of the simplified 2-grade scale (normal-versus-pathologic vessels), VWMRI reached an excellent positive predictive value (100%). However, TOF-MRA featured a poor positive predictive value (11%; 95% CI, 9%–12%). False stenosis was prevalent on TOF-MRA. Normal vessels on DSA were overestimated as pathologic vessels on TOF-MRA in 34/47 patients.

There were 4 cases of stent-related complications. An in-stent thrombus occurred after stent-assisted coiling for a paraclinoid ICA aneurysm (Fig 1). According to the 3-point scale, this case was classified as a stenosis, but 2 readers interpreted it as a thrombus on VWMRI. An angiogram obtained immediately after the final coil insertion revealed the acute small in-stent thrombosis. A 30-minute-delayed DSA performed after rescue use of tirofiban demonstrated no thrombus growth and uncompromised distal arterial flow velocity. Thus, we decided to follow-up without further interventional treatment. VWMRI revealed that the thrombosis had increased in size in the stent 2 days after the procedure. However, TOF-MRA showed luminal narrowing of the stented parent artery. Immediate, same-day follow-up DSA confirmed the thrombus growth in the stent, consistent with the VWMRI findings. The other stent-re-

---

### Table 1: Characteristics of the 47 patients and 47 aneurysms that underwent stent-assisted coiling

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (range) (yr)</td>
<td>57.2 ± 8.9 (39–78)</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>33:14</td>
</tr>
<tr>
<td>Ruptured aneurysms</td>
<td>6 (15%)</td>
</tr>
<tr>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>Internal carotid artery</td>
<td>27</td>
</tr>
<tr>
<td>Middle cerebral artery</td>
<td>9</td>
</tr>
<tr>
<td>Anterior cerebral artery</td>
<td>5</td>
</tr>
<tr>
<td>Communicating artery</td>
<td>6</td>
</tr>
<tr>
<td>Vertebral artery</td>
<td></td>
</tr>
<tr>
<td>Aneurysm size</td>
<td></td>
</tr>
<tr>
<td>&lt;5 mm</td>
<td>24</td>
</tr>
<tr>
<td>5–10 mm</td>
<td>21</td>
</tr>
<tr>
<td>&gt;10 mm</td>
<td>2</td>
</tr>
<tr>
<td>Initial occlusion result</td>
<td></td>
</tr>
<tr>
<td>Complete occlusion</td>
<td>38</td>
</tr>
<tr>
<td>Remnant neck</td>
<td>7</td>
</tr>
<tr>
<td>Residual aneurysm</td>
<td>2</td>
</tr>
<tr>
<td>Stent</td>
<td></td>
</tr>
<tr>
<td>Neuroform</td>
<td>31</td>
</tr>
<tr>
<td>Solitaire</td>
<td>16</td>
</tr>
</tbody>
</table>

### Table 2: Concordance rate of vessel wall MRI findings and TOF-MRA using results of DSA as a standard of reference

<table>
<thead>
<tr>
<th>Vessel Wall MRI</th>
<th>Patent</th>
<th>Stenosis</th>
<th>Occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSA</td>
<td>43</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Stenosis</td>
<td>0</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Occlusion</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MRA</th>
<th>Patent</th>
<th>Stenosis</th>
<th>Occlusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSA</td>
<td>9</td>
<td>29</td>
<td>5</td>
</tr>
<tr>
<td>Stenosis</td>
<td>0</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Occlusion</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Concordance rate (κ = 1) 100% (κ = 0.038)
lated complication observed in 3 cases was in-stent restenosis following stent-assisted coiling. VWMRI assisted in the identification of the 3 stenosis cases (Fig 2). All 3 cases were also classified as pathologic vessels on TOF-MRA, but we were unable to determine whether this represented artifactual luminal narrowing or a true lesion.

Additional Results

In our preliminary study, we evaluated coiled aneurysm stability with VWMRI. On the basis of the evolution of blood clots, the signal of clots decreases in the chronic phase on T1WI. Even in the chronic phase, the SI of hematoma is higher than the dark SI of blood. Thus, we hypothesized that SI in the coiled aneurysm would appear higher than that in the parent artery and that the residual flow signal in the coiled aneurysm would appear dark on the proton-density image. We therefore sought to evaluate aneurysm stability with VWMRI using SI differences between treated aneurysms and residual flow. Of the 47 patients, follow-up DSA results showed complete occlusion in 42 patients, a remnant neck in 4 patients, and residual aneurysm in 1 patient. Regarding the depiction of residual flow in the coiled aneurysms, the concordance rate of VWMRI was lower than that of TOF-MRA (38% versus 96%). In 42 cases of complete occlusion identified via DSA, 25 were erroneously interpreted as residual neck or residual aneurysm on VWMRI. In 2 patients whose TOF-MRA results were underestimated relative to DSA, a tiny residual neck was erroneously interpreted as complete occlusion.

DISCUSSION

An intracranial stent is a powerful tool for the endovascular treatment of wide-neck and fusiform aneurysms. However, stent-related complications can cause permanent neurologic complications. Identifying these complications is important for patient diagnosis, management, and prognosis. Although DSA is standard for the follow-up of coiled aneurysms, it is invasive and exposes patients to procedure-related complications, such as cerebral thromboembolism, contrast nephrotoxicity, and radiation. Thus, follow-up imaging after endovascular treatment is vital. We evaluated the usefulness of VWMRI after stent-assisted coil embolization of intracranial aneurysms. The primary finding of our study was that VWMRI could reliably identify in-stent complications.

First, we evaluated the relative SI of the stented parent arteries

FIG 1. A 60-year-old woman with a paraclinoid internal carotid artery aneurysm. A, Cerebral angiography performed immediately after stent-assisted coiling shows an acute in-stent thrombus. The arrowheads indicate the proximal and distal markers of the stent. B, Oblique and axial (upper right image) reformatted images of the proton-density image obtained from a vessel wall MR imaging performed 2 days after coiling reveal the in-stent thrombus. C, Time-of-flight MR angiography demonstrates artifactual luminal narrowing of the stented parent artery. D. Cerebral angiography on the same day shows the thrombus within the stent, consistent with vessel wall MR imaging results.

FIG 2. A 50-year-old man with a paraclinoid internal carotid artery aneurysm. A, Cerebral angiography performed immediately after stent-assisted coiling shows the normal parent artery. B, Time-of-flight MR angiography obtained at a 1-year follow-up examination shows signal drop-out with a decreased diameter and signal intensity of distal vessels in the left middle cerebral artery. C, Oblique reformatted images of vessel wall MR imaging reveal stenosis in the left proximal middle cerebral artery (arrow). D, Follow-up cerebral angiography confirms stenosis of the left proximal middle cerebral artery.
on VWMRI after performing stent-assisted coiling with 2 types of intracranial nitinol stents: Neuroform and Solitaire. The signal intensity of the stented artery was different according to stent type. The relative SI for stented arteries fitted with Neuroform stents was higher than that for the stented arteries fitted with Solitaire stents in our VWMRI study. These findings are consistent with an in vivo study that used a silicone tube to reveal that the mean relative in-stent signal for Neuroform stents was higher than that for the Solitaire stents. \(^{14}\) The extent of stent-induced signal loss on TOF-MRA has been shown to depend on the thickness of the strut and cell design. \(^{4}\) The Neuroform stent has an open-cell design and a strut thickness of 65 \(\mu\)m, while the Solitaire stent has a closed cell design and a thickness of 60 \(\mu\)m. Open-cell design stents have been shown to have lower susceptibility to artifacts compared with closed-cell stents. \(^{14}\) Moreover, the partially overlapping strut in the Solitaire stent may cause more in-stent signal reduction than in Neuroform stents.

Second, we evaluated the image quality of the stented artery on VWMRI versus TOF-MRA. An intracranial stent can compromise the evaluation of the patency of the vessel on TOF-MRA. \(^{15}\) Contrast administration can improve vessel lumen visualization. \(^{16,17}\) Lövblad et al \(^{16}\) assessed 19 patients with stent-assisted coil embolization using noncontrast TOF-MRA and contrast-enhanced TOF-MRA with 1.5T MR imaging; the contrast administration allowed better visualization of the vessel lumen in the cases that used nitinol stents. Furthermore, the in-stent signal loss was present in all TOF-MRA cases except for contrast-enhanced MRA images. Thamburaj et al \(^{17}\) assessed 42 patients with stent-assisted coiling and found that contrast-enhanced MRA showed a tendency to demonstrate superior in-stent flow, smoother margins, and minimal-to-no stenosis relative to noncontrast TOF-MRA. However, although complications of contrast agent administration for contrast-enhanced MRA are rare, contrast dye can cause severe allergic reactions and adverse effects. To avoid administration of contrast, we compared VWMRI with TOF-MRA: VWMRI provided better image quality compared with TOF-MRA. The latter method is based on a gradient-echo sequence. Image artifacts due to metal are caused by inhomogeneity in the static magnetic field, and gradient-echo-based sequences are therefore more prone to these artifacts. In contrast, VWMRI is based on a spin-echo sequence, and its use of 3D techniques allows very thin slices; compared with thin 2D slices, susceptibility artifacts are reduced because of the (fast) spin-echo technique. \(^{9}\) In contrast to cases in which Neuroform stents were used, neither TOF-MRA nor VWMRI could evaluate the segment near the proximal marker of Solitaire stents. This issue is because the relatively thick, proximal marker near the detachment zone of the Solitaire stent caused complete signal loss of the lumen due to the susceptibility artifacts. However, when the proximal marker was excluded, the image quality of the stented artery on VWMRI was superior to that of TOF-MRA. Agid et al \(^{18}\) reported a “marker band effect” appearing in arteries \(\leq\)2 mm in diameter. The markers of Neuroform stents are made of platinum, which creates strong magnetic susceptibility artifacts. We observed this effect on TOF-MRA in cases in which the Neuroform stent was used in the middle cerebral or posterior cerebral artery. However, this phenomenon did not occur on VWMRI.

Third, we compared VWMRI and TOF-MRA with DSA to evaluate the status of the stented parent artery. Several studies found that MRA with or without contrast material does not seem to provide an effective alternative to DSA for assessing parent artery patency. \(^{19-21}\) In a direct comparison between contrast-enhanced MRA and DSA in 27 patients with 28 aneurysms, Agid et al \(^{18}\) reported 6 cases of false stenosis and 2 of exaggerated stenosis on contrast-enhanced MRA, suggesting that the contrast-enhanced MRA did not depict the true status of the artery. Marciano et al \(^{19}\) compared TOF-MRA and contrast-enhanced MRA with DSA in 33 patients with 35 aneurysms treated by stent-assisted coiling. The intermodality agreement was poor for 3D TOF-MRA \((\kappa = 0.12)\) and null for contrast-enhanced MRA \((\kappa = -0.01)\). TOF-MRA \((\kappa = 0.05)\) and contrast-enhanced MRA \((\kappa = -0.04)\) were not able to detect pathologic vessels better than DSA: No difference in accuracy was found \((P = .68)\). Recently, Akkaya et al \(^{20}\) evaluated the usefulness of contrast-enhanced MRA and TOF-MRA in 24 aneurysms treated with low-profile stent-assisted coiling. Although interobserver agreement was substantial in both TOF-MRA \((\kappa = 0.71, P < .001)\) and contrast-enhanced MRA \((\kappa = 0.64, P = .001)\), intermodality agreement values of TOF-MRA and contrast-enhanced MRA with DSA were insignificant in terms of stent patency \((\kappa = 0.065, P = .27)\) and contrast-enhanced MRA \((\kappa = 0.158, P = .15)\). Choi et al \(^{21}\) compared 4D-MRA and 3D TOF-MRA in a group of 26 patients with aneurysms treated with stents. Although the visualization of the stented arteries on 4D-MRA was significantly superior to that on 3D TOF-MRA \((P < .001)\), the investigators doubted whether the degree of in-stent restenosis was accurately measured by 4D-MRA. The ability of 4D-MRA to evaluate in-stent stenosis thus remains undetermined.

Recent studies have demonstrated that Silent MRA (Discovery MR750w; GE Healthcare) might be useful for follow-up imaging after stent-assisted coil embolization. \(^{22,23}\) In Silent MRA, an ultrashort TE can minimize the phase dispersion of the labeled blood flow signal in the vessel and decrease magnetic-susceptibility artifacts; accordingly, the artifacts from stents or coils are theoretically decreased. \(^{23}\) Thus, Silent MRA could improve visualization of the stent without contrast administration more clearly than could 3D TOF-MRA. \(^{22,23}\) However, in Silent MRA, the angiographic image is obtained by subtraction of images scanned before and after labeling. Thus, static tissue such as a thrombus cannot be detected in Silent MRA. \(^{22}\)

In contrast to previous studies that found that MRA techniques were unable to provide a precise evaluation of the stent lumen, our study showed that diagnostic accuracy and the concordance rate between VWMRI and DSA were excellent. VWMRI is helpful in identifying the morphology of intracranial vessels. \(^{15}\) The present study found that VWMRI was more accurate than TOF-MRA for evaluating the status of the stented parent artery. VWMRI assisted the identification of 3 cases of stenosis and 1 of thrombosis, and its images demonstrated features similar to those shown by DSA.

In our preliminary study, VWMRI did not appear to be useful for evaluating aneurysm stability. We observed that in most cases, the SI of coiled aneurysms on VWMRI was heterogeneous regardless of follow-up duration. Thus, completeness of the coil embo-
lization was overestimated by VWMRI. Various factors such as thrombus organization, fibrosis, and coil-related low SI seem to contribute to heterogeneous SI in the coiled aneurysm. TOF-MRA (particularly with contrast) is good at detecting residual flow and aneurysm recurrence. It would seem that the techniques could be complementary.

The in-stent complication rates in our study were high. We observed that 3 of 4 patients were asymptomatic at follow-up. When a follow-up was performed with only TOF-MRA, DSA was recommended in cases of suspected abnormal findings with associated symptoms. In asymptomatic cases, follow-up was recommended but was often rejected by patients. However, after we used VWMRI, a subsequent DSA test was highly recommended and consequently less often rejected by patients. We speculate that this bias could be attributed to the high incidence of complications.

Asymptomatic in-stent stenosis can change into symptomatic stenosis, or spontaneous resolution of stenosis can occur. These events have important clinical implications for the continuation of dual-antiplatelet medication, close observation of neurologic symptoms, and follow-up. For clinical purposes, if MRA with or without contrast material depicts in-stent stenosis or stent occlusion, DSA should be performed to rule out in-stent stenosis or stent occlusion due to false-positive results. Our findings indicate that VWMRI provides a clear depiction of the patency of the parent artery. Accordingly, it is possible to avoid performing DSA in a group of patients in whom there are no particular clinical concerns for stent stenosis/occlusion. In practice, we believe that noninvasive imaging techniques such as VWMRI could be used more frequently than invasive conventional angiography as a follow-up technique.

This retrospective study has several limitations. First, follow-up MR imaging and DSA evaluations were not performed on the same day in most cases. Therefore, these 2 modalities might not reflect the exact same conditions in terms of the state of aneurysms and stented parent arteries. Second, intracranial stents were limited to the Neuroform and Solitaire varieties. Multiple flow diverters or flow-disruption devices are currently available for the treatment of cerebral aneurysms. Several series have reported the usefulness of MRA with contrast material in the follow-up of flow diverters or flow-disruption devices. These studies showed that contrast-enhanced MRA yielded better accuracy than TOF-MRA for the status of the parent artery. However, intraluminal evaluation remains difficult due to artifacts in MRA, regardless of the sequence used. This difficulty may be explained by the difference in composition but also porosity, metal coverage, and pore density between stents and flow diverters. The usefulness of VWMRI for variable flow diverters or flow-disruption devices should be determined in future studies.

Third, the goal of VWMRI is to reduce the intraluminal signal to zero. Intraluminal SI is not always suppressed fully on VWMRI. Visually, intraluminal SI appeared to be dark in our study. However, intraluminal signals were not zero. Thrombus was assumed if visual assessment revealed higher SI than intraluminal SI. However, there are limitations to visual evaluation when blood suppression is less effective in the presence of slow or complex flow. Novel blood-suppression techniques, including the Delay Altering with Nutation for Tailored Excitation, can be used to reduce artifacts.

Fourth, there are limitations concerning the TOF acquisition techniques. The SNR in the stent can be improved by a higher flip angle on the TOF technique. However, we did not use these techniques to improve image acquisition. With the optimization of MR imaging parameters of TOF-MRA according to the various intracranial stents, the luminal visualization of stents could be improved. We performed multislab TOF-MRA with multiple overlapping thin-slab acquisitions. The slab boundaries typically show some artifacts and intensity variations, even if acquired with a generous slab overlap. In our study, the slab artifacts did not significantly affect the reader’s interpretation of the image quality. However, the slab boundary artifacts may reduce image quality if the stent is located directly in a slab boundary zone. The single-slab or sliding interleaved projection reconstruction technique can be used to reduce slab boundary artifacts over the conventional TOF technique.

CONCLUSIONS

The present study performed quantitative and qualitative analyses of stented parent artery imaging using VWMRI and TOF-MRA. Even without contrast administration, VWMRI provided better image quality and higher accuracy in the evaluation of stented parent arteries than TOF-MRA. The high concordance rate of VWMRI for the analysis of pathologic parent artery status suggests that VWMRI could be useful in evaluating the patency of stented arteries after stent-assisted coiling.

ACKNOWLEDGMENTS

This work was supported by the Dong-A University Research Fund.

REFERENCES


8. The American College of Radiology. 

Spinal Epidural Arteriovenous Fistula with Perimedullary Venous Reflux: Clinical and Neuroradiologic Features of an Underestimated Vascular Disorder

M. Mull, A. Othman, M. Dafotakis, F.-J. Hans, G.A. Schubert, and F. Jablawi

ABSTRACT

BACKGROUND AND PURPOSE: The purpose of this study was to discuss the clinical and radiologic characteristics of spinal epidural arteriovenous fistulas (SEAVF) and demonstrate their specific angiomorphology in a single-center series.

MATERIALS AND METHODS: Thirteen consecutive patients were diagnosed with SEAVF at RWTH Aachen University Hospital between 2006 and 2018 and were included in this study. All patients had MR imaging and DSA before treatment; 10 of these 13 patients received contrast-enhanced MRA (CE-MRA).

RESULTS: The mean patient age was 72 ± 8 years. Paraparesis was present in 12 (92%) patients. Sphincter dysfunction and sensory symptoms were observed in 7 (54%) and 6 (46%) patients, respectively. The mean duration of symptoms was 6 ± 8 months. Congestive myelopathy on MR imaging was present in all patients. Prominent arterialized perimedullary veins were demonstrated in only 3 cases. CE-MRA revealed arterialized perimedullary veins and an arterialized epidural pouch in 9/10 (90%) patients, mostly located ventrolaterally. DSA demonstrated a multisegmental extension of the arterialized ventrolateral epidural pouch in 6 (46%) cases. An intradural radicular drainage vein was localized distant from the original fistula point in 3 (23%) patients.

CONCLUSIONS: Congestive myelopathy with an acute/subacute clinical course was the dominant finding in spinal epidural arteriovenous fistulas. CE-MRA is a powerful diagnostic tool for identifying arterialized perimedullary veins as well as an arterialized epidural pouch. While arterialized perimedullary veins frequently present with only mild enlargement and elongation in spinal epidural arteriovenous fistulas, the arterialized epidural pouch is frequently located ventrolaterally and may extend over several vertebral levels. DSA remains the criterion standard to precisely visualize a spinal epidural arteriovenous fistula and its intradural radicular drainage vein, which may be located distant from the fistulous point.

ABBREVIATIONS: AV = arteriovenous; CE-MRA = contrast-enhanced MRA; SDAVF = spinal dural arteriovenous fistula; SEAVF = spinal epidural arteriovenous fistula

Various classifications have been established for spinal vascular malformations and fistulas based on their vascular supply, venous drainage pattern, and nidus location and morphology. The most common classification of spinal vascular diseases was developed by Oldfield and Doppman in 1988.¹ They classified these lesions into 4 types comprising classic spinal dural arteriovenous fistulas (SDAVFs), glomus arteriovenous malformations, congenital juvenile arteriovenous malformations, and perimedullary arteriovenous fistulas. The much rarer spinal epidural arteriovenous fistulas (SEAVFs) were not included in this classification.

In contrast to the SDAVF, the arteriovenous (AV) shunt in the SEAVF is located in the epidural space. The venous drainage of these AV shunts varies from pure epidural fistulas with extradural venous drainage to combined epidural and intradural venous reflux.²

A SEAVF with perimedullary venous reflux has been thought to present with nonspecific myelopathic symptoms comparable with those of a typical SDAVF.³,⁴ However, their precise angiographic and clinical presentations have not yet been investigated in a large number of patients and might still be unfamiliar to most neurologic and radiologic physicians.

A clear recommendation for treatment technique and strategy...
is also still lacking in the literature. The goal of treatment is, however, the interruption of the intradural radicular drainage vein to stop the arterialization of perimedullary veins and additionally the obliteration of the arterialized epidural pouch to decrease the risk of residual or recurrent fistula. These goals can be achieved either surgically or endovascularly.

To further characterize this extremely rare subgroup of fistulas, we identified 13 patients presenting with an SEAVF with perimedullary venous reflux to demonstrate their anatomic features and clinical and radiologic presentation.

MATERIALS AND METHODS
After obtaining permission from our local ethics board, we retrospectively evaluated the medical and radiologic reports of patients with an SEAVF diagnosed between January 2006 and February 2018 in RWTH Aachen University Hospital. All clinical data, including demographics and clinical presentation, were assessed by the treating physicians and re-evaluated for this study. In particular, we re-evaluated the neurologic status at time of admission to our institution, the duration of symptoms from onset until diagnosis, as well as previous misdiagnoses and treatment. The documented functional condition at time of discharge was rated as worse, stable, or improved.

All patients underwent spinal MR imaging \( (n = 13) \) and/or contrast-enhanced MRA (CE-MRA) \( (n = 10) \) before spinal angiography. Five (39%) of these 13 patients underwent repetitive DSA for a definite diagnosis. As a rather new technique, C-arm flat panel CT was performed in the last 5 patients of this cohort.

Radiologic data were analyzed blinded to all clinical data by both the first and last author. The first author is an interventional neuroradiologist with >30 years’ experience in spinal angiography and spinal vascular diseases; the last author is a consultant neurosurgeon with a many years’ experience in clinical, radiologic, and surgical aspects of spinal vascular diseases. A reference standard for statistical analysis was established in a consensus reading. We retrospectively evaluated the arterial supply, venous drainage patterns, and location and extension of the arterialized epidural pouch in our DSA findings of all included patients.

MR/CE-MRA Imaging
MR imaging was performed in 7 patients at 1.5T (Intera, Release 10.3; Philips Healthcare, Best, the Netherlands) and in 6 patients at 3T (Prisma; Siemens, Erlangen, Germany) \( (n = 6) \) as part of the routine clinical work-up. Sagittal T2- and pre- and postcontrast T1-weighted images were obtained as well as axial T2- and contrast-enhanced T1 images of the thoracolumbar region. In 1 patient, examination was limited to the lumbar and deep thoracic regions only. The cranio-caudal extension of the T2 signal hyperintensity and the medullary contrast enhancement were qualified by the number of vertebral levels shown to be affected on T1 and T2 MR images. The appearance of the perimedullary veins was rated subjectively as mild, moderate, or prominent due to their tortuous and dilated appearance in the T1 and T2 images.

Contrast-enhanced MR angiography was performed on a clinical 1.5T MR imaging system with a phased array spine coil in 4 patients. To emphasize the arterial phase of the bolus enhancement relative to the venous enhancement, we sampled the k-space using elliptic centric ordering, which allowed separation into arterial and mixed arterial-venous enhancement. Further details about this CE-MRA technique have been previously described by our group elsewhere.\(^5,6\)

In 6 patients, time-resolved angiography with stochastic trajectories was performed on a clinical 3T MR imaging system. This CE-MRA also divides k-space into 2 regions but samples them alternately using a semi-randomized method. It allows a rapid acquisition of multiple images during the passage of the contrast bolus.

DSA
Selective spinal DSA was performed via a femoral approach in a dedicated biplanar neuroangiographic suite (Artis zee biplane; Siemens). Standardized angiography included selective manual injections of 4–5 mL of 300 mg/mL of iodinated nonionic contrast medium into the lumbar and intercostal arteries. If the preceding MRA examination suggested the level of a SEAVF, DSA protocol included at least injection of the segmental arteries, on both sides, 1 level above and below the suggested level. Imaging was in the anteroposterior direction with 2 frames per second. Oblique and lateral views were added to depict the morphology of the AV shunt as well as the intradural course of the draining vein. Film sequences of at least 5–20 seconds were obtained. Furthermore, 3D C-arm conebeam CT acquisitions (so-called Dyna-CT; Siemens) were performed in the last 5 patients in this cohort with a total acquisition time of 8 seconds. The arterial injection for the conebeam CT angiogram allowed both early and late opacification throughout the acquisition. MPRs were performed using an external postprocessing workstation.

The extension of the epidural pouch, the arterialized perimedullary veins, and the location of the perimedullary veins (dorsal, ventral) were analyzed on the basis of CE-MRA and DSA.

RESULTS

Clinical Presentations
Ten (77%) of 13 patients were men. The mean age was 72 ± 8 years (median, 77 years; range, 59–83 years). Overall, 10 (77%) patients presented with a relatively short clinical course (<6 months) with progressive motor weakness in the lower extremities. The remaining 3 (23%) patients experienced a gradual onset and progressive deterioration of neurologic function. The mean interval between symptom onset and diagnosis was 6 ± 8 months (median, 3 months; range, 1–24 months) when excluding 1 statistical outlier in this series with a symptom duration of 60 months (Table 1).

The most common neurologic findings at admission in our institution were gait disturbances due to paraparesis in 12 (92%) patients. The remaining 1 (8%) patient had neurogenic claudication without manifest motor deficits. Eight (62%) patients reported sphincter dysfunction at admission to our institution. Sensory symptoms in various severities were documented in 7 (54%) patients and comprised diffuse loss of sensation and/or paresthesia in the lower extremities.

All 13 patients underwent microsurgical interruption at our center. Microsurgical dorsal lumbar decompressions and discectomies due to assumption of a spinal degenerative disease were
performed elsewhere before a definite diagnosis in 3 (23%) of these 13 patients.

**Radiologic Findings**

Data of preoperative MR images were available in all 13 patients (Table 2). There was a centromedullary multisegmental T2WI hypointense signal with involvement of the conus medullaris in all patients (mean, 7 vertebral levels; range, 1–13 vertebral levels). Intramedullary contrast enhancement was present in 10/12 (83%) patients (mean, 3 vertebral levels; range, 1–10 vertebral levels).

Enlargement and elongation of arterialized perimedullary veins in the thoracic and/or thoracolumbar region were detected in various manifestations in all patients, mild in 6 (50%), moderate in 3 (25%), and prominent in the remaining 3 (25%) patients. The arterialized perimedullary veins were localized predominately dorsal to the spinal cord in 5 (42%) and ventrally in 3 (25%). In the other 5 patients, arterialized perimedullary veins were observed dorsal and ventral to the spinal cord. In 9 (90%) of 10 patients who underwent CE-MRA before DSA at our center, the arterialized ventrolateral epidural pouch was additionally detected, triggering the diagnosis of an SEAVF.

In 5 patients, >2 DSA examinations were necessary to establish the diagnosis of SEAVF (Table 2).

Angiographically, 10 (77%) of the 13 fistulas were in the lumbar region, and 2, (15%) in the lower thoracic region below T10, respectively. The remaining (8%) fistula was located in the sacral region. The arterialized ventrolateral epidural pouch in 6 (46%) of 13 patients extended over several vertebral levels (mean, 2 vertebral levels; range, 1–3 vertebral levels). Multiple arterial feeders were detected in 3 (23%) patients.

Furthermore, the intradural radicular drainage vein originated in 3 (23%) patients distant from the level of the fistula-feeding segmental artery, ipsilaterally in 2, patients 6 and 7, and bilaterally in patient 11 (range, 1–3 vertebral levels) (Table 2).

**DISCUSSION**

**Definition and Pathogenic Aspects of SEAVF**

Arteriovenous disorders of the epidural venous plexus have been rarely reported in the literature.2,7,8 Paraspinal AV shunts were first clearly described by Cognard et al9 in 2 patients with retrograde filling of intradural veins. The first SEAVF in our institution was diagnosed in 2006 and reported elsewhere.10 Since then, SEAVFs have been more frequently diagnosed in our center. The finding might reflect a better understanding of this particular vascular disorder as well as the growing diagnostic impact of spinal MR angiography.

The angioarchitecture, namely the feeding arteries, the venous

---

**Table 1: Clinical presentation of patients with spinal epidural arteriovenous fistula**

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr)/Sex</th>
<th>Duration of Symptoms (mo)</th>
<th>Symptoms at Diagnosis</th>
<th>Status at Discharge</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>78, M</td>
<td>6</td>
<td>Paraparesis, sphincter dysfunction</td>
<td>Improved</td>
</tr>
<tr>
<td>2</td>
<td>63, M</td>
<td>1</td>
<td>Paraparesis, sphincter dysfunction, hypesthesia below T10</td>
<td>Stable</td>
</tr>
<tr>
<td>3</td>
<td>77, M</td>
<td>1.5</td>
<td>Paraparesis, hypesthesia, L4, axia, sphincter dysfunction</td>
<td>Stable</td>
</tr>
<tr>
<td>4</td>
<td>60, F</td>
<td>1.5</td>
<td>Paraplegia, hypesthesia disturbances below T10</td>
<td>Improved</td>
</tr>
<tr>
<td>5</td>
<td>68, F</td>
<td>24</td>
<td>Neurogenic claudication &lt;100 m</td>
<td>Improved</td>
</tr>
<tr>
<td>6</td>
<td>77, M</td>
<td>1.5</td>
<td>Paraplegia, hypesthesia below L1, sphincter dysfunction</td>
<td>Stable</td>
</tr>
<tr>
<td>7</td>
<td>64, F</td>
<td>1</td>
<td>Paraparesis, sphincter dysfunction</td>
<td>Improved</td>
</tr>
<tr>
<td>8</td>
<td>83, M</td>
<td>60</td>
<td>Paraparesis, hypesthesia, sphincter dysfunction</td>
<td>Stable</td>
</tr>
<tr>
<td>9</td>
<td>72, M</td>
<td>0</td>
<td>Paraparesis, hypesthesia, sphincter dysfunction</td>
<td>Stable</td>
</tr>
<tr>
<td>10</td>
<td>80, M</td>
<td>12</td>
<td>Paraparesis, sphincter dysfunction</td>
<td>Stable</td>
</tr>
<tr>
<td>11</td>
<td>77, M</td>
<td>2</td>
<td>Paresis of left foot, ataxia</td>
<td>Stable</td>
</tr>
<tr>
<td>12</td>
<td>78, M</td>
<td>3</td>
<td>Paraparesis, hypesthesia</td>
<td>Stable</td>
</tr>
<tr>
<td>13</td>
<td>59, M</td>
<td>5</td>
<td>Ataxia</td>
<td>Stable</td>
</tr>
</tbody>
</table>

**Table 2: Angiomorphologic characteristics of spinal epidural arteriovenous fistulas**

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Arterial Feeder</th>
<th>Origin of Intradural Radicular Drainage Vein</th>
<th>Extension of Epidural Pouch</th>
<th>Extension of Arterialized Perimedullary Veins</th>
<th>Location of Arterialized Perimedullary Veins</th>
<th>No. of DSA until Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>L3 R</td>
<td>L3 L</td>
<td>L3–L4</td>
<td>T8–T12</td>
<td>D = V</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>L3 bilateral, L4 L</td>
<td>L3 L</td>
<td>L2–L4</td>
<td>T3–T12</td>
<td>D = V</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>L1 R</td>
<td>L1 R</td>
<td>L1</td>
<td>ND</td>
<td>D &lt; V</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>L3 bilateral</td>
<td>L3 R</td>
<td>L3</td>
<td>T9–L1</td>
<td>D &gt; V</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>Left iliacolumbar artery</td>
<td>S1</td>
<td>S1</td>
<td>T7–T12</td>
<td>D &gt; V</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>T10 L and T11 L</td>
<td>L2 L</td>
<td>T10–L3</td>
<td>D = V</td>
<td>D = V</td>
<td>3</td>
</tr>
<tr>
<td>7</td>
<td>L1 L</td>
<td>L2 L</td>
<td>L1–L2</td>
<td>T3–T12</td>
<td>D = V</td>
<td>1</td>
</tr>
<tr>
<td>8</td>
<td>T12 L</td>
<td>T12 L</td>
<td>T12 L</td>
<td>T11</td>
<td>D &gt; V</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>L3 L</td>
<td>L3 L</td>
<td>L3</td>
<td>T6–T12</td>
<td>D &lt; V</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>L4 R</td>
<td>L4 R</td>
<td>L2–L4</td>
<td>T3–T10</td>
<td>D = V</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>L3 L</td>
<td>S1 bilateral</td>
<td>L3–S1</td>
<td>T10–L1</td>
<td>D &gt; V</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>L3 R</td>
<td>L3 R</td>
<td>L3 R</td>
<td>T9–T12</td>
<td>D &lt; V</td>
<td>1</td>
</tr>
<tr>
<td>13</td>
<td>L1 R</td>
<td>L1 R</td>
<td>L1 R</td>
<td>T10–L1</td>
<td>D &gt; V</td>
<td>1</td>
</tr>
</tbody>
</table>

Note: —D indicates dorsal to spinal cord; V, ventral to spinal cord; L, left; R, right; ND, no data.

a DSA.

b MRA/DSA.
drainage pattern, and the location of the AV shunt itself, differentiate these SEAVFs from the more frequent SDAVF.8

Concerning the angioarchitecture in SEAVF, the blood supply of the epidural arterial arcade is usually derived from numerous osseous and epidural branches of the segmental arteries with multisegmental and/or collateral anastomoses running along the spinal epidural space.7,11 In contrast, SDAVFs are usually supplied via radiculomeningeal branches of the radicular arteries, which run within the dural sleeve of the respective nerve roots.12

The venous drainage in SEAVF can occur epidurally and transdurally via an intradural radicular drainage vein into the perimedullary venous plexus, in contrast to the venous drainage in classic SDAVF, which occurs exclusively transdurally into the perimedullary venous plexus.2

Concerning the location of the AV shunt, the fistulous zone in all our patients was in the ventral and ventrolateral epidural spaces with variable cranio-caudal extension of the arterialized epidural pouch along several vertebral levels (Fig 1).

In 1 patient, the epidural shunt was even more complex, crossing the midline; multiple compartments of the epidural pouch were filled ventrally as well as the contralateral intradural radicular vein on the same vertebral level (Fig 2).

The frequent ventral/ventrolateral location of the arterialized ventrolateral epidural pouch in a SEAVF could be explained by the rich venous anastomoses of the relatively wide ventral epidural space in the thoracic and lumbar regions.13 The posterior venous plexus is not well-appreciated angiographically and is not regularly involved in any pathologic process.3,14 In contrast to the SEAVF, the AV shunt in a classic SDAVF is usually located within the dural sleeve of the nerve root dorsolaterally in the thoracolumbar region and mainly ventrolaterally in the deep lumbar sacral region.5,15

Nonetheless, the precise pathomechanism of the transdural venous drainage in both SDAVFs and SEAVFs is still unclear.15,16 An anti-reflux-impeding mechanism between both the epidural and perimedullary venous systems has been a matter of dispute in various anatomic studies.12,17-21 Tadié et al17 reported an anti-backflow system within the transdural course of the radicular veins, resulting from narrowing and zigzagging of the vein walls while crossing the dura. Thron et al12 differentiated 2 types of transdural venous courses: a slit-like and a zigzag bulgy type. Both types of transdural venous courses might act as a valve protecting against reflux from the epidural into the coronal venous plexus.10,12 Nonetheless, due to the valveless venous walls of the epidural plexus, it is also conceivable that this anti-reflux mechanism might decompensate under high-pressure conditions and the venous blood could flow in either direction.16,19,21-23 A retrograde filling of radicular veins from the epidural venous plexus has also been observed in a few anatomic studies.10,12,17,19,21-25 Moreover, during spinal DSA s and epidural phlebography, epidural shunts without reflux into the perimedullary veins have been occasionally visualized.15

FIG 1. A, Sagittal T2T-weighted images (3 T; T2-TSE; slice thickness, 3 mm) reveal extensive congestive myelopathy (white arrowhead). B-D, Spinal CE-MRA (3T; time-resolved imaging with stochastic trajectories (TWIST); sagittal MIP; coronal and axial MPR) shows arterialized pouch in the lumbar ventrolateral epidural space (white arrows) in association with arterialized perimedullary veins in the thoracic region (white arrowheads) suspicious for a SEAVF in the lumbar region. E, DSA in lateral projection shows a SEAVF (white arrow) supplied via branches of the left L2 segmental artery (black arrowhead) and drained via the respective intradural radicular vein (white arrowheads). Note the extraspinal venous outlet (asterisk).
On the basis of these observations, one could assume that epidural shunts might occur more frequently than previously thought, but they often remain asymptomatic as long as the transdural anti-reflux mechanism remains intact. An intravenous stasis and/or acute hydrostatic disturbances within these arterialized elongated epidural compartments might reinforce the development of venous thrombosis. This may, in turn, induce acute disruption of the dural anti-reflux mechanisms causing transdural venous drainage and subsequent congestive myelopathy. Supporting this hypothesis, the origin of the arterialized radicular vein in 3 (23%) patients in our series was caudal to the epidural AV shunt (Fig 3).

Clinical Presentation
Due to the extremely low incidence of SEAVFs, clinical presentations of these lesions have been rarely reported systematically in larger sample series. Most patients in our study presented with motor weakness of the lower extremities, sphincter dysfunction, and sensory disturbances (Table 1) at admission. After treatment, clinical symptoms of most patients in our study stabilized or were mildly improved at discharge. This result is in accordance with those in case series reported by Kiyosue et al. and Nasr et al.

Due to the arterialization of the perimedullary venous plexus, several progressive pathophysiologic changes can occur in the spinal cord and its vessels, such as hyalinization, vascular calcification, necrosis, and gliosis, all potential contributors to irreversible functional deterioration of the spinal cord.

One major finding in our current analysis was the relatively rapid clinical course of SEAVFs compared with classic SDAVFs. This might be triggered by acute hemodynamic changes of the venous outflow of the spinal cord caused by thrombosis and/or hydrostatic changes in the epidural and perimedullary venous plexus.

Radiologic Findings
The hallmarks of SEAVFs on MR imaging in our current cohort were the following: 1) congestive thoracolumbar myelopathy with a high rate of conus medullaris involvement, 2) a predominantly nonprominent appearance of the pathologically arterialized perimedullary veins in most cases (75%), and 3) the presence of ventrally/ventrolaterally located arterialized epidural venous pouches detected in 9 of 10 patients with CE-MRA preceding DSA.

The value of CE-MRA in diagnosing an SDAVF has been previously reported by our group. In a series of 19 patients with SDAVFs, the correct localization could be achieved in 14 (74%) patients. In the remaining 5 patients, a mismatch of only 1 vertebral level was noted. Our current findings are supported by...
Mathur et al., who recently observed, in a series of 7 patients with SEAVFs, a high accuracy and reliability of CE-MRA for identification and localization of these lesions.

DSA is, however, still regarded as a basic diagnostic tool for the angiomorphologic, pretherapeutic evaluation in spinal AV fistulas and malformations. In 5 (38%) of 13 patients, even repetitive spinal DSA remained inconclusive and did not sufficiently depict the suspected AV shunt before referral to our center.

Based on our experience, reasons for this failure rate were insufficient opacification of the respective segmental artery based on atherosclerosis and anatomic obstacles and a too-short DSA series, resulting in missing the intradural radicular and/or perimedullary veins. Moreover, 4 of these 5 patients did not undergo spinal CE-MRA initially, which may have facilitated the diagnosis via subsequent DSA.

Spinal angiography offers a dynamic visualization of the angioarchitecture of vascular malformations, including the arterial feeders, the morphology of AV shunts/venous pouches, and the draining veins.

Overall, 12 (92%) fistulas were located in the thoracolumbar region and were supplied by segmental arteries. The remaining (8%) fistula was located in the sacral region and was supplied by branches of the left iliolumbar artery. Also, multisegmental or collateral arterial feeders of the arterialized ventrolateral epidural pouch were present in 3 (23%) of our patients. In contrast, of 196 patients with SDAVFs treated at our center between 1990 and 2017, only 9 (4.6%) fistulas presented with a multisegmental or bilateral arterial supply.

The predominant thoracolumbar location of SEAVFs and the higher rate of multiple arterial feeders of SEAVFs compared with classic SDAVFs could also be explained by the wide epidural space and the rich epidural anastomotic arterial network in this region.

The arterialized epidural pouch extended over several vertebral levels in 6 (46%) patients. The intradural radicular drainage vein in 3 of these 6 patients was distant from the epidural fistulous point. This multisegmental distance between the fistulous feeding artery and the origin of the intradural radicular drainage vein has never been previously observed in any classic SDAVF at our center.

Because the main goal of treatment of SEAVF is the disconnection of the intradural radicular drainage vein as well as the complete interruption of arterialized epidural compartments, the precise localization of the intradural radicular drainage vein in SEAVF is essential to reduce the risk of residual or recurrent fistulas irrespective of the treatment technique and strategy.
spinal cord veins: a microangiographical and morphosurgical study. 

13. Takai K, Taniguchi M. Comparative analysis of spinal extradural arteriovenous fistulas with or without intradural venous drainage: a systematic literature review. 
Neurosurge Focus 2012;32:E8 CrossRef Medline


15. Thron AK. Applications in spinal dural AV fistulas. In: Thron A. Vascular Anatomy of the Spinal Cord: Radioanatomy as the Key to Diagnosis and Treatment. 2nd ed. Cham: Springer International Publishing; 2016

World Neurosurg 2017;103:360–63 CrossRef Medline


18. Merland J, Riche MC, Chiras J. Intraspinal extradural arteriovenous fistulae draining into the medullary veins [in French]. 


Spine 2004;29:1465–71 CrossRef Medline

Clin Anat 2005;18:397–403 CrossRef Medline

22. Clemens HJ, Vogelsang H. Transsosseous phlebography of the vertebral column and spinal canal: morphological and clinical aspects [in German]. 

23. Vogelsang H, Pia HW. Importance of spinal angiography for the diagnosis of spinal angioma [in German]. 
Fortschr Geb Rontgenstr Nuklearmed 1965;102:661–66 Medline

J Neurol 1999;246:181–85 CrossRef Medline

25. Jürgen O. Morphologie des Sperrenmechanismus am Duradurchtritt der Venae Radiculares des Menschen: neuroradiologische und histologische Befunde [doctoral thesis]. Aachen: Faculty of Medicine, RWTH Aachen University; 1990

World Neurosurg 2018;114:e698–705 CrossRef Medline

J Neurosurg Spine 2017;26:613–20 CrossRef Medline

Neurol 1995;45:1309–13 CrossRef Medline


Mod Pathol 2005;18:710–18 CrossRef Medline


REFERENCES


Neurosurg Focus 2009;26:E5 CrossRef Medline


Brain 1974;97:211–18 CrossRef Medline


J Neurosurg Spine 2007;6:552–58 CrossRef Medline


J Neurosurg Spine 2006;5:353–58 CrossRef Medline

Berlin: Springer-Verlag; 1990


Limitations
A major limitation of our study is the small sample size and the retrospective approach. Because spinal epidural arteriovenous fistulas are a very rare but clinically relevant entity, our results may, nevertheless, serve as an orientation for future studies, in particular because there are scarce data concerning this topic in large cohorts in the literature.

CONCLUSIONS
Congestive myelopathy with an acute or subacute clinical course is a dominant finding in SEAVFs. The presence of myelopathic symptoms combined with medullary venous congestion with or without contrast enhancement on MR imaging should require CE-MRA, even in cases of nonprominent perimedullary veins. In SEAVFs, CE-MRA is a powerful noninvasive diagnostic tool to identify the epidural AV shunt itself and detect arterialized perimedullary veins. DSA remains obligatory for the angiomorphologic analysis of the epidural AV shunt, which frequently extends ventrolaterally over several vertebral levels. DSA is mandatory for identifying the origin of the intradural radicular drainage vein that may be located distant from the epidural fistulous point.

32. Thron A. Spinal dural arteriovenous fistulas [in German]. Radiologe 2001;41:955–60 Medline
Facial Venous Malformations Are Associated with Cerebral Developmental Venous Anomalies


ABSTRACT

BACKGROUND AND PURPOSE: A number of studies have demonstrated the existence of segmental vascular disorders affecting soft tissues of the head and neck along with the intracranial vasculature. The purpose of this study was to determine whether there is an association between cerebral developmental venous anomalies and venous malformations of the face, head, and neck.

MATERIALS AND METHODS: A consecutive series of patients with head and neck venous malformations who underwent MR imaging of the brain with postcontrast T1- or T2*-weighted imaging were included. Developmental venous anomaly prevalence in this patient population was compared with an age- and sex-matched control group without venous malformations at a ratio of 1:2. All images were interpreted by 2 neuroradiologists. Data were collected on venous malformation location, developmental venous anomaly location, developmental venous anomaly drainage pattern, and metameric location of venous malformations and developmental venous anomalies. Categoric variables were compared using χ² tests.

RESULTS: Forty-two patients with venous malformations were included. The mean age was 38.1 ± 11.1 years, and 78.6% of patients were female. The prevalence of developmental venous anomalies in this patient population was 28.6%. The control population of 84 patients had a mean age of 40.0 ± 5.9 years, and 78.6% of patients were female. The prevalence of developmental venous anomalies in this patient population was 9.5% (P = .01). In 83.3% of cases, developmental venous anomalies were ipsilateral to the venous malformation, and in 75% of cases, they involved the same metamere.

CONCLUSIONS: Our case-control study demonstrated a significant association between brain developmental venous anomalies and superficial venous malformations. These findings suggest that there may be a similar pathophysiologic origin for these 2 entities.

ABBREVIATIONS: CVMS = Cerebrofacial venous metameric syndrome; DVA = developmental venous anomaly; VM = venous malformation

With increased use of cross-sectional imaging, developmental venous anomalies (DVAs) are discovered more frequently. DVAs consist of dilated intramedullary veins that converge into a larger draining vein, which then drains into either the superficial or deep venous system. Population-based studies have found that up to 10% of the general population has incidental DVAs.¹

While DVAs are generally common, superficial venous vascular malformations of the head and neck are quite rare. Venous malformations (VMs) are slow-flow vascular malformations that manifest as soft-tissue swellings under normal or bluish skin. These lesions are exacerbated by increased central venous pressure such as a Valsalva maneuver. Pathologically, VMs consist of dilated venous channels in the dermis or muscular tissues that usually drain into larger tributaries of the external jugular venous system.²

During the past several years, we have noticed a possible association between the presence of VMs and intracranial DVAs on cross-sectional imaging. This may be a logical association given that the presence of metameric disorders in which patients have vascular malformations involving the brain and soft tissues of the head, face, and neck is well-established.¹ Identification of such an association could also be important because it could provide some insight into the pathogenesis of both of these entities. In order to study the association between DVAs and VMs, we performed a case-control study examining the prevalence of DVAs on MR imaging of a consecutive population of patients with VMs compared to a group of age- and sex-matched controls.
MATERIALS AND METHODS

Patient Population
Following institutional review board approval at Toronto Western Hospital, we queried our data base of >250 patients with VMs for patients who had an MR imaging of the brain including either T2*-weighted imaging and/or postcontrast T1-weighted imaging. VMs were confirmed by a combination of physical examination and imaging-based findings. Imaging criteria for a VM on MR imaging were the following: 1) a septate lobulated T2 hyperintense and T1 hypointense mass without mass effect; 2) phleboliths, which are characteristically hypointense on T1/T2; 3) the presence of fluid-fluid levels; 4) no flow voids on spin-echo sequences; 5) the lesion infiltrating tissue planes; 6) no arterial or early venous enhancement; and 7) diffuse enhancement on delayed images. On clinical examination, VMs appear as faint blue, soft, and easily compressible nonpulsatile masses. The lesions characteristically enlarge with a Valsalva maneuver and in dependent positions and decompress with local compression. Only adult patients with VMs were included in this study because our institution is not a pediatric center. We also selected a group of age- and sex-matched controls (case:control ratio of 1:2) from a data base used to estimate the prevalence of brain DVAs in the general population, which was reviewed by 2 board-certified neuroradiologists. Age matching was performed with an error margin of ±1 year. Thus, a 37-year-old woman could be matched with a 36- to 38-year-old woman.

Imaging Analysis
For the VM population, all images were analyzed by 2 neuroradiologists. Images were reviewed to document the following: 1) the presence or absence of a DVA, 2) the location and side of the DVA if present, and 3) the location and side of the VM. Locations were categorized by metamer as well. The 3 metameres of the craniofacial system include the medial prosencephalic group (olfactory) with involvement of the forehead, nose hypothalamus, corpus callosum, and hypophysis (cerebrofacial venous metameric syndrome [CVMS] 1); the lateral prosencephalic group (optic) with involvement of the temporoparieto-occipital lobes, optic nerve, retina, thalamus, eye, cheek, and maxilla (CVMS 2); and the rhombencephalic/mesencephalon (otic) group with involvement of the cerebellum, brain stem, lower face, mandible, petrous bone, and maxilla (CVMS 3). Statistical Analysis
The primary outcome of this study was the prevalence of DVAs in the VM population and in controls. Prevalence rates were compared using a \( \chi^2 \) test. A Student \( t \) test was used to compare continuous variables. All statistical analyses were performed using JMP 13.0 (SAS Institute, Cary, North Carolina).

RESULTS

Patient Population
Forty-two patients with VMs were included along with 84 controls. In the VM population, the mean age was 38.1 ± 11.1 years, and 78.6% of patients were women (33/42). The control population had a mean age of 40.0 ± 5.9 years, and 78.6% of patients were women (66/84). Among the patients with VMs, 3 patients had bilateral VMs and 39 patients had unilateral facial VMs. Of the patients in the control group, 11 patients underwent MR imaging for evaluation of seizure, 7 patients underwent MR imaging for evaluation of an intracranial mass, and 66 patients underwent MR imaging for other causes, including headache, metastatic disease screening, and other indications such as ruling out ischemia.

DVA Prevalence and Characteristics
Of the 42 patients with VMs, a diagnosis of DVA was made in 12 patients (28.6%). The prevalence of DVAs in the control population was 9.5% (8/84). This difference was statistically significant \( (P = .01) \).

Of the patients with VMs and DVAs, none were men and 12 were women. All 12 had extensive cutaneous VMs. DVAs were unilateral in 8 patients and bilateral in 4 patients. There were 35 DVAs, with 7 patients having multiple DVAs. Thirty DVAs had deep drainage, and 5 had superficial venous drainage. In 23 cases, DVAs were supratentorial, and in 12 cases, they were infratentorial. In 83.3% of cases, DVAs were ipsilateral to the VM, and in 75% of cases, they involved the same metamer. The On-line Table summarizes the characteristics of all patients with VMs with associated DVAs. Case examples are provided in Figs 1–3.

DISCUSSION
Our case-control study examining the prevalence of DVAs in patients with VMs and a group of control patients demonstrated a number of interesting findings. First, the prevalence of DVAs in the VM population was >2 times higher than that in the general population. Most interesting, more often than not, DVAs were located along the same metamer and/or side as the VM. These findings are important because they suggest that there may be a similar pathophysiologic or embryologic basis to both craniofacial VMs and intracranial DVAs.

Prior studies have demonstrated a possible association between DVAs and VMs. However, no case-control studies have been performed to date comparing the prevalence of DVAs in patients with VMs and in a group of patient controls without VMs. In a series of 40 patients who underwent cerebral angiography as part of the evaluation of facial venous vascular malformations, Boukobza et al7 identified 8 patients (20%) with complex DVAs, with most patients having multiple DVAs. Unlike Sturge-Weber Syndrome, these complex DVAs were associated with a normal superficial cortical venous system. Most DVAs were supratentorial and had large flaming venous radicles that drained into a tortuous deep venous system, and most were ipsilateral to the facial VM. One patient had a symptomatic cavernoma that required resection. Overall, the DVA prevalence rate and clinical presentation of these VM-associated DVAs are very similar to those seen in our patient population. A number of additional case reports have been published concerning patients with extensive facial venous malformations and associated ipsilateral DVAs. Such an association hardly appears to be coincidental.2,3,6,8–10

DVAs are thought to form in later periods of cerebral venous development as functional adaptations to thrombosis or failure
of development of superficial or deep veins. It is possible that early postnatal venous occlusion could trigger remodeling of medullary veins, thus resulting in DVA formation. Furthermore, when DVAs become symptomatic, it is invariably due to thrombosis of the collector vein or a venous radicle. Nonetheless, the common final pathway is an error in vascular embryogenesis resulting in occlusion and maldevelopment of normal venous structures in a given part of the brain. To date, there have been no genetic mutations associated with DVA development.

Some authors have postulated that a similar error in vascular embryogenesis (ie, thrombosis resulting in occlusion and maldevelopment) affecting the craniofacial venous vasculature could result in the formation of VMs as well. Like DVAs, VMs generally do not develop de novo or proliferate and spread to other vascular beds in adult life. Most interesting, some authors have suggested that VMs are also thought to form due to a procoagulable state. In a case-control study of patients with and without VMs, Dompmartin et al found that 43% of patients with VMs have an elevated D-dimer level compared with just 4% of patients without VMs. Up to one-third of children with VMs have some form of prothrombotic coagulopathy. In another study, Dompmartin et al found that almost 50% of patients with VMs have local intravascular coagulation, a factor thought to be responsible for VM enlargement and pain. So how can we explain the link between DVAs and extensive facial VMs in a more or less unilateral distribution in this patient population? Given that both VMs and DVAs are associated with some degree of prothrombotic state, we hypothesize that VMs and DVAs may develop due to an increased predilection for local venous thrombosis and occlusion, possibly due to a metameric disorder related to venous endothelial dysfunction.

Our study has both practical implications and implications for future research. First, on the basis of these findings, one might consider a whole-head MR imaging for patients with VMs to evaluate intracranial vascular abnormalities. Two patients had DVA-associated cavernomas, one of which developed de novo and was associated with clinical
and postcontrast imaging are no longer performed at our institution for evaluation of patients with VMs, and often, these imaging studies are performed for evaluation of orbital vascular malformations or in patients with VMs with neurologic symptoms such as headaches. Another limitation is that while all patients in the control group underwent a postcontrast T1-weighted sequence, this was not the case in our patient population with VMs. Postcontrast T1-weighted imaging is more sensitive than T2*-weighted imaging for the detection of smaller DVAs. Thus, we could have underestimated the DVA prevalence in the VM population. On the other hand, it is possible that our study is prone to selection bias because only a subset of patients presented with brain MR imaging. Last, our study is small, including only 42 patients with VMs.

CONCLUSIONS

Our case-control study demonstrated a significant association between DVAs and superficial VMs. More often than not, DVAs were located along a similar metamere or side as the VMs. These findings suggest that there may be a similar pathophysiologic origin for these 2 entities.

REFERENCES


MR Venous Flow in Sigmoid Sinus Diverticulum


ABSTRACT

BACKGROUND AND PURPOSE: Case reports demonstrate that coiling of a sigmoid sinus diverticulum can treat pulsatile tinnitus. We hypothesized that MR imaging 4D flow and computational fluid dynamics would reveal distinct blood flow patterns in the venous outflow tract in these patients.

MATERIALS AND METHODS: Patients with pulsatile tinnitus of suspected venous etiology underwent MR imaging at 3T, using venous phase contrast-enhanced MR angiography, 4D flow, and 2D phase contrast. The contrast-enhanced MRA contours were evaluated to determine the presence and extent of a sigmoid sinus diverticulum. Computational fluid dynamics analysis was performed using the 4D flow inlet flow and the luminal contours from contrast-enhanced MRA as boundary conditions. In addition, computational fluid dynamics was performed for the expected post treatment conditions by smoothing the venous geometry to exclude the sigmoid sinus diverticulum from the anatomic boundary conditions. Streamlines were generated from the 4D flow and computational fluid dynamics velocity maps, and flow patterns were examined for the presence of rotational components.

RESULTS: Twenty-five patients with pulsatile tinnitus of suspected venous etiology and 10 control subjects were enrolled. Five (20%) of the symptomatic subjects had sigmoid sinus diverticula, all associated with an upstream stenosis. In each of these patients, but none of the controls, a stenosis-related flow jet was directed toward the opening of the sigmoid sinus diverticulum with rotational flow patterns in the sigmoid sinus diverticulum and parent sigmoid sinus on both 4D flow and computational fluid dynamics.

CONCLUSIONS: Consistent patterns of blood flow can be visualized in a sigmoid sinus diverticulum and the parent sinus using 4D flow and computational fluid dynamics. Strong components of rotational blood flow were seen in subjects with sigmoid sinus diverticula that were absent in controls.

ABBREVIATIONS: CFD = computational fluid dynamics; 4DF = 4D flow; PT = pulsatile tinnitus; SSD = sigmoid sinus diverticulum; SSIJ = sigmoid sinus and internal jugular vein; UCSF = University of California, San Francisco

Tinnitus is the auditory perception of sound in the absence of an extracorporeal source, which affects millions of Americans. Patients’ lives can be severely impacted by tinnitus, and it is not uncommon for patients to have insomnia, depression, or even suicidal ideations because of their tinnitus. A subset of tinnitus is rhythmic, termed “pulsatile tinnitus” (PT). PT accounts for up to 10% of patients with tinnitus. Some causes of PT are associated with a very high risk of intracranial hemorrhage, stroke, or blindness. Even the more benign causes of PT have a very high association with debilitating comorbid psychiatric disease. Some causes of PT can be treated. In our experience, treating an underlying cause of PT not only alleviates the risks of hemorrhage, stroke, or blindness but can also mitigate the comorbid psychiatric disease. Thus, identifying and treating causes of PT can be very beneficial to patients.

PT may be related to abnormal flow in vascular structures near
the cochlea and is often pulse-synchronous.¹,¹¹ The vascular structures with aberrant flow can be either venous or arterial. Approximately 40% of PT etiologies are venous, approximately 35% are arterial, and in nearly 25%, the cause of PT is never identified.¹³ One of the venous etiologies of PT is a sigmoid sinus diverticulum (SSD). SSD is an outpouching from the sigmoid dural venous sinus that is usually laterally or anteriorly oriented and is often associated with an upstream transverse or sigmoid sinus stenosis.¹,¹³-¹⁶ Altering the flow of venous blood through the SSD and the parent sinus by manual compression of the ipsilateral internal jugular vein is known to mitigate symptoms. Patients report an increase in symptoms in high-flow states such as contralateral internal jugular vein compression, after exercise, or during pregnancy.¹³,¹⁷ Treatment of the offending SSD, which has been reported with both endovascular and open surgical techniques, can resolve PT.¹⁷–²²

However, the exact pattern of blood flow in patients with SSD has not been studied. Two recent approaches provide the ability to explore the flow patterns in complex vascular geometries. One is direct measurement of the velocity field using MR imaging techniques; the other is using a numeric simulation approach to compute the velocity field. Advances in MR imaging have facilitated the visualization of the 3D velocity field of blood flow through the cardiac cycle. We have adapted these techniques for imaging the flow patterns in the transverse sinus, sigmoid sinus, and the internal jugular vein near to and including the jugular bulb (a region of venous sinus anatomy we will refer to as the SSII) using 3T MR imaging.²³–²⁵ Alternatively, with known boundary conditions (ie, the luminal surface and the inlet flow waveform), numeric simulations (computational fluid dynamics [CFD]) can be used to calculate the velocity field. The aim of this study was to apply these techniques to subjects with SSD and evaluate the blood flow patterns in this venous anomaly. We hypothesize that subjects with PT with SSD demonstrate a distinct flow pattern in the SSII and SSD that is absent in control subjects.

MATERIALS AND METHODS
We prospectively performed MR imaging analysis on adult patients with suspected venous etiology of pulsatile tinnitus and control subjects without pulsatile tinnitus using a study protocol approved by our institutional review board. All patients signed written informed consent to participate in this study.

Patient Selection
Patients were recruited from the University of California, San Francisco (UCSF) Pulsatile Tinnitus Clinic. The UCSF Pulsatile Tinnitus Clinic is a multispecialty clinic that evaluates patients with PT. PT was suspected to be of venous etiology if the patient described a low-pitched, pulse-synchronous PT that improved with ipsilateral neck compression and potential arterial (or other) etiologies (such as carotid atherosclerosis, fibromuscular dysplasia, tumor, or dural arteriovenous fistula) were not identified on prior imaging studies. All patients underwent the UCSF Pulsatile Tinnitus Clinic MR imaging and MRA protocol, which included brain MR imaging with fat-saturated postcontrast sequences, time-of-flight MRA of the head, time-resolved contrast-enhanced MRA of the neck through the circle of Willis, and postcontrast spoiled gradient-recalled imaging to evaluate venous sinus anatomy.

Imaging
The imaging protocol used in this study is an adaptation of contrast-enhanced MRA and 4D flow (4DF) described in prior articles.²³–²⁵ High-resolution contrast-enhanced MRA was performed on a 3T Magnetom Skyra scanner (Siemens, Erlangen, Germany). A 3D time-resolved imaging with a stochastic trajectory timing run with a 2-mL gadolinium bolus was used to determine the venous phase of contrast opacification as the point when the contrast first appears in the distal transverse sinus. The full contrast-enhanced MRA study was then performed with a 20-mL injection of gadolinium-based contrast agent at 2 mL/s with an acquisition time of 35 seconds. Images had 0.7-mm isotropic resolution covering an FOV of 280 × 180 mm with an 84-mm-thick slab. Image acquisition used an elliptic centric k-space ordering with the center of k-space synchronized to the venous phase as determined from the timing run. Following acquisition of the MRA, a finger-pulse-triggered 4D MR velocimetry study (4DF) was acquired at a 1.3-mm isotropic resolution and 32-mm slab coverage. Subsequently, 2D phase contrast was acquired in a slice transverse to the vessel in the mid-transverse sinus and proximal to any stenosis if one was present. Phase contrast in-plane resolution was 0.65 × 0.65 mm.

Postprocessing
The contrast-enhanced MRA vein and 4D MR velocimetry datasets were segmented using Clem-volume, an in-house software package. The velocity field, streamlines, path lines, vorticity, and helicity maps were generated from these data using Paraview (Kitware, Clifton Park, New York). In addition, a numeric simulation of the velocity field (ie, a CFD analysis) was performed using the contrast-enhanced MRA for the luminal surface boundary conditions and the inlet flow condition as acquired from the 2D phase contrast study. Several assumptions were made in our CFD analysis, including Newtonian flow, steady flow conditions, pressure of 0 cm H₂O at the outlet of the modeled segment, and rigid walls, as per our previously published method.²⁴ To investigate the effects of an interventional treatment on the velocity field, we altered the geometry to provide a simulated, smooth, and continuous luminal surface that excluded the SSD. Path lines and streamlines were generated from the CFD-predicted velocity field.

Flow Pattern Analysis
The streamlines were extracted and visualized in Paraview, using seed points dispersed throughout the flow domain. As can be seen in the figures, regions of recirculating or vortical flow were identified by visual inspection.

RESULTS
Twenty-five patients with a suspected venous etiology of PT and 10 control subjects without PT were imaged using our protocol. Of the 25, five (20%) had an SSD identified on MRA (Table). Streamlines of the CFD- and 4DF-resolved velocity field images for the 5 patients with SSD and 1 control subject are shown in
**Anatomic characteristics and treatments performed for the identified sigmoid sinus diverticula**

<table>
<thead>
<tr>
<th>Subject</th>
<th>SSD Dimensions (mm)</th>
<th>Neck Maximum Width (mm)</th>
<th>Orientation of Long Axis of SSD</th>
<th>Laterality</th>
<th>Associated Upstream Stenosis</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>6.0 × 2.8 × 3.2</td>
<td>3.2</td>
<td>Lateral</td>
<td>Left</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>2</td>
<td>6.8 × 8.0 × 4.2</td>
<td>3.4</td>
<td>Lateral</td>
<td>Right</td>
<td>Yes</td>
<td>Coiled</td>
</tr>
<tr>
<td>3</td>
<td>7.4 × 5.5 × 6.3</td>
<td>5.1</td>
<td>Anterior</td>
<td>Right</td>
<td>Yes</td>
<td>Surgical resurfacing</td>
</tr>
<tr>
<td>4</td>
<td>8.8 × 5.7 × 8.4</td>
<td>6.4</td>
<td>Anterior</td>
<td>Right</td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td>5</td>
<td>8.3 × 3.9 × 6.9</td>
<td>6.6</td>
<td>Lateral</td>
<td>Right</td>
<td>Yes</td>
<td>None</td>
</tr>
</tbody>
</table>

**Fig 1.** MRA isosurface MIP rendering, CFD-predicted flow fields, and 4D-flow MR imaging from 6 subjects. The first subject is a control subject. The other 5 are subjects clinically suspected of having a venous cause for pulsatile tinnitus who were found to have a sigmoid sinus diverticulum on MRA. The following observations are made in symptomatic subjects with a sigmoid diverticulum: 1) high velocity flow jet in an upstream stenosis in the transverse sinus directed at the SSD opening; 2) a flow jet into the SSD along the long axis of the SSD, either anteriorly or laterally directed; 3) a vortex of flow in the SSD; and 4) a strong vortex component of flow in the sigmoid sinus from the SSD. In the control subject, none of these flow components were present.

**Observations of Blood Flow from 4DF (In Vivo Measurement)**

In vivo measurement of blood flow in the SSIJ revealed some commonalities among patients with SSD: 1) a high-velocity flow jet is demonstrated at the stenosis in the transverse sinus, directed distally at the SSD opening; 2) the flow jet into the SSD is oriented along the long axis of the SSD (either anteriorly or laterally directed); 3) there is a vortical flow in the SSD; 4) a large component of rotational flow is present in the sigmoid sinus downstream from the SSD; and 5) none of these flow features were seen in the SSIJ of control subjects.

**Observations from CFD Flow Analysis**

The flow patterns observed in the CFD analysis were very similar to those identified by 4DF. The flow jets through the stenoses, the vortices of flow in the SSD, and the flow recirculation in the sigmoid sinuses were all comparable between modalities. While the gross flow features were similar, there were some minor differences in the velocity fields resolved by 4DF and CFD in certain locations.

**Observations from Post treatment**

CFD analysis was performed on the expected post treatment geometries lacking SSDs and demonstrated the absence of flow recirculation in the parent sinus. Subject 2 elected to have surgical resurfacing of her SSD, which resulted in resolution of her PT symptoms. This subject subsequently underwent repeat MR imaging evaluation using our protocol. No flow was identified at the site of the prior SSD, and recirculation was no longer present in the parent sinus. The pre- and post treatment 4DF and CFD flow fields based on the pre- and post treatment MRA are shown in Fig 2. The SSD was excluded from the flow domain to simulate resurfacing of the pretreatment sinus geometry, and CFD was performed. For this simulated post-treatment geometry, the flow jet through the stenosis remained unchanged but the vortices in the sigmoid sinus downstream from the diverticulum remained.

**DISCUSSION**

We present a case series of 5 subjects with suspected venous PT and SSD in whom we imaged the anatomy and blood flow of the venous anomaly as well as the parent sinus using contrast-enhanced MRA and 4DF, and we also performed CFD analysis. All SSDs had similar anatomic and flow imaging, consisting of a bulbous outpouching projecting anteriorly or laterally from the sigmoid sinus, with the long axis of the SSD in the direction of a flow jet through the upstream transverse sinus stenosis. This study was an observational analysis that provides an illustration of the ability of imaging and computational methods to visualize complex...
flow patterns present in patients with venous diverticula. To have a clinical impact, inclusion of a broader range of geometrically varying SSDs is needed to provide a definitive link between geometry and flow and subsequently to the manifestation of PT symptoms.

While 4DF has been used fairly extensively in the vasculature, it has found the greatest application on the arterial side. To develop confidence in the 4DF measurement of the velocity field in the tortuous venous anatomy, we also performed numeric simulations of the flow fields using a CFD approach. Both 4DF and CFD demonstrated comparable flow patterns consisting of a flow jet through the stenosis, a vortex of flow in the SSD, and an additional vortex of flow in the parent sigmoid sinus. One case of repeat 4DF and CFD after SSD surgical exclusion, which resulted in cessation of PT, demonstrated an absence of flow in the SSD as well as resolution of the vortex of flow in the sigmoid sinus.

Previous publications have demonstrated the ability to evaluate flow in the SSIJ of patients with pulsatile tinnitus using both in vivo and patient-specific flow models,23 evaluate flow differences in the SSIJ of subjects with and without PT using CFD,24 and provide an overview of the varying flow patterns that can be seen in subjects with PT with different SSIJ anatomies using 4DF.25LEVIT et al26 used patient-specific MR imaging and catheter-obtained pressure measurements to generate CFD models of transverse sinus stenoses. The current work expands on prior articles by systematically reviewing a series of subjects with an anatomic aberration, SSD. In addition, we are the first group to evaluate flow in the dural venous sinuses of patients to establish the boundary conditions for the inlet flow conditions of our CFD analysis. This work also includes pre- and postsurgical evaluation of flow using both 4DF and CFD. In keeping with our group’s prior publications of blood flow evaluation in the cerebral venous structures, we have again identified several interesting flow features in these patients.

The role that these flow patterns, specifically the vortices in the SSD and parent sinus, play in sound generation in patients with SSD and PT is unclear, and in fact, they may play no role at all. It is conceivable that turbulent flow downstream of the stenosis, within the SSD or at the outlet of the SSD, may contribute to sound generation. However, the unique pattern of flow presented in this work has not been previously demonstrated, to our knowledge. Our hope is to eventually use this technique to prospectively identify patients whose PT would be well-treated with surgical or endovascular exclusion of the SSD.

All subjects with SSDs had a concomitant transverse sinus stenosis. Transverse sinus stenosis has also been shown to be a cause of PT, and the high rate of comorbid sinus stenosis and SSD has been previously reported.18,20,22,27-32 The stenosis and subsequent flow jet may cause the SSD, similar to the effects of complex patterns of wall shear stress and spatial wall shear stress gradients previously reported in intracranial bifurcation aneurysms such as at the basilar tip.33,34 Our observation that the long axis of the SSD is coincident with the flow jet from the stenosis would seem to lend credence to this hypothesis; however, the relationship between the entities remains speculative.

To establish the role that geometric features of the diverticulum, such as maximal diameter and neck width, have in defining specific flow patterns such as vortices in the SSD and parent sinus, it will be necessary to expand this study to include a broader spectrum of geometric conditions. Expanding the study will similarly contribute to defining the link between flow patterns and sound generation in patients with SSD and PT. The unique pattern of flow presented in this work has not been previously demonstrated.

It is also unclear whether the stenosis, the SSD, or both are causing patients’ symptoms. Many authors have treated both the stenosis and the diverticulum and reported resolution of symptoms;27,31,32,33 others have treated only the SSD and also reported resolution of symptoms.18,22,28-30 We suspect that sound generation in these patients with PT is multifactorial, and the source of sound generation remains a focus of ongoing research.

All 5 patients with PT found to have an SSD were women. This may be simply a result of the small sample size, though there may be a component of idiopathic intracranial hypertension contributing to the transverse sinus stenosis in these patients, and idiopathic intracranial hypertension is more common in females.35 In fact, subject 5 was found to have idiopathic intracranial hypertension based on standard criteria,36 and her symptoms greatly improved with stent placement in a transverse sinus stenosis, which decreased the pretreatment pressure gradient across the stenosis from 13 to 3 mm Hg.

There are several limitations to our study. Our small sample size limits the extent of the conclusions we can derive. Several assumptions were made in our CFD analysis, including Newtonian flow, steady flow conditions, zero pressure at the outflow, and a noncompliant vessel wall. While Newtonian flow is a reasonable assumption in capacious vessels such as the sigmoid sinus and jugular vein, the flow may be non-Newtonian in transverse–sigmoid junction stenosis. Steady flow conditions have been used in our prior work and have previously captured most flow information with a high degree of fidelity.24 Rigid wall conditions are likely a reasonable assumption in the transverse and sigmoid sinuses, which are encased by the thick dura and bone. However, the validity of this assumption is challenged by known changes in PT with lumbar puncture and removal of CSF, particularly in patients with idiopathic intracranial hypertension.37 In addition,
the jugular vein has a high capacitance and is known to not be a rigid structure. Our models in this work include only the jugular bulb that is, at least partly, bounded by the skull base.

**CONCLUSIONS**

This prospective case series applied 4DF and CFD analysis to patients suspected of having a venous etiology of PT and identified a consistent pattern of blood flow that was absent in controls. The flow pattern consists of a high-velocity jet through a transverse sinus stenosis directed into the SSD, vertical flow in the SSD, and a vortex of flow returning to the sigmoid sinus from the SSD. 4DF and CFD of the post treatment state show resolution of flow in the SSD and resolution of the vortex in the sigmoid sinus. The role the vortices play in sound generation for PT is unclear and remains a subject of future investigation.

Disclosures: Matthew R. Amans—**RELATED**: Grant: National Institutes of Health, Comments: This project was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number B27552C. In addition, the research reported in this publication was supported by the National Institutes of Health under award number R21 DC016087–01A1. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health—**UNRELATED**: Consulting: Covidien, Comments: I have worked as a proctor for Pipeline embolization procedures. The total annual compensation is less than $25,000. David Saloner—**RELATED**: Total annual compensation is less than $25,000. David Saloner—**RELATED**: Disclosures: Matthew R. Amans—**RELATED**: Grant: National Institutes of Health—**UNRELATED**: Grants/Grants Pending: National Institutes of Health, Comments: The National Institutes of Health is funding a grant related to this article. *Money paid to the institution.

**REFERENCES**

33. Meng H, Wang Z, Hoi Y, et al. Complex hemodynamics at the apex of an arterial bifurcation induces vascular remodeling re-
MR Imaging in Menière Disease: Is the Contact between the Vestibular Endolymphatic Space and the Oval Window a Reliable Biomarker?

G. Conte, L. Caschera, S. Calloni, S. Barozzi, F. Di Berardino, D. Zanetti, C. Scuffi, E. Scola, C. Sina, and F. Triulzi

ABSTRACT

BACKGROUND AND PURPOSE: No reliable MR imaging marker for the diagnosis of Menière disease has been reported. Our aim was to investigate whether the obliteration of the inferior portion of the vestibule and the contact with the stapes footplate by the vestibular endolymphatic space are reliable MR imaging markers in the diagnosis of Menière disease.

MATERIALS AND METHODS: We retrospectively enrolled 49 patients, 24 affected by unilateral sudden hearing loss and 25 affected by definite Menière disease, who had undergone a 4-hour delayed 3D-FLAIR sequence. Two readers analyzed the MR images investigating whether the vestibular endolymphatic space bulged in the third inferior portion of the vestibule contacting the stapes footplate. This sign was defined as the vestibular endolymphatic space contacting the oval window.

RESULTS: We analyzed 98 ears: 27 affected by Menière disease, 24 affected by sudden sensorineural hearing loss, and 47 that were healthy. The vestibular endolymphatic space contacting the oval window showed an almost perfect interobserver agreement (Cohen $\kappa = 0.87$, 95% CI, 0.69–1). The vestibular endolymphatic space contacting oval window showed the following: sensitivity = 81%, specificity = 96%, positive predictive value = 88%, and negative predictive value = 93% in differentiating Menière disease ears from other ears. The vestibular endolymphatic space contacting the oval window showed the following: sensitivity = 81%, specificity = 96%, positive predictive value = 96%, negative predictive value = 82% in differentiating Menière disease ears from sudden sensorineural hearing loss ears.

CONCLUSIONS: The vestibular endolymphatic space contacting the oval window has high specificity and positive predictive value in differentiating Menière disease ears from other ears, thus resulting in a valid tool for ruling in Menière disease in patients with mimicking symptoms.

ABBREVIATIONS: AAO-HNS = American Academy of Otolaryngology–Head and Neck Surgery; BLB = blood-labyrinth barrier; CH = cochlear hydrops; HC = healthy control; MD = Menière disease; nMD = normal in a patient with MD; NPV = negative predictive value; PPV = positive predictive value; SSHL = sudden sensorineural hearing loss; VEH = vestibular endolymphatic hydrops; VES = vestibular endolymphatic space; VESCO = vestibular endolymphatic space contacting the oval window.
calculating the ratio of the area of the VES to the entire vestibule (VES/vestibule ratio) in the axial plane and defining VEH as present if this ratio is >33%. More recently, Attié et al.2 have established a morphology-based method: Saccular hydrops is considered when a saccule-to-utricle ratio of ≧1 is present. However, both of these scores seem to lack high accuracy in differentiating MD from other otologic disorders.7

There is an unmet clinical need to understand the role of the contact between the VES and the stapes footplate. Our aim was to investigate whether the obliteration of the inferior portion of the vestibule with the contact between the ES and the stapes footplate is a reliable MR imaging marker in differentiating MD ears from healthy ears and from those affected by other otologic disorders. In addition, we assessed whether the blood-labyrinthine barrier (BLB) breakdown is associated with the presence of symptoms on the MR image.

**MATERIALS AND METHODS**

**Subject Enrollment**

This study was approved by the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico institutional review board; patient informed consent was waived. We retrospectively enrolled consecutive patients affected by unilateral sudden sensorineural hearing loss (SSHL) and uni-/bilateral definite MD, who had undergone MR imaging at our department from July 2016 to January 2018. According to the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) guidelines, SSHL was defined by sensorineural hearing loss of at least 30 decibels over 3 contiguous frequencies occurring within a 72-hour period.8,9 The diagnosis of definite MD fulfilled the criteria of both the Bárány Society and the AAO-HNS. According to the Bárány Society guidelines, definite MD was diagnosed if there was a history of at least 2 consecutive spontaneous episodes of vertigo lasting 20 minutes or longer, tinnitus, or aural fullness and audiometrically documented sensorineural hearing loss of at least 30 dB (or low-to-medium frequency sensorineural hearing loss).4 According to the AAO-HNS, definite MD was diagnosed if there was a history of at least two spontaneous episodes of vertigo lasting 20 minutes to 12 hours; audiometrically documented low-to-medium frequency sensorineural hearing loss in 1 ear, defining the affected ear on at least 1 occasion before, during, or after one of the episodes of vertigo; and fluctuating aural symptoms (hearing, tinnitus, or fullness) in the affected ear, not better accounted for by another vestibular diagnosis.10

Exclusion criteria were the following: a history of neurologic or psychiatric disorders; systemic autoimmune diseases; previous otosurgical procedures; middle ear pathologies; and other causes of sensorineural hearing loss, such as inherited hearing loss, the use of ototoxic drugs, noise trauma, exposure to industrial solvents, labyrinthine fistula, and/or previous episodes of SSHL.

**Audiologic Assessment**

Diagnoses of SSHL and definite MD were made by an otolaryngologist by otomicroscopy, vestibular evaluation, complete audiologic examination by pure-tone audiometry with measurement of air conduction at all octave frequencies between 125 and 8000 Hz and of bone conduction thresholds at 250–4000 Hz, immittance audiometry, speech audiometry, and distortion product otoacoustic emissions. The functional level score of MD was measured on the day of MR imaging for each patient.10 In patients with unilateral SSHL and unilateral MD, the unaffected contralateral ear was defined as the healthy control (HC) and normal in a patient with MD (nMD), respectively, if the audiologic assessment revealed normal hearing, including the presence of distortion product otoacoustic emissions. Thus, after the audiologic assessment, ears could be categorized into 4 types: HC, SSHL, MD, and nMD.

**MR Imaging Acquisition and Image Analysis**

All patients were imaged on a 3T Achieva scanner (Philips Healthcare, Best, the Netherlands) using a 32-channel head coil. The imaging protocol consisted of sequences performed for whole-brain evaluation (axial diffusion-weighted sequence and 3D FLAIR) and specific sequences for temporal bone assessment (Table 1). Contrast-agent (gadoteridol, ProHance; Bracco Diagnostics, Princeton, New Jersey) was administered intravenously at the recommended dose (0.2 mmol/kg). MR imaging acquisition data are listed in Table 1. According to our protocol, all patients with SSHL were scanned within 10 days after onset.

Two observers, a senior neuroradiologist and a radiology resident with 6 years and 6 months of experience in otoradiology, respectively, assessed the delayed 3D-FLAIR images independently and, in a second reading session, in consensus. Multplanar reconstructions were obtained using the local PACS viewer with a slice thickness of 0.33 mm. Image analysis was conducted using 2 oblique planes: parasagittal, parallel to the superior semicircular canal; para-axial, parallel to the lateral semicircular canal (Fig 1). According to our new proposed method, readers had to report when the VES bulged in the third inferior portion of the vestibule, which meant below the para-axial plane at the level of the lateral

---

**Table 1: Scanning parameters (3T)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre- and Postcontrast</th>
<th>Pre- and Postcontrast</th>
<th>3D</th>
<th>Delayed Postcontrast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plane</td>
<td>T1 FSE</td>
<td>3D-FLAIR</td>
<td>T2-SSFP</td>
<td>3D-FLAIR</td>
</tr>
<tr>
<td>TR (ms)</td>
<td>Axial</td>
<td>Axial</td>
<td>Axial</td>
<td>Axial</td>
</tr>
<tr>
<td>TE (ms)</td>
<td>500</td>
<td>6000</td>
<td>1500</td>
<td>7600</td>
</tr>
<tr>
<td>TI (ms)</td>
<td>10</td>
<td>350</td>
<td>194</td>
<td>345</td>
</tr>
<tr>
<td>Flip angle</td>
<td>/</td>
<td>2350</td>
<td>/</td>
<td>2100</td>
</tr>
<tr>
<td>Fat saturation</td>
<td>SPIR</td>
<td>SPIR</td>
<td>/</td>
<td>SPAIR</td>
</tr>
<tr>
<td>TSE factor</td>
<td>3</td>
<td>182</td>
<td>40</td>
<td>100</td>
</tr>
<tr>
<td>Slice thickness (mm)</td>
<td>90°</td>
<td>90°</td>
<td>90°</td>
<td>90°</td>
</tr>
<tr>
<td>Slices (no.)</td>
<td>15</td>
<td>30</td>
<td>22</td>
<td>40</td>
</tr>
<tr>
<td>FOV (mm²)</td>
<td>180 × 160</td>
<td>230 × 190</td>
<td>140 × 140</td>
<td>200 × 255</td>
</tr>
<tr>
<td>Matrix</td>
<td>256 × 205</td>
<td>232 × 229</td>
<td>264 × 248</td>
<td>250 × 252</td>
</tr>
<tr>
<td>Parallel imaging</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Averages</td>
<td>4</td>
<td>6</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>Scan time</td>
<td>2 min 51 sec</td>
<td>10 min 6 sec</td>
<td>6 min 35 sec</td>
<td>9 min 15 sec</td>
</tr>
</tbody>
</table>

**Note:**—SSFP indicates steady-state free precession; SPIR, spectral presaturation with inversion recovery; SPAIR, spectral-tuned inversion recovery; 3D FLAIR, Three dimensionally Fluid Attenuated Inversion Recovery; FSE, Fast spin echo; TR, time of repetition; TE, time of echo; T1, time of inversion; TSE, Turbo Spin-Echo; FOV, field of view; /, specific parameter is not available.
subject, showing the vestibule filled by the perilymph (arrow).

struction parallel to the lateral semicircular canal at the inferior third of the vestibule in a healthy

the perilymph filling the inferior third of the vestibule with preservation of the perilymph signal

was assessed the presence of cochlear hydrops (CH) and VEH according to the classic criteria by Nakashima et al. VEH was defined as “absent” if the ratio was

According to the Nakashima score, VEH (32 mild, 10 severe)

structural space did not exceed the area of the scala vestibuli; and “significant” if the area of the endolymphatic space exceeded the area of the scala vestibuli.

The presence or absence of BLB breakdown of the inner ear structures was also assessed in patients with MD. The BLB breakdown was defined as a higher perilymph gadolinium-enhancement of the inner ear structures compared with the contralateral ones (Fig 3). If the enhancement was symmetric in a subject, BLB breakdown was judged absent.

Statistical Analysis

The interobserver agreement was calculated with the Cohen κ coefficient. The clinical examination was used as a reference standard. Because we performed a per-ear analysis, we calculated the intra-ear correlation coefficient to demonstrate the independence of measurements within a subject. Using the in-consensus reading for VESCO, the Nakashima method, and both combined, we calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) in differentiating MD ears from other ears (HC, nMD, SSHL). The McNemar test was used to compare the sensitivity and specificity between VESCO alone and VESCO combined with CH according to the Nakashima method. We used the Mann-Whitney U test to investigate the association between BLB breakdown and the functional level score in patients with MD. Statistical analysis was performed using SPSS, Version 20.0 (IBM, Armonk, New York). Significance was defined at \( P < .05 \).

RESULTS

We included 24 patients affected by unilateral SSHL (male/female: 11:13; mean age, 54.9 ± 11.7 years) and 25 patients affected by definite MD (male/female: 15:10; mean age, 60.6 ± 18.6 years). There were no significant differences in the mean ages (\( P = .08 \)) or sex (\( P = .48 \)) of the SSHL and MD groups. Twenty-three of 25 patients with MD had unilateral disease (10 right, 13 left), and 2 had bilateral disease. The mean interval of disease duration in the patients with MD was 6.4 years (range, 1–25 years). No MD ears showed an air-bone gap at the audiometric examination. The functional level score at the time of MR imaging was 1 in 7 patients, 2 in 6 patients, 3 in 4 patients, 4 in 3 patients, 5 in 6 patients, and 6 in 1 patient.

We therefore analyzed 98 ears: 27 with MD, 24 with SSHL, 24 HC, and 23 nMDs. VESCO was detected in 22 of 27 MD ears (true-positives), 1 of 24 SSHL ears, 1 of 24 HC ears, and 1 of 23 nMD ears (false-positives). The intraclass correlation coefficient of within-subject ear measurements was 0.07 with a 95% CI, (null-hypothesis intraclass correlation coefficient = 0; \( F(48,48) = 1.16, P = .30 \)). Data on the sensitivity, specificity, PPV, and NPV in differentiating MD ears from other ears are shown in Table 2. The interreader agreement was almost perfect (Cohen κ = 0.867; 95% CI, 0.689–1).

According to the Nakashima score, VEH (32 mild, 10 severe)
was correctly detected in 20 of 27 MD ears (true-positives) and misdiagnosed (in all cases as mild hydrops) in 10 SSHL ears, 4 HC ears, and 8 nMD ears (false-positives). Furthermore, CH was correctly detected in 20 of 27 MD ears (true-positives) and misdiagnosed in 4 SSHL ears, 1 HC ear, and 5 nMD ears (false-positives). Data on the sensitivity, specificity, PPV, and NPV in differentiating MD ears from other ears are shown in Tables 3 and 4.

In Table 5, the comparison between VESCO and VEH and CH according to the Nakashima criteria is reported in patients with MD. VESCO or CH or both were detected in 24 of 27 MD ears and in 11 of 71 other ears (HC, SSHL, nMD). Thus, the presence of at least 1 of these imaging biomarkers did not show a significant difference in terms of sensitivity (89%; 95% CI, 70%–97%; McNemar test, \( P = .50 \)) compared with VESCO alone, but it caused a significant reduction of the specificity (85%; 95% CI, 74%–92%; McNemar test, \( P = .008 \)) in differentiating MD ears from the others.

BLB breakdown was identified in 14 of 23 patients with unilateral MD, always on the side of the affected ear, and in 1 of 2 patients with bilateral MD. The functional level score at the time of the MR imaging study was significantly higher in patients with BLB breakdown (\( P = .03 \)).

**DISCUSSION**

Our study showed that VESCO alone has high specificity (96%) and PPV (88%) in differentiating MD ears from other ears. On the contrary, the combined evaluation of VESCO and CH according to the Nakashima method resulted in a significant reduction of the specificity (85%; McNemar test, \( P = .008 \)), without a significant advantage in terms of sensitivity (89%; McNemar test, \( P = .50 \)). These results suggest that VESCO could be used to confirm MD after clinical examination. However, the good but not excellent sensitivity of VESCO (81%) prevents radiologists from using it as biomarker to definitively rule out MD.

Most studies published on MR imaging of MD used the Nakashima score to identify VEH and CH, but this method showed low specificity in the diagnosis...
of MD, resulting in poor utility in clinical practice. The main limitations of this method are the following: 1) the conspicuity of the endolymphatic space depends on the MR image parameters such as TI, making results from different imaging centers less comparable; and 2) the endolymphatic space is a volume, with extreme variability in morphology; therefore, the evaluation of its expansion simply on a single axial plane is not a suitable method to obtain a reliable estimate of the hydrops state.

However, MR imaging evidence from the literature using the Nakashima score is in line with the pathologic findings that have been described in cadavers, suggesting that CH and VEH are not exclusive findings in patients with MD and are probably not always pathologic. Thus, the ambitious objective for radiologists is to determine a method to distinguish clinically relevant hydrops. We support the idea that morphology-based imaging methods, such as ours, can be more accurate than quantitative-based ones, such as ours: We used a parasagittal plane parallel to the lateral semicircular canal, which does not correspond to the parasagittal plane along the long axial axis of the vestibule as represented by these authors. Recently, some authors reported that patients with significant VEH adjacent to the saccule-to-utricle ratio showed higher average air-bone gaps at 250 Hz compared with patients with nonadjacent significant VEH.

In contrast, we did not find air-bone gaps in our patients with MD. First, audiograms of patients with MD showed unexplained air-bone gaps at low frequencies from 13% to 32% in the literature, even though no middle ear pathology could be demonstrated. In addition, some methodologic differences between our study and the aforementioned study should be stated to understand why the results are in disagreement. The authors of this study enrolled not only patients with MD (66% of the total) but also patients with other otologic disorders who presented with severe hydrops according to the Nakashima score. As evidenced by our results, severe hydrops was found only in 9/22 (41%) patients with MD with VESCO. According to these observations, the populations of the studies are not comparable. In addition, the authors used "HYDROPS" imaging, performed by subtracting the positive endolymph images from the positive perilymph images. This type of postprocessing transformation can alter the MR imaging anatomy of the endolymphatic space by inducing researchers to incorrectly locate the endolymph liquid within the inner ear structures for problems of registration between the 2 MR images. This limitation could be more relevant when CH is adjacent to the footplate, which is surely different from ours: We used a parasagittal plane parallel to the lateral semicircular canal, which does not correspond to the parasagittal plane along the long axial axis of the vestibule.

We support the idea that morphology-based imaging methods, such as ours, can be more accurate than quantitative-based ones, such as ours: We used a parasagittal plane parallel to the lateral semicircular canal, which does not correspond to the parasagittal plane along the long axial axis of the vestibule as represented by these authors. Recently, some authors reported that patients with significant VEH adjacent to the saccule-to-utricle ratio showed higher average air-bone gaps at 250 Hz compared with patients with nonadjacent significant VEH.

Table 3: Vestibular endolymphatic hydrops according to Nakashima grading

<table>
<thead>
<tr>
<th>Comparison</th>
<th>SE (%) (95% CI)</th>
<th>SP (%) (95% CI)</th>
<th>PPV (%) (95% CI)</th>
<th>NPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic MD vs asymptomatic MD</td>
<td>74 (53–88)</td>
<td>65 (43–83)</td>
<td>71 (51–86)</td>
<td>68 (45–85)</td>
</tr>
<tr>
<td>Symptomatic MD vs healthy</td>
<td>74 (53–88)</td>
<td>83 (62–95)</td>
<td>83 (62–95)</td>
<td>74 (53–88)</td>
</tr>
<tr>
<td>Symptomatic MD vs SSHL</td>
<td>74 (53–88)</td>
<td>58 (37–77)</td>
<td>67 (47–82)</td>
<td>67 (43–85)</td>
</tr>
<tr>
<td>Symptomatic MD vs other</td>
<td>74 (53–88)</td>
<td>69 (57–79)</td>
<td>48 (32–63)</td>
<td>88 (75–94)</td>
</tr>
</tbody>
</table>

Note: SE indicates sensitivity; SP, specificity.

Table 4: Cochlear hydrops according to Nakashima grading

<table>
<thead>
<tr>
<th>Comparison</th>
<th>SE (%) (95% CI)</th>
<th>SP (%) (95% CI)</th>
<th>PPV (%) (95% CI)</th>
<th>NPV (%) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptomatic MD vs asymptomatic MD</td>
<td>74 (53–88)</td>
<td>78 (56–92)</td>
<td>80 (59–92)</td>
<td>72 (50–87)</td>
</tr>
<tr>
<td>Symptomatic MD vs healthy</td>
<td>74 (53–88)</td>
<td>96 (77–100)</td>
<td>95 (74–100)</td>
<td>77 (57–89)</td>
</tr>
<tr>
<td>Symptomatic MD vs SSHL</td>
<td>74 (53–88)</td>
<td>83 (62–95)</td>
<td>83 (62–95)</td>
<td>74 (53–88)</td>
</tr>
<tr>
<td>Symptomatic MD vs other</td>
<td>74 (53–88)</td>
<td>86 (75–93)</td>
<td>67 (47–82)</td>
<td>90 (79–95)</td>
</tr>
</tbody>
</table>

Note: SE indicates sensitivity; SP, specificity.

Table 5: Presence of VESCO versus VEH and CH according to the Nakashima criteria in patients with MD

<table>
<thead>
<tr>
<th>VESCO</th>
<th>VEH</th>
<th>CH</th>
</tr>
</thead>
<tbody>
<tr>
<td>VESCO</td>
<td>No</td>
<td>Mild</td>
</tr>
<tr>
<td>No (n = 7)</td>
<td>2 (40%)</td>
<td>3 (60%)</td>
</tr>
<tr>
<td>Yes (n = 22)</td>
<td>2 (23%)</td>
<td>8 (36%)</td>
</tr>
<tr>
<td>VESCO</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>No (n = 5)</td>
<td>3 (60%)</td>
<td>2 (40%)</td>
</tr>
<tr>
<td>Yes (n = 20)</td>
<td>4 (18%)</td>
<td>18 (82%)</td>
</tr>
</tbody>
</table>
matory pathology similar to that proposed as causative in autoimmune inner ear disease.\textsuperscript{17}

Some limitations of our study should be acknowledged. Our standard reference for the definition of MD was clinical instead of histopathologic. Furthermore, while enrolling only patients with definite MD, we did not test the accuracy of VESCO in those clinical conditions, such as possible or probable MD or MD-mimicking disorders, which represent the true diagnostic challenges in clinical practice. Thus, the reported specificity of VESCO could be overestimated. For example, is VESCO accurate in early differentiate recurrent peripheral vestibulopathy from MD? Future studies should therefore aim to answer this question using clinical follow-up or histology as a reference standard. Because in SSHL we performed MR imaging within 10 days after the onset of the pathology, we cannot exclude the possibility that these patients could develop late vestibular hydrops and that VESCO could be detected in them later.

We did not correlate imaging results with audiometric tests, the duration of MD, or vestibular-evoked myogenic potentials. In particular, the vestibular-evoked myogenic potentials are a reliable tool for the investigation of saccular function\textsuperscript{18}; thus, they can elucidate the role of the saccule in the definition of VESCO, considering that in our opinion, it is impossible to clearly delineate the saccule from the other endolymphatic structures when marked hydrops is present. Some technical aspects in the imaging acquisition could have influenced our results; a recent study has shown that it is easy to shift from the normal condition to VEH disease simply by varying the TI sequence by 100 ms.\textsuperscript{19} The same group of researchers suggested that different contrast agents can provide different anatomic details regarding endolymphatic space and the semicircular canals.\textsuperscript{19}

CONCLUSIONS

VESCO is a promising MR imaging biomarker for MD and BLB breakdown, as depicted by the enhancement on MR imaging, to identify patients with higher functional levels probably due to florid inflammatory activity within the inner ear structures.

Disclosures: Diego Zanetti—UNRELATED: Payment for Lectures Including Service on Speakers Bureau: Advanced Bionics, Staefa [Switzerland], Comments: honorarium and travel expenses for lecturing at an international course on cochlear implants, Hannover, Germany 2017.

REFERENCES

Corticopallidal Connectome of the Globus Pallidus Externus in Humans: An Exploratory Study of Structural Connectivity Using Probabilistic Diffusion Tractography

S.S. Grewal, V.M. Holanda, and E.H. Middlebrooks

ABSTRACT

BACKGROUND AND PURPOSE: Electrophysiologic abnormalities of the globus pallidus externus have been shown in several disease processes including Parkinson disease, dystonia, and Huntington disease. However, the connectivity, nuclear structure, and function of the globus pallidus externus are still not well-understood. Increasing evidence for the existence of direct corticopallidal connections challenges traditional understanding of the connectivity of the globus pallidus externus; nevertheless, these corticopallidal connections have yet to be fully characterized in humans. The objective of this study was to assess the corticopallidal connections of the globus pallidus externus by means of probabilistic diffusion-weighted MR imaging tractography using high-resolution, multishell data.

MATERIALS AND METHODS: Imaging data from the open-access Human Connectome Project database were used to perform probabilistic tractography between the globus pallidus externus and the cerebral cortex using 34 distinct cortical regions. Group averages were calculated for normalized percentages of tracts reaching each of the cortical targets, and side-to-side comparison was made.

RESULTS: Cortical connectivity was demonstrated between the globus pallidus externus and multiple cortical regions, including direct connection to putative sensorimotor, associative, and limbic areas. Connectivity patterns were not significantly different between the right and left hemispheres with the exception of the frontal pole, which showed a greater number of connections on the right (P = .004).

CONCLUSIONS: Our in vivo study of the human globus pallidus externus using probabilistic tractography supports the existence of extensive corticopallidal connections and a tripartite functional division, as found in animal studies. A better understanding of the connectivity of the globus pallidus externus may help to understand its function and elucidate the effects of programming the higher contacts in pallidal deep brain stimulation.

ABBREVIATIONS: DBS = deep brain stimulation; GPe = globus pallidus externus

The globus pallidus externus (GPe) is the lateral component of the globus pallidus known to have extensive connections with other basal ganglia nuclei. Traditionally thought to primarily function in motor control, more recent evidence has challenged this belief, showing additional function in associative and limbic processes. GPe dysfunction has been shown in several disease processes, including a decreased spontaneous discharge rate in Parkinson disease and dystonia and an increased spontaneous discharge rate in Huntington disease. These findings suggest an important role of the GPe in the pathophysiology of several disease processes and a potential clinical relevance.

In 2003, Silberstein et al showed that the local field potentials recorded in the globus pallidus externus in patients who underwent deep brain stimulation (DBS) were greater in patients with Parkinson disease (11–30 Hz) than in those with dystonia (4–10 Hz). This finding indicated the importance of understanding the GPe connections to help in elucidating the mechanistic basis of DBS when treating these diseases. Fifteen years later, the connectivity, nuclear structure, and function of the GPe are still not well-understood.

Traditionally, the basal ganglia circuitry has been thought to involve 2 pathways, a “direct” and an “indirect” pathway, with the striatum being the main input source for cortical efferents. Nevertheless, this model was challenged with the postulation of a “hyperdirect” pathway, connecting the subthalamic nucleus to
the cortex. Subsequently, there was increasing work in both animal and in vivo human models highlighting the existence of direct corticopallidal connections; however, these corticopallidal connections specific to the globus pallidus externus have yet to be fully characterized in humans. The objective of this study was to access corticopallidal connections of the GPe by means of probabilistic diffusion-weighted MR imaging tractography, using high-resolution, multishell data.

**MATERIALS AND METHODS**

**Data Acquisition**

Imaging data from the open-access Human Connectome Project data base were used (https://www.humanconnectome.org). Twenty healthy subjects were consecutively selected from the data base. Full imaging acquisition details are freely available at the Human Connectome Project data base Web site (https://www.humanconnectome.org), but briefly, the imaging was obtained using a modified 3T Magnetom Skyra scanner (Siemens, Erlanger, Germany). The multidirection diffusion-weighted imaging used a spin-echo EPI sequence with an isotropic resolution of 1.25 mm$^3$. Diffusion b-values were acquired at 1000, 2000, and 3000 s/mm$^2$ in 90 diffusion directions for each shell. A multiband factor of 3 with 6/8 phase partial Fourier was used, and 111 axial slices were obtained with no gap. The parameters were the following: TR = 5520 ms, TE = 89.5 ms, flip angle = 89°. Images were obtained in both the left-to-right and right-to-left phase-encoding directions. Total imaging time for the diffusion data was 59 minutes. The T1-weighted 3D MPRAGE structural scan used an isotropic resolution of 0.7 mm$^3$. Additional acquisition parameters included the following: TR = 2400 ms, TE = 2.14 ms, TI = 1000 ms, flip angle = 8°, generalized autocalibrating partially parallel acquisition = 2, and bandwidth = 210 Hz/Px for an acquisition time of 7 minutes and 40 seconds.

Preprocessing of the diffusion data included realignment, B$_0$ image-intensity normalization, EPI distortion correction with the FSL Topup algorithm (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/topup), gradient nonlinearity correction, and eddy current correction.

The diffusion data were co-registered to the structural MPRAGE images using a boundary-based registration method (BBR) implemented in the FMRIB Linear Registration Tool (FLIRT; http://www.fmrib.ox.ac.uk/fslwiki/FLIRT) followed by the “bregister” function in FreeSurfer (https://surfer.nmr.mgh.harvard.edu). All preprocessing steps used standard options as detailed in the Human Connectome Project data base preprocessing pipeline.

**Data Processing**

Segmentation of the MPRAGE data was performed with FreeSurfer (https://surfer.nmr.mgh.harvard.edu). The left and right cerebral cortices were segmented into 34 distinct volumes of interest in FreeSurfer based on the Desikan-Killiany cortical atlas using the FreeSurfer mri_label2vol function. VOIs were also generated of the right and left GPe in the Montreal Neurological Institute template space from the Montreal Neurological Institute Basal Ganglia Human Area Template. The GPe VOIs were then transformed from Montreal Neurological Institute space to FreeSurfer space using a linear registration implemented in FSL FLIRT.

Voxel-wise diffusion parameters were estimated via a Markov Chain Monte Carlo sampling implemented in FSL bedpost (http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT/UserGuide#BEDPOSTX). A multifiber approach (2 fiber orientations) was used along with a multishell model. Next, probabilistic tractography was performed using the FSL protrackx2 function (https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FDT/UserGuide) with the network option to estimate the connectivity between each GPe VOI and the 34 ipsilateral cortical targets. Standard tracking parameters include a 0.2 curvature threshold, 2000 steps per sample, a step length of 0.5 mm, and 5000 samples per side.

**Data Analysis**

For each subject, the weighted connectivity was calculated between each of the 34 cortical ROIs and the ipsilateral GPe ROI by means of bidirectional fiber tracking between the GPe ROIs and each cortical target ROI. Because the distance traveled has a positive correlation with fiber-tract uncertainty, the tracts were normalized by the distance traveled, as implemented in FSL protrackx2. To account for potential tracking bias due to variable sizes of the ROIs, we normalized the connectivity matrix by the surface area of the ROIs according to the method proposed by Hagmann et al. The number of paths was normalized among all patients by dividing the total number of paths by the waytotal for each subject to facilitate between-subject comparison. Group averages were calculated for normalized percentages of tracts reaching each of the cortical targets. In an attempt to account for false fibers generated by probabilistic tractography, a normalized fiber threshold level was set to exclude all target VOIs. Appropriate threshold levels remain a point of contention in the literature; therefore, we have selected a probabilistic threshold that is in the range of that used in prior studies of $\geq$2% of the total (98% confidence level) in either hemisphere. The VOIs exceeding the threshold were used to generate a connectogram for both the left and right GPe in Matlab 9.1 (MathWorks, Natick, Massachusetts). Last, differences between the connectivity profile of the left and right GPe were assessed for each cortical target in GraphPad Prism 7.0 software (GraphPad Software, San Diego, California) by means of a Mann-Whitney U test to account for non-normality in distribution.

**RESULTS**

Of the 34 cortical targets evaluated (Table), 17 exceeded the fiber count threshold on either side (Figure). The right GPe exhibited maximal cortical connectivity to the frontal pole (14.4% $\pm$ 9.4%), and the left GPe had maximal cortical connectivity to the temporal pole (10.5% $\pm$ 8.0%). The greatest difference in the connectivity profile between sides was related to the frontal pole (14.4% $\pm$ 9.4% on the right and 7.7% $\pm$ 5.4% on the left), insula (11.0% $\pm$ 4.2% on the right and 8.5% $\pm$ 4.6% on the left), and entorhinal cortex (5.1% $\pm$ 4.4% on the right and 7.4% $\pm$ 6.6% on the left). The side-to-side variation was also only significant for the frontal pole ($P = .004$). The remaining targets showed no significant variation between sides ($P > .05$).
Cortical ROIs meeting the tract threshold for connectivity to the globus pallidus externus for both hemispheres

<table>
<thead>
<tr>
<th>Cortical Region</th>
<th>Right Hemisphere (% Tract Probability (SD))</th>
<th>Left Hemisphere (% Tract Probability (SD))</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frontal pole</td>
<td>14.4% (9.4%)</td>
<td>7.7% (5.4%)</td>
<td>.004</td>
</tr>
<tr>
<td>Insula</td>
<td>11.0% (4.2%)</td>
<td>8.5% (4.6%)</td>
<td>.1</td>
</tr>
<tr>
<td>Temporal pole</td>
<td>9.2% (7.7%)</td>
<td>10.5% (8.0%)</td>
<td>.49</td>
</tr>
<tr>
<td>Medial orbitofrontal</td>
<td>6.7% (5.9%)</td>
<td>8.3% (4.9%)</td>
<td>.21</td>
</tr>
<tr>
<td>Entorhinal</td>
<td>5.1% (4.4%)</td>
<td>7.4% (6.6%)</td>
<td>.22</td>
</tr>
<tr>
<td>Superior frontal</td>
<td>4.3% (3.5%)</td>
<td>4.8% (3.2%)</td>
<td>.56</td>
</tr>
<tr>
<td>Pars orbitals</td>
<td>3.8% (2.6%)</td>
<td>3.2% (2.6%)</td>
<td>.4</td>
</tr>
<tr>
<td>Lateral orbitofrontal</td>
<td>3.8% (3.9%)</td>
<td>4.1% (3.9%)</td>
<td>.72</td>
</tr>
<tr>
<td>Paracentral</td>
<td>3.4% (2.9%)</td>
<td>3.9% (2.9%)</td>
<td>.5</td>
</tr>
<tr>
<td>Postcentral</td>
<td>3.2% (2.2%)</td>
<td>4.3% (2.2%)</td>
<td>.1</td>
</tr>
<tr>
<td>Pars triangularis</td>
<td>3.1% (4.1%)</td>
<td>3.2% (3.7%)</td>
<td>.96</td>
</tr>
<tr>
<td>Precentral</td>
<td>2.9% (1.9%)</td>
<td>4.4% (2.5%)</td>
<td>.07</td>
</tr>
<tr>
<td>Rostral anterior cingulate</td>
<td>2.7% (2.8%)</td>
<td>1.2% (1.2%)</td>
<td>.06</td>
</tr>
<tr>
<td>Superior parietal</td>
<td>2.3% (1.3%)</td>
<td>2.9% (1.2%)</td>
<td>.1</td>
</tr>
<tr>
<td>Rostral middle frontal</td>
<td>2.3% (1.4%)</td>
<td>2.0% (1.2%)</td>
<td>.83</td>
</tr>
<tr>
<td>Isthmus cingulate</td>
<td>2.2% (1.2%)</td>
<td>3.5% (3.2%)</td>
<td>.27</td>
</tr>
<tr>
<td>Parahippocampal</td>
<td>1.4% (1.2%)</td>
<td>2.1% (1.5%)</td>
<td>.12</td>
</tr>
</tbody>
</table>

*The P value is reported for left-to-right tract comparison.*

**DISCUSSION**

Our probabilistic tractography study highlights the potential widespread direct cortical connectivity of the GPe. As predicted from prior animal functional studies, direct cortical connections were found between the GPe and areas functioning in sensorimotor, associative, and limbic tasks. These direct corticopallidal connections challenge the traditional hypotheses regarding the GPe as merely a subcortical relay within the indirect pathway of the basal ganglia. Initial descriptions of basal ganglia connectivity were largely based on the work of DeLong and Albin et al, elucidated through a combination of both immunohistochemistry and in situ hybridization techniques. These models defined 2 corticofugal networks, a direct and indirect pathway of basal ganglia circuitry, and considered the dorsal striatum as the main input area for cortical efferent neurons to these pathways. More recently, a third network, a hyperdirect pathway, has been discovered in which glutamatergic cortical efferents synapse directly on the subthalamic nucleus. The existence of this hyperdirect pathway challenged the traditional hypotheses of basal ganglia connectivity. Indeed, evidence has mounted for additional subpopulations of efferent neurons with direct cortical connection to basal ganglia nuclei outside the dorsal striatum, including the GPe.

Direct cortical connection to the GPe was described as early as 1977 in primates. It was again described in an anterograde tracing study in rodents, linking the precentral cortex of rodents to the GPe. Additional studies have also described both cholinergic and GABAergic neurons within the GPe, sending direct efferent connections to the cortex. One in vivo human study used constrained spherical deconvolution to assess the existence of a corticopallidal network with connections from the GP to Brodmann areas 2, 11, 46, 48, 6, 4, and 5; however, distribution of fiber densities between areas was not assessed. Using a similar technique, Cacciola et al described 2 separate corticopallidal networks: an anatomic pallidal-temporal network involving the hippocampus and amygdala and a sensorimotor-pallidal network mainly involving the precentral, postcentral, and paracentral gyri, in addition to higher order functional areas, such as the superior frontal gyrus. Unfortunately, due to grouping the GPe and globus pallidus internus as 1 ROI (pallidum), it is uncertain how the GPe and globus pallidus internus connectivity profiles differ. Our current study clarifies the distribution and density of corticopallidal connections specifically to the GPe.

The GPe is classically considered as part of the indirect pathway and extensively connected to deep brain structures. Animal studies of bicuculline injections into various regions of the GPe have elicited behavioral disturbances that can be functionally segmented into 3 zones: the ventrolateral “sensorimotor territory,” the middle “associative territory,” and the anterior ventral “limbic territory.” To assess the potential role of direct corticopallidal connections in these functional areas, prior studies used rabies virus injections to trace these potential connections. An injection into the limbic GPe labeled areas with known cortical projections: the rostromedial prefrontal cortex, insula, and orbitofrontal cortex, among others. Injection in the associative GPe labeled areas with known cortical projections to the supplementary motor area and pre-supplementary motor area as well as the associative parietal, motor, and premotor cortices. Finally, injection into the sensorimotor GPe labeled areas with known cortical projections to the premotor, primary motor, and somatosensory cortices.

In line with these animal studies, we were able to illustrate GPe direct cortical connectivity to similar putative associative, sensorimotor, and limbic areas. Direct cortical connections corresponding to the limbic GPe include the rostral middle frontal region (presumed dorsolateral prefrontal cortex), entorhinal cortex, parahippocampal gyrus, isthmus of the cingulate cortex, insula, and orbitofrontal cortex. Likewise, associative connections to the supplementary motor area/pre-supplementary motor area regions, superior parietal cortex, primary motor cortex, and premotor cortex were found. Last, as suggested by the sensorimotor function, we found corticopallidal connections between the GPe and the premotor, primary motor, and somatosensory cortices.

Animal studies have revealed attention deficits and hyperactivity induced by regional damage to the GPe, raising the possibility of a GPe role in the symptoms of attention deficit/hyperactivity disorder. The symptomatology of attention deficit/hyperactivity disorder would suggest dysfunction in attention processing as well as motor planning. Although the role of the frontal pole is not well-understood, it has been implicated in the process of managing multiple cognitive tasks and attention. Spatial attention has also been attributed to function within the premotor and dorsolateral prefrontal cortices. Additionally, the rostral cingulate and supplementary motor area, both showing GPe connectivity in our study, have been implicated in the hyperactive symptoms seen in attention deficit/hyperactivity dis-
order. Taken together, the connectivity between the GPe and these cortical regions in our study would corroborate the attention and hyperactivity symptoms elicited in animal studies of the GPe.

Animal studies have also implicated the GPe in movement symptoms, such as dyskinesia, as well as stereotyped behavioral symptoms. Although they are not fully understood, it has been suggested that the ventral pallidum and striatal projections to the orbitofrontal cortex, insula, anterior cingulate, and amygdalohippocampal complex (regions functioning in the processing of motivation and emotion) may facilitate such behavioral symptoms. In addition to these known projections from other portions of the striatum, our study suggests the existence of direct corticopallidal connections originating from the GPe to similar regions, which could also contribute to the behaviors observed in obsessive-compulsive disorder and Tourette syndrome. Support that these symptoms are also mediated through the GPe includes reports that pallidal lesions can result in obsessive-compulsive-type behavior. Additionally, DBS of the GPe has been shown to reduce tics in patients with Tourette syndrome.

Broad connectivity of the GPe to primary and secondary sensorimotor regions, including the superior frontal, precentral, and postcentral gyri may play an additional role in mediating symptoms of movement disorders, such as Parkinson disease, Huntington disease, and dystonia. In fact, DBS of the GPe has been shown as a potential treatment for both Parkinson disease and dystonia. Whether these treatment effects are, in part, mediated by direct corticopallidal connectivity remains to be determined, but they could potentially provide an additional treatment targeting for these debilitating conditions.

FIGURE. Connectogram showing the connectivity profile for the right and left globus pallidus externus. Lines are weighted by tract count.
In summary, the connectivity and function of the GPe are not as well-understood compared with other components of the basal ganglia. Current evidence supports a role of the GPe in limbic, associative, and sensorimotor processes. Animal tracer studies have demonstrated connectivity of the GPe to additional sites in the basal ganglia that have secondary cortical connections to areas of matching function; however, we were also able to demonstrate primary connections to similar cortical areas from cortico-pallidal fibers. A more complete understanding of the function of the GPe may help shed light on its role in pathologic conditions, including Parkinson disease, Huntington disease, obsessive-compulsive disorder, attention deficit/hyperactivity disorder, and dystonia. In the future, the knowledge of connectivity beyond the motor network may also reveal a role of the GPe in other disorders of the limbic and associative networks.

Several limitations of this study are noteworthy. Firstly, limitations of diffusion-based tractography itself include the inability to determine the directionality (afferent-efferent) of fiber tracts, the limited resolution of crossing fibers, and the potential for “false fibers.” Probabilistic tractography is a more sensitive and robust method compared with deterministic tractography; however, probabilistic tractography is associated with a higher incidence of false fiber detection. Additionally, the selection of thresholds for fiber tract probabilities has pitfalls. For instance, a very small bundle of true fibers may be rejected as a statistical error simply due to the small number of fibers, effectively biasing the results to larger fiber bundles. Second, the diffusion-based tractography method is unable to directly provide any functional information regarding the fiber tracts; therefore, the function of the identified tracts is merely speculative. Nevertheless, the anatomic connectivity illustrated in our study is well-aligned with functional deficits identified in prior animal studies.

CONCLUSIONS

Our in vivo study of the human GPe using probabilistic tractography supports the existence of extensive corticopallidal connections. Direct cortical connections to putative sensorimotor, associative, and limbic areas support this tripartite functional division found in animal studies. A better understanding of the connectivity of the GPe may help to understand its function and elucidate the effects of programming the higher contacts in pallidal DBS. Further electrophysiologic studies are needed to investigate the significance of these connections and their ultimate role in basal ganglia circuitry.

REFERENCES

44. Singh-Bains MK, Waldvogel HJ, Faull RL. The role of the human globus pallidus in Huntington’s disease. *Brain Pathol* 2016;26;741–51 CrossRef Medline
Expanding the Distinctive Neuroimaging Phenotype of ACTA2 Mutations


ABSTRACT

BACKGROUND AND PURPOSE: Arg179His mutations in ACTA2 are associated with a distinctive neurovascular phenotype characterized by a straight course of intracranial arteries, absent basal Moyamoya collaterals, dilation of the proximal internal carotid arteries, and occlusive disease of the terminal internal carotid arteries. We now add to the distinctive neuroimaging features in these patients by describing their unique constellation of brain malformative findings that could flag the diagnosis in cases in which targeted cerebrovascular imaging has not been performed.

MATERIALS AND METHODS: Neuroimaging studies from 13 patients with heterozygous Arg179His mutations in ACTA2 and 1 patient with pathognomonic clinicoradiologic findings for ACTA2 mutation were retrospectively reviewed. The presence and localization of brain malformations and other abnormal brain MR imaging findings are reported.

RESULTS: Characteristics bending and hypoplasia of the anterior corpus callosum, apparent absence of the anterior gyrus cinguli, and radial frontal gyration were present in 100% of the patients; flattening of the pons on the midline and multiple indentations in the lateral surface of the pons were demonstrated in 93% of the patients; and apparent “squeezing” of the cerebral peduncles in 85% of the patients.

CONCLUSIONS: Because α-actin is not expressed in the brain parenchyma, only in vascular tissue, we speculate that rather than a true malformative process, these findings represent a deformation of the brain during development related to the mechanical interaction with rigid arteries during the embryogenesis.

The cerebral arteriopathy associated with Arg179His mutations in ACTA2 is a prototypical example of nonatherosclerotic cerebral arteriopathies, some of which are Mendelian disorders. Patients with the ACTA2 mutation have distinctive clinical (multisystem smooth-muscle involvement) and angiographic features specifically, a combination of ectasia and stenosis, a straight arterial course, absence of basal collaterals, and more widespread cerebrovascular involvement in comparison with Moyamoya disease. The diagnosis is suggested by these imaging features and has important implications for the management of the patient (increased risks associated with arterial instrumentation) and other family members, but it also provides important mechanistic insights that may be more generalizable. Previously, the imaging phenotype associated with ACTA2 mutations had been confined to cerebrovascular abnormalities and associated leukoencephalopathy, apart from a single case report of a patient with a dysmorphic corpus callosum.

Here we expand the neuroimaging phenotype and describe characteristic brain parenchymal abnormalities that could flag the diagnosis when targeted cerebrovascular imaging has not been performed.

MATERIALS AND METHODS

We reviewed in detail the brain MR imaging findings in a cohort of patients with ACTA2 mutations to describe the characteristics of brain congenital abnormalities in addition to known neuroan-
Clinically acquired, anonymized brain and cerebrovascular imaging studies from 13 unrelated patients with heterozygous Arg179His mutations in ACTA2 were retrospectively included from 4 pediatric hospitals and 3 general university hospitals (University Hospital of North Midlands; Hospital Das Clinicas, Sao Paulo, Brazil; Imperial College Healthcare National Health Service Trust, London, UK), with appropriate governance permissions from each site. The patients were selected after a search for ACTA2 mutation in the electronic data management systems of the centers involved in the study (past 10 years). Inclusion criteria were confirmed mutation and/or pathognomonic neuroradiologic and clinical findings and availability of MR imaging of diagnostic quality.

The presence of associated ischemic brain damage was also reported and divided into large territorial infarction of the brain and evidence of watershed infarctions/small vessel disease.

The presence of specific brain malformations found in our cohort was compared with known similar brain malformation patterns and analyzed in view of known embryologic knowledge to elucidate possible pathogenetic mechanisms.

Review through the electronic data management systems of the MR imaging scans and clinical data of all the patients from the main institution (ie, Great Ormond Street Hospital for Children) excluded the presence of similar brain abnormalities.

**RESULTS**

Clinical, radiologic, and genetic findings in our patients are summarized in the On-line Table. Thirteen patients had heterozygous missense Arg179His in ACTA2, and 1 patient without genetic confirmation had clinical and radiologic findings pathognomonic for ACTA2 mutation (subject 14) and was included in the case series.

All patients had the neuroangiographic features previously described. Clinically acquired, anonymized brain and cerebrovascular imaging studies from 13 unrelated patients with heterozygous Arg179His mutations in ACTA2 were retrospectively included from 4 pediatric hospitals and 3 general university hospitals (University Hospital of North Midlands; Hospital Das Clinicas, Sao Paulo, Brazil; Imperial College Healthcare National Health Service Trust, London, UK), with appropriate governance permissions from each site. The patients were selected after a search for ACTA2 mutation in the electronic data management systems of the centers involved in the study (past 10 years). Inclusion criteria were confirmed mutation and/or pathognomonic neuroradiologic and clinical findings and availability of MR imaging of diagnostic quality.

This included re-analysis of 8 patients already published by Munot et al. All 13 patients had the genetic diagnosis confirmed in a clinically accredited laboratory as part of their clinical evaluation.
All patients showed different degrees of abnormal brain morphology, namely the following:

1) Bending (excessive curvature inferiorly and anteriorly) and hypoplasia (rostrum not well-formed and flattened genu) of the anterior corpus callosum (Fig 1A, -B) with a relatively normal or mildly hypoplastic posterior corpus callosum were present. On axial images, the anterior corpus callosum demonstrates a characteristic V-shaped appearance (Fig 1C, -D). This finding was present in all (100%) patients.

2) Abnormal radial gyration of the frontal lobes and a deficient anterior cingulate gyrus (Fig 1A, -B) (100%) was present.

3) “Twin peaks” pons (appreciable in all the patients with the exception of patient 1: 93%): The pons was flattened with subjective reduction of the anteroposterior diameter noted on the midline and an impression of the basilar artery on the anterior surface with the consequent presence of 2 symmetric prominences resembling twin mountains (Fig 2). In the parasagittal slice, the patients had multiple indentations on the surface of the pons (Fig 3), probably due to the straightened pontine arterial branches creating compression of the pontine surface (see the “Discussion”).

FIG 2. Infratentorial malformations in ACTA2 mutation. Upper row: axial T2WI (A and B) at the level of the pons. The twin peaks sign is demonstrated; the pons is flattened with reduction of the anteroposterior diameter and an impression of the basilar artery on the anterior surface with consequent presence of 2 symmetric prominences resembling twin mountains. Middle row: axial T2WI at the level of the cerebral peduncles (C and D) shows mild antero-posterior elongation of the midbrain with reduction of the laterolateral diameter and squeezing of the cerebral peduncles. Right column: normal for comparison.

FIG 3. In the parasagittal slice, the patients show multiple indentations on the surface of the pons. We speculate that these may be due to stretching of the straightened pontine arterial branches.
4) Apparent “squeezing” of the cerebral peduncles in the midbrain (Fig 2C, -D) was present in 12 patients (85%).

5) A variable degree of horizontal orientation and thickening of the fornix (ie, fornix parallel to the corpus callosum) was present in all patients (Fig 1A, -B).

The radiologic and clinical findings of the patient without confirmed mutations were similar to those in the confirmed cases, with the typical ACTA2 cerebrovascular changes.2

Most interesting, we also found an adult patient with a similar and pronounced ACTA2-like cerebrovascular phenotype (patient 15 in the On-line Table), which showed the same spectrum of brain abnormalities, straightening of posterior circulation arteries, and abnormal radial gyration also involving the posterior temporal lobes (Fig 4). This patient refused genetic testing and did not have pathognomonic clinical findings associated with ACTA2 mutation. Nevertheless, this case is extremely interesting for understanding the possible pathophysiology of the brain abnormalities related to vascular dysplasia (see the “Discussion”).

In 8 subjects (patients 1, 5, 8, 10, 11, 12, 13, and 15), follow-up MR imaging was not available. The others had a different evol-
tion of the ischemic cerebral lesions. In all patients with follow-up available, the abnormalities in the corpus callosum, gyration, and brain stem were stable with time as well as the degree of arteriopathy. None of the patients showed cortical malformations such as focal cortical dysplasia, polymicrogyria, agyria, or pachygyria, as described in literature.⁷

**DISCUSSION**

Actin is an abundant protein in eukaryotic organisms and plays an essential role in the protein-protein interactions. The actin protein represents a monomeric subunit of 2 main varieties of filaments in cells that make up the cytoskeleton and form part of the contractile apparatus in muscle cells. The mammalian genome comprises 6 distinct actin isoforms (α-skeletal, α-cardiac, α-smooth, β-cyttoplasmic, γ-smooth, and γ-cyttoplasmic actin) encoded by 6 different genes.⁸ Alpha-smooth-muscle actin, encoded by ACTA2, located on 10q22-q24,⁸ is a principal element of the contractile units of vascular smooth-muscle cells but is not expressed in the brain parenchyma. However, α-actin cross-reacts with γ-actin to reinforce the cytoskeleton.⁹ The arterial phenotype in Arg179His ACTA2 mutations, with ectasia of the large arteries and occlusive disease in the small arteries, appears to reflect the local influence on the presence or absence of elastin within the arterial wall on the vascular phenotype.² These arterial features are also observed in the mouse model.¹¹ Vascular smooth-muscle cells are derived from the mesoderm in the posterior fossa/brain stem/thalamus and form the neural crest supratentorially (anterior neural plate)¹²; however, there are no data, to the best of our knowledge, to suggest differences in expression of ACTA2 related to different embryologic origins.

The occlusive disease observed in intracranial vessels is a result of fibrosis, thickening of the vascular wall, flattening and disorganization of the internal lamina, and proliferation of smooth-muscle cells.¹³ We previously postulated that this process renders the arteries more rigid and less deformable.² Arterial growth follows the contours of brain growth and gyration during normal development.¹² Thus, we speculate that in patients with these ACTA2 mutations, the increased rigidity of the intracranial arteries results in both the characteristic “straight” appearance and the morphologic brain changes that we have described as a consequence of the local mechanical effect from these vessels. Interestingly, the muscular layers do not appear in the basal perforator vessels until the gestational age of 27 weeks and, progressively, until term over the convexity. However, studies on rat embryos show that actin expression in the vasculature starts very early,¹⁴ and histologic specimens in subjects with ACTA2 mutations demonstrate that the rigidity is also due to abnormality in elastic and intima laminae.¹³ Furthermore, although the shape of the corpus callosum is complete by the gestational age of 20 weeks, this structure enlarges together with the connectivity and the development of the cortex; thus, it is still possible that interaction with abnormally formed vessels is responsible for the observed deformity despite these differences in the embryologic age of development. In addition, because the actin cytoskeleton participates directly or indirectly in almost every aspect of neuronal development and function,¹⁵ any instability in the cytoskeleton resulting from abnormal cross-linkage between actin subtypes could also influence neuronal migration.⁶ Alpha-actin is not expressed in the brain parenchyma but only in vessels (different from other isoforms), so it is unlikely that a mutation of this isoform will directly influence brain development, but it is possible that cross-regulation between different isoforms may play a role in subjects with the ACTA2 mutation.

There are other examples of malformative disorders being related to local mechanical factors, for example, arachnoid cysts with surrounding brain hypoplasia and Chiari I malformation, in which a small posterior fossa results in distortion and inferior displacement of the cerebellar tonsils, which is why the term “Chiari I deformity” was proposed instead of “malformation.”¹⁶ In patients with the ACTA2 mutation, the abnormal arterial morphology and structural brain abnormalities parallel each other in both supratentorial and infratentorial parenchyma—universally so in the anterior part of the corpus callosum, anterior cingulate gyrus, and abnormal radial frontal gyration, and variably in the brain stem. In fact, the characteristic twin peaks appearance of the pons in the axial plane seems to be related to impression by the basilar artery as well as the indentation of the lateral pontine surface that may be due to the impression by the pontine arteries coming from the basilar artery (Fig 3).

We have observed a particularly extreme example of this phenotype in a genetically untested patient who showed neuroradiologic features similar to those in ACTA2 mutations (patient 15). In this patient, the posterior cerebral arteries are also severely straightened and are associated with abnormal radial gyration involving the posterior temporal lobes and marked brain stem compression (Fig 4). The vascular phenotype present in this patient is similar to that in the others and is only described in patients with ACTA2 mutation, with the exception of an isolated case report¹⁷ in which a mutation was not found and brain images were very similar to those in our patient. Thus, even though it is possible that this patient (despite neurovascular findings) does not have an ACTA2 mutation, we think that the striking association between severe vascular and brain phenotypes in this subject is supportive of our hypothesis that brain abnormalities are secondary to vessel rigidity.

The apparent absence/definition of a segment of the anterior cingulate and the frontal radial pattern are both likely associated with a callosal abnormality at that level, which itself probably translates into the axial callosal V-shape. The horizontal fornix (or rather, the fornix that is parallel to the anterior callosum) results from an abnormally developed septum pellucidum (ie, too thick), which itself may well relate to the abnormal cingulate.⁵ The brain malformation features do not appear to have a clear clinical correlate in patients with Arg179His ACTA2 mutations; epilepsy is rare, other than in the context of brain ischemia, and intellectual outcomes again seem related to brain injury rather than to developmental abnormalities per se. However, the extreme reproducibility of the brain phenotype could represent an asset in the diagnosis when neuroangiographic studies are not available; for instance, in patient 8, standard MR imaging sequences showed typical bending of corpus callosum and radial frontal gyration that triggered the addition of an MRA sequence, which confirmed the radiologic diagnosis.

These observations contribute to defining the distinctive neu-
radiologic features of ACTA2 mutations, as well to shedding light on mechanisms, both genetic and mechanical, that result in structural changes to the brain and its vasculature.

CONCLUSIONS

We describe a characteristic and potentially pathognomonic (in specific clinical context) brain phenotype in patients with ACTA2 mutations and/or the typical clinical and neurovascular picture. A possible explanation for these brain imaging findings, which can be helpful in diagnosis, is a mechanical effect on the brain parenchyma during development by abnormal rigid vessels with possible contribution of cross-regulation between different actin isoforms.

Disclosures: Marius Grima—UNRELATED: Employment: University Hospitals of North Midlands. Comments: I am a salaried doctor in this institution; Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: University Hospitals of North Midlands. Comments: study-leave budget.

REFERENCES

Cerebral Blood Flow and Marrow Diffusion Alterations in Children with Sickle Cell Anemia after Bone Marrow Transplantation and Transfusion

M.T. Whitehead, A. Smith Hedhin, J. Webb, E.S. Mahdi, Z.P. Khademian, J.L. Carpenter, and A. Abraham

ABSTRACT

BACKGROUND AND PURPOSE: Hematopoietic marrow hyperplasia and hyperperfusion are compensatory mechanisms in sickle cell anemia. We have observed marrow diffusion and arterial spin-labeling perfusion changes in sickle cell anemia following bone marrow transplantation. We aimed to compare arterial spin-labeling perfusion and marrow diffusion/ADC values in patients with sickle cell anemia before and after bone marrow transplantation or transfusion.

MATERIALS AND METHODS: We reviewed brain MRIs from patients with sickle cell anemia obtained during 6 consecutive years at a children’s hospital. Quantitative marrow diffusion values were procured from the occipital and sphenoid bones. Pseudocontinuous arterial spin-labeling perfusion values (milliliters/100 g of tissue/min) of MCA, anterior cerebral artery, and posterior cerebral artery territories were determined. Territorial CBF, whole-brain average CBF, and marrow ADC values were compared for changes before and after either bone marrow transplantation or transfusion. Bone marrow transplantation and transfusion groups were compared. Two-tailed paired and unpaired Student t tests were used; \( P < .05 \) was considered significant.

RESULTS: Fifty-three examinations from 17 patients with bone marrow transplantation and 29 examinations from 9 patients with transfusion were included. ADC values significantly increased in the sphenoid and occipital marrow following bone marrow transplantation in contrast to patients with transfusion \( (P < .83) \). Whole-brain mean CBF significantly decreased following bone marrow transplantation \( (77.39 \pm 13.78 \text{ to } 60.39 \pm 13.62 \text{ ml/100 g tissue/min}; P < .001) \), without significant change thereafter. CBF did not significantly change following the first \( (81.11 \pm 12.23 \text{ to } 80.25 \pm 8.27 \text{ ml/100 g tissue/min}; P = .47) \) or subsequent transfusions. There was no significant difference in mean CBF between groups before intervention \( (P = .22) \).

CONCLUSIONS: Improved CBF and marrow diffusion eventuate following bone marrow transplantation in children with sickle cell anemia in contrast to transfusion therapy.

ABBREVIATIONS: ACA = anterior cerebral artery; ASL = arterial spin-labeling; BMT = bone marrow transplantation; PCA = posterior cerebral artery; SCA = sickle cell anemia; T1 = relaxation time

Sickle cell anemia (SCA) is an inherited hematopoietic disorder, rare in the general US population but more common in African Americans (0.3%; 1/365).\(^1\) The mutated hemoglobin contained in the red blood cells of patients with SCA (HbSS) forms insoluble polymers under low oxygen conditions and deforms the cells, giving them their sickle shape. The “sickle cells” have decreased deformability, rendering them unable to easily pass through small vessels, and can reduce or occlude blood flow to tissues. Enhanced red blood cell production and blood flow are compensatory mechanisms used by the body in an attempt to maintain homeostasis. Hematopoietic marrow hyperplasia causes marrow signal alterations on MR imaging, including T1 lengthening, T2 shortening, and reduced diffusion.\(^2,3\) Elevated cardiac output, increased arterial blood flow, and vasodilation contribute to cerebral hyperperfusion.\(^4\) However, end organs remain vulnerable to ischemic injury because these compensatory adjustments are often insufficient. Furthermore, small- and large-vessel vasculopathy can potentiate this rather tenuous situation.\(^5\) In the brain, injury may take the form of borderzone ischemia, focal small-vessel lacunar infarcts (symptomatic or silent), or large vascular territory infarctions.

Arterial spin-labeling (ASL) perfusion is a noninvasive MR imaging technique that uses flowing blood as an intrinsic tracer to
assess cerebral blood flow in milliliters/100 g of tissue/min.\textsuperscript{7–9} Thus, it is an MR imaging technique well-suited to the SCA population because it readily depicts the present state of blood flow to the brain without the need for intravenous gadolinium. In compensated patients with SCA, the combination of hyperperfusion and anemia leads to a generalized increase in ASL brain signal. The signal is then reduced in patients with cerebrovascular disease, including delayed arterial transit (eg, vasculopathy) and hypoperfusion (eg, ischemia or encephalomalacia), or increased in states of hyperperfusion (eg, luxury perfusion or seizure-related).\textsuperscript{8,10,11} Notable limitations of the ASL technique include a relatively poor signal-to-noise ratio and variables often represented as estimations in calculating the ASL perfusion equation, such as tagging efficiency, postlabel delay, the cortex-blood partition coefficient, and the T1 of blood.\textsuperscript{9} The latter, however, can be measured directly or calculated with knowledge of the magnetic field strength, hemoglobin, and oxygen saturation.\textsuperscript{12}

Primary therapeutic measures in symptomatic patients with SCA include hydroxyurea, red blood cell transfusions, and, in the appropriate population, bone marrow transplantation (BMT), which is curative if successful. Human leukocyte antigen-matched sibling donors offer the best hope for a cure with BMT, with a success rate as high as 98%.\textsuperscript{13} However, failure can occur in up to 10% and is more common with nonsibling human leukocyte antigen–matched donors and nonmatched donors.\textsuperscript{14–20} Repeat transplantation would be necessary under these circumstances to achieve success. Imaging markers for transplantation failure would thus be useful adjuncts to guide early treatment decisions.

We have observed changes in brain blood flow and marrow diffusion values following bone marrow transplant in SCA, potentially representing imaging biomarkers of a favorable therapeutic response. The aim of this study was to compare and contrast alterations in ASL perfusion and bone marrow diffusion/ADC values in patients with SCA before and after BMT or initiation of chronic, monthly transfusion therapy.

**MATERIALS AND METHODS**

This Health Insurance Portability and Accountability Act–compliant retrospective study was performed after institutional review board approval. The brain MR imaging data base from a single academic children’s hospital was queried for all examinations performed in patients with sickle cell anemia during a consecutive 6-year period (January 1, 2012, to December 31, 2017) using the terms “sickle cell,” “ASL,” and “arterial spin-labeling” to build a cohort for retrospective analysis. Each patient’s medical record was reviewed to confirm a diagnosis of sickle cell disease, including delayed arterial transit (eg, vasculopathy) and hypoperfusion (eg, ischemia or encephalomalacia), or increased in states of hyperperfusion (eg, luxury perfusion or seizure-related). We excluded from further evaluation those with substantial marrow hypointensity defined as hypointense marrow signal with respect to muscle on all pulse sequences.

**ASL: Technique, Processing, and Assessment**

Each subject underwent pseudocontinuous ASL with background suppression and a segmented 3D fast spin-echo readout in accordance with current consensus guidelines using the following scan parameters: flip angle, 111°–155°; inversion time/postlabel delay, 1025–1525 ms; labeling duration, 1500–2000 ms; TR, 4300–4600 ms; TE, 11 ms; ETL (echo train length), 1; NEX, 2–3; matrix, 512 × 8; FOV, 24–55 × 24–29 cm; 32–35 slices; 3- to 4-mm slice thickness; 3- to 4-mm spacing; total sequence acquisition time, 4–5 minutes. Anatomic landmarks were used to select the labeling plane just below the inferior margin of the cerebellum. ASL post-processing was performed on the MR imaging scanner. Gray-scale ASL perfusion images and pseudocolor images were generated and displayed with age-dependent scaling based on the age of clinical experience after board certification who was blinded to the type of therapy/intervention at the time of assessment.
magnitude of normal cerebral blood flow from the neonatal-to-
early childhood period (younger than 1 year: 0 – 60 mL/100 g of
tissue/min; older than 1 year: 0 –100 mL/100 g of tissue/min).21

Arterial territory–specific quantitative ASL data in milliliters/100
g of tissue/min were procured using an AW workstation with Func-
tool software (GE Healthcare). The T1 value of arterial blood was
calculated in each patient using patient-specific hematocrit levels,
T1 of the blood (calculated for each patient using the hematocrit,
oxxygen saturation, and magnetic field strength
based on Hales et al12); τ, labeling duration (1500 ms); PW, perfusion
weighted signal intensity; PD, proton density signal
intensity; and PLD, postlabeling delay time. Mean whole-brain perfusion
was estimated in each examination by averaging CBF values from all 6 evalu-
ated territories. Gray-scale and corre-
sponding postprocessed pseudocolor
data were also evaluated together qual-
itatively. Qualitative cerebral signal magnitude was recorded
using a 3-point scale: 1, hypoperfusion; 2, within normal lim-
its; and 3, hyperperfusion.

**Statistical Methods**
The normal Gaussian distribution of the data mean was deter-
mined and confirmed by a Shapiro-Wilk test. Subsequently,
2-tailed paired t tests were used separately in each group of pa-
tients with SCA before and after BMT and transfusion, respec-
tively. Two-tailed unpaired t tests were then performed to evalu-
ate differences in the mean cerebral blood flow and narrow
diffusion values between the posttransplantation and postrans-
fusion arms. The Wilcoxon signed rank test was used to evaluate
correlated samples of qualitative ordinal data. Observed power was
calculated on the basis of the postintervention whole-brain CBF
mean and SD differences between groups. P ≤ .05 was considered
significant.

**RESULTS**
Fifty-three brain MR imaging examinations from 17 patients with
BMT (mean, 3; range, 2–5; mean length of follow-up, 1.9 ± 0.9
years; range, 0.7–4.2 years) (9 male, 8 female) and 29 brain MR

### Table 1: Transplant group—hemoglobinopathy subtype, transplant data, and MR imaging data analyzed

<table>
<thead>
<tr>
<th>Pt</th>
<th>Diagnosis</th>
<th>Source</th>
<th>Donor</th>
<th>HLA Match</th>
<th>Scans (No.)</th>
<th>Age (yr)</th>
<th>DWI (No.)</th>
<th>ASL (Right Cerebrum) (No.)</th>
<th>ASL (Left Cerebrum) (No.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>2</td>
<td>18.19</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>4</td>
<td>15.16</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>3</td>
<td>HbSS-BOTh</td>
<td>PBSC</td>
<td>R, H</td>
<td>4/8</td>
<td>2</td>
<td>12.13</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>HbSC</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>5</td>
<td>13.14</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>5</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>4</td>
<td>7.10</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>2</td>
<td>7.9</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>HbSS-BOTh</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>2</td>
<td>10.12</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>3</td>
<td>11.12</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>4</td>
<td>5.7</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>10</td>
<td>HbSS</td>
<td>UCB</td>
<td>R</td>
<td>5/6</td>
<td>4</td>
<td>8.8</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>11</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>3</td>
<td>8.9</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>12</td>
<td>HbSS</td>
<td>PBSC</td>
<td>R, H</td>
<td>3/6</td>
<td>3</td>
<td>4.5</td>
<td>3</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>13</td>
<td>HbSS</td>
<td>BM</td>
<td>U</td>
<td>8/8</td>
<td>5</td>
<td>18.18</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>14</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>2</td>
<td>1.2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>15</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>10/10</td>
<td>3</td>
<td>3.3</td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>HbSS</td>
<td>BM</td>
<td>R</td>
<td>8/8</td>
<td>2</td>
<td>15.16</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>17</td>
<td>HbSS</td>
<td>UCB</td>
<td>U</td>
<td>6/6</td>
<td>3</td>
<td>3.3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: Pt indicates patient; BM, bone marrow; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; R, related; H, haplodentical; U, unrelated; HbSS, homozygous
hemoglobin S; HbSC, sickle cell hemoglobin C; HbSS-BOTh, hemoglobin S-β-thalassemia disease; HLA, human leukocyte antigen.

### Table 2: Chronic transfusion group—hemoglobinopathy subtype and MR imaging data analyzed

<table>
<thead>
<tr>
<th>Pt</th>
<th>Diagnosis</th>
<th>Scans (No.)</th>
<th>Age (yr)</th>
<th>DWI (No.)</th>
<th>ASL (Right Cerebrum) (No.)</th>
<th>ASL (Left Cerebrum) (No.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HbSS</td>
<td>3</td>
<td>7.9</td>
<td>0</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>HbSS</td>
<td>6</td>
<td>0.12</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>HbSS</td>
<td>2</td>
<td>7.8</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>HbSS</td>
<td>2</td>
<td>8.1</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>5</td>
<td>HbSS</td>
<td>6</td>
<td>2.34</td>
<td>0</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>HbSS</td>
<td>2</td>
<td>4.6</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>7</td>
<td>HbSS</td>
<td>2</td>
<td>6.8</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>HbSS</td>
<td>3</td>
<td>3.45</td>
<td>1</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>HbSS</td>
<td>3</td>
<td>9.10</td>
<td>0</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

Note: Pt indicates patient; HbSS, homozygous hemoglobin S.

---

**CBF** = \( \frac{\lambda (1 - e^{-T_{ip} \alpha}) PW}{2 \alpha T_{ip} (1 - e^{-PLD}) PD e^{-t_{sat}} \tau} \)

where \( \lambda \) indicates the cortex-blood partition coefficient (0.9, as-
sumed); \( t_{sat} \) time of saturation before imaging (2000 ms); \( T_{ip} \) T1

---

\( CBF = \frac{\lambda (1 - e^{-T_{ip} \alpha}) PW}{2 \alpha T_{ip} (1 - e^{-PLD}) PD e^{-t_{sat}} \tau} \)

---

---
imaging examinations from 9 patients with transfusion (mean, 3; range, 2–6; mean length of follow-up, 3.1 ± 1.4 years; range, 1.1–5.6 years) (3 male, 6 female) met the inclusion criteria (Tables 1 and 2). Two patients with transfusion were excluded; one lacked ASL, and the other had severe vasculopathy with multiple infarctions and excessive motion artifacts. Three follow-up examinations after BMT were excluded from 2 different patients due to posterior reversible encephalopathy syndrome. One hemisphere was excluded from ASL analysis due to infarctions or vasculopathy in 4 cases from 2 patients in the transplant group and in 5 cases from 3 patients in the transfusion group; however, there was no significant difference between pre- and posttransfusion and pre- and posttransplantation CBF values between the subgroups that underwent unilateral and bilateral cerebral analysis. At the time of the initial MR imaging, the mean age of the BMT group was 9.8 ± 5 years (range, 1–18 years), while the mean age of the transfusion group was 6.3 ± 4 years (range, 0–9 years) (*P* = .13). Transfusions were initiated 20 days before the follow-up MR imaging on average (range, 4–60 days). The mean time between BMT and the first follow-up MR imaging was 281 ± 170 days (range, 3–875 days). No patients who underwent BMT had graft failure.

### Marrow ADC Values

ADC values significantly increased in the marrow of the greater sphenoid wing (0.97 ± 0.34 to 1.59 ± 0.55 × 10^{-3} mm²/s; *P* = .025) and occipital bone (1.11 ± 0.27 to 1.44 ± 0.51 × 10^{-3} mm²/s; *P* = .043) following bone marrow transplantation (Fig 1). Qualitatively, ADC sequences also demonstrated visually brighter marrow following BMT (the mean score decreased from 3 to 1), representing more facilitated diffusion (*P* = .01428) (Fig 1). These changes were sustained across time on follow-up examinations, with no significant difference in the interval mean ADC values (*P* > .05). There was no significant difference in sphenoid wing and occipital marrow mean ADC values between the pre- and posttransplantation scans.

### Table 3: Pre- and posttransplantation ASL perfusion changes

<table>
<thead>
<tr>
<th>Pt</th>
<th>Pretransplantation</th>
<th>Posttransplantation</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MCA (R)</td>
<td>MCA (L)</td>
<td>ACA (R)</td>
</tr>
<tr>
<td>1</td>
<td>71</td>
<td>70</td>
<td>68</td>
</tr>
<tr>
<td>2</td>
<td>92</td>
<td>82</td>
<td>88</td>
</tr>
<tr>
<td>3</td>
<td>82</td>
<td>80</td>
<td>79</td>
</tr>
<tr>
<td>4</td>
<td>66</td>
<td>63</td>
<td>64</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>80</td>
<td>93</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
<td>89</td>
<td>96</td>
</tr>
<tr>
<td>7</td>
<td>68</td>
<td>65</td>
<td>68</td>
</tr>
<tr>
<td>8</td>
<td>76</td>
<td>72</td>
<td>73</td>
</tr>
<tr>
<td>9</td>
<td>84</td>
<td>65</td>
<td>77</td>
</tr>
<tr>
<td>10</td>
<td>NA</td>
<td>57</td>
<td>NA</td>
</tr>
<tr>
<td>11</td>
<td>73</td>
<td>81</td>
<td>76</td>
</tr>
<tr>
<td>12</td>
<td>89</td>
<td>NA</td>
<td>77</td>
</tr>
<tr>
<td>13</td>
<td>63</td>
<td>66</td>
<td>59</td>
</tr>
<tr>
<td>14</td>
<td>85</td>
<td>81</td>
<td>79</td>
</tr>
<tr>
<td>15</td>
<td>68</td>
<td>71</td>
<td>67</td>
</tr>
<tr>
<td>16</td>
<td>76</td>
<td>73</td>
<td>76</td>
</tr>
<tr>
<td>17</td>
<td>100</td>
<td>99</td>
<td>101</td>
</tr>
<tr>
<td>T</td>
<td>81</td>
<td>76</td>
<td>79</td>
</tr>
</tbody>
</table>

Note: Pt indicates patient; R, right; L, left; Avg, average/mean whole-brain CBF; NA, not applicable/excluded; T, mean of each arterial territory.

a Arterial territory–specific and mean whole-brain CBF values (in milliliters/100 g of tissue/min) from 17 patients with BMT prior to (left columns) and at the first scan after (right columns) transplantation. In the interest of space and simplicity, CBF values were rounded to the nearest whole number for this display.

b Significant increase in mean whole-brain CBF.

c Significant.
between patients pre- and posttransfusion \( P > .83 \); however, only 2 patients could be evaluated posttransfusion due to MR imaging evidence of marrow iron deposition. Post-BMT and posttransfusion marrow ADC values were significantly different from one another \( P = .0323 \). There was no significant difference between marrow ADC values obtained at 1.5T and 3T in either group \( P > .05 \).

**Cerebral Blood Flow**

Preintervention mean whole-brain perfusion for both groups combined was 78.43 \( \pm 11.18 \) mL/100 g of tissue/min. CBF values obtained at 1.5T were not significantly different from those obtained at 3T in either group \( P > .05 \). There was no significant difference in mean quantitative cerebral blood flow between the BMT and transfusion groups before intervention \( P = .22 \). Mean whole-brain cerebral blood flow was significantly lower after BMT compared with transfusion \( P = .0004 \). The observed power was strong at 99.6%.

Whole-brain mean quantitative cerebral blood flow significantly decreased following BMT, from 77.39 \( \pm 13.78 \) to 60.39 \( \pm 13.62 \) mL/100 g tissue/min (first scan; \( P = .00004 \)), and did not significantly change thereafter (Table 3 and Figs 2 and 3). The mean CBF significantly decreased in all bilateral vascular territories (anterior cerebral artery [ACA], MCA, posterior cerebral artery [PCA]) on the first scan following BMT, and most of these significant differences were sustained across time. On an individual level, most patients (11/17) had a significant drop in whole-brain CBF on the first scan following BMT. Half of the patients who did not experience significantly decreased CBF on the first scan were reimaged at a later time point; CBF ultimately decreased significantly in two-thirds of these patients. The first posttransplantation scan was performed at 0.8 \( \pm 6 \) years on average.

**FIG 2.** An 11-year-old boy with sickle cell disease. Pre-bone marrow transplantation, axial pseudo-color ASL (A) depicts manual ROIs drawn to interrogate CBF from the bilateral ACA, MCA, and PCA territories. Diffusely increased signal is present throughout the cerebrum, consistent with elevated cerebral blood flow. Follow-up MR imaging at 12 years of age from the same patient, post-bone marrow transplantation, with axial pseudo-color ASL (B) depicting persistent-but-improved/decreased hyperperfusion.

**FIG 3.** Comparison of arterial territory-specific quantitative mean CBF in patients with SCA before BMT (left) and at the first scan after BMT (right). R indicates right; L, left.

**Table 4: Pre- and postinitiation of chronic transfusion therapy ASL perfusion changes**

<table>
<thead>
<tr>
<th>Pt</th>
<th>Pretransfusion</th>
<th>Posttransfusion</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>96</td>
<td>NA</td>
<td>78</td>
</tr>
<tr>
<td>2</td>
<td>79</td>
<td>71</td>
<td>64</td>
</tr>
<tr>
<td>3</td>
<td>103</td>
<td>91</td>
<td>102</td>
</tr>
<tr>
<td>4</td>
<td>NA</td>
<td>89</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>90</td>
<td>96</td>
<td>81</td>
</tr>
<tr>
<td>6</td>
<td>84</td>
<td>102</td>
<td>88</td>
</tr>
<tr>
<td>7</td>
<td>98</td>
<td>93</td>
<td>88</td>
</tr>
<tr>
<td>8</td>
<td>70</td>
<td>68</td>
<td>70</td>
</tr>
<tr>
<td>9</td>
<td>70</td>
<td>70</td>
<td>64</td>
</tr>
<tr>
<td>T</td>
<td>86</td>
<td>78</td>
<td>79</td>
</tr>
</tbody>
</table>

**Note:** Pt indicates patient; R, right; L, left; Avg, average/mean whole-brain CBF; NA, not applicable/excluded; T, mean of each arterial territory.

a Arterial territory-specific and mean whole-brain CBF values (in milliliters/100 g of tissue/min) from 9 patients with transfusion prior to (left columns) and at the first scan after (right columns) transfusion initiation. In the interest in space and simplicity, CBF values were rounded to the nearest whole number for this display.

b Significant.

c Significant increase in mean whole-brain CBF.
after BMT. There was no significant difference in the time interval between transplant and the first posttransplantation brain MR imaging between patients who did and did not experience decreased CBF ($P = .5$). One of the 6 patients without significant CBF alteration had an unrelated BMT without myeloablative preconditioning.

Whole-brain mean perfusion values did not significantly change following the first transfusion ($81.11 \pm 12.23$ to $80.25 \pm 8.27$ mL/100 g tissue/min; $P = .47$) or across time after subsequent transfusions (Table 4 and Figs 4 and 5). Whole-brain CBF did not significantly decline in 6 of the 9 patients and actually significantly increased in 2 of these patients. A minority of patients (3/9) did experience significantly decreased whole-brain CBF after transfusion; unfortunately, none of these patients had further follow-up imaging to determine the duration of the change.

**DISCUSSION**

Marrow diffusion and cerebral perfusion significantly improved in patients with sickle cell anemia following bone marrow transplantation and did not change significantly after transfusion alone. Because marrow ADC values negatively correlate and CBF positively correlates with the severity of anemia, these may be useful surrogate imaging biomarkers for therapeutic success.2-4,12

Apparent diffusion coefficient values of bone marrow are inversely proportional to the degree of hematopoietic constituents. Red marrow hyperplasia causes T1 prolongation, T2 shortening, and reduced diffusion.2-4 Proliferative hematopoietic marrow changes in SCA are an attempt to compensate for the diminished oxygen-carrying capacity of the sickled erythrocytes and to replenish red blood cells prematurely removed from circulation. All patients in our cohort had evidence of reduced diffusion in the sphenoid and occipital bone marrow before intervention. Although SCA-associated quantitative ADC values in the skull have not been previously assessed in the literature to our knowledge, the significant increase in ADC and facilitated diffusion following BMT raises the possibility that marrow diffusion is reduced at baseline compared with age-expected values. These increased marrow ADC values were sustained across time on follow-up examinations after BMT, suggesting diminished or resolved hematopoietic marrow proliferation. No significant change in marrow ADC values was found in patients with SSA pre- to posttransfusion. However, interpretation was confounded because transfusion causes increased bone marrow T1 prolongation and T2 shortening due to iron deposition.2,3 Thus, we excluded examinations with qualitative marrow hypointensity from marrow DWI assessment. Unfortunately, in the transfusion group, this exclusion left only 2 patients for analysis.

The ASL signal magnitude is influenced by a number of factors in addition to blood flow, namely the spin-lattice relaxation time (T1) of arterial blood, blood flow velocity, labeling efficiency, and the brain-blood partition coefficient of water. The latter variable is difficult to accurately measure and is therefore typically estimated at 0.9 mL/g for averaged brain gray and white matter.7 Labeling efficiency is inversely related to blood flow velocity and requires additional measurements for calculation, such as with phase-contrast imaging. However, the T1 of blood can and should be adjusted on a patient-to-patient basis, especially if there are known deviations from normal hematocrit. Anemia will prolong the T1 value of blood and cause spuriously increased ASL signal that, all other factors being equal, would be interpreted as hyper-

**FIG 4.** A 31-month-old girl with sickle cell disease. Pretransfusion axial pseudocolor ASL (A) depicts manual ROIs drawn to interrogate CBF from the bilateral ACA, MCA, and PCA territories. Diffusely increased signal is present throughout the cerebrum, consistent with elevated cerebral blood flow. Follow-up MR imaging at 36 months of age from the same patient at the same level posttransfusion with axial pseudocolor ASL (B) depicting persistent hyperperfusion without significant change.

**FIG 5.** Comparison of arterial territory–specific quantitative mean CBF in patients with SCA before initial transfusion (left) and at the first scan after transfusion initiation (right). R indicates right; L, left.
perfusion. Arterial T1 values can be measured directly, but specific sequences are required at the time of MR imaging. Alternatively, as used in our study, the T1 value can be calculated after determining the hematocrit, O2 saturation, and magnetic field strength.12

Cerebral perfusion decreases during childhood in normal states.20 It has been shown that anemia positively correlates with cerebral blood flow and negatively correlates with cerebrovascular reserve and that these relationships are strongly associated with anemia severity in children with SCA.5 In untreated patients with asymptomatic sickle cell anemia, cerebral blood flow is diffusely elevated relative to aged-matched healthy subjects without regard for age, manifested on ASL as diffusely increased brain signal.6 Before intervention, we estimated the mean whole-brain CBF in our SCA cohort (transfusion and BMT groups combined) to be elevated at 78 ± 11 mL/100 g of tissue/min (64 ± 14 mL/100 g of tissue/min is considered normal).27 Previous literature reported quantitative whole-brain CBF values in patients with SCA to be in a similar range (83–87 ± 24 mL/100 g of tissue/min), though different ASL techniques were used and anemia-related blood T1 value adjustments were not made in that study, possibly accounting for slightly higher reported values.6,28

Therapeutic measures in SCA include blood transfusions and allogenic bone marrow transplantation. The improved O2 delivery conferred by transfused normal red blood cells enhances cerebrovascular reserve, decreases the oxygen extraction fraction, and decreases CBF.5,23 Guillaums et al23 reported a significant mean CBF drop following transfusion, from 88 to 82 mL/100 g of tissue/min. A minority of patients in our cohort also experienced decreased CBF posttransfusion; however, the mean whole-brain CBF encompassing the entire group did not change significantly (from 81 to 80 mL/100 g of tissue/min). It is unclear whether this finding could relate to a smaller sample size and/or differences in techniques among studies. In contrast, whole-brain CBF significantly decreased after BMT (from 76 to 63 mL/100 g of tissue/min) and was sustained across time on follow-up MR imaging. This change occurred as early as 3 days after transplantation and, therefore, could be a neuroimaging marker heralding favorable engraftment. Engraftment can be observed clinically from 1 to 4 weeks posttransplantation with the definition based on a sustained rebound in the absolute neutrophil count of ≥500/μL and platelet count of ≥20,000/μL.29

Several study limitations should be noted. The sample size is relatively small due to the rarity of SCA-related BMT, the high prevalence of brain and vascular pathology factoring into exclusions, and the novelty of ASL. The posttransfusion bone marrow diffusion data were particularly sparse because iron deposition precluded accurate interpretation in most cases. In the few cases that required single cerebral hemisphere exclusion from analysis, contralateral cerebral ASL perfusion data could have been unreliable to some extent; however, there was no significant difference between pre- and posttransfusion and pre- and posttransplantation CBF values between the subgroups that underwent unilateral and bilateral cerebral analysis to suggest that unilateral cerebral hemisphere exclusion from analysis had any bearing on the results. Future studies with a larger number of subjects will be useful to confirm our findings. Increased blood velocity due to chronic anemia is a known cause of decreased labeling efficiency using ASL, which may have resulted in underestimation of absolute CBF.30,31 Because this was a retrospective study, we did not have corresponding phase data available to approximate labeling efficiency in each case. However, relative changes across time and between groups would be unaffected. In addition, we used a single rather than a multicompartmental model for quantitative ASL calculation, and we did not account for venous outflow effects in SSA.24,30

CONCLUSIONS

Improved cerebral blood flow and marrow diffusion ensue following bone marrow transplantation in children with sickle cell anemia. We found no significant alteration in CBF or marrow diffusion in patients with SCA who underwent transfusion therapy, though the sample size is a limitation. ASL perfusion and quantitative marrow diffusion values are useful posttherapeutic imaging biomarkers.

Disclosures: Alistair Abraham—UNRELATED: Grant: American Society of Hematology.* *Money paid to the institution.

REFERENCES

12. Hales PW, Kirkham FJ, Clark CA. A general model to calculate the spin-lattice (T1) relaxation time of blood, accounting for haemat-


ABSTRACT

BACKGROUND AND PURPOSE: Differences in structural brain connectivity that underlie inattention have been previously investigated in adolescents with attention deficit/hyperactivity disorder, but not in the context of premature birth, which is often associated with attentional problems. The purpose of this study was to identify the neural correlates of attentional problems in adolescents born prematurely and determine neonatal predictors of those neural correlates and attention problems.

MATERIALS AND METHODS: The study included 24 adolescents (12.5 ± 1.8 years of age; 12 girls, 12 boys) who were born prematurely and underwent MR imaging of the brain and cognitive assessment, both shortly after birth and as adolescents. Structural connectivity was assessed at adolescence using diffusion tensor imaging and tractography.

RESULTS: Of the 24 subjects, 12 had attention deficits. A set of axonal pathways connecting the frontal, parietal, temporal, and occipital lobes had significantly lower fractional anisotropy in subjects with attentional problems. The temporoparietal connection between the left prefrontal and left middle temporal gyrus was the most significantly underconnected interlobar axonal pathway. Low birth weight and ventriculomegaly, but not white matter injury or intraventricular hemorrhage on neonatal MR imaging, predicted temporoparietal hypoconnectivity in adolescence. However, neither birth weight nor other neonatal characteristics were associated with attention deficits directly.

CONCLUSIONS: We identified an aberrant structural brain connectivity pattern, involving temporoparietal hypoconnectivity, in prematurely born adolescents with attentional problems. We also identified birth weight as a potential neonatal predictor of the temporoparietal hypoconnectivity. These findings add to our understanding of the neural basis and etiology of inattention in adolescents after premature birth.

ABOUT 1 in 10 children are born prematurely and, as a result, enter the world with a higher risk of several health problems as well as early death. Those who survive often have life-long neurodevelopmental problems, with attention deficit being among the most consistently reported cognitive impairment related to prematurity. This deficit impacts daily functioning, and many individuals meet the formal diagnostic criteria for attention deficit/hyperactivity disorder (ADHD). It is essential to better understand the underlying neurologic causes of attentional problems and their etiologies to develop effective interventions.

Diffusion tensor imaging allows noninvasive assessment of white matter microstructure. This methodology enables 3D visualization of white matter properties and has been used for several decades to study neurologic and psychiatric disorders in an attempt to relate white matter abnormalities to clinical manifestations. A commonly used metric derived from DTI is fractional anisotropy (FA). A general, simplified interpretation is that higher FA represents higher white matter integrity in specific brain regions. With regard to attentional problems, several studies have focused on the FA in the brains of individuals with ADHD, reporting both higher\(^{6-8}\) and lower\(^{9-11}\) FA values compared with healthy controls. The effects of premature birth on
DTI parameters have also been investigated, showing that children born prematurely tend to have lower FA values in several regions of the brain consistently from infancy to adulthood.\textsuperscript{12-16} Recently, neurologic and psychiatric disorders, including ADHD, are increasingly being viewed not as anomalies of focal brain regions but rather as disorders arising from disruption of distributed brain networks (connectomes).\textsuperscript{17} These networks are modeled as sets of nodes, with pairs of nodes connected by edges. In a structural connectivity study, cortical and subcortical gray matter structures typically play the role of nodes, whereas tractography-derived white matter connections between them serve as edges. This network approach differs in an important way from the voxel-based DTI approaches in that it moves away from focal abnormalities to network-level disruptions and offers new explanations of observed dysfunctions.

To date, there are 3 studies examining white matter network properties in youth with ADHD.\textsuperscript{18-20} The main findings include aberrant connectivity of the frontal and striatal regions,\textsuperscript{18-20} but also parietal,\textsuperscript{18,20} occipital,\textsuperscript{18,20} temporal,\textsuperscript{20} and cerebellar regions.\textsuperscript{19} One additional study used T1-weighted images and showed differences in topologic properties of structural covariance networks in youth with ADHD compared with controls.\textsuperscript{21} However, there have been no studies examining structural connectivity associated with inattention in adolescents born prematurely. This is an important gap in knowledge because understanding the underlying mechanisms of attentional dysfunction is crucial for the development of targeted interventions. The purpose of this study was to identify network-level neural correlates of attentional problems in adolescents born prematurely and assess neonatal predictors of those neural correlates.

**MATERIALS AND METHODS**

**Participants and Clinical Information**

The study was approved by the local institutional review board, and all participants in the study provided written informed consent, and their parents or legal guardians provided written informed consent in accordance with the Declaration of Helsinki. Prematurely born adolescents who were enrolled in a longitudinal MR imaging study of preterm infants were invited to return for optional MR imaging and neuropsychological testing at 10–14 years of age. Inclusion criteria for the cohort were birth before 33 weeks’ gestation. Exclusion criteria included clinical evidence of a congenital malformation or syndrome, congenital infection, or clinical status too unstable for MR imaging. The group included in this study consisted of 24 adolescents (10–14 years of age; average age, 12.5 ± 1.8 years; 12 girls and 12 boys) who were born prematurely (including 11 extremely premature subjects, <28 weeks’ gestation) and came for the 10- to 14-year follow-up visit and had both neuropsychological and diffusion MR imaging data available.

**Neonatal Clinical Assessments**

Trained research nurses blinded to the MR imaging findings reviewed medical records and extracted clinical data. Maternal and antenatal variables included exposure to prenatal steroids as well as maternal age, primiparity, maternal smoking, placenta previa, preeclampsia, and twin gestation.

Demographic variables included gestational age at birth, birth weight, and sex. The z score for birth weight was calculated. Perinatal variables included placental abruption, chorioamnionitis, and mode of delivery, which was classified as vaginal or cesarean delivery. Chorioamnionitis was diagnosed clinically (maternal fever, >38°C during labor or fetal tachycardia with uterine tenderness, treated with antibiotics).\textsuperscript{22} Neonatal variables included duration of mechanical ventilation, infection, hypotension, symptomatic patent ductus arteriosus, necrotizing enterocolitis, neonatal surgery, and chronic lung disease. Neonates with culture-positive sepsis, clinical signs of sepsis with blood culture negative for sepsis, or meningitis were classified as having infection. Hypotension was defined as a period of sustained low blood pressure treated with intravenous fluid bolus and/or inotropes. Neonates with clinical signs of patent ductus arteriosus (prolonged systolic murmur, bounding pulses, and hyperdynamic precordium) and evidence of left-to-right flow through the patent ductus arteriosus on echocardiogram were classified as having symptomatic patent ductus arteriosus. Necrotizing enterocolitis was diagnosed according to the Bell stage 2 criteria.\textsuperscript{23} Chronic lung disease was defined as an oxygen requirement at 36 weeks’ postmenstrual age.

**Neonatal MR Imaging**

MR imaging scans were obtained after birth as soon as the neonates were clinically stable and again near term-equivalent age when possible. A custom MR imaging–compatible incubator with a specialized neonatal head coil was used to provide a quiet, well-monitored environment for the neonates, minimizing patient movement and improving the signal-to-noise ratio.\textsuperscript{24} MR imaging scans were acquired using a 1.5T scanner and a specialized, high-sensitivity, neonatal head coil built into the MR imaging–compatible incubator. MR imaging scans included axial spin-echo T2-weighted images (TR = 3 seconds; TE = 60 and 120 ms; FOV = 240 mm with a 256 × 256 matrix; slice thickness = 4 mm; gap = 2 mm) and sagittal volumetric 3D spoiled gradient-echo T1-weighted images (TR = 36 ms; minimum TE; FOV = 180 mm; 1.0-mm isotropic). A single pediatric neuroradiologist (A.J.B.) blinded to the clinical history (other than premature birth) evaluated all MR images. The severity of the white matter injury (WMI) on T1-weighted MR imaging was scored according to our published criteria as none, mild (<3 areas of signal abnormality, each <2 mm in diameter), moderate (>3 areas of signal abnormality or areas of signal abnormality of >2 mm but <5% of the hemisphere involved), or severe (>5% of hemisphere involved).\textsuperscript{25} WMI was further classified as absent/mild or moderate/severe. Neonates were diagnosed with mild ventriculomegaly if the largest atrial ventricular diameter (at the level of the glomus of the choroid plexus) measured 8–10 mm and with moderate/severe ventriculomegaly if it measured >10 mm.\textsuperscript{26} Intraventricular hemorrhage was classified according to the Papile grading system.\textsuperscript{27}

**Adolescent Attention Assessments**

A psychologist blinded to imaging findings administered performance-based measures and parent report forms targeting attention. Attentional problems in most subjects (n = 17 of the 24
Table 1: Neonatal clinical characteristics of the study participants

<table>
<thead>
<tr>
<th>Abnormal Attention</th>
<th>No (n = 12)</th>
<th>Yes (n = 12)</th>
<th>P Valueb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>6</td>
<td>6</td>
<td>1.0</td>
</tr>
<tr>
<td>Gestational age at birth (mean) (wk)</td>
<td>29.4 ± 1.83</td>
<td>27.8 ± 2.9</td>
<td>0.93</td>
</tr>
<tr>
<td>BW (median) (IQR) (g)</td>
<td>1167 (900–1365)</td>
<td>875 (708–898)</td>
<td>0.43</td>
</tr>
<tr>
<td>BW z score, (median) (IQR)</td>
<td>−0.35 (−1.05–0.48)</td>
<td>−0.22 (−0.73–0.34)</td>
<td>0.82</td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td>6</td>
<td>4</td>
<td>0.41</td>
</tr>
<tr>
<td>Intubated at birth</td>
<td>5</td>
<td>11</td>
<td>0.27</td>
</tr>
<tr>
<td>Apgar 5 (median) (IQR)</td>
<td>8 (6.5–8)</td>
<td>5.5 (5.5–8)</td>
<td>0.84</td>
</tr>
<tr>
<td>Apgar 10 (median) (IQR)</td>
<td>7 (4–7)</td>
<td>6.5 (5–8)</td>
<td>0.56</td>
</tr>
<tr>
<td>Hypotension</td>
<td>5</td>
<td>10</td>
<td>0.89</td>
</tr>
<tr>
<td>Patent ductus arteriosus</td>
<td>2</td>
<td>7</td>
<td>0.89</td>
</tr>
<tr>
<td>Necrotizing enterocolitis</td>
<td>0</td>
<td>5</td>
<td>0.37</td>
</tr>
<tr>
<td>Chronic lung disease</td>
<td>1</td>
<td>6</td>
<td>0.69</td>
</tr>
<tr>
<td>Neonatal surgery</td>
<td>2</td>
<td>8</td>
<td>0.36</td>
</tr>
<tr>
<td>Infection</td>
<td>2</td>
<td>10</td>
<td>0.22</td>
</tr>
</tbody>
</table>

Note: —BW indicates birth weight; IQR, interquartile range.

a All neonates with necrotizing enterocolitis had surgery.
b Kruskal-Wallis for continuous variables; Fisher exact test for categoric variables.

subjects included in this study) were evaluated using the Test of Variables of Attention (TOVA), a continuous performance test used to measure the speed and accuracy of attentional processing. Negative TOVA Attention Comparison Scores were interpreted as indicative of attentional problems. Six subjects were evaluated using the Conners Comprehensive Behavior Rating Scales, suitable for assessing children ages 6–18. Conners attention t-scores of >60 were interpreted as indicative of attentional problems. One subject was evaluated using the Child Behavior Checklist. The Child Behavior Checklist attention t-scores of >66 were interpreted as indicative of attentional problems. The comparability of ADHD-related metrics has been previously reported for the TOVA and Child Behavior Checklist, and for the TOVA and Conners Rating Scales.

Adolescent MR Imaging Data Acquisition and Processing

Each adolescent underwent an hour-long MR imaging protocol using a 3T MR750 MR imaging scanner (GE Healthcare, Milwaukee, Wisconsin) and a 32-channel Nova Medical head coil (Siemens, Erlangen, Germany). The scan included a standard T1-weighted sequence and a spin-echo echo-planar DTI sequence (TR = 7.5 seconds, minimum TE, FOV = 25.6 cm with a 128 × 128 matrix, slice thickness = 2 mm). Diffusion-sensitizing gradients were applied at a b-value of 1000 s/mm² along 30 noncollinear directions. An array spatial sensitivity encoding technique acceleration factor was set to 2, resulting in a sequence scan time of 4 minutes.

Preprocessing was performed using the FMRIB Software Library (FSL 5.0.8; http://www.fmrib.ox.ac.uk/fsl) and Matlab (MathWorks, Natick, Massachusetts). A quality-assurance step was performed, in which diffusion volumes affected by motion were rejected and the remaining images were corrected for eddy current distortions, affine head motion, and b-vector rotation. DTI reconstruction and deterministic whole-brain streamline fiber tractography were performed using the Diffusion Toolkit (TrackVis; http://www.trackvis.org/dtk/). For whole-brain tractography, the Fiber Assignment by Continuous Tracking algorithm with 1 seed per voxel was applied using the entire diffusion-weighted volume as the mask image. Streamlines were terminated if the tract curvature exceeded 35°, a value chosen on the basis of previous work in adolescents.

Each brain was segmented into ROIs using the Automated Anatomical Labeling (AAL; https://omictools.com/aal-tool) atlas. Only 90 cerebral regions were considered, because the cerebellum is often affected by stronger artifacts and is not always fully covered in the FOV. T1-weighted data were registered to the B0 volume of the DTI dataset and to the Montreal Neurological Institute space template using the FMRIB Linear Image Registration Tool (FLIRT; http://www.fmrib.ox.ac.uk/fsl/fslwiki/FLIRT).

This step allowed the application of the AAL atlas in the DTI space to produce the 90 nodes of the network. The registration and segmentation results were visually inspected for errors. The resultant ROIs were dilated by 1 voxel. To define the connections between the ROIs, we considered only streamlines with at least 5 points, and we used the average FA value within voxels along streamlines connecting the ROIs as a proxy for the connectivity strength.

Statistical Analysis

Adolescent Structural Connectivity Analysis. Our main assumption was that aberrant connectivity underlies attentional problems. To test whether significant associations between connectivity and attention exist, we performed t tests using attention as the grouping variable. We did not assume that the connections associated with this contrast of interest form a connected component. To control for the massive number of multiple comparisons, we applied a standard link-based controlling procedure, the false discovery rate (FDR). We used the implementation in Matlab by Zalesky et al with default parameters (a significance value of 0.05 and 1000 permutations). In this context, the FDR is referred to as a link-based controlling procedure because each link is treated independently for the sake of the family-wise error rate control.

The rest of the statistical analyses were performed using SPSS Statistics software (Version 25; IBM, Armonk, New York). Neonatal predictors of attentional problems in adolescence were tested using the Kruskal-Wallis test for continuous variables and the Fisher exact test for categoric variables. Neonatal predictors of abnormal structural connectivity associated with attentional problems in teens were investigated using a linear regression model with abnormal connectivity as the dependent variable and neonatal clinical and imaging metrics and the age at the adolescent MR imaging visit as independent variables. Additionally, the number of rejected diffusion volumes affected by motion was compared between the groups of adolescents with normal and abnormal attention using the independent-samples t test.

No matching of intelligence quotient (IQ) was performed in the analyses because this can be problematic in the case of children...
with attentional problems. On the traditional Wechsler IQ tests, the subtests tend to be rote, repetitive, and require attention and memory and are difficult for a child with attentional problems, and he or she may therefore perform slowly and/or inaccurately.43

RESULTS

Of the 24 adolescents, 12 have been determined to have attention deficits (6 girls/6 boys). There were no statistically significant differences in the number of rejected diffusion-weighted volumes, indicating that adolescents’ movements during the MR imaging scan did not differ depending on the attentional problems ($t = 1.1, P = .28$).

Neonatal Predictors of Attentional Problems in Adolescence

Details about the participants’ neonatal characteristics grouped by attentional deficits can be found in Tables 1 and 2. The groups did not differ significantly by sex, gestational age at birth, or birth weight $z$ scores (Table 1). However, there was a group difference in variables that denote increased illness severity, with infection, necrotizing enterocolitis, neonatal surgery, and intubation at birth reaching statistical significance (Table 1). Among neonatal scan results, only WMI at the first neonatal scan indicated a potential difference between the 2 groups with normal and abnormal attention ($P = .05$) (Table 2).

Adolescent Structural Connectivity Correlates of Attentional Problems

A set of tracts connecting frontal, parietal, temporal, and occipital lobes, including frontal cortices and subcortical regions, had significantly lower FA values in adolescents with attentional problems compared with those with normal attention. Connections

<table>
<thead>
<tr>
<th>Table 2: Neonatal scan results for study participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal Attention</td>
</tr>
<tr>
<td>---------------------</td>
</tr>
<tr>
<td>Scan 1</td>
</tr>
<tr>
<td>WMI*</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Severe</td>
</tr>
<tr>
<td>IVH</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Grade I</td>
</tr>
<tr>
<td>Grade II</td>
</tr>
<tr>
<td>Grade III</td>
</tr>
<tr>
<td>Grade IV</td>
</tr>
<tr>
<td>VM</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate/severe</td>
</tr>
<tr>
<td>Scan 2</td>
</tr>
<tr>
<td>WMI</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate</td>
</tr>
<tr>
<td>Severe</td>
</tr>
<tr>
<td>IVH</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Grade I</td>
</tr>
<tr>
<td>Grade II</td>
</tr>
<tr>
<td>Grade III</td>
</tr>
<tr>
<td>Grade IV</td>
</tr>
<tr>
<td>VM</td>
</tr>
<tr>
<td>Absent</td>
</tr>
<tr>
<td>Mild</td>
</tr>
<tr>
<td>Moderate/severe</td>
</tr>
</tbody>
</table>

Note: IVH indicates intraventricular hemorrhage; VM, ventriculomegaly.

*Note for WMI, scan 1, when dichotomized as absent/mild vs moderate/severe, $P = .16$.}

FIG 1. Results of the connection-wise group comparison of connectivity matrices using an FDR-corrected $t$ test with 1000 permutations ($P = .05$). The connections highlighted in blue (46 edges, involving 44 nodes) were statistically significantly weaker in the attention deficit group. The connection highlighted in red, between the left precuneus and left middle temporal gyrus, was the most statistically significantly hypoconnected interlobular connection.
that survived the FDR correction are presented in Fig 1 and Tables 3 and 4. Connections of the left middle temporal gyrus were the most prevalent hypoconnected connections (10 connections), and among them, the most statistically significantly hypoconnected interlobular connection was the left precuneus–left middle temporal gyrus connection (test statistic: 4.18; average FA of 0.34 in the inattention group compared with 0.37 in the group with normal attention), which we explored further. Figure 2 shows an example of the participant’s tractography streamlines going through the left precuneus and left middle temporal gyrus. None of the connections were stronger in the inattention group compared with the group with normal attention.

Table 3: Structural connectivity analysis results—connections with weaker connectivity in the inattention group that survived the FDR correction*

<table>
<thead>
<tr>
<th>Connection (AAL Abbreviation)</th>
<th>Test Statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frontal_Sup_Orb_L to Frontal_Inf_Tri_L</td>
<td>3.39</td>
</tr>
<tr>
<td>Frontal_Mid_L to Frontal_Inf_Tri_L</td>
<td>4.12</td>
</tr>
<tr>
<td>Frontal_Inf_Oper_L to Frontal_Inf_Tri_L</td>
<td>4.16</td>
</tr>
<tr>
<td>Frontal_Mid_R to Frontal_Inf_Tri_R</td>
<td>3.61</td>
</tr>
<tr>
<td>Frontal_Mid_L to Frontal_Inf_Orb_L</td>
<td>3.75</td>
</tr>
<tr>
<td>Frontal_Mid_Orb_L to Cingulum_Mid_L</td>
<td>2.82</td>
</tr>
<tr>
<td>Olfactory_R to Cingulum_Post_L</td>
<td>4.56</td>
</tr>
<tr>
<td>Frontal_Sup_Orb_L to Cingulum_Post_R</td>
<td>3.72</td>
</tr>
<tr>
<td>Olfactory_R to Cingulum_Post_R</td>
<td>4.01</td>
</tr>
<tr>
<td>Rolandic_Oper_L to Amygdala_L</td>
<td>2.74</td>
</tr>
<tr>
<td>Cingulum_Mid_L to Parietal_Sup_L</td>
<td>4.12</td>
</tr>
<tr>
<td>Cingulum_Mid_R to Parietal_Sup_L</td>
<td>3.87</td>
</tr>
<tr>
<td>Cingulum_Mid_R to Parietal_Sup_R</td>
<td>3.52</td>
</tr>
<tr>
<td>Precentral_L to Parietal_Inf_L</td>
<td>4.31</td>
</tr>
<tr>
<td>Cingulum_Mid_L to Parietal_Inf_L</td>
<td>4.10</td>
</tr>
<tr>
<td>Cingulum_Mid_R to Parietal_Inf_L</td>
<td>4.72</td>
</tr>
<tr>
<td>Cingulum_Post_L to Parietal_Inf_L</td>
<td>4.11</td>
</tr>
<tr>
<td>Cingulum_Post_R to Parietal_Inf_L</td>
<td>4.48</td>
</tr>
<tr>
<td>Postcentral_L to Parietal_Inf_L</td>
<td>4.44</td>
</tr>
<tr>
<td>Parietal_Sup_L to Parietal_Inf_L</td>
<td>5.40</td>
</tr>
<tr>
<td>Parietal_Sup_R to Parietal_Inf_L</td>
<td>3.45</td>
</tr>
<tr>
<td>Supp_Motor_Area_R to SupraMarginal_L</td>
<td>2.34</td>
</tr>
<tr>
<td>Parietal_Inf_L to SupraMarginal_L</td>
<td>3.48</td>
</tr>
<tr>
<td>Frontal_Sup_Medial_R to Angular_L</td>
<td>2.6</td>
</tr>
<tr>
<td>Fusiform_L to Putamen_L</td>
<td>3.49</td>
</tr>
<tr>
<td>Parietal_Sup_L to Temporal_Sup_L</td>
<td>2.37</td>
</tr>
<tr>
<td>Precentral_L to Temporal_Pole_Sup_L</td>
<td>3.73</td>
</tr>
<tr>
<td>Precentral_L to Temporal_Sup_L</td>
<td>2.30</td>
</tr>
<tr>
<td>Cingulum_Mid_L to Temporal_Pole_Sup_L</td>
<td>2.41</td>
</tr>
<tr>
<td>Hippocampus_L to Temporal_Mid_L</td>
<td>3.33</td>
</tr>
<tr>
<td>Hippocampus_R to Temporal_Mid_L</td>
<td>3.56</td>
</tr>
<tr>
<td>ParaHippocampal_L to Temporal_Mid_L</td>
<td>3.75</td>
</tr>
<tr>
<td>Amygdala_L to Temporal_Mid_L</td>
<td>3.38</td>
</tr>
<tr>
<td>Calcarine_R to Temporal_Mid_L</td>
<td>3.81</td>
</tr>
<tr>
<td>Lingual_L to Temporal_Mid_L</td>
<td>3.65</td>
</tr>
<tr>
<td>Lingual_R to Temporal_Mid_L</td>
<td>3.21</td>
</tr>
<tr>
<td>Fusiform_L to Temporal_Mid_L</td>
<td>3.45</td>
</tr>
<tr>
<td>Precuneus_L to Temporal_Mid_L</td>
<td>4.18</td>
</tr>
<tr>
<td>Temporal_Sup_L to Temporal_Mid_L</td>
<td>4.35</td>
</tr>
<tr>
<td>Palilium_R to Temporal_Mid_R</td>
<td>3.44</td>
</tr>
<tr>
<td>Frontal_Inf_Tri_L to Temporal_Pole_Mid_L</td>
<td>2.33</td>
</tr>
<tr>
<td>Rolandic_Oper_L to Temporal_Pole_Mid_L</td>
<td>2.08</td>
</tr>
<tr>
<td>Hippocampus_L to Temporal_Pole_Mid_L</td>
<td>3.46</td>
</tr>
<tr>
<td>Temporal_Mid_L to Temporal_Pole_Mid_L</td>
<td>3.59</td>
</tr>
<tr>
<td>Temporal_Sup_R to Temporal_Pole_Mid_R</td>
<td>3.25</td>
</tr>
</tbody>
</table>

* AAL abbreviations can be found in Table 4.

Table 4: AAL abbreviations and standardized names of the corresponding brain regions

<table>
<thead>
<tr>
<th>AAL Abbreviation</th>
<th>Standardized Name of the Brain Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amygdala</td>
<td>Amygdala</td>
</tr>
<tr>
<td>Angular</td>
<td>Angular</td>
</tr>
<tr>
<td>Calcarine</td>
<td>Calcarine fissure and surrounding cortex</td>
</tr>
<tr>
<td>Caudate</td>
<td>Caudate nucleus</td>
</tr>
<tr>
<td>Cingulum_Mid</td>
<td>Median cingulate and paracingulate gyri (&gt;20% overlap with anterior cingulate)</td>
</tr>
<tr>
<td>Cingulum_Post</td>
<td>Posterior cingulate gyrus</td>
</tr>
<tr>
<td>Frontal_Inf_Oper</td>
<td>Inferior frontal gyrus, opercular part</td>
</tr>
<tr>
<td>Frontal_Inf_Orb</td>
<td>Inferior frontal gyrus, orbital part</td>
</tr>
<tr>
<td>Frontal_Inf_Tri</td>
<td>Inferior frontal gyrus, triangular part</td>
</tr>
<tr>
<td>Frontal_Mid</td>
<td>Middle frontal gyrus</td>
</tr>
<tr>
<td>Frontal_Mid_Orb</td>
<td>Middle frontal gyrus, orbital part</td>
</tr>
<tr>
<td>Frontal_Sup_Medial</td>
<td>Superior frontal gyrus, medial</td>
</tr>
<tr>
<td>Frontal_Sup_Orb</td>
<td>Superior frontal gyrus, orbital part</td>
</tr>
<tr>
<td>Fusiform</td>
<td>Fusiform</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>Hippocampus</td>
</tr>
<tr>
<td>Lingual</td>
<td>Lingual</td>
</tr>
<tr>
<td>Olfactory</td>
<td>Olfactory cortex</td>
</tr>
<tr>
<td>Pallidum</td>
<td>Lenticular nucleus, pallidum</td>
</tr>
<tr>
<td>ParaHippocampal</td>
<td>Parahippocampal gyrus</td>
</tr>
<tr>
<td>Parietal_Inf</td>
<td>Inferior parietal, excluding supramarginal and angular gyri</td>
</tr>
<tr>
<td>Parietal_Sup</td>
<td>Superior parietal gyrus</td>
</tr>
<tr>
<td>Postcentral</td>
<td>Postcentral gyrus</td>
</tr>
<tr>
<td>Precentral</td>
<td>Precentral gyrus</td>
</tr>
<tr>
<td>Precuneus</td>
<td>Precuneus</td>
</tr>
<tr>
<td>Putamen</td>
<td>Lenticular nucleus, putamen</td>
</tr>
<tr>
<td>Rolandic_Oper</td>
<td>Rolandic operculum</td>
</tr>
<tr>
<td>Supp_Motor_Area</td>
<td>Supplementary motor area</td>
</tr>
<tr>
<td>SupraMarginal</td>
<td>Supramarginal gyrus</td>
</tr>
<tr>
<td>Temporal_Mid</td>
<td>Middle temporal gyrus</td>
</tr>
<tr>
<td>Temporal_Pole_Mid</td>
<td>Temporal pole, middle temporal gyrus</td>
</tr>
<tr>
<td>Temporal_Pole_Sup</td>
<td>Temporal pole, superior temporal gyrus</td>
</tr>
<tr>
<td>Temporal_Sup</td>
<td>Superior temporal gyrus</td>
</tr>
</tbody>
</table>

Neonatal Predictors of Abnormal Structural Connectivity Associated with Attentional Problems in Adolescents

Linear regression analysis was performed with left precuneus–left middle temporal gyrus connectivity as the dependent variable and neonatal clinical and imaging metrics and the age at the adolescent MR imaging visit as independent variables. Only low birth weight in grams and ventriculomegaly detected at the second neonatal scan independently and statistically significantly predicted hypoconnectivity between the left precuneus and left middle temporal gyrus (t = 4.874, P < .000 and t = 4.617, P < .000, respectively). None of the other variables showed statistical significance (neonatal clinical characteristics listed in Table 1 or neonatal scan results listed in Table 2, or age at the adolescent MR imaging visit). Similar results were obtained using the average FA as the dependent variable: Low birth weight and ventriculomegaly at the second neonatal scan independently and statistically significantly predicted hypoconnectivity between the left precuneus and left middle temporal gyrus (t = 2.382, P = .027; R² = 0.213. Figure 3 shows a scatterplot of the
variables. The result remained significant when using birth weight z scores.

DISCUSSION
The results of this study indicate that attentional problems in adolescents who were born prematurely may be associated with a weaker structural connectivity among the frontal, parietal, temporal, and occipital lobes, including frontal cortices and subcortical regions. The resulting hypoconnected edges linked to attentional problems in our study are known to underlie general attentional processes. Specifically, the frontoparietal attentional network is known to facilitate voluntary spatial attention, whereas reorienting of attention recruits other brain areas, such as the temporoparietal junction and lateral inferior frontal cortex.

Our findings are generally supported by previous literature reporting microstructural abnormalities in children formally diagnosed with ADHD and in prematurely born children, as well as by the structural network analysis literature in children with ADHD, though contradictory results have been reported. Among other regions, we detected lower connectivity of the left middle temporal gyrus to other regions in the subjects with attentional deficits. This finding is aligned with results published by Lei et al., who observed microstructural abnormalities in the left middle temporal gyrus in children with ADHD, inattentive type. Most interesting, they also observed microstructural disruptions within the right middle temporal gyrus in children with the combined ADHD types compared with controls. Our results indicate a weaker connectivity between the right pallidum and the right middle temporal gyrus in the group with attentional deficits, which is also consistent with those findings.

The conflicting findings within the ADHD literature are, however, of particular interest. Different etiologies might be the reason for some of these differences. Specifically, in a study by Beare et al., individuals with ADHD presented with a subnetwork of stronger connectivity encompassing bilateral frontostriatal connections as well as left occipital, temporal, and parietal regions, in which the white matter microstructure was associated with ADHD symptom severity. This result differs from those in previous studies, as well as from the study described here. The prematurity status was, however, not reported in these prior studies. The only previous study linking prematurity, ADHD, and white matter metrics is the one by Skranes et al., which investigated the relationship between clinical findings and FA measurements in white matter of 34 adolescents born prematurely with very low birth weights compared with 47 age-matched controls born at term. In their study, high inattention scores on the ADHD Rating Scale (based on mothers’ reports) correlated with low FA values in the right superior and left middle fasciculus.

Previous studies have reported that adolescents with very low birth weights are more likely to have attention and/or executive function difficulties.

FIG 2. Left: example of study participant’s whole-brain tractography. Right: tractography streamlines going through the left precuneus (purple) and left middle temporal gyrus (blue). The anterior cingulate cortex is shown in red; the thalamus, in green.

FIG 3. Linear regression: left precuneus–left middle temporal gyrus connectivity as a dependent variable and birth weight as independent variable.

FIG 4. A model that describes the relationship between neonatal characteristics of prematurely born children, structural brain connectivity at adolescence, and attention at adolescence. The model is supported by the findings of this study.
function deficits compared with controls, which is consistent with our findings. In our study, low birth weight and ventriculomegaly (but not white matter injury or intraventricular hemorrhage) detected on the neonatal MR imaging were associated with altered temporoparietal connectivity in adolescence. Because ventriculomegaly was only detected in 1 study participant, we do not draw any conclusions. The obtained results are summarized in the model in Fig 4. A potential explanation for the association of low birth weight (but not gestational age) with temporoparietal hypoconnectivity is the substantial risk of children with very low birth weights for perinatal hemorrhages and injury. The subsequent hypoconnectivity can be caused by perinatal white matter damage that has long-term effects on myelin disturbances, disorganization, or a reduced number of axons in projectional, commissural, and association tracts. Although neonatal white matter injury or intraventricular hemorrhage was not associated with hypoconnectivity in adolescence in our study, this may relate to the lower resolution of MR images 14 years ago when some of the neonatal scans were performed, as well as limited power to detect a difference between groups, given the small sample size. Lower birth weight was also associated with other markers of illness severity, which, in turn, were also linked to inattention, and it is likely that unmeasured variables are a source of residual confounding. Additionally, other factors (eg, parenting style, adverse events, and so forth) may have a strong influence on performance in attentional tasks.

Several methodologic limitations need to be considered when interpreting our findings. First, a DTI-based tractography method was used to reconstruct structural brain networks, which is the most widely used tractography method but is limited in terms of its capacity for resolving crossing fibers. Second, our study did not include a typically developing control group or a group of term-born adolescents with attentional problems. Third, the assessment of attention in creating the binary variable of the attention/inattention group was nonuniform across subjects. Finally, the study sample was limited and included only 24 adolescents who came for the 10- to 14 year follow-up visit and had diffusion MR imaging data. Nevertheless, the main result of an aberrant structural connectivity associated with attentional problems was statistically significant after correction for multiple comparisons. This result contributes to our understanding of the mechanisms underlying the development of attentional deficits in children born prematurely and can help direct future studies.

It would be advantageous if future studies of aberrant neural networks in ADHD included information about the gestational age at birth (prematurity) of study participants. Another important step would be a comparison of 4 groups in 1 study: term-born adolescents without attention deficits, term-born adolescents with attention deficits, pre-term-born adolescents without attention deficits, and pre-term-born adolescents with attention deficits.

CONCLUSIONS
In this study, we examined network-level neural correlates of attentional deficits in adolescents born prematurely as well as neonatal predictors of those neural correlates and attentional problems. Our major findings are the hypoconnected axonal tracts in the frontal, parietal, temporal, and occipital lobes in adolescents with attentional problems, with temporoparietal connection being the most prominent and low birth weight being a predictor of this hypoconnectivity. This knowledge could lead to a better understanding of the mechanisms that play a role in the development of attentional deficits in children/adolescents born prematurely and could possibly lead to new therapeutic agents and additional interventions.

ACKNOWLEDGMENTS
We would like to thank all of the study participants and their parents who made this work possible. We also thank Drs Bridget Johnson and Elizabeth Rogers for their help with the psychological assessments of the study participants. Finally, we thank Laurel Hausslein, Veronica de Santiago, Shrey Goel, and Kristyn Casalino for the study coordination.

REFERENCES

Spinal Coccidioidomycosis: MR Imaging Findings in 41 Patients

R.N. Crete, W. Gallmann, J.P. Karis, and J. Ross

ABSTRACT

BACKGROUND AND PURPOSE: Coccidioides immitis is a dimorphic fungus endemic to the Southwest United States and Mexico, and at our institution, it is a relatively common pathogen presenting with a broad spectrum of associated spine diseases. We describe the various spinal manifestations resulting from coccidioidal infection and provide MR imaging examples from 41 pathologically proved cases.

MATERIALS AND METHODS: Retrospective electronic medical record and PACS searches were performed. Patients found to have both MR imaging findings positive for infection and confirmative biopsy and/or CSF studies were included. Abnormal MR imaging findings were identified, categorized, and quantified. Patient demographics and associated intracranial involvement if present were also recorded.

RESULTS: Forty-one patients were included. Positive findings were categorized as leptomeningeal enhancement (26 patients, 63%), arachnoiditis (22 patients, 54%), osteomyelitis-discitis (14 patients, 34%), cord edema (11 patients, 27%), and true syrinx (3 patients, 7%). Thirty patients had documented brain involvement (73%), most commonly in the form of basilar meningitis. Four patients were positive for HIV (10%). Fifteen patients had pulmonary manifestations at presentation (37%).

CONCLUSIONS: C. immitis results in various spinal manifestations, most commonly leptomeningeal enhancement and arachnoiditis/adhesive disease followed by osteomyelitis, which may resemble tuberculous or pyogenic infection on MR imaging.

ABBREVIATION: T1+C = T1-weighted images with contrast

Coccidioides immitis is a dimorphic fungus well-known to be endemic to the Southwest United States and Mexico.1,2 At our institution, we experience C. immitis as a relatively common pathogen, presenting with variable pulmonary, intracranial, and spinal diseases regardless of immune status. The spectrum of spine disease reported in the literature is extensive, with involvement of the leptomeninges, epidural/paraspinal space, vertebral bodies both with and without disc involvement, and, rarely, the spinal cord. Although previous case reports and articles have discussed the imaging appearance of spinal coccidioidomycosis, to our knowledge, there has not been a comprehensive review of both intrathecal and vertebral/paraspinal involvement of this magnitude.3-9

We describe the spinal MR imaging findings from 41 patients with pathologically proved Coccidioides infection.

MATERIALS AND METHODS

This retrospective study was approved by the St. Joseph Hospital and Medical Center institutional review board and was conducted in accordance with Health Insurance Portability and Accountability Act guidelines.

A broad retrospective search was performed using the electronic medical record for patients with a history of coccidioidomycosis during a 6-year period. Key words used for the search included “Coccidioides,” “coccidioidomycosis,” “coccid,” and “valley fever.” Patients were screened with spinal MR imaging and individually overread to evaluate abnormal findings. Patients with an abnormal spine MRI were then cross-referenced for evidence of true coccidioidal infection. True infection was defined as culture positive for C. immitis obtained from a paraspinal mass, fluid collection, or vertebral body or positive CSF complement fixation titers. Only patients found to have both MR imaging findings positive for infection and laboratory evidence of true infection were included. Abnormal MR imaging findings were categorized as cord edema, syrinx, cord enhancement, leptomeningeal...
Table 1: Patient demographics

<table>
<thead>
<tr>
<th>Ethnicity</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>17 (41)</td>
</tr>
<tr>
<td>African American</td>
<td>12 (29)</td>
</tr>
<tr>
<td>Latino</td>
<td>7 (17)</td>
</tr>
<tr>
<td>Native American</td>
<td>3 (7)</td>
</tr>
<tr>
<td>Asian</td>
<td>2 (5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sex</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>34 (83)</td>
</tr>
<tr>
<td>Female</td>
<td>7 (17)</td>
</tr>
</tbody>
</table>

| Patient age (mean) (SD) (yr) | 42.0 (14.7) |

Table 2: Abnormal findings on spinal MR imaging

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leptomeningeal enhancement</td>
<td>26 (63)</td>
</tr>
<tr>
<td>Arachnoid adhesive disease</td>
<td>22 (54)</td>
</tr>
<tr>
<td>Osteomyelitis/discitis</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Cord edema</td>
<td>11 (27)</td>
</tr>
<tr>
<td>Syrinx</td>
<td>3 (7)</td>
</tr>
</tbody>
</table>

Table 3: Distribution of intrathecal disease

<table>
<thead>
<tr>
<th>Location</th>
<th>Leptomeningeal Enhancement</th>
<th>Adhesive Arachnoiditis</th>
<th>Cord Edema/Syrinx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical</td>
<td>23</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>Thoracic</td>
<td>20</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>Lumbar</td>
<td>19</td>
<td>18</td>
<td>NA</td>
</tr>
</tbody>
</table>

Table 4: Osteomyelitis-discitis distribution and characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Segment</td>
<td></td>
</tr>
<tr>
<td>Cervical</td>
<td>5 (36)</td>
</tr>
<tr>
<td>Thoracic</td>
<td>11 (79)</td>
</tr>
<tr>
<td>Lumbar</td>
<td>9 (64)</td>
</tr>
<tr>
<td>Characteristic</td>
<td></td>
</tr>
<tr>
<td>Paraspinal involvement</td>
<td>11 (78)</td>
</tr>
<tr>
<td>Disc involvement</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Skip levels</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Destructive (osseous)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Epidural involvement</td>
<td>6 (43)</td>
</tr>
<tr>
<td>Well-circumscribed (osseous)</td>
<td>5 (36)</td>
</tr>
<tr>
<td>Well-circumscribed (paraspinal)</td>
<td>4 (29)</td>
</tr>
<tr>
<td>Disc sparing with involvement of adjacent levels</td>
<td>2 (14)</td>
</tr>
<tr>
<td>Gibbus deformity</td>
<td>1 (7)</td>
</tr>
</tbody>
</table>

Table 5: Disease involvement and overlap

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrathecal disease</td>
<td>30 (73)</td>
</tr>
<tr>
<td>Discitis-osteomyelitis</td>
<td>14 (34)</td>
</tr>
<tr>
<td>Overlap</td>
<td>3 (7)</td>
</tr>
</tbody>
</table>

RESULTS

Forty-one patients with confirmed C. immitis were identified as having abnormalities on spinal MR imaging. Of the 41 patients, 34 were men (83%) and 7 were women (17%). Seventeen patients were white (41%); 12, African American (29%); 7, Latino (17%); 3, Native American (7%); and 2, Asian (5%) (Table 1). The average patient age was 42.0 ± 14.7 years.

Abnormal findings on intrathecal, vertebral/spinal, and intracranial MR imaging are addressed below and are summarized in Tables 2–5.

The most common finding was leptomeningeal enhancement (26 of 41 patients, 63%) (Fig 1), often associated with arachnoiditis/adhesive disease (22 of 41, 54%) (Fig 2). Cord edema was observed in 11 patients (27%) (Fig 3A), and true syrinx was observed in 3 patients (7%) (Fig 3B–D). Cord enhancement was not definitively observed.

The distribution of intrathecal findings is summarized in Table 3. Leptomeningeal enhancement was most often diffuse and affected the cervical cord, thoracic cord, and conus medullaris/cauda equina fairly evenly (23, 20, and 19 patients, respectively). Adhesive arachnoiditis was most common in the lumbar spine where nerve root clumping was the most common finding (18 patients). Cervical and thoracic cord adhesive disease was observed in 14 and 11 patients, respectively. Collectively, cord edema and syrinx were observed equally in the cervical and thoracic cord (9 patients each). In total, 30/41 (73%) patients had intrathecal involvement.

Fourteen of 41 patients presented with vertebral osteomyelitis and/or discitis (34%, Fig 4). Disease distribution and characteristics are summarized in Table 4. Paraspinal involvement (Figs 5 and 6) was most common, occurring in 11 patients. Disc involvement, osseous destruction (Fig 4A), and skip lesions involving noncontiguous vertebral bodies occurred in 7 patients each. Epidural involvement (Figs 5 and 6) was identified in 6 patients. Well-circumscribed osteomyelitis was observed in 5 patients; 2 instances involved the disc space. Four patients had a well-circumscribed paravertebral epidural phlegmon as well (Fig 4B). Sparing of the disc space and involvement of adjacent vertebral levels in a pattern resembling tuberculosis was observed in 2 patients (Fig 4C). Gibbus deformity (focal kyphosis) was observed in 1 patient (Fig 6). The thoracic spine was most commonly involved (11 patients).

Intracranial disease was identified in each (30/30) patient with intrathecal disease. Twenty-seven of 30 patients had MR imaging of the brain performed, while 3 other patients had evidence of posterior fossa involvement by cervical MR imaging. Nineteen of 30 (63%) had either exclusively basilar or basilar-predominant leptomeningeal enhancement, while 4 patients (13%) had diffuse leptomeningeal enhancement. Less typical intracranial manifestations identified included the following: middle cranial fossa enhancement, arachnoiditis, and osteomyelitis-discitis with or without epidural/paraspinal abscess/phlegmon. Cord edema and syrinx were differentiated from one another by the degree of hypointensity on T1, in which syrinx more closely followed the CSF signal. Patient demographics, immune status, and the presence of associated intracranial or pulmonary involvement were also recorded.

During the 6-year period, patients were scanned using either GE (GE Healthcare, Milwaukee, Wisconsin) or Phillips (Phillips Healthcare, Best, the Netherlands) magnets at 1.5 or 3T. All patients included received intravenous gadolinium. Patients did not require total spine imaging to be included in the study.

Patients with intrathecal disease were screened for brain MR imaging and intracranial involvement. In patients without brain MR imaging, the posterior fossa was reviewed on cervical spine MR imaging to assess basilar meningitis.
pachymeningeal enhancement, diffuse pachymeningeal enhancement, preptontine abscess, suprasellar leptomeningeal enhancement, Sylvian fissure leptomeningeal enhancement, interpeduncular/infundibular enhancement, and right temporal lobe intra-axial and leptomeningeal enhancement.

Only three (7%) patients in our study group had both intrathecal and vertebral disease (Table 5). Each of these 3 patients had intracranial disease.

Four patients were positive for HIV (10%). Fifteen patients had documented pulmonary involvement (36%).

Patient clinical manifestations varied. Four patients (4/30) with intrathecal disease presented with acute myelopathy. Clinical
Spinal infection with *C. immitis* is relatively common at our institution due to its location within a highly endemic region. Morbidity is high, and treatment strategies are complex and often lengthy.10,11 These observations illustrate the importance of understanding characteristic imaging findings to aid in diagnosis, especially in areas where a high index of suspicion must be maintained.

Osteomyelitis-discitis is a well-known association of infection with *C. immitis*.3,4,7,8 However, leptomeningeal disease is a more common manifestation. Extensive leptomeningeal enhancement involving the entire neural axis is common and requires complete spinal and brain imaging to evaluate the full extent. Only 5 patients with leptomeningeal enhancement did not have evidence of adhesive disease, but all patients with adhesive disease had leptomeningeal enhancement, implicating both as related processes in which the antigen incites inflammation and inflammation plus exudate formation across time leads to adhesions.

The pathophysiology of the relationship to syrinx and cord edema is controversial. The Gardner hydrodynamic theory proposes that pulsatile ventricular CSF pressure is transmitted from the fourth ventricle to the central canal, eventually resulting in a progressive dilation (water-hammer effect).4 Only 1 case in our review demonstrated a dilated connection from the fourth ventricle to the central canal; however, it is most likely that syrinx and cord edema in the remainder of our patients are better explained by the theory that increased subarachnoid pressure due to CSF flow disturbances results in excess interstitial intramedullary fluid via the perivascular spaces.12 Increased intramedullary pulse pressures also promote circulatory disturbances within the cord and further intramedullary fluid accumulation. All patients with cord signal abnormality and syrinx had evidence of leptomeningeal disease.

Many patients with extensive leptomeningeal enhancement and cord edema were not myelopathic. This is congruent with the findings of Lammering et al,4 who noted that 7 of 8 patients with intrathecal disease were without back pain or radiculopathy. The 4 patients with myelopathy had syrinx formation or severe adhesion/cord deformity.

Meningitis is the most common and lethal form of disseminated coccidioidal disease, consisting of pyogranulomatous and fibroblastic processes affecting the meninges as well as the small vessels and perivascular zones.13 Once the intracranial meninges are involved, CSF dissemination can and often does occur. In our case review, 30/30 patients with intrathecal disease had evidence of intracranial involvement, most commonly in the form of basilar leptomeningitis (19/30). Lammering et al4 documented intracranial disease in 19/19 patients with intrathecal disease. It would appear that intracranial involvement either does not or is highly unlikely to occur in the absence of intracranial involvement.

Osteomyelitis-discitis seen in the study population often resembled pyogenic spondylitis with aggressive endplate destruction and paravertebral phlegmon formation (7/14) (Fig 4A).2 A common misconception is that coccidioidal spondylitis is identical to tuberculous disease. Osteomyelitis that clearly spares the disc space commonly evokes the differential diagnosis of tuberculosis/fungal infection. This is not altogether incorrect; however, it leads to secondary misperception by affiliation. It suggests that because *C. immitis* is a fungus, it cannot appear similar to pyogenic disease. The origin of this error may stem from a survey report in the 1960s in which the authors observed only a single *Trichophyton* among 30 different fungal species that were capable of collagen digestion. The group included all major dimorphic mycotic pathogens, with the exception of *C. immitis*.14,15 It was not until 1985 that a group in Nevada using different culture media observed that *C. immitis* could, in fact, digest collagen.16 The authors postulated that a fungal-specific collagenase or a more broadly functioning protease may be responsible. This finding appears to be unique to *C. immitis* among fungal species and explains the appearance often similar to pyogenic osteomyelitis-discitis.

Spinal infection with *Coccidioides* uncommonly resembled tuberculous spondylitis in our population, with sparing of the disc

---

**FIG 4.** Osteomyelitis-discitis. Sagittal STIR of the lumbar spine (A) shows destructive endplate changes similar to pyogenic disease at L3/4 with paravertebral phlegmon. Sagittal STIR of the lumbar spine (B) shows destructive endplate changes of L5/S1, but note the well-circumscribed nature of L5 and the L4 skip lesion. Sagittal STIR of the cervicothoracic junction (C) shows a well-circumscribed signal abnormality of the vertebral bodies with paravertebral phlegmon that appears to skip disc spaces, similar to tuberculous disease.

**FIG 5.** Axial T2 (A) and T1C+ (B) sequences demonstrate right T8–9 paraspinal and epidural phlegmon, producing mild effacement of the thecal sac and leftward cord displacement.

History was considered incomplete for 5 patients with intrathecal disease (25 had sufficient information obtained via the electronic medical record). The 4 are summarized as follows: quadriplegia secondary to severe cervical cord deformity/adhesive disease (Fig 7), quadriparesis secondary to a large loculated cervical cord syrinx (Fig 3C), neuropathic pain and quadriparesis secondary to cord edema and intermittent syrinx, and bilateral foot numbness secondary to extensive cord edema and arachnoid adhesive disease. Many other patients with ataxia had hydrocephalus along with other symptoms that could not be attributed solely to spinal disease.

**DISCUSSION**

Spinal infection with *C. immitis* is relatively common at our institution due to its location within a highly endemic region. Morbidity is high, and treatment strategies are complex and often lengthy.10,11 These observations illustrate the importance of understanding characteristic imaging findings to aid in diagnosis, especially in areas where a high index of suspicion must be maintained.

Because *C. immitis* is a fungus, it cannot appear similar to pyogenic disease. The origin of this error may stem from a survey report in the 1960s in which the authors observed only a single *Trichophyton* among 30 different fungal species that were capable of collagen digestion. The group included all major dimorphic mycotic pathogens, with the exception of *C. immitis*.14,15 It was not until 1985 that a group in Nevada using different culture media observed that *C. immitis* could, in fact, digest collagen.16 The authors postulated that a fungal-specific collagenase or a more broadly functioning protease may be responsible. This finding appears to be unique to *C. immitis* among fungal species and explains the appearance often similar to pyogenic osteomyelitis-discitis.

Spinal infection with *Coccidioides* uncommonly resembled tuberculous spondylitis in our population, with sparing of the disc.
spaces and involvement of adjacent vertebral levels (2/14) (Fig 4C).\(^{17}\) Most interesting, a common finding was that of a well-circumscribed osteomyelitis that does indeed involve the disc space (5/14) (Fig 4B), contrasting with typical aggressive pyogenic bone destruction. The authors of this study suggest the terminology of “clean” osteomyelitis-discitis when observing this pattern and considering coccidioidal disease, especially in endemic areas. Skip lesions are common, supporting the need for entire neuraxis imaging. Gibbus deformity, historically associated with tuberculous spondylitis, was observed in 1 patient.

Overlapping intrathecal/intracranial disease and spondylitis were observed in only 3 patients (7%). The lack of overlap suggests alternate routes of infection (eg, CSF seeding versus hematogenous spread).

Intramedullary spinal cord enhancement was not a finding associated with coccidioidal infection in our study population. Such involvement has been reported rarely in the form of intramedullary abscess and enhancing intramedullary lesions.\(^{18,19}\)

Men are much more commonly affected, potentially secondary to environmental/work exposure. The military has studied this extensively due to marine base locations in the San Joaquin Valley and frequent engagement in outdoor exercises.\(^{20,21}\) According to the 2016 US Census Bureau, 5% of the greater Phoenix, Arizona, population is composed of African Americans, and our study population was composed of 29% African Americans.\(^{22}\) This suggests a disproportionate amount of African Americans in the study group, implicating a predisposition, possibly due to genetics or secondary to occupational/environmental exposure. This finding is in concordance with other observations.\(^{2}\) Associated pulmonary disease is common and agrees with other investigations.\(^{4}\) Immunocompromised state is not required. In fact, only a minority of patients in our study were immunocompromised, suggesting complex host-pathogen interactions.

A recent neurosurgical review of spinal coccidioidomycosis included 140 patients and yielded similar patient characteristics. Males were disproportionately affected (95%) as were African Americans (52%). One-third of patients had concurrent pulmonary disease.\(^{23}\)

**CONCLUSIONS**

The pathology associated with *C immitis* infection is most commonly manifested as leptomeningeal enhancement and arachnoiditis, followed by osteomyelitis. Osteomyelitis and leptomeningeal disease are uncommonly seen simultaneously, suggesting different pathophysiology leading to infection. Cord edema and true syrinx states are secondary findings commonly seen in association with leptomeningeal disease. Coccidioidal spondylitis is protean and can mimic pyogenic spondylodiscitis, though it can also appear as well-circumscribed spondylitis with or without discitis. Skip lesions are common, necessitating imaging of the entire neuraxis. Myelopathy was an uncommon clinical presentation in

---

**FIG 6.** Sagittal T1 (A), STIR (B), and T1+C+ (C) images depict destructive thoracolumbar spondylodiscitis with obliteration of the central canal, multilevel height loss, and associated kyphosis (Gibbus deformity).

**FIG 7.** Sagittal T2-weighted image reveals severe multifocal cord tethering and deformity with associated intramedullary T2 signal at the C3 level.
our patient population, only documented in patients with syrinx or severe arachnoid adhesive disease.

REFERENCES

MR Neurography of the Lumbosacral Plexus for Lower Extremity Radiculopathy: Frequency of Findings, Characteristics of Abnormal Intraneural Signal, and Correlation with Electromyography

X J.L. Chazen, X J. Cornman-Homonoff, X Y. Zhao, X M. Sein, and X N. Feuer

ABSTRACT

BACKGROUND AND PURPOSE: MR neurography enables high resolution imaging of peripheral nerves. Our aim was to evaluate the utility of MR neurography in lumbosacral radiculopathy and correlate abnormal intraneural signal with history, physical examination, and abnormal electrodiagnostic study findings.

MATERIALS AND METHODS: Retrospective review of lumbosacral MR neurography examinations performed from December 2014 through January 2017 on a 3T scanner was undertaken. MR neurography examinations were independently reviewed in a blinded fashion by 2 radiologists, and the intraneural signal was graded on a 0–2 scale relative to adjacent vasculature. Abnormal nerve signal was correlated with subjective and objective findings from clinical notes in the electronic medical record and compared with results of electrodiagnostic studies (nerve conduction study/electromyography).

RESULTS: Three hundred three lumbosacral MR neurography examinations were performed during the study period, 64 of which met the inclusion criteria, including symptoms of radiculopathy on electromyography performed within 3 months of MR neurography. Twenty-nine (45%) MR neurography examinations had abnormal intraneural signal. There was no statistically significant correlation between subjective clinical findings and intraneural signal abnormality on MR neurography. There was a statistically significant correlation between abnormal intraneural T2 signal and findings of active radiculopathy on electromyography ($P < .001$).

CONCLUSIONS: Lumbosacral MR neurography appears to demonstrate abnormal intraneural signal in a substantial portion of patients with clinical symptoms of lower extremity radiculopathy and correlates with findings of active radiculopathy on electromyography. This finding further bolsters the growing body of evidence on the utility of MR neurography and suggests that abnormal intraneural signal may provide a useful adjunct to electrophysiological testing. Further research is required to evaluate the prognostic value of MR neurography, which may help guide therapeutic decision-making.

ABBREVIATIONS: EMG = electromyography; MRN = MR neurography; MUAP = motor unit action potential; NCS = nerve conduction study; SPAIR = spectral adiabatic inversion recovery

Lumbosacral radiculopathy has a prevalence of approximately 3%–5% in the general population.1 It affects men and women equally, though the onset in men is, on average, a decade earlier than in women.1 Clinical evaluation relies predominantly on history and physical examination. Electrodiagnostic testing including needle electromyography (EMG) has been described as an “extension” of the clinical examination but remains an imperfect test with a sensitivity ranging from 49% to 86% for lumbosacral radiculopathy.2,3 Despite its limitations, EMG can be a useful adjunct examination, given the high rate of false-positive findings on spinal MR imaging in asymptomatic individuals.4,5

MR neurography (MRN), first described in 1992, is a novel technique increasingly used in clinical practice to evaluate extraspinal neuropathy.6 The MRN technique relies on high-field-strength magnets, anisotropic diffusion along the nerve path, and fat-suppressed T2-based imaging with long TEs to optimize intraneural signal. Endoneural fluid and T2 signal are increased with nerve irritation and compression.7 A variety of neuropathies can be evaluated with MRN, including neoplastic, traumatic, and inflammatory/autoimmune disease.8 MRN of extraspinal nerve entrapment has generated particular interest. In an investigation by Lewis et al.,9 abnormal sciatic nerve signal and findings of entrapment were seen in 12 of 14 patients on MRN, with sciatica symptoms and unrevealing lumbar spine MR...
imaging. Furthermore, additional important anatomic findings such as a split piriformis muscle belly and aberrant sciatic nerve course can be evaluated at the time of MRN, influencing interventional and surgical decision-making.10

The role of MRN in the work-up of radiculopathy has been recently explored with promising results.11 There are scattered reports correlating MRN and EMG findings in individuals; however, it remains difficult to draw reliable conclusions about the agreement between MRN and EMG based on limited research studies in the literature with small sample sizes. Retrospective investigations suggest a significant rate of extraspinal pathology in patients with lower extremity radicular symptoms that can be detected with MRN sequences.12 The frequency of abnormal intraneural signal in patients presenting with lower extremity radiculopathy is not known.

This study evaluated the frequency of abnormal intraneural T2 signal abnormality in patients presenting with lumbosacral radiculopathy and correlates MRN abnormalities with those described on EMG. MRN can precisely identify abnormal signal in extraspinal nerves as they exit the neuroforamen and traverse anatomic corridors to join the lumbosacral plexus. This extraspinal signal abnormality may allow more accurate and specific evaluation of abnormal nerves responsible for clinical symptoms than traditional methods. Furthermore, extraspinal extraneural causes for symptomatology (eg, hip osteoarthritis masquerading as high lumbar “radicular” symptoms) can be identified at the time of MRN.

**MATERIALS AND METHODS**

**Study Participants**
Weill Cornell Medicine institutional review board approval was obtained for this retrospective study with a waiver of informed consent. Patients included in the analysis had clinical signs of active lower extremity radiculopathy and both a MR neurogram and EMG performed within a 3-month timeframe at our institution. Patients were excluded if they had spinal fusion hardware, which could limit the MR neurogram evaluation from susceptibility artifact.

**MR Imaging Protocol and Evaluation**
MR imaging was performed at 3T on a Magnetom Skyra platform (Siemens, Erlangen, Germany). The MRN imaging protocol is described in Table 1 and consisted of limited sagittal lumbar spine imaging along with axial and coronal T1 and fat-suppressed T2 sequences through the lumbosacral plexus. Imaging studies were evaluated by a radiologist with a Certificate of Added Qualification in neuroradiology (J.L.C.), and scores were recorded for statistical analysis. Following a 10-case training session, MRN examinations were independently evaluated by a radiology senior resident (J.C.-H.) to determine interrater reliability. The radiologists were blinded to clinical history, including the laterality of pain. Abnormal nerves were graded on a categorical scale from 0–2 with 0 representing normal signal; 1, increased intraneural signal but less than adjacent vasculature; and 2, marked increased intraneural signal similar to that in adjacent vascular structures. If multiple abnormal nerves were iden-

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Matrix</th>
<th>TR (ms)</th>
<th>TE (ms)</th>
<th>NEX</th>
<th>FOV (cm)</th>
<th>In-Plane Resolution (mm)</th>
<th>Slice Thickness (mm)</th>
<th>Acquisition Time (min: sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axial T1 TSE</td>
<td>320 × 240</td>
<td>663</td>
<td>12</td>
<td>2</td>
<td>31</td>
<td>1.0 × 1.3</td>
<td>3.5</td>
<td>6:18</td>
</tr>
<tr>
<td>Axial T2 FS SPAIR</td>
<td>320 × 192</td>
<td>6220</td>
<td>83</td>
<td>2</td>
<td>31</td>
<td>1.0 × 1.6</td>
<td>3.5</td>
<td>7:52</td>
</tr>
<tr>
<td>Coronal T1</td>
<td>384 × 216</td>
<td>3160</td>
<td>9.9</td>
<td>1</td>
<td>36</td>
<td>1.0 × 1.7</td>
<td>3</td>
<td>3:49</td>
</tr>
<tr>
<td>Coronal PD SPAIR</td>
<td>320 × 224</td>
<td>4380</td>
<td>35</td>
<td>2</td>
<td>36</td>
<td>1.1 × 1.6</td>
<td>3</td>
<td>4:10</td>
</tr>
<tr>
<td>3D Coronal SPACE STIR</td>
<td>256 × 256</td>
<td>1500</td>
<td>119</td>
<td>1.4</td>
<td>38</td>
<td>1.5 × 1.5</td>
<td>1.5</td>
<td>8:23</td>
</tr>
<tr>
<td>Sagittal T2 Dixon (lumbar spine)</td>
<td>448 × 300</td>
<td>4160</td>
<td>83</td>
<td>2</td>
<td>28</td>
<td>0.6 × 0.9</td>
<td>3</td>
<td>3:59</td>
</tr>
</tbody>
</table>

Note: —PD indicates proton density; SPACE, sampling perfection with application-optimized contrasts by using different flip angle evolution (Siemens); FS, fat suppressed.

All lumbosacral plexus MR imaging was performed on a 3T Magnetom Skyra (Siemens) scanner without contrast.

*Exclusionary criteria:*
- Spinal fusion hardware
- Presence of spinal malignancy
- Chief complaint of pelvic pain
- Nonstandard protocol
- Excessively degraded images
- No prior EMG
If the most pronounced signal abnormality was recorded and the proximal nerve was considered for analysis (for example, if the ipsilateral L4 and femoral nerves were abnormal, it was graded as an L4 radiculopathy).

Imaging findings of muscular denervation were rated as positive if T2 hyperintense edema was present in the substance of the paraspinous, psoas, iliacus, gluteal, piriformis, adductor, or proximal thigh musculature.

**Nerve Conduction Studies/EMG Protocol and Evaluation**

Nerve conduction studies (NCSs) and needle EMG were performed by board-certified neuromuscular neurologists at our institution. Reports were individually reviewed by an experienced neuromuscular neurologist (N.F.). Nerve conduction studies included standard tested sensory (superficial peroneal and sural) and motor (peroneal and tibial) nerves in the legs. These were analyzed by measuring the waveform latency, amplitude, duration, and conduction velocity. Late responses were also evaluated, including the F-Responses and H-reflex, to aid in the evaluation of the proximal nerve segments.

Needle electromyography was performed using a concentric needle in leg muscles representing L2–S1 myotomes. Muscles were evaluated for the presence of active denervation, motor unit action potential (MUAP) morphology, and MUAP recruitment and activation patterns. When present, active denervation was determined by fibrillation potentials and positive sharp waves. Chronic re-innervation changes in a muscle were defined by the decreased activation and recruitment of neurogenic (long duration and high amplitude) MUAPs.

**Electronic Medical Record Review**

The electronic medical records of the included subjects were reviewed for subjective findings of lower extremity weakness, numbness, leg pain, back pain, tingling, burning, pain quality, and severity (Visual Analog Scale 1–10). Patient history was recorded, including the inciting event, history of surgery, diabetes mellitus, and symptom duration. Physical examination findings were collected, including the presence of atrophy, weakness, decreased sensation, decreased reflexes, and positive findings on straight leg raises.

**Table 2: Demographics/clinical characteristics and MRN/EMG findings**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
<th>Range/Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Age (yr)</td>
<td>57</td>
<td>20–84</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>33</td>
<td>51.6%</td>
</tr>
<tr>
<td>Symptom duration (mo)</td>
<td>26</td>
<td>1–312</td>
</tr>
<tr>
<td>Diabetes</td>
<td>12</td>
<td>18.8%</td>
</tr>
<tr>
<td>Prior surgery</td>
<td>9</td>
<td>14.1%</td>
</tr>
<tr>
<td>Weakness</td>
<td>29</td>
<td>45.3%</td>
</tr>
<tr>
<td>Numbness</td>
<td>31</td>
<td>48.4%</td>
</tr>
<tr>
<td>Leg pain</td>
<td>48</td>
<td>75.0%</td>
</tr>
<tr>
<td>Back pain</td>
<td>28</td>
<td>43.8%</td>
</tr>
<tr>
<td>Tingling</td>
<td>23</td>
<td>35.9%</td>
</tr>
<tr>
<td>MRN intraneural T2 signal abnormality</td>
<td>28</td>
<td>43.8%</td>
</tr>
<tr>
<td>(grade I or II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRN evidence of muscular denervation</td>
<td>8</td>
<td>12.5%</td>
</tr>
<tr>
<td>EMG findings of active radiculopathy</td>
<td>20</td>
<td>31.3%</td>
</tr>
</tbody>
</table>

**Statistical Analysis**

Demographic variables and MR imaging parameters were summarized by mean/SD (continuous variables) and frequency/percentage (categoric variables). The comparison between ordinal variables (ie, signal, in 2 groups) was achieved with a Wilcoxon rank sum test. The association between categorical variables was...
measured by the \( \varphi \) coefficient under a Pearson \( \chi^2 \) test or a Fisher exact test. A \( \kappa \) statistic was calculated for interrater reliability between the 2 interpreters of MRN examinations. All the statistical analyses were performed by R statistical and computing software, Version 3.4.3 (http://www.r-project.org/). For the statistical tests, relevant \( P \) values are reported with a significant level of .05.

**RESULTS**

Three hundred three MRN studies were performed during the study period from December 2014 through January 2017. Of these, 64 patients were included in the final analysis when both MR neurograms and EMG were acquired within a 3-month timeframe and exclusion criteria were not met (Fig 1). The mean subject age was 57 years (range, 20–84 years), 52% were male, and 75% reported leg pain. Demographics and clinical characteristics are described in Table 2. Half of the patients had decreased lower extremity sensation on physical examination, and 36% showed some signs of objective weakness. On MRN, 28 of 64 patients (44%) of the cohort had at least 1 nerve with abnormal intraneural signal on the fat-suppressed T2-weighted images (Fig 2). Of the 28 patients with abnormal intraneural T2 signal, 18 (64%) had a grade 2 signal abnormality, similar to that in adjacent vasculature (Fig 3). Eight patients (13%) had MRN findings of active muscular denervation. On NCS and EMG evaluations, 20 of 64 patients (31%) had findings of an active radiculopathy with denervation changes (Table 2). There was substantial agreement between readers with a \( \kappa \) statistic of 0.71 (confidence boundary, 0.41, 1) on blinded MRN interpretation. Ten subjects with suspicious findings on MRN had normal electrodiagnostic test findings without evidence of active radiculopathy.

Abnormal intraneural signal was not significantly associated with subjective clinical abnormalities. The association between patient-reported symptom duration, weakness, numbness, leg pain, back pain, or tingling and abnormal intraneural signal on MRN was not significant. Similarly, no significant association was identified between physician-reported findings of weakness, decreased sensation, decreased deep tendon reflexes, the presence of positive straight leg raises, and abnormal intraneural signal. However, there was a statistically significant correlation between objective findings of muscle atrophy and denervation changes on MRN (\( P = .02 \)).

There was a statistically significant association between abnormal intraneural T2 signal and findings of active radiculopathy on EMG with a mean intraneural signal score of 0.3 in patients without findings of active radiculopathy versus 1.7 in patients with EMG findings of active radiculopathy (\( P < .001 \)). Furthermore, when abnormal intraneural signal was treated as a binary variable (normal or abnormal), there was a statistically significant association between signal abnormality on MRN and active radiculopathy on EMG (\( P < .001 \)) (Table 3).

**DISCUSSION**

This study revealed a statistically significant correlation between abnormal intraneural signal on MRN and findings of active denervation on NCS/EMG performed within 3 months. To our knowledge, this correlation has not been demonstrated previ-
ously for lumbosacral radiculopathy. Furthermore, this imaging-electrodiagnostic correlation was one of the only statistically significant findings in our cohort despite the consideration of multiple subjective and physical examination findings. Lumbar radiculopathy is notoriously difficult to diagnose with history or physical examination findings alone.13,14 MRN appears to provide useful diagnostic information, and the statistical correlation with EMG further reinforces its accuracy.

A study by Crim and Ingalls15 revealed a moderate sensitivity (41.2%–70.6%) and very high specificity (97.7%–100%) in the interpretation of brachial plexus MRN when EMG was used as a criterion standard. This study was not limited to radiculopathy and included MRN studies performed at both 1.5T and 3T. A study by Chhabra et al16 revealed a measurable impact of 3T MRN on diagnostic thinking and therapeutic choices. MRN is a recommended study for presurgical planning in patients with peripheral neuropathy. The observed interrater reliability ($\kappa = 0.71$) demonstrates substantial agreement between readers, in line with studies of lumbar spine imaging.17

This study evaluated the intraneural T2 signal as a marker for nerve abnormality on MRN. The authors do not find nerve caliber to be a useful metric in this setting because the abnormal nerves in this cohort had a size similar to that of normal nerves (Figs 2 and 4). Furthermore, it is difficult to reproducibly measure the caliber of nerve fascicles, given their oblique orientation, while excluding the perineural fat and soft tissues. Findings of acute or subacute muscular denervation were recorded when T2 hyperintense signal was seen within the lumbosacral musculature, as described by others.8 Imaging findings of muscular denervation were seen in a minority of patients (12.5%) but were helpful findings to confirm a neuropathy when observed. For example, in 1 subject with an L4 radiculopathy extending to the femoral nerve, ipsilateral denervation changes were observed in the iliacus, a muscle innervated by the femoral nerve (Fig 5). The relatively low rate of observed denervation changes may be related to the timing of imaging to the active period of radiculopathy and the exclusion of lower thigh and lower extremity muscles from the imaging FOV.

Diffusion-weighted imaging or diffusion tensor imaging was not part of the imaging protocol in this study. The authors have not found that DTI provides useful information when evaluating nerve caliber on MRN or when evaluating for nerve compression in the imaging FOV.
the lumbosacral plexus despite initially acquiring a coronal reversed fast imaging with steady-state precession diffusion sequence as part of the imaging protocol. DWI/DTI may have utility in imaging of peripheral nerves where surface coils can be placed close to the nerves of interest for an improved signal-to-noise ratio.

Electrodiagnostic studies are not a perfect criterion standard, and there are variabilities inherent in the performance and interpretation of NCS and EMG. In patients with active radiculopathy, electrodiagnostic studies classically demonstrate a combination of normal NCS and abnormal needle EMG. This pattern is thought to result from the common lateral recess or subarticular location of a disc herniation proximal to the dorsal root ganglion, thus sparing the sensory nerve fibers. Needle EMG reveals fibrillation potentials and positive sharp waves when a neuropathic lesion is present. These denervation potentials represent the spontaneous depolarization of an individual muscle fiber from ongoing or active axonal drop-out. The time course of radiculopathy is not always clear on NCS/EMG, but certain findings can narrow the window, including the MUAP morphology. Active denervation may take some time to be apparent on NCS/EMG; it is only evident following axonal injury once Wallerian degeneration begins. Evidence of active denervation with normal MUAP morphology suggests a subacute time course in which the muscles have not yet undergone reinnervation. Regardless, by the time a patient with true radiculopathy comes to clinical attention, there are typically electrodiagnostic findings.

Electrodiagnostic testing has several limitations and may dem-
onstrate confounding results, for example, when a superimposed peripheral neuropathy or primary myopathy is present. Furthermore, the NCS/EMG is highly operator-dependent, and false-negative studies with equivocal findings are common despite true radiculopathy for a variety of reasons, including a fascicular phenomenon and variations in electromyographer technique and experience. Despite these limitations, EMG remains a useful examination to evaluate active radiculopathy as class II evidence and level B recommendation by the American Association of Neuromuscular and Electrodiagnostic Medicine in lumbosacral radiculopathy in an analysis of 119 articles.20

This study is limited by its retrospective nature and variations in the timing of clinical notes, though all notes reviewed were from neuromuscular neurologists who performed the electrodiagnostic testing. There are also variabilities inherent in MRN interpretation, though the interreader variability was substantial between interpreters. Despite these limitations, it is the largest study performed, to the authors’ knowledge, that correlates MRN and electrodiagnostic findings in patients with lumbosacral radiculopathy.

**CONCLUSIONS**

In this cohort of patients with lower extremity radiculopathy who had both MRN and electrodiagnostic studies performed within 3 months, 44% had abnormal intraneural signal on MRN and 31% had electrodiagnostic findings of active radiculopathy with a statistically significant correlation between positive findings on these modalities. The role of MRN in the work-up and clinical management of patients with lumbosacral radiculopathy is still being explored. The presence of abnormal extraspinal intraneural signal on MRN may identify patients with a high likelihood of response to targeted therapy such as transforaminal epidural steroid injection. It is anticipated that this information will help guide clinical management of patients presenting with active radicular symptoms. These data may prove to be particularly useful in an era of overexuberant epidural injection treatment and personalized medicine with a focus on cost-benefit treatment algorithms.

Disclosures: Michael Sein—UNRELATED: Consultancy: CID Management Solutions.

**REFERENCES**

2. Dillingham TR. Evaluating the patient with suspected radiculopathy. PM R 2013;5:S41–49 CrossRef Medline
Fluoroscopically Guided Facet Injections: Comparison of Intra-Articular and Periarticular Steroid and Anesthetic Injection on Immediate and Short-Term Pain Relief

L.M. Kershen, N.C. Nacey, J.T. Patrie, and M.G. Fox

ABSTRACT

BACKGROUND AND PURPOSE: The effectiveness of facet injections is unclear in the literature. Our objective was to determine the immediate and short-term efficacy of intra-articular and periarticular steroid/anesthetic injections for facet-mediated lumbar pain.

MATERIALS AND METHODS: All outpatient fluoroscopically guided facet injections at a single institution during a 54-month period were retrospectively and independently reviewed by 2 musculoskeletal (MSK) trained radiologists. All intra-articular, all periarticular, and partial intra-/periarticular injection locations were determined. Periarticular and partial peri-/intra-articular injections were combined for analysis. Preinjection, immediate, and 1-week postinjection numeric pain scores, patient age, sex, anesthetic/steroid mixture, fluoroscopic time, and physician performing the procedure were recorded.

RESULTS: Seventy-seven patients (mean age, 51.1 years) had 100 procedures with 205 total facet joints injected. All intra-articular, all periarticular, and partial peri-/intra-articular injections constituted 54%, 20%, and 26% of the cases, respectively. The immediate and 1-week postprocedural change in pain was 3.7 (95% CI, 4.5 to 2.8; P < .001) and 1.4 (95% CI, 2.2 to −0.6; P = .001) for the all intra-articular and 3.6 (95% CI, −4.4 to 2.9; P < .001) and 1.2 (95% CI, −1.9 to 0.4; P = .002) for the combined group. Changes in immediate pain were significantly associated with the prepain level (P < .001) and patient age (P = .002) but not with the anesthetic used. Analyses revealed no significant difference in pain reduction between the groups either immediately or 1 week postinjection. Intra-articular injections required less fluoroscopic time (geometric mean, 39 versus 52 seconds) (P < .005).

CONCLUSIONS: Intra-articular and periarticular fluoroscopically guided facet injections provide statistically significant and similar pain relief both immediately and 1 week postinjection.

Given the variety of presentations and factors that contribute to low back pain, determining the optimal treatment method may be challenging. The facet joint is 1 possible etiology of axial low back pain with both surgical and nonsurgical treatment methods used to provide pain relief. Facet-mediated pain or “facet syndrome” may account for up to 45% of cases of axial low back pain. The characteristic pain in facet syndrome is located in the low back with involvement of the buttock/greater trochanteric region with occasional unilateral extension along the lateral thigh. The pain is usually more pronounced after immobilization and with low back extension. The injection of a local anesthetic is often used to both diagnose and manage facet-mediated pain. Even though there is a paucity of literature to support the use of intra-articular steroid injections in this patient population, corticosteroids are often injected to provide longer term pain relief and restore functional status. Whether intra-articular or periarticular placement of the injectate substantially alters the efficacy of the injection is also debated. Therefore, we retrospectively evaluated patients with fluoroscopically guided facet injections for clinically suspected facet syndrome to determine the immediate and short-term efficacy of those injections and to evaluate whether an intra-articular or periarticular injection provided greater pain relief.

Received March 27, 2018; accepted after revision July 30.
From the Colorado Imaging Associates (L.M.K.), Golden, Colorado; Departments of Radiology and Medical Imaging (N.C.N.) and Public Health Sciences (J.T.P.), University of Virginia, Charlottesville Virginia; and Department of Radiology (M.G.F.), Mayo Clinic Arizona, Phoenix, Arizona. Drs. Fox and Kershen were previously affiliated with the Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, Virginia.


Please address correspondence to Michael G. Fox, MD, MBA, Mayo Clinic Arizona, Department of Radiology, 5777 E Mayo Blvd, Phoenix, AZ 85054; e-mail: Fox.Michael@mayo.edu
http://dx.doi.org/10.3174/ajnr.A5805

MATERIALS AND METHODS

Institutional review board approval was obtained from The University of Virginia for the study. All outpatient fluoroscopically guided facet injections performed during a 4-year period (June 2010 to October 2014) at a single institution were retrospectively reviewed. More than 90% of the patients were referred by orthopedic spine specialists (n = 94) for treatment of suspected facet syndrome or to help quantify the degree of back pain accounted for by the facet arthropathy; physical medicine and rehabilitation (n = 4) and neurosurgery (n = 2) accounted for the remainder of the patient referrals.

Technique

After we obtained written informed consent, the patients were placed prone on the fluoroscopic table with a bolster placed under their lower abdomen to reduce lordosis. The patients were steriley prepped and draped in the usual manner and a 22-ga 3.5-inch spinal needle was directed toward the inferior articular recess of the facet joint using fluoroscopic guidance (Fig 1).13 Following needle placement, 0.5–1 mL of iohexol (Omnipaque 300) was injected to confirm placement. Opacification of the facet joint and/or superior articular recess was used as the criterion for determining an intra-articular injection (Fig 2). When contrast was not demonstrated in the facet joint, the injection was considered periarticular (Fig 3). The patients were then injected with either 0.5 mL of 0.25% bupivacaine (n = 29 procedures); 0.5 mL of 0.5% bupivacaine (n = 39 procedures); or 0.5 mL of 1% lidocaine (n = 32 procedures) and either 20 mg (0.5 mL) of methylprednisolone acetate (Depo-Medrol) (n = 92 procedures), 3 mg (0.5 mL) of betamethasone (Celestone) (n = 4 procedures), or 20 mg (0.5 mL) of triamcinolone acetonide (Kenalog) (n = 4 procedures). The injection was performed by either a musculoskeletal (MSK) fellow (n = 30), an MSK faculty member (n = 2), or an MSK fellow with an MSK faculty member present (n = 68).
**Pain Analysis**

All patients reported their preinjection and 5- to 10-minute postinjection pain scores to a radiology nurse using an 11-point Numeric Pain Rating Scale; 0 (no pain) to 10 (worst pain imaginable). In addition, patients were called 1 week postinjection, and the current pain score was recorded using the same 11-point scale. We were able to record a 1-week pain score for 49% (49/100) of the procedures. Patients were excluded if a different concentration of steroid was injected, if a preinjection or 5- to 10-minute postinjection pain score was not recorded, or if a pars defect was present. Patients younger than 16 years of age were also excluded from the study.

**Image Analysis**

Two fellowship-trained MSK radiologists, with 2 and 16 years of experience in performing facet injections, independently reviewed the fluoroscopic images to determine whether the injections were intra-articular or periarticular. When a discrepancy was present, the discrepant cases were re-analyzed in a blinded fashion and a consensus interpretation was rendered. The consensus interpretation was used for the statistical analyses. If an injection of >1 facet joint was performed in the same setting, all injections needed to be within the facet joint for the injection to be considered “all-in.” Likewise, all the injected facet joints needed to be periarticular to be considered “all-out.” When bilateral or 2-level facet injections were performed, if ≥1 of the injections was determined to be periarticular and ≥1, intra-articular, the injection was considered “partial.” Partial and all-out groups were combined for analysis.

**Statistical Analysis**

**Data Summary.** Categoric data were summarized as frequencies and percentages, and continuous scaled data were generally summarized by the mean and SD of the distribution.

**Interreader Agreement.** The concordance between the 2 readers’ assessments of whether the intra-articular injection was “all-in”, partially in, or “all-out” was evaluated by the κ statistic. An exact binomial confidence interval was used to establish a plausible range of values for the underlying level of concordance between the 2 readers’ injection classifications.

**Postprocedure Pain Analysis**

ANCOVA models were used to estimate the immediate and short-term postinjection mean changes in the pain scores. The ANCOVA model for examining the immediate change in pain was specified so that the partial variability in the immediate change in pain attributable to the anesthetic type (0.25% bupivacaine, 0.5 mL of 0.50% bupivacaine, or 0.5 mL of 1% lidocaine) could be examined after accounting for the variabilities in immediate change in pain attributable to patient age, sex, prepain level, and procedure personnel (attending physician involvement). The ANCOVA model for examining short-term (1 week postinjection) change in pain was specified in the same way as the ANCOVA model for the immediate change in pain, except that the “anesthetic type” was excluded. All null hypotheses related to the immediate and short-term changes in pain were tested via F tests, and a P < .05 decision rule was used as the null hypothesis rejection rule.

**Fluoroscopic Time**

Fluoroscopic time was analyzed on the natural logarithmic scale via ANCOVA, with the injection location the ANCOVA model factor of interest, and the personnel preforming the procedure as the ANCOVA covariates. Comparison of fluoroscopic time was with the geometric mean fluoroscopic time, and a P < .05 decision rule was used for testing the null hypothesis that the geometric mean ratio is equal to 1.

**Statistical Software**

The statistical software package SAS, Version 9.4 (SAS Institute, Cary, North Carolina) was used to conduct the aforementioned statistical analyses.

**RESULTS**

One hundred procedures were performed on 77 patients (29 males, 48 females; mean age, 51.1 years; range, 16–67 years) with a total of 205 facet joints injected. Sixty-six patients underwent 1 procedure, 8 patients underwent 2 procedures, and 1 patient each underwent 3, 4, and 11 procedures. Twenty-four procedures (24%, 24 facets) were single-facet injections, 61 (61%, 122 facets) procedures were 2-facet injections in the same sitting, 1 procedure had 3 facet injections (1%, 3 facets), and 14 (14%, 56 facets) procedures had 4 facets injected in the same sitting. We injected the following facet levels: T12–L1 (n = 4), L1–L2 (n = 2), L2–L3 (n = 9), L3–L4 (n = 20), L4–L5 (n = 104), and L5–S1 (n = 66).

The consensus interpretation in 54 of 100 procedures (100/205 facets injected) was all intra-articular; in 20 procedures (33/205 facets), it was all periarticular; and in 26 procedures (72/205 facets), it was partial intra-articular. Exact agreement between the 2 readers was present in 77% (77/100) (95% CI, 0.68–0.84) of the procedures with a κ statistic of 0.60 (95% CI, 0.46–0.75).

Analysis of the immediate (5- to 10-minute) change in pain yielded a statistically significant association with the prepain level (P < .001) and patient age (P = .024) (older patients experienced greater pain relief) but no significant association with the anesthetic used (P = .431), sex (P = .205), or the radiology team member performing the procedure (P = .153). Analysis of the 1-week change in pain revealed no statistically significant association with the prepain level (P = .979), patient age (P = .462), sex (P = .979), or the radiology team member performing the procedure (P = .672).

The mean prepain and 5- to 10-minute postinjection pain scores for the 54 procedures in the all intra-articular group were 6.3 and 2.7, respectively, with a mean change in pain of −3.7 (95% CI, −4.5 to −2.8; P < .001). The mean prepain and 5- to 10-minute postinjection pain scores for the 46 periarticular/partial procedures were 5.8 and 2.1, respectively, with a mean change in pain of −3.6 (95% CI, −4.4 to −2.9; P < .001) (Table 1). Twenty-four of the all intra-articular injections had a 1-week postprocedure pain score recorded with the mean 1-week postin-
periarticular/partial injections

Table 2: Mean pain level 1 week postinjection when accounting for intra-articular-versus-periarticular/partial groups at 1 week postinjection was 0.27 (95% CI, 0.56–1.49). The mean difference in the change in pain between the intra-articular and periarticular/partial groups was 0.46 (95% CI, −0.56 to 1.49; P = .371), and the mean difference in the change in pain between the intra-articular and periarticular/partial groups at 1 week postinjection was 0.27 (95% CI, −0.94 to 1.48; P = .652) (Table 3). The mean fluoroscopic time for intra-articular, periarticular, and partial injection was 44, 59, and 54 seconds, respectively. After adjusting for the person performing the injection (fellow alone, and so forth), a statistically significant difference in the ratio of geometric means between the intra-articular and periarticular/partial groups was noted (geometric mean ratio = 1.31; 95% CI, 1.08–1.58; P = .005).

**DISCUSSION**

The facet joint is a known contributor to axial low back pain. However, diagnosing facet-mediated pain can be challenging due to confounding factors in pain generation such as concomitant lumbar disk and sacroiliac joint degenerative changes. In addition, dual innervation of the facet joint by medial branches of the dorsal ganglion at and above the level of the target facet may further complicate the diagnosis and treatment of facet-mediated pain.

Even though injections have been used for decades to diagnose and manage facet-mediated pain, the utility of injections to relieve this pain as reported in the literature is inconclusive. Local anesthetics inhibit nerve conduction and excitation to various degrees with the 3 most commonly used agents being lidocaine (shortest acting), bupivacaine, and ropivacaine (longest acting). Corticosteroids can interrupt the inflammatory cascade, which is thought to contribute to axial back pain, ideally resulting in longer pain relief than that provided by local anesthetics. The 4 most commonly used corticosteroid agents include the following: methylprednisolone, triamcinolone, betamethasone, and dexamethasone, with only dexamethasone considered nonparticulate unless it is combined with ropivacaine, which will result in particulate formation. While the use of corticosteroids in back injections is generally accepted, the specific use of intra-articular steroid injections for facet-mediated pain is less clear. Mooney and Robertson reported that 20% of patients achieved complete and 33% of patients experienced partial pain relief 6 months following steroid injection. Similarly, Destouet et al determined that 54% of patients, many of whom had prior spinal surgery, responded to facet steroid injections. In fact, 38% of the responders achieved long-term (6–12 months) clinical improvement. In contrast, Lilius et al randomized patients into 3 facet-injection groups: steroid, anesthetic only, and normal saline. They found a significant improvement in the pain and disability scores for all 3 groups, with no significant difference among the groups. As a result, they questioned the utility of steroid and anesthetic injections for managing facet pain. More recently, Manchikanti et al, using a meta-analysis, concluded that there is limited evidence to support the use of intra-articular lumbar facet steroid injections based on 3 high-quality studies demonstrating effectiveness for follow-up <6 months and 2 moderate to high-quality studies demonstrating a lack of effectiveness. Similarly, Bogduk concluded that the efficacy of intra-articular steroid injections was no better than that of sham treatments. Because there is limited evidence to support the routine use of steroid facet injections, Bykowski and Wong advocated a more tailored use of steroid injections, reserving them for patients in whom radiofrequency ablation was refused or contraindicated.

We found no difference in the 1-week postinjection pain relief between the all intra-articular and the combined all periarticular and partial peri-/intra-articular groups, which is similar to the results reported by Lilius et al. In contrast, Lynch and Taylor reported that intra-articular injections were substantially better than periarticular injections in relieving facet-mediated pain 2 weeks postinjection.

The imaging guidance used to perform facet injections is often based on operator familiarity and the availability of equipment. In our experience, fluoroscopically guided facet injections can be performed with minimal radiation exposure. We found that intra-articular injections required less fluoroscopic time compared with periarticular injections, which is likely because some radiologists were more diligent in attempting to access to the facet joint. When accessing the joint or joint recess was more challenging, due to facet joint degeneration and hypertrophy, some perform-
ing radiologists were less concerned about being intra-articular because the efficacy of intra-articular compared with periarticular steroid injections remains unclear. We suspect that if a periarticular injection was the primary goal of all of the performing radiologists, the fluoroscopy time would be substantially lower in this group. Nevertheless, the mean fluoroscopic time in our study was <60 seconds in each group.

Our study is limited because it is retrospective and lacks a randomized control group. In addition, our 1-week response rate was only 49%, which limits our patient population in this category. However, the 1-week response rate was fairly equal between the 2 groups. The lack of follow-up beyond 1 week is also a limitation.

CONCLUSIONS
Both intra-articular and periarticular facet injections provide similar and statistically significant immediate and 1-week postinjection relief of facet-mediated pain.

ACKNOWLEDGMENTS
The data for this project originated from and were provided by the University of Virginia.

REFERENCES
Celebrating 35 Years of the AJNR
November 1983 edition
Standards of Practice in Acute Ischemic Stroke Intervention: International Recommendations


PREAMBLE

After the five positive randomized controlled trials showing the benefit of mechanical thrombectomy (MT) in the management of acute ischemic stroke (AIS) with emergent large vessel occlusion (ELVO), a multisociety meeting was organized during the 16th Congress of the World Federation of Interventional and Therapeutic Neuroradiology (WFITN), October 2015, Gold Coast (Australia). This meeting was dedicated to the training of physicians performing MT, and recommendations were published thereafter in multiple scientific journals.1

The same group of scientific societies decided to organize a similar meeting during the 17th WFITN Congress, October 2017, Budapest (Hungary). This multisociety meeting was dedicated to standards of practice in acute ischemic stroke intervention (AISI), aiming for a consensus on the minimum requirements for centers providing such treatment.

In an ideal situation, all patients would be treated at a center offering a full spectrum of neuroendovascular care (a level 1 center). However, for geographical reasons, some patients are unable to reach such a center in a reasonable period of time. With this in mind, the group paid special attention to define recommendations on the prerequisites of organizing stroke centers providing MT for AIS, but not for other neurovascular diseases (a level 2 center). Finally, some centers will have a stroke unit and offer intravenous thrombolysis, but not any endovascular stroke therapy (a level 3 center). Together, these level 1, 2, and 3 centers form a complete stroke system of care. The requirements for these centers are summarized in Table 1.

Due to the relatively short time elapsed since the evidence in favor of MT has been published, some organizational aspects still require scientific validation. However, considering the extremely fast growth of such activities around the world, the multisociety group considered it timely and rational to set-up recommendations and a framework for the development of MT services in all parts of the world. The requirements included in this document are proposed to help countries and centers to properly implement MT.

COMPOSITION OF THE CONSENSUS GROUP

This working group is composed of delegates from the following societies: Asian-Australian Federation of Interventional and Therapeutic Neuroradiology (AAFITN), Australian and New Zealand Society of Neuroradiology (ANZSNR), American Society of Neuroradiology (ASNR), Canadian Society of Neuroradiology (CSNR), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Japanese Society for NeuroEndovascular Therapy (JSNET), the French Society of Neuroradiology (SFNR), Ibero-Latin American Society of Diagnostic and Therapeutic Neuroradiology (SILAN), Society of NeuroInterventional Surgery (SNIS), Society of Vascular and Interventional Neurology (SVIN), World Stroke Organization (WSO), World Federation of Interventional Neuroradiology (WFITN).

DEFINITIONS

Neuroendovascular procedures: minimally invasive, image guided procedures to treat diseases of the brain and spinal cord. These include embolization, for treatment of intracranial aneurysms, arteriovenous malformations, tumors, and revascularization techniques, such as angioplasty and stent placement for atherosclerotic disease.

Acute ischemic stroke intervention (AISI) involves percutaneous endovascular procedures to treat ischemic stroke in adults and children, and may involve thrombectomy, aspiration, percu-
taneous transluminal angioplasty, and stent implantation, as well as superselective drug infusion.

**Stroke unit:** a dedicated, geographically clearly defined area or ward in a hospital where stroke patients are admitted and cared for by a multi-professional team (medical, nursing, and therapy staff) who have specialist knowledge, training, and skills in stroke care with well defined individual tasks, regular interaction with other disciplines, and stroke leadership. This team shall coordinate stroke care through regular (weekly) multi-professional meetings (http://stroke.ahajournals.org/content/44/3/828#T1).

**Stroke center:** a hospital infrastructure and related processes of care that provide the full pathway of stroke unit care. A stroke center is the coordinating body of the entire chain of care. This covers prehospital care, emergency room assessment and diagnosis, emergency medical treatment, stroke unit care, ongoing rehabilitation, and secondary prevention, and access to related neurological and vascular intervention. A stroke unit is the most important component of a stroke center. A stroke center provides stroke unit services for the population of its own catchment area and serves as a referral center for peripheral hospitals with stroke units in case their patients need services that are not locally available (http://stroke.ahajournals.org/content/44/3/828#T1).

### BACKGROUND AND SIGNIFICANCE

AIS caused by ELVO is the leading cause of adult disability in the world.² Strokes caused by occlusion of the large intracranial vessels, such as the internal carotid artery, proximal middle cerebral artery, or basilar artery have low rates of response to intravenous tissue plasminogen activator and, subsequently, poor outcomes.³ The major revolution in acute stroke intervention began in 2015 when five randomized trials showed that rapid MT significantly improves outcomes in anterior circulation (internal carotid artery, M1) ELVO stroke patients.⁴–⁸ The degree of benefit is profound, with a number needed to treat as low as 2.5 to have one patient be less disabled.⁹,¹⁰ Few, if any, therapies in medicine can approach that level of benefit. Two additional trials have further confirmed that indeed rapid thrombectomy dramatically improves outcomes, including up to 24 hours from the last known normal.¹¹–¹⁴

Training guidelines for physicians performing AISI were already proposed by the same working group.¹ Delivering the benefit of this therapy to a population that is applicable in diverse localities throughout the world, as reflected by the breath of international societies sponsoring this guideline, requires a concerted effort. Critical to this is ensuring the proper facility capabilities to deliver this treatment in a safe yet timely fashion.

The goal of this document is to provide recommendations that outline the minimum requirements to provide AISI to as large of a population as possible, including those that do not have timely access to a level 1 center, which is capable of treating all vascular diseases of the brain and spine.

### PURPOSE

This is a document which provides recommendations based on expert opinions and best available evidence, in relation to the optimal conditions for the safe practice of AISI.

In order to replicate the dramatic results of the major randomized trials, we must ensure patients throughout the world are treated in a center with the capabilities necessary to handle not just the procedural aspects, but also the medical management of the patient prior to, during, and post-thrombectomy.

These general recommendations are not a substitute for existing national and regional guidelines, recommendations, and regulations in the field of AIS. Rather, this describes the minimum organization and workload that, based on expert consensus, is necessary for a hospital to practice AISI.

The best option for the management of AIS is to have patients transferred to and treated in high volume, level 1 centers, as demonstrated by scientific evidence.¹⁵ However, in some situations, specifically due to geographical, traffic, and transportation con-

<table>
<thead>
<tr>
<th>Table 1: General summary of capabilities of level 1, 2, and 3 centers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Offers full spectrum of neuroendovascular therapy (including aneurysm treatment, surgical and endovascular, arteriovenous malformations, arteriovenous fistulas, etc)</td>
</tr>
<tr>
<td>Offers endovascular stroke therapy</td>
</tr>
<tr>
<td>Offers intravenous tissue plasminogen activator</td>
</tr>
<tr>
<td>Minimum No of stroke patients per year</td>
</tr>
<tr>
<td>Minimum thrombectomy volume per year</td>
</tr>
<tr>
<td>Dedicated neuro-intensive care unit</td>
</tr>
<tr>
<td>Dedicated stroke unit</td>
</tr>
<tr>
<td>Open neurosurgical services on site</td>
</tr>
<tr>
<td>Geographic restriction?</td>
</tr>
<tr>
<td>Inter-facility transfers</td>
</tr>
</tbody>
</table>
conditions, access of patients to such centers in an acceptable time frame may not be possible. In that case, it would be wise to have a system of care that incorporates level 2 centers, able to provide AISI but not necessarily the full spectrum of neuroendovascular procedures.

WHERE IS AISI PERFORMED?
The practice of AISI should ideally take place in healthcare institutions that routinely provide services for all neurological disorders and neurointerventional treatments to patients with all kinds of neurovascular disorders (level 1 centers). Recommendation for these centers have been recently published. However, if a level 1 center is not regionally available, a center treating only ischemic stroke (level 2) can be established under the following conditions:

- There is no level 1 center available within 2 hours of interfacility transport time.
- The level 2 center must care for a reasonable number of AIS treatments a year (at least 100 treatments, including intravenous thrombolysis and AISI).
- The institution must incorporate an acute stroke center or stroke unit with fully trained stroke physicians.
- It is highly recommended that the level 2 center is organized in cooperation with a level 1 center, and should pursue the objective of collaborative work with the level 1 center for neurointervention training, continuous medical education, mortality and morbidity rounds, expertise advice by tele-consultations or by practice, 24 hour/7 week day coverage, referrals, among other).

LEVEL 2 CENTER: STANDARDS OF PRACTICE
For those centers established under these conditions the standards of practice described below apply.

1. Facilities
Facilities that must be available on site include:

- Stroke unit beds: a sufficient number of stroke unit beds should be available in stroke units to accommodate interventional strokes at any time.
- Intensive care unit.
- A radiology/neuroradiology service, with competence in neuroimaging, and a suitable angiography room (as defined below): high quality, rapidly available noninvasive imaging is vital to the management of the acute stroke patient. At a minimum, CT scanners should be available on a 24/7 basis to image patients with noncontrast CT and CT angiography. The availability of CT perfusion and/or MRI may also assist in patient selection for AISI beyond 6 hours from onset. The necessary technologists and support personnel for this imaging should be available and onsite at the time of patient admission. Diagnostic radiologists/neuroradiologists with sufficient training and experience in the interpretation of these imaging studies shall be available on a 24/7 basis. Finally, cerebrovascular ultrasound facilities will be available.
- A team of trained acute stroke neurointerventionists.
- A dedicated ‘stroke unit’ and a ‘stroke team’ with fully trained stroke physicians.
- A department of neurosurgery ideally in house or, if that is not possible, in a nearby hospital.

2. Angiography Suite
A suitable interventional angiographic suite implies the ability to routinely accommodate general anesthesia. Optimally, procedures should be carried out under the image guidance of a biplane digital angiography unit with flat panel CT capabilities and necessary software and hardware to perform high quality cerebral angiography.

As a minimum, each suite should include a single plane high resolution digital subtraction angiography unit with road mapping capabilities.

Radiation protection measures in accordance with national regulations should be in place with designated individuals responsible for carrying out the necessary checks and audits.

3. Treatment Availability
AISI should be offered to every appropriate patient according to international guidelines, not excluding/discriminating against any patient, appropriate at the right time to obtain the best results, with population treatment access equity, in centers providing safe, effective, and efficient treatment.

A suitable level 2 center should be able to provide the services defined in the definition section, on a full time basis, 24/7, all year around.

4. Procedural Volume
The randomized trials demonstrating a clear benefit from thrombectomy were almost exclusively performed in high volume centers. It has been shown that high volume centers have a significantly lower mortality, even if the patient has to be transferred from a low volume center. Rinaldo et al found that centers performing 35 or more thrombectomy cases per year would classify as ‘high volume’ and offer the lowest mortality rate for patients. Similarly, the American College of Cardiology Foundation, the American Heart Association, and the Society for Cardiovascular Angiography and Interventions suggest a minimum of 36 percutaneous coronary interventions for acute myocardial infarction per year per center as a minimum requirement.

We acknowledge that the thresholds listed below are generally low. Multiple regional/national recommendations with higher limits are available and should be observed in regions/countries having already advanced healthcare networks providing services for AIS patients. The current recommendations are international and have to be compatible with the development of this new activity in areas and countries where there had been previously limited availability. Subsequently, these thresholds should be considered as the minimum caseload providing the lowest limit of safe operation. With the increased implementation of AISI in the world, it may be desirable to revise these thresholds in the future.

On the other hand, we also acknowledge that these thresholds are potentially difficult to reach in newly created level 2 centers and recognize that, during a transitory period, the activity can be...
AISI should ideally be practiced in neurointerventional teams with the possibility to exchange experience and knowledge. Clinical research should be encouraged. The solitary practice of AISI is strongly discouraged.

5. Operational Guidelines/Medical Personnel

5.1 Stroke Team
Outstanding stroke care does not exist in a vacuum solely focused on the procedure but instead is part of a successful multidisciplinary team. The stroke team comprises fully trained stroke physicians (vascular neurologists or neurointensivists), allied professionals, and nurse that are all led by a stroke physician with a strong background in the management of neurovascular disease.

5.2 Level 2 Stroke Intervention Team

- The team should have a minimum of three clinicians with training and qualification in AISI.\(^\text{16}\)
- The team should organize 24/7/365 acute ELVO stroke coverage (possibly in a rotation system organized with other level 2 centers or a level 1 center).
- It is recommended that stroke neurointerventionists involved in AISI maintain outpatient clinics for follow-up and have admitting privileges either in units/beds dedicated to Interventional neuroradiology or in other appropriate inpatient facilities.
- The stroke neurointerventionist/interventionist, in collaboration with the stroke team, should have shared responsibility for preoperative and postoperative patient care with input from the appropriate specialties.
- AISI should ideally be practiced in neurointerventional teams with the possibility to exchange experience and knowledge. Clinical research should be encouraged. The solitary practice of AISI is strongly discouraged.

5.3 Anesthesia Team
There shall be 24/7 in hospital anesthesia coverage with anesthesiologists with experience in caring for patients undergoing AISI. At many centers, the use of anesthesia, whether monitored anesthetic care or general anesthesia, is routine during thrombectomy. Even at centers primarily using moderate sedation, patients may deteriorate clinically prior to, or during, the procedure such that immediate access to general anesthesia is necessary to safely complete the procedure.

5.4 Others
Given the significant amount of assistance stroke patients need re-integrating into the community, the center should have access to physical therapy, speech therapy, occupational therapy services, as well as a coordinated plan for assessment for rehabilitation needs.

5.5 Individual Procedures
With regard to individual procedures, ideally the following staff roles are present for each case:

- One first operator: a neurointerventionist
- One assistant: a second scrubbed individual (ie, a supporting AIS interventionist, physician in training (resident or fellow), nurse practitioner, physician assistant, a scrub nurse, or a radiographer)
- One radiographer
- One nurse or nurse assistant
- Regardless of the type of anesthesia, an anesthesiology service must be readily available 24/7.

As a minimum, a neurointerventionist, a radiographer, and appropriately trained nursing must be present.

5.6 Quality Improvement Processes
Treatment of AIS by using AISI techniques is a novel method that involves the consumption of significant human and material resources and carries the risk of severe complications. Accurate documentation of medical and technical details as well as patient outcome and follow-up results is inevitable to ensure the highest benefit of such complex and demanding procedures.

To secure such documentation and data management, it is recommended that:

- The level 2 stroke center team includes a dedicated individual, preferably a stroke nurse or a stroke fellow, with the responsibility of data recording and data base management.
- All technical and clinical data of AISI procedures, patient outcomes, and follow-up must be entered into an electronic database either locally or (preferably) nationally or internationally.
- The center shall establish target time metrics for all cases in accordance with the most recent requirements by international standards. Cases that exceed their chosen metrics should trigger an internal process for quality improvement.\(^\text{17}\)
- The database should be regularly audited. At a minimum, process metrics such as time from arrival to intravenous tissue plasminogen activator, to start of angiography, and to recanalization, as well as overall recanalization rates, are to be reviewed and compared against reasonable published benchmarks.
The center provides routine continuing education (suggested minimum of 8 hours per year) related to cerebrovascular disease and stroke for all core members of the center, as designated by the medical director.

All cases of symptomatic intracranial hemorrhage shall be reviewed. For the purposes of this document, we broadly define symptomatic intracranial hemorrhage as the presence of new intracranial hemorrhage on post-treatment brain imaging, with clinical deterioration that is potentially attributable to the hemorrhage.

Standardized care pathways should be implemented with clinical practice guidelines, order sets, and other tools to ensure consistent care delivery and minimize practice variability. This should apply to providers, and nursing and ancillary staff. These pathways should be developed by the multidisciplinary Asian-Australian Federation of Interventional and Therapeutic Neuroradiology (AAFITN), Australian and New Zealand Society of Neuroradiology (ANZSNR), American Society of Neuroradiology (ASNR), Canadian Society of Neuroradiology (CSNR), European Society of Minimally Invasive Neurologic Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Japanese Society for NeuroEndovascular Therapy (JSNET), The French Society of Neuroradiology (SFNR) Ibero-Latin American Society of Diagnostic and Therapeutic Neuroradiology (SILAN), Society of NeuroInterventional Surgery (SNIS), Society of Vascular and Interventional Neurology (SVIN), World Stroke Organization (WSO), World Federation of Interventional Neuroradiology (WFITN) leadership of the center and reflect evidence based practice.

6. Community and EMS Outreach

Outstanding stroke care starts not in the hospital but in the field. Increasingly, operators will likely promote selection of the most appropriate destination for suspected ELVO patients based on distance to a center from the field. Such a mechanism should decrease time to treatment. As such, the level 2 center should interface with local emergency medical services (EMS) in order to coordinate care in the prehospital arena.

Specifically, we feel there are some key items in this area.

- Representatives of the center shall work with local and regional EMS officials to ensure they are aware of the system’s capabilities, as well as which patients (based on the region’s chosen severity scale) are appropriate for direct field triage to the level 2 or 1 centers.
- Additionally, some patients may be distant from the level two (or 1) and present to a level 3 center. The level 2 center should work with these local centers to assist in identification of suspected or confirmed ELVO patients and facilitate rapid transfer as part of a ‘hub and spoke’ model of care. However, if a level 1 center is available in a similar transfer time, it is preferable that interfacility transfers are directed to the highest level facility.
- A mechanism should exist for providing feedback to the EMS and referring non-thrombectomy centers to highlight which aspects of care went well and identify areas for improvement. This would be similar to quality assessment work done on patients presenting directly to the level 2 and 1 centers.

REFERENCES

tomy after intravenous alteplase versus intravenous alteplase alone. Stroke 2016;47:2331–8
intravenous alteplase versus alteplase alone after stroke (THRACE): a
13. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24
hours after stroke with a mismatch between deficit and infarct.
N Engl J Med 2018;378:11–21
to 16 hours with selection by perfusion imaging. N Engl J Med
2018;378:708–18
15. Rinaldo L, Brinjikji W, Rabinstein AA. Transfer to high-volume cen-
ters associated with reduced mortality after endovascular treat-
ment of acute stroke. Stroke 2017;48:1316–21
tional neuroradiology. Neuroradiology 2017;59:541–4
17. Harold JG, Bass TA, Bashore TM, et al. ACCF/AHA/SCAI 2013 up-
date of the clinical competence statement on coronary artery in-
terventional procedures: a report of the American College of
Cardiology Foundation/American Heart Association/American
College of Physicians Task Force on Clinical Competence and
Training (writing committee to revise the 2007 clinical compe-
tence statement on cardiac interventional procedures). Circula-
tion 2013;128:436–72
management of patients with emergent large vessel occlusion
(ELVO): report of the standards and guidelines committee of the
2017;9:316–23
increase delivery to endovascular centers without excessive harm
from misclassifications. Stroke 2017;48:568–73

We would like to congratulate the authors for a very well-written article on a subject that may strongly affect the interpretation of vessel wall enhancement obtained on 3T brain MR imaging.

Several studies performed on various MR imaging units have demonstrated that aneurysm wall enhancement may be a marker for instability, thus a noninvasive biomarker for patient counseling and therapeutic decision-making. In this article, the authors demonstrated that part of the enhancement may be due to intra-aneurysmal slow blood flow because the wall enhancement decreased and sometimes vanished when a motion-sensitized driven equilibrium sequence was used. We agree that T1-shortened enhanced blood signal near the wall may cause nonspecific wall enhancement-like signal. However, in our opinion, the observation that slow-flow artifacts may contribute to the observed wall enhancement does not invalidate the fact that contrast enhancement is strongly linked to aneurysm status.

Computational fluid dynamics studies demonstrated that slow flow contributes to low wall shear stress, hence promoting aneurysm wall inflammation. Slow flow, low wall shear stress, and wall inflammation probably all contribute to the observed enhancement. We agree that histopathologic confirmation is strongly warranted to confirm the inflammatory nature of aneurysm wall enhancement.

**REFERENCES**


---

M. Edjlali
Department of Neuroradiology
Université Paris Descartes Sorbonne Paris Cité
Centre Hospitalier Sainte-Anne
Paris, France

C. Oppenheim
O. Naggara
Department of Neuroradiology
Université Paris Descartes Sorbonne Paris Cité, Centre Hospitalier Sainte-Anne
Paris, France

http://dx.doi.org/10.3174/ajnr.A5777
We thank our colleagues for their comments about our recent article, "Blood Flow Mimicking Aneurysmal Wall Enhancement: A Diagnostic Pitfall of Vessel Wall MRI Using the Postcontrast 3D Turbo Spin-Echo MR Imaging Sequence."

Black-blood techniques such as motion-sensitized driven equilibrium or delay alternating with nutation for tailored excitation (DANTE) offer new perspectives for a better understanding of the nature of intracranial aneurysm enhancement. In our experience, flow-related artifacts are frequently encountered using the postcontrast 3D-TSE sequence for a wide range of incidental aneurysms (at the center of the aneurysmal cavity but also in contact with the wall of the aneurysm). It is now clear that the slow-flowing blood near the aneurysmal wall may represent all or part of the visible enhancement using conventional 3D-TSE sequences. Such findings raise the question of the relevance of this parameter for the management of asymptomatic patients.

The relationship among contrast enhancement on 3D-TSE, slow-flowing blood, low shear stress, and aneurysmal instability is poorly reported and is still speculative. In addition, studies with a long-term follow-up and/or histologic correlation are lacking in the literature. Thus, it appears difficult to assume that the enhancement related to slow-flowing blood and that of the aneurysmal wall itself are both related to inflammation/instability. Quite on the opposite, we think that it would be interesting to independently analyze each component of the enhancement visible on conventional 3D-TSE, including slow-flowing blood. Such an approach would allow us to identify patients in whom the slow-flowing blood is predominant versus those in whom the addition of a black-blood technique has little or no influence on the enhancement already visible on conventional sequences (and therefore potentially related to a "true" enhancement of the wall).

A better understanding of the factors likely to promote slow-flowing blood near the aneurysmal wall (such as the size of the aneurysm?) also appears important. In our opinion, the real ability of the 3D-TSE sequence to assess arterial wall inflammation remains uncertain because we cannot formally exclude residual slow-flowing blood (even including the additional black-blood technique). Further studies are required to evaluate alternative/complementary MR sequences less sensitive to flow artifacts and with a higher spatial resolution.

We hope that this discussion will encourage other teams to continue evaluating the circumferential wall enhancement of intracranial aneurysms, which remains a particularly complex entity.

REFERENCE


J. Hodel
E. Kalsoum
T. Tuilier
A. Benaissa
Department of Neuroradiology
Centre Hospitalier Universitaire Henri Mondor
Créteil, France
R. Blanc
Department of Interventional Neuroradiology
Rothschild Foundation Hospital
Paris, France
P. Brugieres
Department of Neuroradiology
Centre Hospitalier Universitaire Henri Mondor
Créteil, France

http://dx.doi.org/10.3174/ajnr.A5789
We read with great interest the recent article by Zhang et al regarding brain MR imaging characteristics of 53 patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis. In their important analysis, the authors describe 4 distinct imaging patterns: normal MR imaging findings (type 1, 53% of patients), isolated hippocampal involvement (type 2, 13%), other brain lesions without hippocampal involvement (type 3, 13%), and other brain lesions with hippocampal involvement (type 4, 21%).

The authors provide representative images of these 4 imaging types. The image example for type 4 (lesions in both the hippocampus and other brain areas, Fig 1D1 and D2) shows an asymmetric T2/FLAIR hyperintense presentation of both medial temporal lobes and large parts of the left lateral temporal lobe as well as bilateral frontal, insular, and cingulate involvement. In our experience, this MRI pattern is very atypical for anti-NMDA receptor encephalitis, for which we have observed much more circumscribed hippocampal T2/FLAIR hyperintense signal alterations, and only in a few patients, but would be compatible with herpes simplex encephalitis (HSE) imaging findings.

Recently, it has been shown that up to 20% of patients with HSE develop postviral anti-NMDA receptor encephalitis. These patients have HSE followed by autoimmune encephalitis with NMDA receptor autoantibodies weeks to months after initial recovery. In light of these findings and the imaging pattern suggestive of HSE in the article by Zhang et al, we would like to suggest that the presented patient did not have isolated anti-NMDA receptor encephalitis but rather HSE followed by anti-NMDA receptor encephalitis. In our opinion, it would be most important to discriminate these 2 patient groups, and it would therefore be very interesting to know how many patients with type 4 have an imaging pattern that would be compatible with HSE MR imaging findings. We would like to encourage the authors to present MR imaging examples of all group 4 patients in an article supplement. This would be of great interest to the readers and of immense help in clinical practice.

If some patients with type 4 presented by Zhang et al indeed have post-HSE anti-NMDA receptor encephalitis, it would also affect the interpretation of the correlation analysis, in which a worse outcome was associated with hippocampal lesions. While most patients with anti-NMDA receptor encephalitis recover quite well and frequently do not show any specific MR imaging changes, most patients with HSE have persistent cognitive impairment associated with hippocampal/medial temporal lobe damage and corresponding MR imaging findings. Hence, including patients with post-HSE anti-NMDA receptor encephalitis in this correlation analysis could bias the analysis toward an association of hippocampal involvement with poor outcome. It would therefore also be very interesting to reconsider this correlation analysis.


REFERENCES

M. Scheel
NeuroCure Cluster of Excellence and NeuroCure Clinical Research Center
Department of Neuroradiology
Charité-Universitätsmedizin Berlin
Berlin, Germany
C. Finke
Department of Neurology
Charité-Universitätsmedizin Berlin
Berlin, Germany
Berlin School of Mind and Brain, Humboldt-Universität zu Berlin
Berlin, Germany

http://dx.doi.org/10.3174/ajnr.A5788
We thank Drs Scheel and Finke for their insightful comments and for sharing their opinions on our article, "Brain MR Imaging Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome." We agree with Drs Scheel and Finke’s important comments that it is crucial to differentiate isolated anti-N-methyl-D-aspartate (NMDA) receptor encephalitis from herpes simplex encephalitis (HSE) followed by anti-NMDA receptor encephalitis.

In this publication, we tried to investigate the brain MR imaging characteristics of patients with anti-NMDA receptor encephalitis. We classified the brain MR imaging manifestations into 4 types: type 1, normal MR imaging findings; type 2, only hippocampal lesions; type 3, lesions not involving the hippocampus; and type 4, lesions in both the hippocampus and other brain areas. Type 4 (11 patients) was relatively common in our study; we presented in this article the brain MRIs of the remaining 10 patients presenting with type 4 lesions (not including the sample figure in our article) (Figure).

In our study, the patients were diagnosed as having anti-NMDA receptor encephalitis by 2 experienced neurologists (one with >20 years of experience and one with 5 years of experience in neurology) on the basis of the clinical symptoms, physical examinations, laboratory tests, and treatment responses. The neurologists were careful to exclude the herpes simplex virus followed by anti-NMDA receptor encephalitis, and they reached a consensus that all the patients had isolated anti-NMDA receptor encephalitis. Furthermore, the virus antibody tests such as those for herpes simplex virus and cytomegalovirus antibodies in the CSF were regularly performed in our hospital when encephalitis was suspected, and the results of virus antibody tests were negative in all the patients in our group. Despite the above effort, it is still very difficult to fully exclude HSE followed by anti-NMDA receptor encephalitis from isolated anti-NMDA receptor encephalitis in the routine clinical setting. Thus, our results about the type 4 lesions of patients with anti-NMDA receptor encephalitis should be interpreted carefully and need to be further validated. Further studies are warranted to investigate the association between isolated anti-NMDA receptor encephalitis and HSE followed by anti-NMDA receptor encephalitis, and to develop a differential diagnosis strategy.

We thank Drs Michael Scheel and Carsten Finke again for their constructive comments on our article, as well as sharing their experience for a deeper understanding of this disease entity.
FIGURE. Axial FLAIR images of the 10 patients from A to J with anti-NMDA with type 4 lesions.
Methodologic Issues on Interrater Reliability Regarding Structural and DTI-Based Corticospinal Tract Asymmetry

We read, with interest, the article by Foesleitner et al1 published in the June 2018 issue of the American Journal of Neuroradiology. The purpose was to investigate a clinically feasible imaging approach to assess corticospinal tract (CST) asymmetry in unilateral polymicrogyria (PMG), check diffusion-based tractography as a guide to the presumed motor area within the dysplastic cortex, and investigate whether the “rule” of CST asymmetry as a good prognostic factor for postsurgical motor function preservation specifically applies to cases of unilateral PMG involving the central region. The interrater reliability was calculated by the Cohen coefficient.1 The authors reported that the interrater reliability in the assessment of corticospinal tract asymmetry was most robust at the level of the cerebral crus. Also, excellent congruence was reached by categorizing the asymmetry degree into no or minimal asymmetry or moderate/severe asymmetry (κ = 1.0) in the event that the other levels of assessment did not result in considerable agreement (κ = 0.21–0.6).1

It is of crucial importance to know that the κ value cannot be a sign of good agreement. In assessing the agreement of a qualitative variable, the κ value has 2 major weaknesses: 1) It depends on the prevalence in each class—that is, there might be different κ values of the same percentages for concordant and discordant cells. As can be seen in the Table, the prevalence of concordant cells in both (a) and (b) situations is 90%, while that of discordant cells is 10%. However, we can get different values of κ (0.44 and 0.80) for concordant and discordant cells, respectively. 2) The κ value also depends on the number of classes. It is preferable to use a weighted κ in such situations to obtain unbiased results.2–4

They concluded that visual assessment of structural and diffusion tensor images of the corticospinal tract (especially at the cerebral crus) is a reliable and clinically feasible imaging approach in the preoperative work-up of patients with unilateral PMG affecting the central region. Also, in noncompliant patients, DTI-based tractography is a useful alternative to task-based fMRI and helps in the anatomic localization of the primary motor cortex. If one considered the above-mentioned limitations of the κ value to assess reliability, such a conclusion may be misleading. Therefore, misinterpretation cannot be avoided.2–4

In this letter, we discuss the limitations of the κ value to assess reliability. Therefore, any conclusion especially in reliability analysis should be supported by the above mentioned statistical and methodological issues.

REFERENCES
2. Szklo M, Nieto FJ. Epidemiology: Beyond the Basics. 2nd ed. Sudbury: Jones and Bartlett Publisher; 2007

F. Jalalvandi
M. Naderi
Department of Operating Room
School of Paramedical
Kermanshah University of Medical Sciences
Kermanshah, I.R. Iran

http://dx.doi.org/10.3174/ajnr.A5799
We would like to comment on the letter to the Editor regarding our article on corticospinal tract asymmetries in unilateral polymicrogyria.1 We thank Drs Jalalvandi and Naderi for their interest in our work and appreciate the opportunity to respond to their remarks.

In most radiologic studies, the κ value is commonly used to assess interrater reliability. However, as emphasized by the authors and initially shown by Byrt et al,2 it has important weaknesses due to bias and prevalence issues. Byrt et al recommended using the bias and the prevalence indices to address these shortcomings. In addition to several other observations, we documented a high concordance in detecting the presence or absence of corticospinal tract asymmetry in cases of unilateral polymicrogyria by 2 independent observers (9/10 consistent ratings, Table). The low bias (0.22) and prevalence (0.11) indices support the validity of our κ values. If, however, one wanted to use the prevalence-adjusted bias-adjusted κ,2 in our case reaching 0.78, interrater agreement would still show a substantial strength of agreement.2,3 Because the issues mentioned above do not apply to our sample, we opted for the classic κ value.

In conclusion, we support the call of the letter for caution when using the κ coefficient. However, the issue of neither prevalence nor bias is relevant for our study. Thus, our results allow the conclusion of reliable visual assessment of corticospinal tract asymmetry in unilateral polymicrogyria involving the motor cortex based on T1-weighted and color-coded diffusion tensor imaging maps at the level of the midbrain.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Rater A</th>
<th>Rater B</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>1</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>1</td>
<td>1</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
<td>0</td>
<td>Yes</td>
</tr>
</tbody>
</table>

*1 = asymmetry, 0 = symmetry (data published in Foesleitner et al).*

REFERENCES